#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Positron emission tomography assessment of cerebral glucose metabolic rates in autism spectrum disorder and schizophrenia
#Text=Several models have been proposed to account for observed overlaps in clinical features and genetic predisposition between schizophrenia and autism spectrum disorder.
1-1	0-8	Positron	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[1]	
1-2	9-17	emission	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[1]	
1-3	18-28	tomography	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[1]	
1-4	29-39	assessment	_	
1-5	40-42	of	_	
1-6	43-51	cerebral	_	
1-7	52-59	glucose	_	
1-8	60-69	metabolic	_	
1-9	70-75	rates	_	
1-10	76-78	in	_	
1-11	79-85	autism	http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder[2]	
1-12	86-94	spectrum	http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder[2]	
1-13	95-103	disorder	http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder[2]	
1-14	104-107	and	_	
1-15	108-121	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
1-16	122-129	Several	_	
1-17	130-136	models	_	
1-18	137-141	have	_	
1-19	142-146	been	_	
1-20	147-155	proposed	_	
1-21	156-158	to	_	
1-22	159-166	account	_	
1-23	167-170	for	_	
1-24	171-179	observed	_	
1-25	180-188	overlaps	_	
1-26	189-191	in	_	
1-27	192-200	clinical	_	
1-28	201-209	features	_	
1-29	210-213	and	_	
1-30	214-221	genetic	_	
1-31	222-236	predisposition	_	
1-32	237-244	between	_	
1-33	245-258	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
1-34	259-262	and	_	
1-35	263-269	autism	http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder[3]	
1-36	270-278	spectrum	http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder[3]	
1-37	279-287	disorder	http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder[3]	
1-38	287-288	.	_	

#Text=This study assessed similarities and differences in topological patterns and vectors of glucose metabolism in both disorders in reference to these models.
2-1	289-293	This	_	
2-2	294-299	study	_	
2-3	300-308	assessed	_	
2-4	309-321	similarities	_	
2-5	322-325	and	_	
2-6	326-337	differences	_	
2-7	338-340	in	_	
2-8	341-352	topological	_	
2-9	353-361	patterns	_	
2-10	362-365	and	_	
2-11	366-373	vectors	_	
2-12	374-376	of	_	
2-13	377-384	glucose	_	
2-14	385-395	metabolism	_	
2-15	396-398	in	_	
2-16	399-403	both	_	
2-17	404-413	disorders	_	
2-18	414-416	in	_	
2-19	417-426	reference	_	
2-20	427-429	to	_	
2-21	430-435	these	_	
2-22	436-442	models	_	
2-23	442-443	.	_	

#Text=Co-registered 18F-FDG PET and MRI scans were obtained in 41 schizophrenia, 25 ASD, and 55 healthy control subjects.
3-1	444-457	Co-registered	_	
3-2	458-465	18F-FDG	_	
3-3	466-469	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography	
3-4	470-473	and	_	
3-5	474-477	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging	
3-6	478-483	scans	_	
3-7	484-488	were	_	
3-8	489-497	obtained	_	
3-9	498-500	in	_	
3-10	501-503	41	_	
3-11	504-517	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
3-12	517-518	,	_	
3-13	519-521	25	_	
3-14	522-525	ASD	http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder	
3-15	525-526	,	_	
3-16	527-530	and	_	
3-17	531-533	55	_	
3-18	534-541	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[4]	
3-19	542-549	control	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[4]	
3-20	550-558	subjects	_	
3-21	558-559	.	_	

#Text=AFNI was used to map cortical and subcortical regions of interest.
4-1	560-564	AFNI	_	
4-2	565-568	was	_	
4-3	569-573	used	_	
4-4	574-576	to	_	
4-5	577-580	map	_	
4-6	581-589	cortical	_	
4-7	590-593	and	_	
4-8	594-605	subcortical	_	
4-9	606-613	regions	_	
4-10	614-616	of	_	
4-11	617-625	interest	_	
4-12	625-626	.	_	

#Text=Metabolic rates were compared between three diagnostic groups using univariate and multivariate repeated-measures ANOVA.
5-1	627-636	Metabolic	_	
5-2	637-642	rates	_	
5-3	643-647	were	_	
5-4	648-656	compared	_	
5-5	657-664	between	_	
5-6	665-670	three	_	
5-7	671-681	diagnostic	_	
5-8	682-688	groups	_	
5-9	689-694	using	_	
5-10	695-705	univariate	_	
5-11	706-709	and	_	
5-12	710-722	multivariate	_	
5-13	723-740	repeated-measures	_	
5-14	741-746	ANOVA	_	
5-15	746-747	.	_	

#Text=Compared to controls, metabolic rates in schizophrenia subjects were decreased in the frontal lobe, anterior cingulate, superior temporal gyrus, amygdala and medial thalamic nuclei; rates were increased in the occipital cortex, hippocampus, basal ganglia and lateral thalamic nuclei.
6-1	748-756	Compared	_	
6-2	757-759	to	_	
6-3	760-768	controls	_	
6-4	768-769	,	_	
6-5	770-779	metabolic	_	
6-6	780-785	rates	_	
6-7	786-788	in	_	
6-8	789-802	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
6-9	803-811	subjects	_	
6-10	812-816	were	_	
6-11	817-826	decreased	_	
6-12	827-829	in	_	
6-13	830-833	the	_	
6-14	834-841	frontal	_	
6-15	842-846	lobe	_	
6-16	846-847	,	_	
6-17	848-856	anterior	_	
6-18	857-866	cingulate	_	
6-19	866-867	,	_	
6-20	868-876	superior	_	
6-21	877-885	temporal	_	
6-22	886-891	gyrus	_	
6-23	891-892	,	_	
6-24	893-901	amygdala	_	
6-25	902-905	and	_	
6-26	906-912	medial	_	
6-27	913-921	thalamic	_	
6-28	922-928	nuclei	_	
6-29	928-929	;	_	
6-30	930-935	rates	_	
6-31	936-940	were	_	
6-32	941-950	increased	_	
6-33	951-953	in	_	
6-34	954-957	the	_	
6-35	958-967	occipital	_	
6-36	968-974	cortex	_	
6-37	974-975	,	_	
6-38	976-987	hippocampus	_	
6-39	987-988	,	_	
6-40	989-994	basal	_	
6-41	995-1002	ganglia	_	
6-42	1003-1006	and	_	
6-43	1007-1014	lateral	_	
6-44	1015-1023	thalamic	_	
6-45	1024-1030	nuclei	_	
6-46	1030-1031	.	_	

#Text=In ASD subjects metabolic rates were decreased in the parietal lobe, frontal premotor and eye-fields areas, and amygdala; rates were increased in the posterior cingulate, occipital cortex, hippocampus and basal ganglia.
7-1	1032-1034	In	_	
7-2	1035-1038	ASD	http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder	
7-3	1039-1047	subjects	_	
7-4	1048-1057	metabolic	_	
7-5	1058-1063	rates	_	
7-6	1064-1068	were	_	
7-7	1069-1078	decreased	_	
7-8	1079-1081	in	_	
7-9	1082-1085	the	_	
7-10	1086-1094	parietal	_	
7-11	1095-1099	lobe	_	
7-12	1099-1100	,	_	
7-13	1101-1108	frontal	_	
7-14	1109-1117	premotor	_	
7-15	1118-1121	and	_	
7-16	1122-1132	eye-fields	_	
7-17	1133-1138	areas	_	
7-18	1138-1139	,	_	
7-19	1140-1143	and	_	
7-20	1144-1152	amygdala	_	
7-21	1152-1153	;	_	
7-22	1154-1159	rates	_	
7-23	1160-1164	were	_	
7-24	1165-1174	increased	_	
7-25	1175-1177	in	_	
7-26	1178-1181	the	_	
7-27	1182-1191	posterior	_	
7-28	1192-1201	cingulate	_	
7-29	1201-1202	,	_	
7-30	1203-1212	occipital	_	
7-31	1213-1219	cortex	_	
7-32	1219-1220	,	_	
7-33	1221-1232	hippocampus	_	
7-34	1233-1236	and	_	
7-35	1237-1242	basal	_	
7-36	1243-1250	ganglia	_	
7-37	1250-1251	.	_	

#Text=In relation to controls, subjects with ASD and schizophrenia showed opposite changes in metabolic rates in the primary motor and somatosensory cortex, anterior cingulate and hypothalamus; similar changes were found in prefrontal and occipital cortices, inferior parietal lobule, amygdala, hippocampus, and basal ganglia.
8-1	1252-1254	In	_	
8-2	1255-1263	relation	_	
8-3	1264-1266	to	_	
8-4	1267-1275	controls	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject	
8-5	1275-1276	,	_	
8-6	1277-1285	subjects	_	
8-7	1286-1290	with	_	
8-8	1291-1294	ASD	http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder	
8-9	1295-1298	and	_	
8-10	1299-1312	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
8-11	1313-1319	showed	_	
8-12	1320-1328	opposite	_	
8-13	1329-1336	changes	_	
8-14	1337-1339	in	_	
8-15	1340-1349	metabolic	_	
8-16	1350-1355	rates	_	
8-17	1356-1358	in	_	
8-18	1359-1362	the	_	
8-19	1363-1370	primary	_	
8-20	1371-1376	motor	_	
8-21	1377-1380	and	_	
8-22	1381-1394	somatosensory	_	
8-23	1395-1401	cortex	_	
8-24	1401-1402	,	_	
8-25	1403-1411	anterior	_	
8-26	1412-1421	cingulate	_	
8-27	1422-1425	and	_	
8-28	1426-1438	hypothalamus	_	
8-29	1438-1439	;	_	
8-30	1440-1447	similar	_	
8-31	1448-1455	changes	_	
8-32	1456-1460	were	_	
8-33	1461-1466	found	_	
8-34	1467-1469	in	_	
8-35	1470-1480	prefrontal	_	
8-36	1481-1484	and	_	
8-37	1485-1494	occipital	_	
8-38	1495-1503	cortices	_	
8-39	1503-1504	,	_	
8-40	1505-1513	inferior	_	
8-41	1514-1522	parietal	_	
8-42	1523-1529	lobule	_	
8-43	1529-1530	,	_	
8-44	1531-1539	amygdala	_	
8-45	1539-1540	,	_	
8-46	1541-1552	hippocampus	_	
8-47	1552-1553	,	_	
8-48	1554-1557	and	_	
8-49	1558-1563	basal	_	
8-50	1564-1571	ganglia	_	
8-51	1571-1572	.	_	

#Text=Schizophrenia and ASD appear to be associated with a similar pattern of metabolic abnormalities in the social brain.
9-1	1573-1586	Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
9-2	1587-1590	and	_	
9-3	1591-1594	ASD	http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder	
9-4	1595-1601	appear	_	
9-5	1602-1604	to	_	
9-6	1605-1607	be	_	
9-7	1608-1618	associated	_	
9-8	1619-1623	with	_	
9-9	1624-1625	a	_	
9-10	1626-1633	similar	_	
9-11	1634-1641	pattern	_	
9-12	1642-1644	of	_	
9-13	1645-1654	metabolic	_	
9-14	1655-1668	abnormalities	_	
9-15	1669-1671	in	_	
9-16	1672-1675	the	_	
9-17	1676-1682	social	_	
9-18	1683-1688	brain	_	
9-19	1688-1689	.	_	

#Text=Divergent maladaptive trade-offs, as postulated by the diametrical hypothesis of their evolutionary relationship, may involve a more circumscribed set of anterior cingulate, motor and somatosensory regions and the specific cognitive functions they subserve.
10-1	1690-1699	Divergent	_	
10-2	1700-1711	maladaptive	_	
10-3	1712-1722	trade-offs	_	
10-4	1722-1723	,	_	
10-5	1724-1726	as	_	
10-6	1727-1737	postulated	_	
10-7	1738-1740	by	_	
10-8	1741-1744	the	_	
10-9	1745-1756	diametrical	_	
10-10	1757-1767	hypothesis	_	
10-11	1768-1770	of	_	
10-12	1771-1776	their	_	
10-13	1777-1789	evolutionary	_	
10-14	1790-1802	relationship	_	
10-15	1802-1803	,	_	
10-16	1804-1807	may	_	
10-17	1808-1815	involve	_	
10-18	1816-1817	a	_	
10-19	1818-1822	more	_	
10-20	1823-1836	circumscribed	_	
10-21	1837-1840	set	_	
10-22	1841-1843	of	_	
10-23	1844-1852	anterior	_	
10-24	1853-1862	cingulate	_	
10-25	1862-1863	,	_	
10-26	1864-1869	motor	_	
10-27	1870-1873	and	_	
10-28	1874-1887	somatosensory	_	
10-29	1888-1895	regions	_	
10-30	1896-1899	and	_	
10-31	1900-1903	the	_	
10-32	1904-1912	specific	_	
10-33	1913-1922	cognitive	_	
10-34	1923-1932	functions	_	
10-35	1933-1937	they	_	
10-36	1938-1946	subserve	_	
10-37	1946-1947	.	_	

#Text=Introduction
#Text=Recent developments in genome-wide association studies of psychiatric disorders have led to renewed interest in their interrelationships.
11-1	1948-1960	Introduction	_	
11-2	1961-1967	Recent	_	
11-3	1968-1980	developments	_	
11-4	1981-1983	in	_	
11-5	1984-1995	genome-wide	_	
11-6	1996-2007	association	_	
11-7	2008-2015	studies	_	
11-8	2016-2018	of	_	
11-9	2019-2030	psychiatric	_	
11-10	2031-2040	disorders	_	
11-11	2041-2045	have	_	
11-12	2046-2049	led	_	
11-13	2050-2052	to	_	
11-14	2053-2060	renewed	_	
11-15	2061-2069	interest	_	
11-16	2070-2072	in	_	
11-17	2073-2078	their	_	
11-18	2079-2097	interrelationships	_	
11-19	2097-2098	.	_	

#Text=This is particularly true of schizophrenia and autism spectrum disorders (ASD), which were among the last major psychiatric diagnoses to be nosologically separated, with ASD accorded its own set of formal diagnostic criteria in DSM-III.
12-1	2099-2103	This	_	
12-2	2104-2106	is	_	
12-3	2107-2119	particularly	_	
12-4	2120-2124	true	_	
12-5	2125-2127	of	_	
12-6	2128-2141	schizophrenia	_	
12-7	2142-2145	and	_	
12-8	2146-2152	autism	_	
12-9	2153-2161	spectrum	_	
12-10	2162-2171	disorders	_	
12-11	2172-2173	(	_	
12-12	2173-2176	ASD	_	
12-13	2176-2177	)	_	
12-14	2177-2178	,	_	
12-15	2179-2184	which	_	
12-16	2185-2189	were	_	
12-17	2190-2195	among	_	
12-18	2196-2199	the	_	
12-19	2200-2204	last	_	
12-20	2205-2210	major	_	
12-21	2211-2222	psychiatric	_	
12-22	2223-2232	diagnoses	_	
12-23	2233-2235	to	_	
12-24	2236-2238	be	_	
12-25	2239-2252	nosologically	_	
12-26	2253-2262	separated	_	
12-27	2262-2263	,	_	
12-28	2264-2268	with	_	
12-29	2269-2272	ASD	_	
12-30	2273-2281	accorded	_	
12-31	2282-2285	its	_	
12-32	2286-2289	own	_	
12-33	2290-2293	set	_	
12-34	2294-2296	of	_	
12-35	2297-2303	formal	_	
12-36	2304-2314	diagnostic	_	
12-37	2315-2323	criteria	_	
12-38	2324-2326	in	_	
12-39	2327-2334	DSM-III	_	
12-40	2334-2335	.	_	

#Text=Both are viewed as neurodevelopmental conditions with prominent impairments in social cognition, and falling on a spectrum that fades into a population variance in normal psychological traits.
13-1	2336-2340	Both	_	
13-2	2341-2344	are	_	
13-3	2345-2351	viewed	_	
13-4	2352-2354	as	_	
13-5	2355-2373	neurodevelopmental	_	
13-6	2374-2384	conditions	_	
13-7	2385-2389	with	_	
13-8	2390-2399	prominent	_	
13-9	2400-2411	impairments	_	
13-10	2412-2414	in	_	
13-11	2415-2421	social	_	
13-12	2422-2431	cognition	_	
13-13	2431-2432	,	_	
13-14	2433-2436	and	_	
13-15	2437-2444	falling	_	
13-16	2445-2447	on	_	
13-17	2448-2449	a	_	
13-18	2450-2458	spectrum	_	
13-19	2459-2463	that	_	
13-20	2464-2469	fades	_	
13-21	2470-2474	into	_	
13-22	2475-2476	a	_	
13-23	2477-2487	population	_	
13-24	2488-2496	variance	_	
13-25	2497-2499	in	_	
13-26	2500-2506	normal	_	
13-27	2507-2520	psychological	_	
13-28	2521-2527	traits	_	
13-29	2527-2528	.	_	

#Text=With a general consensus that disturbance of the social brain is a major feature of both disorders, the nature of this disturbance remains debatable and several distinct views on this can be discerned.
14-1	2529-2533	With	_	
14-2	2534-2535	a	_	
14-3	2536-2543	general	_	
14-4	2544-2553	consensus	_	
14-5	2554-2558	that	_	
14-6	2559-2570	disturbance	_	
14-7	2571-2573	of	_	
14-8	2574-2577	the	_	
14-9	2578-2584	social	_	
14-10	2585-2590	brain	_	
14-11	2591-2593	is	_	
14-12	2594-2595	a	_	
14-13	2596-2601	major	_	
14-14	2602-2609	feature	_	
14-15	2610-2612	of	_	
14-16	2613-2617	both	_	
14-17	2618-2627	disorders	_	
14-18	2627-2628	,	_	
14-19	2629-2632	the	_	
14-20	2633-2639	nature	_	
14-21	2640-2642	of	_	
14-22	2643-2647	this	_	
14-23	2648-2659	disturbance	_	
14-24	2660-2667	remains	_	
14-25	2668-2677	debatable	_	
14-26	2678-2681	and	_	
14-27	2682-2689	several	_	
14-28	2690-2698	distinct	_	
14-29	2699-2704	views	_	
14-30	2705-2707	on	_	
14-31	2708-2712	this	_	
14-32	2713-2716	can	_	
14-33	2717-2719	be	_	
14-34	2720-2729	discerned	_	
14-35	2729-2730	.	_	

#Text=Various authors describe this shared involvement of the social brain as coincidental (due to etiologically unrelated pathological processes in each disorder, encompassing partially overlapping structures of the brain) or epiphenomenal (primary in schizophrenia, but only secondary in ASD and stemming from an ontogenetically earlier disturbance in primary sensory processing).
15-1	2731-2738	Various	_	
15-2	2739-2746	authors	_	
15-3	2747-2755	describe	_	
15-4	2756-2760	this	_	
15-5	2761-2767	shared	_	
15-6	2768-2779	involvement	_	
15-7	2780-2782	of	_	
15-8	2783-2786	the	_	
15-9	2787-2793	social	_	
15-10	2794-2799	brain	_	
15-11	2800-2802	as	_	
15-12	2803-2815	coincidental	_	
15-13	2816-2817	(	_	
15-14	2817-2820	due	_	
15-15	2821-2823	to	_	
15-16	2824-2837	etiologically	_	
15-17	2838-2847	unrelated	_	
15-18	2848-2860	pathological	_	
15-19	2861-2870	processes	_	
15-20	2871-2873	in	_	
15-21	2874-2878	each	_	
15-22	2879-2887	disorder	_	
15-23	2887-2888	,	_	
15-24	2889-2901	encompassing	_	
15-25	2902-2911	partially	_	
15-26	2912-2923	overlapping	_	
15-27	2924-2934	structures	_	
15-28	2935-2937	of	_	
15-29	2938-2941	the	_	
15-30	2942-2947	brain	_	
15-31	2947-2948	)	_	
15-32	2949-2951	or	_	
15-33	2952-2965	epiphenomenal	_	
15-34	2966-2967	(	_	
15-35	2967-2974	primary	_	
15-36	2975-2977	in	_	
15-37	2978-2991	schizophrenia	_	
15-38	2991-2992	,	_	
15-39	2993-2996	but	_	
15-40	2997-3001	only	_	
15-41	3002-3011	secondary	_	
15-42	3012-3014	in	_	
15-43	3015-3018	ASD	_	
15-44	3019-3022	and	_	
15-45	3023-3031	stemming	_	
15-46	3032-3036	from	_	
15-47	3037-3039	an	_	
15-48	3040-3055	ontogenetically	_	
15-49	3056-3063	earlier	_	
15-50	3064-3075	disturbance	_	
15-51	3076-3078	in	_	
15-52	3079-3086	primary	_	
15-53	3087-3094	sensory	_	
15-54	3095-3105	processing	_	
15-55	3105-3106	)	_	
15-56	3106-3107	.	_	

#Text=Still others consider the overlap to be predilect by selective evolutionary pressures, with each disorder representing an extreme case of a diametric trade-off in population variance for cognitive sets of social and nonsocial abilities.
16-1	3108-3113	Still	_	
16-2	3114-3120	others	_	
16-3	3121-3129	consider	_	
16-4	3130-3133	the	_	
16-5	3134-3141	overlap	_	
16-6	3142-3144	to	_	
16-7	3145-3147	be	_	
16-8	3148-3157	predilect	_	
16-9	3158-3160	by	_	
16-10	3161-3170	selective	_	
16-11	3171-3183	evolutionary	_	
16-12	3184-3193	pressures	_	
16-13	3193-3194	,	_	
16-14	3195-3199	with	_	
16-15	3200-3204	each	_	
16-16	3205-3213	disorder	_	
16-17	3214-3226	representing	_	
16-18	3227-3229	an	_	
16-19	3230-3237	extreme	_	
16-20	3238-3242	case	_	
16-21	3243-3245	of	_	
16-22	3246-3247	a	_	
16-23	3248-3257	diametric	_	
16-24	3258-3267	trade-off	_	
16-25	3268-3270	in	_	
16-26	3271-3281	population	_	
16-27	3282-3290	variance	_	
16-28	3291-3294	for	_	
16-29	3295-3304	cognitive	_	
16-30	3305-3309	sets	_	
16-31	3310-3312	of	_	
16-32	3313-3319	social	_	
16-33	3320-3323	and	_	
16-34	3324-3333	nonsocial	_	
16-35	3334-3343	abilities	_	
16-36	3343-3344	.	_	

#Text=Neuroimaging techniques naturally lend themselves to exploration of the proposed models of the social brain and other impairments in schizophrenia and ASD as reflected in differential topological patterns and vectors of brain changes predicted by each model.
17-1	3345-3357	Neuroimaging	_	
17-2	3358-3368	techniques	_	
17-3	3369-3378	naturally	_	
17-4	3379-3383	lend	_	
17-5	3384-3394	themselves	_	
17-6	3395-3397	to	_	
17-7	3398-3409	exploration	_	
17-8	3410-3412	of	_	
17-9	3413-3416	the	_	
17-10	3417-3425	proposed	_	
17-11	3426-3432	models	_	
17-12	3433-3435	of	_	
17-13	3436-3439	the	_	
17-14	3440-3446	social	_	
17-15	3447-3452	brain	_	
17-16	3453-3456	and	_	
17-17	3457-3462	other	_	
17-18	3463-3474	impairments	_	
17-19	3475-3477	in	_	
17-20	3478-3491	schizophrenia	_	
17-21	3492-3495	and	_	
17-22	3496-3499	ASD	_	
17-23	3500-3502	as	_	
17-24	3503-3512	reflected	_	
17-25	3513-3515	in	_	
17-26	3516-3528	differential	_	
17-27	3529-3540	topological	_	
17-28	3541-3549	patterns	_	
17-29	3550-3553	and	_	
17-30	3554-3561	vectors	_	
17-31	3562-3564	of	_	
17-32	3565-3570	brain	_	
17-33	3571-3578	changes	_	
17-34	3579-3588	predicted	_	
17-35	3589-3591	by	_	
17-36	3592-3596	each	_	
17-37	3597-3602	model	_	
17-38	3602-3603	.	_	

#Text=Two recent structural MRI studies, directly comparing subjects with schizophrenia and ASD, found opposite changes in both gray and white matter volumes in several brain regions in relation to healthy controls, consistent with the diametrical hypothesis of social brain involvement in each of the disorders.
18-1	3604-3607	Two	_	
18-2	3608-3614	recent	_	
18-3	3615-3625	structural	_	
18-4	3626-3629	MRI	_	
18-5	3630-3637	studies	_	
18-6	3637-3638	,	_	
18-7	3639-3647	directly	_	
18-8	3648-3657	comparing	_	
18-9	3658-3666	subjects	_	
18-10	3667-3671	with	_	
18-11	3672-3685	schizophrenia	_	
18-12	3686-3689	and	_	
18-13	3690-3693	ASD	_	
18-14	3693-3694	,	_	
18-15	3695-3700	found	_	
18-16	3701-3709	opposite	_	
18-17	3710-3717	changes	_	
18-18	3718-3720	in	_	
18-19	3721-3725	both	_	
18-20	3726-3730	gray	_	
18-21	3731-3734	and	_	
18-22	3735-3740	white	_	
18-23	3741-3747	matter	_	
18-24	3748-3755	volumes	_	
18-25	3756-3758	in	_	
18-26	3759-3766	several	_	
18-27	3767-3772	brain	_	
18-28	3773-3780	regions	_	
18-29	3781-3783	in	_	
18-30	3784-3792	relation	_	
18-31	3793-3795	to	_	
18-32	3796-3803	healthy	_	
18-33	3804-3812	controls	_	
18-34	3812-3813	,	_	
18-35	3814-3824	consistent	_	
18-36	3825-3829	with	_	
18-37	3830-3833	the	_	
18-38	3834-3845	diametrical	_	
18-39	3846-3856	hypothesis	_	
18-40	3857-3859	of	_	
18-41	3860-3866	social	_	
18-42	3867-3872	brain	_	
18-43	3873-3884	involvement	_	
18-44	3885-3887	in	_	
18-45	3888-3892	each	_	
18-46	3893-3895	of	_	
18-47	3896-3899	the	_	
18-48	3900-3909	disorders	_	
18-49	3909-3910	.	_	

#Text=While volumetric analyses appear well-suited for elucidation of evolutionary and developmental impacts on related cerebral structures, functional imaging techniques may be used to delineate more proximate patterns of differential, task-induced activation.
19-1	3911-3916	While	_	
19-2	3917-3927	volumetric	_	
19-3	3928-3936	analyses	_	
19-4	3937-3943	appear	_	
19-5	3944-3955	well-suited	_	
19-6	3956-3959	for	_	
19-7	3960-3971	elucidation	_	
19-8	3972-3974	of	_	
19-9	3975-3987	evolutionary	_	
19-10	3988-3991	and	_	
19-11	3992-4005	developmental	_	
19-12	4006-4013	impacts	_	
19-13	4014-4016	on	_	
19-14	4017-4024	related	_	
19-15	4025-4033	cerebral	_	
19-16	4034-4044	structures	_	
19-17	4044-4045	,	_	
19-18	4046-4056	functional	_	
19-19	4057-4064	imaging	_	
19-20	4065-4075	techniques	_	
19-21	4076-4079	may	_	
19-22	4080-4082	be	_	
19-23	4083-4087	used	_	
19-24	4088-4090	to	_	
19-25	4091-4100	delineate	_	
19-26	4101-4105	more	_	
19-27	4106-4115	proximate	_	
19-28	4116-4124	patterns	_	
19-29	4125-4127	of	_	
19-30	4128-4140	differential	_	
19-31	4140-4141	,	_	
19-32	4142-4154	task-induced	_	
19-33	4155-4165	activation	_	
19-34	4165-4166	.	_	

#Text=Indeed, two such fMRI studies of ASD and schizophrenia lend support to the diametrical hypothesis and another report implied a mere functional overlap. [18F]-fluorodeoxyglucose (FDG) PET, owing to the extended tracer uptake period, is uniquely positioned to evaluate between-group differences in more sustained task-dependent and basal metabolic patterns, thus occupying an intermediate space between structural and functional MRI.
20-1	4167-4173	Indeed	_	
20-2	4173-4174	,	_	
20-3	4175-4178	two	_	
20-4	4179-4183	such	_	
20-5	4184-4188	fMRI	_	
20-6	4189-4196	studies	_	
20-7	4197-4199	of	_	
20-8	4200-4203	ASD	_	
20-9	4204-4207	and	_	
20-10	4208-4221	schizophrenia	_	
20-11	4222-4226	lend	_	
20-12	4227-4234	support	_	
20-13	4235-4237	to	_	
20-14	4238-4241	the	_	
20-15	4242-4253	diametrical	_	
20-16	4254-4264	hypothesis	_	
20-17	4265-4268	and	_	
20-18	4269-4276	another	_	
20-19	4277-4283	report	_	
20-20	4284-4291	implied	_	
20-21	4292-4293	a	_	
20-22	4294-4298	mere	_	
20-23	4299-4309	functional	_	
20-24	4310-4317	overlap	_	
20-25	4317-4318	.	_	
20-26	4319-4320	[	_	
20-27	4320-4323	18F	_	
20-28	4323-4324	]	_	
20-29	4324-4325	-	_	
20-30	4325-4343	fluorodeoxyglucose	_	
20-31	4344-4345	(	_	
20-32	4345-4348	FDG	_	
20-33	4348-4349	)	_	
20-34	4350-4353	PET	_	
20-35	4353-4354	,	_	
20-36	4355-4360	owing	_	
20-37	4361-4363	to	_	
20-38	4364-4367	the	_	
20-39	4368-4376	extended	_	
20-40	4377-4383	tracer	_	
20-41	4384-4390	uptake	_	
20-42	4391-4397	period	_	
20-43	4397-4398	,	_	
20-44	4399-4401	is	_	
20-45	4402-4410	uniquely	_	
20-46	4411-4421	positioned	_	
20-47	4422-4424	to	_	
20-48	4425-4433	evaluate	_	
20-49	4434-4447	between-group	_	
20-50	4448-4459	differences	_	
20-51	4460-4462	in	_	
20-52	4463-4467	more	_	
20-53	4468-4477	sustained	_	
20-54	4478-4492	task-dependent	_	
20-55	4493-4496	and	_	
20-56	4497-4502	basal	_	
20-57	4503-4512	metabolic	_	
20-58	4513-4521	patterns	_	
20-59	4521-4522	,	_	
20-60	4523-4527	thus	_	
20-61	4528-4537	occupying	_	
20-62	4538-4540	an	_	
20-63	4541-4553	intermediate	_	
20-64	4554-4559	space	_	
20-65	4560-4567	between	_	
20-66	4568-4578	structural	_	
20-67	4579-4582	and	_	
20-68	4583-4593	functional	_	
20-69	4594-4597	MRI	_	
20-70	4597-4598	.	_	

#Text=FDG-PET assessments of subjects with schizophrenia have consistently reported hypofrontality (especially in relation to negative symptoms), decreased metabolic rates in the prefrontal and anterior cingulate regions, as well as some thalamic nuclei (mediodorsal, pulvinar), lateralized changes in the temporal lobes, and increased metabolic rates in the basal ganglia (caudate, putamen, especially in relation to positive symptoms).
21-1	4599-4606	FDG-PET	_	
21-2	4607-4618	assessments	_	
21-3	4619-4621	of	_	
21-4	4622-4630	subjects	_	
21-5	4631-4635	with	_	
21-6	4636-4649	schizophrenia	_	
21-7	4650-4654	have	_	
21-8	4655-4667	consistently	_	
21-9	4668-4676	reported	_	
21-10	4677-4691	hypofrontality	_	
21-11	4692-4693	(	_	
21-12	4693-4703	especially	_	
21-13	4704-4706	in	_	
21-14	4707-4715	relation	_	
21-15	4716-4718	to	_	
21-16	4719-4727	negative	_	
21-17	4728-4736	symptoms	_	
21-18	4736-4737	)	_	
21-19	4737-4738	,	_	
21-20	4739-4748	decreased	_	
21-21	4749-4758	metabolic	_	
21-22	4759-4764	rates	_	
21-23	4765-4767	in	_	
21-24	4768-4771	the	_	
21-25	4772-4782	prefrontal	_	
21-26	4783-4786	and	_	
21-27	4787-4795	anterior	_	
21-28	4796-4805	cingulate	_	
21-29	4806-4813	regions	_	
21-30	4813-4814	,	_	
21-31	4815-4817	as	_	
21-32	4818-4822	well	_	
21-33	4823-4825	as	_	
21-34	4826-4830	some	_	
21-35	4831-4839	thalamic	_	
21-36	4840-4846	nuclei	_	
21-37	4847-4848	(	_	
21-38	4848-4859	mediodorsal	_	
21-39	4859-4860	,	_	
21-40	4861-4869	pulvinar	_	
21-41	4869-4870	)	_	
21-42	4870-4871	,	_	
21-43	4872-4883	lateralized	_	
21-44	4884-4891	changes	_	
21-45	4892-4894	in	_	
21-46	4895-4898	the	_	
21-47	4899-4907	temporal	_	
21-48	4908-4913	lobes	_	
21-49	4913-4914	,	_	
21-50	4915-4918	and	_	
21-51	4919-4928	increased	_	
21-52	4929-4938	metabolic	_	
21-53	4939-4944	rates	_	
21-54	4945-4947	in	_	
21-55	4948-4951	the	_	
21-56	4952-4957	basal	_	
21-57	4958-4965	ganglia	_	
21-58	4966-4967	(	_	
21-59	4967-4974	caudate	_	
21-60	4974-4975	,	_	
21-61	4976-4983	putamen	_	
21-62	4983-4984	,	_	
21-63	4985-4995	especially	_	
21-64	4996-4998	in	_	
21-65	4999-5007	relation	_	
21-66	5008-5010	to	_	
21-67	5011-5019	positive	_	
21-68	5020-5028	symptoms	_	
21-69	5028-5029	)	_	
21-70	5029-5030	.	_	

#Text=Findings in ASD proved somewhat less consistent, generally pointing to diminished metabolic rates in the anterior cingulate, parietal cortex, basal ganglia (caudate, putamen), as well as increased metabolic rates in the occipital cortex.
22-1	5031-5039	Findings	_	
22-2	5040-5042	in	_	
22-3	5043-5046	ASD	_	
22-4	5047-5053	proved	_	
22-5	5054-5062	somewhat	_	
22-6	5063-5067	less	_	
22-7	5068-5078	consistent	_	
22-8	5078-5079	,	_	
22-9	5080-5089	generally	_	
22-10	5090-5098	pointing	_	
22-11	5099-5101	to	_	
22-12	5102-5112	diminished	_	
22-13	5113-5122	metabolic	_	
22-14	5123-5128	rates	_	
22-15	5129-5131	in	_	
22-16	5132-5135	the	_	
22-17	5136-5144	anterior	_	
22-18	5145-5154	cingulate	_	
22-19	5154-5155	,	_	
22-20	5156-5164	parietal	_	
22-21	5165-5171	cortex	_	
22-22	5171-5172	,	_	
22-23	5173-5178	basal	_	
22-24	5179-5186	ganglia	_	
22-25	5187-5188	(	_	
22-26	5188-5195	caudate	_	
22-27	5195-5196	,	_	
22-28	5197-5204	putamen	_	
22-29	5204-5205	)	_	
22-30	5205-5206	,	_	
22-31	5207-5209	as	_	
22-32	5210-5214	well	_	
22-33	5215-5217	as	_	
22-34	5218-5227	increased	_	
22-35	5228-5237	metabolic	_	
22-36	5238-5243	rates	_	
22-37	5244-5246	in	_	
22-38	5247-5250	the	_	
22-39	5251-5260	occipital	_	
22-40	5261-5267	cortex	_	
22-41	5267-5268	.	_	

#Text=Only a single study directly compared subjects with schizophrenia and ASD during a continuous performance test, confirming decreased metabolism in the anterior cingulate and increased metabolism in the parietal regions in schizophrenia, as well as decreased metabolism in the medial thalamus in those with infantile autism.
23-1	5269-5273	Only	_	
23-2	5274-5275	a	_	
23-3	5276-5282	single	_	
23-4	5283-5288	study	_	
23-5	5289-5297	directly	_	
23-6	5298-5306	compared	_	
23-7	5307-5315	subjects	_	
23-8	5316-5320	with	_	
23-9	5321-5334	schizophrenia	_	
23-10	5335-5338	and	_	
23-11	5339-5342	ASD	_	
23-12	5343-5349	during	_	
23-13	5350-5351	a	_	
23-14	5352-5362	continuous	_	
23-15	5363-5374	performance	_	
23-16	5375-5379	test	_	
23-17	5379-5380	,	_	
23-18	5381-5391	confirming	_	
23-19	5392-5401	decreased	_	
23-20	5402-5412	metabolism	_	
23-21	5413-5415	in	_	
23-22	5416-5419	the	_	
23-23	5420-5428	anterior	_	
23-24	5429-5438	cingulate	_	
23-25	5439-5442	and	_	
23-26	5443-5452	increased	_	
23-27	5453-5463	metabolism	_	
23-28	5464-5466	in	_	
23-29	5467-5470	the	_	
23-30	5471-5479	parietal	_	
23-31	5480-5487	regions	_	
23-32	5488-5490	in	_	
23-33	5491-5504	schizophrenia	_	
23-34	5504-5505	,	_	
23-35	5506-5508	as	_	
23-36	5509-5513	well	_	
23-37	5514-5516	as	_	
23-38	5517-5526	decreased	_	
23-39	5527-5537	metabolism	_	
23-40	5538-5540	in	_	
23-41	5541-5544	the	_	
23-42	5545-5551	medial	_	
23-43	5552-5560	thalamus	_	
23-44	5561-5563	in	_	
23-45	5564-5569	those	_	
23-46	5570-5574	with	_	
23-47	5575-5584	infantile	_	
23-48	5585-5591	autism	_	
23-49	5591-5592	.	_	

#Text=In the present study, we used FDG PET during a modified California Verbal Learning Test to directly compare cortical and subcortical glucose metabolic rates in subjects with schizophrenia and ASD in relation to healthy controls.
24-1	5593-5595	In	_	
24-2	5596-5599	the	_	
24-3	5600-5607	present	_	
24-4	5608-5613	study	_	
24-5	5613-5614	,	_	
24-6	5615-5617	we	_	
24-7	5618-5622	used	_	
24-8	5623-5626	FDG	_	
24-9	5627-5630	PET	_	
24-10	5631-5637	during	_	
24-11	5638-5639	a	_	
24-12	5640-5648	modified	_	
24-13	5649-5659	California	_	
24-14	5660-5666	Verbal	_	
24-15	5667-5675	Learning	_	
24-16	5676-5680	Test	_	
24-17	5681-5683	to	_	
24-18	5684-5692	directly	_	
24-19	5693-5700	compare	_	
24-20	5701-5709	cortical	_	
24-21	5710-5713	and	_	
24-22	5714-5725	subcortical	_	
24-23	5726-5733	glucose	_	
24-24	5734-5743	metabolic	_	
24-25	5744-5749	rates	_	
24-26	5750-5752	in	_	
24-27	5753-5761	subjects	_	
24-28	5762-5766	with	_	
24-29	5767-5780	schizophrenia	_	
24-30	5781-5784	and	_	
24-31	5785-5788	ASD	_	
24-32	5789-5791	in	_	
24-33	5792-5800	relation	_	
24-34	5801-5803	to	_	
24-35	5804-5811	healthy	_	
24-36	5812-5820	controls	_	
24-37	5820-5821	.	_	

#Text=Topological patterns and vectors of metabolic activity were examined in order to investigate the nature of a proposed relationship between schizophrenia and ASD with respect to the above-referenced theoretical models.
25-1	5822-5833	Topological	_	
25-2	5834-5842	patterns	_	
25-3	5843-5846	and	_	
25-4	5847-5854	vectors	_	
25-5	5855-5857	of	_	
25-6	5858-5867	metabolic	_	
25-7	5868-5876	activity	_	
25-8	5877-5881	were	_	
25-9	5882-5890	examined	_	
25-10	5891-5893	in	_	
25-11	5894-5899	order	_	
25-12	5900-5902	to	_	
25-13	5903-5914	investigate	_	
25-14	5915-5918	the	_	
25-15	5919-5925	nature	_	
25-16	5926-5928	of	_	
25-17	5929-5930	a	_	
25-18	5931-5939	proposed	_	
25-19	5940-5952	relationship	_	
25-20	5953-5960	between	_	
25-21	5961-5974	schizophrenia	_	
25-22	5975-5978	and	_	
25-23	5979-5982	ASD	_	
25-24	5983-5987	with	_	
25-25	5988-5995	respect	_	
25-26	5996-5998	to	_	
25-27	5999-6002	the	_	
25-28	6003-6019	above-referenced	_	
25-29	6020-6031	theoretical	_	
25-30	6032-6038	models	_	
25-31	6038-6039	.	_	

#Text=Our previous morphometric assessment on a sample of subjects with ASD and schizophrenia, overlapping with the present cohort, revealed a diametric relationship among gray matter volumes in these diagnostic groups in relation to healthy controls, with invariably larger volumes in those with ASD.
26-1	6040-6043	Our	_	
26-2	6044-6052	previous	_	
26-3	6053-6065	morphometric	_	
26-4	6066-6076	assessment	_	
26-5	6077-6079	on	_	
26-6	6080-6081	a	_	
26-7	6082-6088	sample	_	
26-8	6089-6091	of	_	
26-9	6092-6100	subjects	_	
26-10	6101-6105	with	_	
26-11	6106-6109	ASD	_	
26-12	6110-6113	and	_	
26-13	6114-6127	schizophrenia	_	
26-14	6127-6128	,	_	
26-15	6129-6140	overlapping	_	
26-16	6141-6145	with	_	
26-17	6146-6149	the	_	
26-18	6150-6157	present	_	
26-19	6158-6164	cohort	_	
26-20	6164-6165	,	_	
26-21	6166-6174	revealed	_	
26-22	6175-6176	a	_	
26-23	6177-6186	diametric	_	
26-24	6187-6199	relationship	_	
26-25	6200-6205	among	_	
26-26	6206-6210	gray	_	
26-27	6211-6217	matter	_	
26-28	6218-6225	volumes	_	
26-29	6226-6228	in	_	
26-30	6229-6234	these	_	
26-31	6235-6245	diagnostic	_	
26-32	6246-6252	groups	_	
26-33	6253-6255	in	_	
26-34	6256-6264	relation	_	
26-35	6265-6267	to	_	
26-36	6268-6275	healthy	_	
26-37	6276-6284	controls	_	
26-38	6284-6285	,	_	
26-39	6286-6290	with	_	
26-40	6291-6301	invariably	_	
26-41	6302-6308	larger	_	
26-42	6309-6316	volumes	_	
26-43	6317-6319	in	_	
26-44	6320-6325	those	_	
26-45	6326-6330	with	_	
26-46	6331-6334	ASD	_	
26-47	6334-6335	.	_	

#Text=We deemed these results strongly supportive of the and in turn hypothesized that this diametric relationship will be upheld by a comparable pattern of gray matter metabolism.
27-1	6336-6338	We	_	
27-2	6339-6345	deemed	_	
27-3	6346-6351	these	_	
27-4	6352-6359	results	_	
27-5	6360-6368	strongly	_	
27-6	6369-6379	supportive	_	
27-7	6380-6382	of	_	
27-8	6383-6386	the	_	
27-9	6387-6390	and	_	
27-10	6391-6393	in	_	
27-11	6394-6398	turn	_	
27-12	6399-6411	hypothesized	_	
27-13	6412-6416	that	_	
27-14	6417-6421	this	_	
27-15	6422-6431	diametric	_	
27-16	6432-6444	relationship	_	
27-17	6445-6449	will	_	
27-18	6450-6452	be	_	
27-19	6453-6459	upheld	_	
27-20	6460-6462	by	_	
27-21	6463-6464	a	_	
27-22	6465-6475	comparable	_	
27-23	6476-6483	pattern	_	
27-24	6484-6486	of	_	
27-25	6487-6491	gray	_	
27-26	6492-6498	matter	_	
27-27	6499-6509	metabolism	_	
27-28	6509-6510	.	_	

#Text=Methods
#Text=Participants
#Text=Study participants comprised 41 subjects with schizophrenia (age=40.0±18.0 years, 9 females), 25 subjects with ASD (age=31.48±11.57, 4 females), and 55 healthy controls (age=33.36±12.85, 26 females).
28-1	6511-6518	Methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod	
28-2	6519-6531	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-3	6532-6537	Study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-4	6538-6550	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-5	6551-6560	comprised	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-6	6561-6563	41	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-7	6564-6572	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-8	6573-6577	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-9	6578-6591	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[6]	
28-10	6592-6593	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-11	6593-6596	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-12	6596-6597	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-13	6597-6601	40.0	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-14	6601-6602	±	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-15	6602-6606	18.0	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-16	6607-6612	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-17	6612-6613	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-18	6614-6615	9	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-19	6616-6623	females	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-20	6623-6624	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-21	6624-6625	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-22	6626-6628	25	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-23	6629-6637	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-24	6638-6642	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-25	6643-6646	ASD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]|http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder[7]	
28-26	6647-6648	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-27	6648-6651	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-28	6651-6652	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-29	6652-6657	31.48	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-30	6657-6658	±	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-31	6658-6663	11.57	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-32	6663-6664	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-33	6665-6666	4	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-34	6667-6674	females	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-35	6674-6675	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-36	6675-6676	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-37	6677-6680	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-38	6681-6683	55	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-39	6684-6691	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[8]	
28-40	6692-6700	controls	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[8]	
28-41	6701-6702	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-42	6702-6705	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-43	6705-6706	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-44	6706-6711	33.36	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-45	6711-6712	±	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-46	6712-6717	12.85	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-47	6717-6718	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-48	6719-6721	26	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-49	6722-6729	females	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-50	6729-6730	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
28-51	6730-6731	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	

#Text=Subjects with schizophrenia were recruited from the inpatient and outpatient services at Pilgrim State Psychiatric Center, Mount Sinai Hospital and the Bronx VA Medical Center in the New York metropolitan area.
29-1	6732-6740	Subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-2	6741-6745	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-3	6746-6759	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[9]	
29-4	6760-6764	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-5	6765-6774	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-6	6775-6779	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-7	6780-6783	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-8	6784-6793	inpatient	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-9	6794-6797	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-10	6798-6808	outpatient	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-11	6809-6817	services	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-12	6818-6820	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-13	6821-6828	Pilgrim	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-14	6829-6834	State	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-15	6835-6846	Psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-16	6847-6853	Center	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-17	6853-6854	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-18	6855-6860	Mount	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-19	6861-6866	Sinai	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-20	6867-6875	Hospital	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-21	6876-6879	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-22	6880-6883	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-23	6884-6889	Bronx	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-24	6890-6892	VA	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-25	6893-6900	Medical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-26	6901-6907	Center	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-27	6908-6910	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-28	6911-6914	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-29	6915-6918	New	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-30	6919-6923	York	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-31	6924-6936	metropolitan	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-32	6937-6941	area	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-33	6941-6942	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	

#Text=They varied in illness chronicity (duration of illness = 15.77±15.64 years, ranging from 1 to 59 years) and level of social functioning (14 with Kraepelinian schizophrenia subtype, 27 with non-Kraepelinian subtype, based on criteria of).
30-1	6943-6947	They	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-2	6948-6954	varied	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-3	6955-6957	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-4	6958-6965	illness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-5	6966-6976	chronicity	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-6	6977-6978	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-7	6978-6986	duration	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-8	6987-6989	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-9	6990-6997	illness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-10	6998-6999	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-11	7000-7005	15.77	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-12	7005-7006	±	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-13	7006-7011	15.64	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-14	7012-7017	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-15	7017-7018	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-16	7019-7026	ranging	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-17	7027-7031	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-18	7032-7033	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-19	7034-7036	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-20	7037-7039	59	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-21	7040-7045	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-22	7045-7046	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-23	7047-7050	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-24	7051-7056	level	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-25	7057-7059	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-26	7060-7066	social	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-27	7067-7078	functioning	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-28	7079-7080	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-29	7080-7082	14	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-30	7083-7087	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-31	7088-7100	Kraepelinian	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-32	7101-7114	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[10]	
30-33	7115-7122	subtype	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-34	7122-7123	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-35	7124-7126	27	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-36	7127-7131	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-37	7132-7148	non-Kraepelinian	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-38	7149-7156	subtype	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-39	7156-7157	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-40	7158-7163	based	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-41	7164-7166	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-42	7167-7175	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-43	7176-7178	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-44	7178-7179	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
30-45	7179-7180	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	

#Text=PANSS scores were 19.14±7.0 (positive), 19.24±7.2 (negative) and 38.36±11.0 (general).
31-1	7181-7186	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[12]	
31-2	7187-7193	scores	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
31-3	7194-7198	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
31-4	7199-7204	19.14	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
31-5	7204-7205	±	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
31-6	7205-7208	7.0	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
31-7	7209-7210	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
31-8	7210-7218	positive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
31-9	7218-7219	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
31-10	7219-7220	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
31-11	7221-7226	19.24	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
31-12	7226-7227	±	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
31-13	7227-7230	7.2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
31-14	7231-7232	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
31-15	7232-7240	negative	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
31-16	7240-7241	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
31-17	7242-7245	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
31-18	7246-7251	38.36	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
31-19	7251-7252	±	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
31-20	7252-7256	11.0	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
31-21	7257-7258	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
31-22	7258-7265	general	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
31-23	7265-7266	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
31-24	7266-7267	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	

#Text=Subjects with ASD were recruited by advertisements at the Seaver Autism Center at the Icahn School of Medicine at Mount Sinai.
32-1	7268-7276	Subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
32-2	7277-7281	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
32-3	7282-7285	ASD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder[13]	
32-4	7286-7290	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
32-5	7291-7300	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
32-6	7301-7303	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
32-7	7304-7318	advertisements	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
32-8	7319-7321	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
32-9	7322-7325	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
32-10	7326-7332	Seaver	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
32-11	7333-7339	Autism	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
32-12	7340-7346	Center	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
32-13	7347-7349	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
32-14	7350-7353	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
32-15	7354-7359	Icahn	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
32-16	7360-7366	School	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
32-17	7367-7369	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
32-18	7370-7378	Medicine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
32-19	7379-7381	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
32-20	7382-7387	Mount	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
32-21	7388-7393	Sinai	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
32-22	7393-7394	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	

#Text=Diagnosis was confirmed by both DSM-IV criteria and Autism Diagnostic Interview-Revised.
33-1	7395-7404	Diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
33-2	7405-7408	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
33-3	7409-7418	confirmed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
33-4	7419-7421	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
33-5	7422-7426	both	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
33-6	7427-7433	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
33-7	7434-7442	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
33-8	7443-7446	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
33-9	7447-7453	Autism	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
33-10	7454-7464	Diagnostic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
33-11	7465-7482	Interview-Revised	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
33-12	7482-7483	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	

#Text=ASD subjects were verbal and were administered the WAIS and the Raven’s Progressive Matrices (not available for 6 participants).
34-1	7484-7487	ASD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder[14]	
34-2	7488-7496	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-3	7497-7501	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-4	7502-7508	verbal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-5	7509-7512	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-6	7513-7517	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-7	7518-7530	administered	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-8	7531-7534	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-9	7535-7539	WAIS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-10	7540-7543	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-11	7544-7547	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-12	7548-7553	Raven	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-13	7553-7554	’	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-14	7554-7555	s	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-15	7556-7567	Progressive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-16	7568-7576	Matrices	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-17	7577-7578	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-18	7578-7581	not	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-19	7582-7591	available	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-20	7592-7595	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-21	7596-7597	6	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-22	7598-7610	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-23	7610-7611	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-24	7611-7612	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	

#Text=The mean full-scale IQ score for the ASD group was 108.80±20.25 (verbal IQ=110.15±20.70, performance IQ=105.70±19.93).
35-1	7613-7616	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-2	7617-7621	mean	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-3	7622-7632	full-scale	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-4	7633-7635	IQ	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-5	7636-7641	score	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-6	7642-7645	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-7	7646-7649	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-8	7650-7653	ASD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder[15]	
35-9	7654-7659	group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-10	7660-7663	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-11	7664-7670	108.80	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-12	7670-7671	±	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-13	7671-7676	20.25	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-14	7677-7678	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-15	7678-7684	verbal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-16	7685-7687	IQ	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-17	7687-7688	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-18	7688-7694	110.15	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-19	7694-7695	±	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-20	7695-7700	20.70	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-21	7700-7701	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-22	7702-7713	performance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-23	7714-7716	IQ	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-24	7716-7717	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-25	7717-7723	105.70	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-26	7723-7724	±	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-27	7724-7729	19.93	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-28	7729-7730	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-29	7730-7731	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	

#Text=All ASD and schizophrenia participants were unmedicated with psychotropic substances for at least 14 days prior to scan date.
36-1	7732-7735	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
36-2	7736-7739	ASD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder[16]	
36-3	7740-7743	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
36-4	7744-7757	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[17]	
36-5	7758-7770	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
36-6	7771-7775	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
36-7	7776-7787	unmedicated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
36-8	7788-7792	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
36-9	7793-7805	psychotropic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
36-10	7806-7816	substances	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
36-11	7817-7820	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
36-12	7821-7823	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
36-13	7824-7829	least	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
36-14	7830-7832	14	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
36-15	7833-7837	days	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
36-16	7838-7843	prior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
36-17	7844-7846	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
36-18	7847-7851	scan	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
36-19	7852-7856	date	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
36-20	7856-7857	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	

#Text=Study participants in the present report were also part of our structural MRI comparison of subjects with schizophrenia and ASD and of FDG PET comparison of subjects with Kraepelinian and non-Kraepelinian schizophrenia, subsample of ASD subjects featured in and.
37-1	7858-7863	Study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
37-2	7864-7876	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
37-3	7877-7879	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
37-4	7880-7883	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
37-5	7884-7891	present	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
37-6	7892-7898	report	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
37-7	7899-7903	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
37-8	7904-7908	also	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
37-9	7909-7913	part	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
37-10	7914-7916	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
37-11	7917-7920	our	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
37-12	7921-7931	structural	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[18]	
37-13	7932-7935	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[18]	
37-14	7936-7946	comparison	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
37-15	7947-7949	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
37-16	7950-7958	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
37-17	7959-7963	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
37-18	7964-7977	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[19]	
37-19	7978-7981	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
37-20	7982-7985	ASD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder[20]	
37-21	7986-7989	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
37-22	7990-7992	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
37-23	7993-7996	FDG	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
37-24	7997-8000	PET	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[21]	
37-25	8001-8011	comparison	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
37-26	8012-8014	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
37-27	8015-8023	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
37-28	8024-8028	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
37-29	8029-8041	Kraepelinian	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
37-30	8042-8045	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
37-31	8046-8062	non-Kraepelinian	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
37-32	8063-8076	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[22]	
37-33	8076-8077	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
37-34	8078-8087	subsample	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
37-35	8088-8090	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
37-36	8091-8094	ASD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder[23]	
37-37	8095-8103	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
37-38	8104-8112	featured	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
37-39	8113-8115	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
37-40	8116-8119	and	_	
37-41	8119-8120	.	_	

#Text=In comparison to the latter two studies, the present report employs a larger cohort of participants, analyzes different regions of interest with a newer automated region-of-interest approach.
38-1	8121-8123	In	_	
38-2	8124-8134	comparison	_	
38-3	8135-8137	to	_	
38-4	8138-8141	the	_	
38-5	8142-8148	latter	_	
38-6	8149-8152	two	_	
38-7	8153-8160	studies	_	
38-8	8160-8161	,	_	
38-9	8162-8165	the	_	
38-10	8166-8173	present	_	
38-11	8174-8180	report	_	
38-12	8181-8188	employs	_	
38-13	8189-8190	a	_	
38-14	8191-8197	larger	_	
38-15	8198-8204	cohort	_	
38-16	8205-8207	of	_	
38-17	8208-8220	participants	_	
38-18	8220-8221	,	_	
38-19	8222-8230	analyzes	_	
38-20	8231-8240	different	_	
38-21	8241-8248	regions	_	
38-22	8249-8251	of	_	
38-23	8252-8260	interest	_	
38-24	8261-8265	with	_	
38-25	8266-8267	a	_	
38-26	8268-8273	newer	_	
38-27	8274-8283	automated	_	
38-28	8284-8302	region-of-interest	_	
38-29	8303-8311	approach	_	
38-30	8311-8312	.	_	

#Text=Data acquisition and processing
#Text=All participants had a negative urine screen for drugs of abuse and all women also had a negative pregnancy test on scan day.
39-1	8313-8317	Data	_	
39-2	8318-8329	acquisition	_	
39-3	8330-8333	and	_	
39-4	8334-8344	processing	_	
39-5	8345-8348	All	_	
39-6	8349-8361	participants	_	
39-7	8362-8365	had	_	
39-8	8366-8367	a	_	
39-9	8368-8376	negative	_	
39-10	8377-8382	urine	_	
39-11	8383-8389	screen	_	
39-12	8390-8393	for	_	
39-13	8394-8399	drugs	_	
39-14	8400-8402	of	_	
39-15	8403-8408	abuse	_	
39-16	8409-8412	and	_	
39-17	8413-8416	all	_	
39-18	8417-8422	women	_	
39-19	8423-8427	also	_	
39-20	8428-8431	had	_	
39-21	8432-8433	a	_	
39-22	8434-8442	negative	_	
39-23	8443-8452	pregnancy	_	
39-24	8453-8457	test	_	
39-25	8458-8460	on	_	
39-26	8461-8465	scan	_	
39-27	8466-8469	day	_	
39-28	8469-8470	.	_	

#Text=An intravenous line was inserted into a forearm vein in each arm of the subject and kept patent by normal saline, 50–75 ml/h.
40-1	8471-8473	An	_	
40-2	8474-8485	intravenous	_	
40-3	8486-8490	line	_	
40-4	8491-8494	was	_	
40-5	8495-8503	inserted	_	
40-6	8504-8508	into	_	
40-7	8509-8510	a	_	
40-8	8511-8518	forearm	_	
40-9	8519-8523	vein	_	
40-10	8524-8526	in	_	
40-11	8527-8531	each	_	
40-12	8532-8535	arm	_	
40-13	8536-8538	of	_	
40-14	8539-8542	the	_	
40-15	8543-8550	subject	_	
40-16	8551-8554	and	_	
40-17	8555-8559	kept	_	
40-18	8560-8566	patent	_	
40-19	8567-8569	by	_	
40-20	8570-8576	normal	_	
40-21	8577-8583	saline	_	
40-22	8583-8584	,	_	
40-23	8585-8587	50	_	
40-24	8587-8588	–	_	
40-25	8588-8590	75	_	
40-26	8591-8593	ml	_	
40-27	8593-8594	/	_	
40-28	8594-8595	h	_	
40-29	8595-8596	.	_	

#Text=The subject was instructed on the serial verbal learning task (SVLT) prior to isotope injection in the sound-attenuated uptake room in the Mount Sinai PET Center.
41-1	8597-8600	The	_	
41-2	8601-8608	subject	_	
41-3	8609-8612	was	_	
41-4	8613-8623	instructed	_	
41-5	8624-8626	on	_	
41-6	8627-8630	the	_	
41-7	8631-8637	serial	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[24]	
41-8	8638-8644	verbal	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[24]	
41-9	8645-8653	learning	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[24]	
41-10	8654-8658	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[24]	
41-11	8659-8660	(	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[24]	
41-12	8660-8664	SVLT	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[24]	
41-13	8664-8665	)	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[24]	
41-14	8666-8671	prior	_	
41-15	8672-8674	to	_	
41-16	8675-8682	isotope	_	
41-17	8683-8692	injection	_	
41-18	8693-8695	in	_	
41-19	8696-8699	the	_	
41-20	8700-8716	sound-attenuated	_	
41-21	8717-8723	uptake	_	
41-22	8724-8728	room	_	
41-23	8729-8731	in	_	
41-24	8732-8735	the	_	
41-25	8736-8741	Mount	_	
41-26	8742-8747	Sinai	_	
41-27	8748-8751	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography	
41-28	8752-8758	Center	_	
41-29	8758-8759	.	_	

#Text=The serial verbal learning task (see for task details) was initiated on a computer screen directly in front of the subject.
42-1	8760-8763	The	_	
42-2	8764-8770	serial	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[25]	
42-3	8771-8777	verbal	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[25]	
42-4	8778-8786	learning	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[25]	
42-5	8787-8791	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[25]	
42-6	8792-8793	(	_	
42-7	8793-8796	see	_	
42-8	8797-8800	for	_	
42-9	8801-8805	task	_	
42-10	8806-8813	details	_	
42-11	8813-8814	)	_	
42-12	8815-8818	was	_	
42-13	8819-8828	initiated	_	
42-14	8829-8831	on	_	
42-15	8832-8833	a	_	
42-16	8834-8842	computer	_	
42-17	8843-8849	screen	_	
42-18	8850-8858	directly	_	
42-19	8859-8861	in	_	
42-20	8862-8867	front	_	
42-21	8868-8870	of	_	
42-22	8871-8874	the	_	
42-23	8875-8882	subject	_	
42-24	8882-8883	.	_	

#Text=Immediately upon starting the SVLT, 5 mCi of 18FDG (185 Mbq) were administered into the venous set rubber diaphragm behind the subject’s back as a 45–60 seconds slow push.
43-1	8884-8895	Immediately	_	
43-2	8896-8900	upon	_	
43-3	8901-8909	starting	_	
43-4	8910-8913	the	_	
43-5	8914-8918	SVLT	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	
43-6	8918-8919	,	_	
43-7	8920-8921	5	_	
43-8	8922-8925	mCi	_	
43-9	8926-8928	of	_	
43-10	8929-8934	18FDG	_	
43-11	8935-8936	(	_	
43-12	8936-8939	185	_	
43-13	8940-8943	Mbq	_	
43-14	8943-8944	)	_	
43-15	8945-8949	were	_	
43-16	8950-8962	administered	_	
43-17	8963-8967	into	_	
43-18	8968-8971	the	_	
43-19	8972-8978	venous	_	
43-20	8979-8982	set	_	
43-21	8983-8989	rubber	_	
43-22	8990-8999	diaphragm	_	
43-23	9000-9006	behind	_	
43-24	9007-9010	the	_	
43-25	9011-9018	subject	_	
43-26	9018-9019	’	_	
43-27	9019-9020	s	_	
43-28	9021-9025	back	_	
43-29	9026-9028	as	_	
43-30	9029-9030	a	_	
43-31	9031-9033	45	_	
43-32	9033-9034	–	_	
43-33	9034-9036	60	_	
43-34	9037-9044	seconds	_	
43-35	9045-9049	slow	_	
43-36	9050-9054	push	_	
43-37	9054-9055	.	_	

#Text=The tube was clamped above the port before administration; after administration the saline was allowed to run at maximum rate for 6 minutes to flush the line, which was then closed.
44-1	9056-9059	The	_	
44-2	9060-9064	tube	_	
44-3	9065-9068	was	_	
44-4	9069-9076	clamped	_	
44-5	9077-9082	above	_	
44-6	9083-9086	the	_	
44-7	9087-9091	port	_	
44-8	9092-9098	before	_	
44-9	9099-9113	administration	_	
44-10	9113-9114	;	_	
44-11	9115-9120	after	_	
44-12	9121-9135	administration	_	
44-13	9136-9139	the	_	
44-14	9140-9146	saline	_	
44-15	9147-9150	was	_	
44-16	9151-9158	allowed	_	
44-17	9159-9161	to	_	
44-18	9162-9165	run	_	
44-19	9166-9168	at	_	
44-20	9169-9176	maximum	_	
44-21	9177-9181	rate	_	
44-22	9182-9185	for	_	
44-23	9186-9187	6	_	
44-24	9188-9195	minutes	_	
44-25	9196-9198	to	_	
44-26	9199-9204	flush	_	
44-27	9205-9208	the	_	
44-28	9209-9213	line	_	
44-29	9213-9214	,	_	
44-30	9215-9220	which	_	
44-31	9221-9224	was	_	
44-32	9225-9229	then	_	
44-33	9230-9236	closed	_	
44-34	9236-9237	.	_	

#Text=The subject remained in the uptake room and performed the SVLT for 32 minutes before being escorted to the adjacent bathroom to void, then positioned in the scanner using their own premolded thermosetting plastic mask.
45-1	9238-9241	The	_	
45-2	9242-9249	subject	_	
45-3	9250-9258	remained	_	
45-4	9259-9261	in	_	
45-5	9262-9265	the	_	
45-6	9266-9272	uptake	_	
45-7	9273-9277	room	_	
45-8	9278-9281	and	_	
45-9	9282-9291	performed	_	
45-10	9292-9295	the	_	
45-11	9296-9300	SVLT	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	
45-12	9301-9304	for	_	
45-13	9305-9307	32	_	
45-14	9308-9315	minutes	_	
45-15	9316-9322	before	_	
45-16	9323-9328	being	_	
45-17	9329-9337	escorted	_	
45-18	9338-9340	to	_	
45-19	9341-9344	the	_	
45-20	9345-9353	adjacent	_	
45-21	9354-9362	bathroom	_	
45-22	9363-9365	to	_	
45-23	9366-9370	void	_	
45-24	9370-9371	,	_	
45-25	9372-9376	then	_	
45-26	9377-9387	positioned	_	
45-27	9388-9390	in	_	
45-28	9391-9394	the	_	
45-29	9395-9402	scanner	_	
45-30	9403-9408	using	_	
45-31	9409-9414	their	_	
45-32	9415-9418	own	_	
45-33	9419-9428	premolded	_	
45-34	9429-9442	thermosetting	_	
45-35	9443-9450	plastic	_	
45-36	9451-9455	mask	_	
45-37	9455-9456	.	_	

#Text=Imaging data acquisition lasted approximately 40 minutes.
46-1	9457-9464	Imaging	_	
46-2	9465-9469	data	_	
46-3	9470-9481	acquisition	_	
46-4	9482-9488	lasted	_	
46-5	9489-9502	approximately	_	
46-6	9503-9505	40	_	
46-7	9506-9513	minutes	_	
46-8	9513-9514	.	_	

#Text=The PET scans were obtained with a head-dedicated scanner (GE Medical Systems model 2048) with measured resolution of 4.5 mm in plane (4.2–4.5 mm across 15 planes) and 5.0 mm axially. 15 slices at 6.5-mm intervals were obtained in two sets so as to cover the entire brain.
47-1	9515-9518	The	_	
47-2	9519-9522	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography	
47-3	9523-9528	scans	_	
47-4	9529-9533	were	_	
47-5	9534-9542	obtained	_	
47-6	9543-9547	with	_	
47-7	9548-9549	a	_	
47-8	9550-9564	head-dedicated	_	
47-9	9565-9572	scanner	_	
47-10	9573-9574	(	_	
47-11	9574-9576	GE	_	
47-12	9577-9584	Medical	_	
47-13	9585-9592	Systems	_	
47-14	9593-9598	model	_	
47-15	9599-9603	2048	_	
47-16	9603-9604	)	_	
47-17	9605-9609	with	_	
47-18	9610-9618	measured	_	
47-19	9619-9629	resolution	_	
47-20	9630-9632	of	_	
47-21	9633-9636	4.5	_	
47-22	9637-9639	mm	_	
47-23	9640-9642	in	_	
47-24	9643-9648	plane	_	
47-25	9649-9650	(	_	
47-26	9650-9653	4.2	_	
47-27	9653-9654	–	_	
47-28	9654-9657	4.5	_	
47-29	9658-9660	mm	_	
47-30	9661-9667	across	_	
47-31	9668-9670	15	_	
47-32	9671-9677	planes	_	
47-33	9677-9678	)	_	
47-34	9679-9682	and	_	
47-35	9683-9686	5.0	_	
47-36	9687-9689	mm	_	
47-37	9690-9697	axially	_	
47-38	9697-9698	.	_	
47-39	9699-9701	15	_	
47-40	9702-9708	slices	_	
47-41	9709-9711	at	_	
47-42	9712-9715	6.5	_	
47-43	9715-9716	-	_	
47-44	9716-9718	mm	_	
47-45	9719-9728	intervals	_	
47-46	9729-9733	were	_	
47-47	9734-9742	obtained	_	
47-48	9743-9745	in	_	
47-49	9746-9749	two	_	
47-50	9750-9754	sets	_	
47-51	9755-9757	so	_	
47-52	9758-9760	as	_	
47-53	9761-9763	to	_	
47-54	9764-9769	cover	_	
47-55	9770-9773	the	_	
47-56	9774-9780	entire	_	
47-57	9781-9786	brain	_	
47-58	9786-9787	.	_	

#Text=Slice counts of 1.5–3 M were typical.
48-1	9788-9793	Slice	_	
48-2	9794-9800	counts	_	
48-3	9801-9803	of	_	
48-4	9804-9807	1.5	_	
48-5	9807-9808	–	_	
48-6	9808-9809	3	_	
48-7	9810-9811	M	_	
48-8	9812-9816	were	_	
48-9	9817-9824	typical	_	
48-10	9824-9825	.	_	

#Text=Scans were reconstructed with a blank transmission scan and the Hann filter.
49-1	9826-9831	Scans	_	
49-2	9832-9836	were	_	
49-3	9837-9850	reconstructed	_	
49-4	9851-9855	with	_	
49-5	9856-9857	a	_	
49-6	9858-9863	blank	_	
49-7	9864-9876	transmission	_	
49-8	9877-9881	scan	_	
49-9	9882-9885	and	_	
49-10	9886-9889	the	_	
49-11	9890-9894	Hann	_	
49-12	9895-9901	filter	_	
49-13	9901-9902	.	_	

#Text=The SVLT, based on the principles of the California Verbal Learning Test, consists of five word lists containing 16 words each divided into 4 semantic categories (e.g., colors, animals, desserts, drinks).
50-1	9903-9906	The	_	
50-2	9907-9911	SVLT	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	
50-3	9911-9912	,	_	
50-4	9913-9918	based	_	
50-5	9919-9921	on	_	
50-6	9922-9925	the	_	
50-7	9926-9936	principles	_	
50-8	9937-9939	of	_	
50-9	9940-9943	the	_	
50-10	9944-9954	California	_	
50-11	9955-9961	Verbal	_	
50-12	9962-9970	Learning	_	
50-13	9971-9975	Test	_	
50-14	9975-9976	,	_	
50-15	9977-9985	consists	_	
50-16	9986-9988	of	_	
50-17	9989-9993	five	_	
50-18	9994-9998	word	_	
50-19	9999-10004	lists	_	
50-20	10005-10015	containing	_	
50-21	10016-10018	16	_	
50-22	10019-10024	words	_	
50-23	10025-10029	each	_	
50-24	10030-10037	divided	_	
50-25	10038-10042	into	_	
50-26	10043-10044	4	_	
50-27	10045-10053	semantic	_	
50-28	10054-10064	categories	_	
50-29	10065-10066	(	_	
50-30	10066-10069	e.g	_	
50-31	10069-10070	.	_	
50-32	10070-10071	,	_	
50-33	10072-10078	colors	_	
50-34	10078-10079	,	_	
50-35	10080-10087	animals	_	
50-36	10087-10088	,	_	
50-37	10089-10097	desserts	_	
50-38	10097-10098	,	_	
50-39	10099-10105	drinks	_	
50-40	10105-10106	)	_	
50-41	10106-10107	.	_	

#Text=Each of the five lists is presented on a computer monitor five times at a rate of one word every 1.5 seconds, avoiding consecutive presentation of words from the same semantic category.
51-1	10108-10112	Each	_	
51-2	10113-10115	of	_	
51-3	10116-10119	the	_	
51-4	10120-10124	five	_	
51-5	10125-10130	lists	_	
51-6	10131-10133	is	_	
51-7	10134-10143	presented	_	
51-8	10144-10146	on	_	
51-9	10147-10148	a	_	
51-10	10149-10157	computer	_	
51-11	10158-10165	monitor	_	
51-12	10166-10170	five	_	
51-13	10171-10176	times	_	
51-14	10177-10179	at	_	
51-15	10180-10181	a	_	
51-16	10182-10186	rate	_	
51-17	10187-10189	of	_	
51-18	10190-10193	one	_	
51-19	10194-10198	word	_	
51-20	10199-10204	every	_	
51-21	10205-10208	1.5	_	
51-22	10209-10216	seconds	_	
51-23	10216-10217	,	_	
51-24	10218-10226	avoiding	_	
51-25	10227-10238	consecutive	_	
51-26	10239-10251	presentation	_	
51-27	10252-10254	of	_	
51-28	10255-10260	words	_	
51-29	10261-10265	from	_	
51-30	10266-10269	the	_	
51-31	10270-10274	same	_	
51-32	10275-10283	semantic	_	
51-33	10284-10292	category	_	
51-34	10292-10293	.	_	

#Text=Ordering of the words within each list, as well as the presentation order of each list were identical for all participants.
52-1	10294-10302	Ordering	_	
52-2	10303-10305	of	_	
52-3	10306-10309	the	_	
52-4	10310-10315	words	_	
52-5	10316-10322	within	_	
52-6	10323-10327	each	_	
52-7	10328-10332	list	_	
52-8	10332-10333	,	_	
52-9	10334-10336	as	_	
52-10	10337-10341	well	_	
52-11	10342-10344	as	_	
52-12	10345-10348	the	_	
52-13	10349-10361	presentation	_	
52-14	10362-10367	order	_	
52-15	10368-10370	of	_	
52-16	10371-10375	each	_	
52-17	10376-10380	list	_	
52-18	10381-10385	were	_	
52-19	10386-10395	identical	_	
52-20	10396-10399	for	_	
52-21	10400-10403	all	_	
52-22	10404-10416	participants	_	
52-23	10416-10417	.	_	

#Text=The participants read each word aloud as it appeared on the computer monitor to maintain steady focus of attention on the task.
53-1	10418-10421	The	_	
53-2	10422-10434	participants	_	
53-3	10435-10439	read	_	
53-4	10440-10444	each	_	
53-5	10445-10449	word	_	
53-6	10450-10455	aloud	_	
53-7	10456-10458	as	_	
53-8	10459-10461	it	_	
53-9	10462-10470	appeared	_	
53-10	10471-10473	on	_	
53-11	10474-10477	the	_	
53-12	10478-10486	computer	_	
53-13	10487-10494	monitor	_	
53-14	10495-10497	to	_	
53-15	10498-10506	maintain	_	
53-16	10507-10513	steady	_	
53-17	10514-10519	focus	_	
53-18	10520-10522	of	_	
53-19	10523-10532	attention	_	
53-20	10533-10535	on	_	
53-21	10536-10539	the	_	
53-22	10540-10544	task	_	
53-23	10544-10545	.	_	

#Text=After completion of each 16-word module, participants are asked to recall as many words as they remembered.
54-1	10546-10551	After	_	
54-2	10552-10562	completion	_	
54-3	10563-10565	of	_	
54-4	10566-10570	each	_	
54-5	10571-10573	16	_	
54-6	10573-10574	-	_	
54-7	10574-10578	word	_	
54-8	10579-10585	module	_	
54-9	10585-10586	,	_	
54-10	10587-10599	participants	_	
54-11	10600-10603	are	_	
54-12	10604-10609	asked	_	
54-13	10610-10612	to	_	
54-14	10613-10619	recall	_	
54-15	10620-10622	as	_	
54-16	10623-10627	many	_	
54-17	10628-10633	words	_	
54-18	10634-10636	as	_	
54-19	10637-10641	they	_	
54-20	10642-10652	remembered	_	
54-21	10652-10653	.	_	

#Text=Each list was repeated five times before moving to the next 16-word list.
55-1	10654-10658	Each	_	
55-2	10659-10663	list	_	
55-3	10664-10667	was	_	
55-4	10668-10676	repeated	_	
55-5	10677-10681	five	_	
55-6	10682-10687	times	_	
55-7	10688-10694	before	_	
55-8	10695-10701	moving	_	
55-9	10702-10704	to	_	
55-10	10705-10708	the	_	
55-11	10709-10713	next	_	
55-12	10714-10716	16	_	
55-13	10716-10717	-	_	
55-14	10717-10721	word	_	
55-15	10722-10726	list	_	
55-16	10726-10727	.	_	

#Text=Responses were scored for total number of correctly recalled words, recall by semantic clustering, recall by serial order, intrusions, and perseverations; each of these scores was averaged across trials.
56-1	10728-10737	Responses	_	
56-2	10738-10742	were	_	
56-3	10743-10749	scored	_	
56-4	10750-10753	for	_	
56-5	10754-10759	total	_	
56-6	10760-10766	number	_	
56-7	10767-10769	of	_	
56-8	10770-10779	correctly	_	
56-9	10780-10788	recalled	_	
56-10	10789-10794	words	_	
56-11	10794-10795	,	_	
56-12	10796-10802	recall	_	
56-13	10803-10805	by	_	
56-14	10806-10814	semantic	_	
56-15	10815-10825	clustering	_	
56-16	10825-10826	,	_	
56-17	10827-10833	recall	_	
56-18	10834-10836	by	_	
56-19	10837-10843	serial	_	
56-20	10844-10849	order	_	
56-21	10849-10850	,	_	
56-22	10851-10861	intrusions	_	
56-23	10861-10862	,	_	
56-24	10863-10866	and	_	
56-25	10867-10881	perseverations	_	
56-26	10881-10882	;	_	
56-27	10883-10887	each	_	
56-28	10888-10890	of	_	
56-29	10891-10896	these	_	
56-30	10897-10903	scores	_	
56-31	10904-10907	was	_	
56-32	10908-10916	averaged	_	
56-33	10917-10923	across	_	
56-34	10924-10930	trials	_	
56-35	10930-10931	.	_	

#Text=The semantic clustering score was defined as the number of contiguously recalled correct words from the same semantic category, yielding a maximum potential score of 12 clustered words per list.
57-1	10932-10935	The	_	
57-2	10936-10944	semantic	_	
57-3	10945-10955	clustering	_	
57-4	10956-10961	score	_	
57-5	10962-10965	was	_	
57-6	10966-10973	defined	_	
57-7	10974-10976	as	_	
57-8	10977-10980	the	_	
57-9	10981-10987	number	_	
57-10	10988-10990	of	_	
57-11	10991-11003	contiguously	_	
57-12	11004-11012	recalled	_	
57-13	11013-11020	correct	_	
57-14	11021-11026	words	_	
57-15	11027-11031	from	_	
57-16	11032-11035	the	_	
57-17	11036-11040	same	_	
57-18	11041-11049	semantic	_	
57-19	11050-11058	category	_	
57-20	11058-11059	,	_	
57-21	11060-11068	yielding	_	
57-22	11069-11070	a	_	
57-23	11071-11078	maximum	_	
57-24	11079-11088	potential	_	
57-25	11089-11094	score	_	
57-26	11095-11097	of	_	
57-27	11098-11100	12	_	
57-28	11101-11110	clustered	_	
57-29	11111-11116	words	_	
57-30	11117-11120	per	_	
57-31	11121-11125	list	_	
57-32	11125-11126	.	_	

#Text=The serial-order score was defined as the number of contiguously recalled items in the same relative order as presented on the list, yielding a maximum of 15 ordered words per list.
58-1	11127-11130	The	_	
58-2	11131-11143	serial-order	_	
58-3	11144-11149	score	_	
58-4	11150-11153	was	_	
58-5	11154-11161	defined	_	
58-6	11162-11164	as	_	
58-7	11165-11168	the	_	
58-8	11169-11175	number	_	
58-9	11176-11178	of	_	
58-10	11179-11191	contiguously	_	
58-11	11192-11200	recalled	_	
58-12	11201-11206	items	_	
58-13	11207-11209	in	_	
58-14	11210-11213	the	_	
58-15	11214-11218	same	_	
58-16	11219-11227	relative	_	
58-17	11228-11233	order	_	
58-18	11234-11236	as	_	
58-19	11237-11246	presented	_	
58-20	11247-11249	on	_	
58-21	11250-11253	the	_	
58-22	11254-11258	list	_	
58-23	11258-11259	,	_	
58-24	11260-11268	yielding	_	
58-25	11269-11270	a	_	
58-26	11271-11278	maximum	_	
58-27	11279-11281	of	_	
58-28	11282-11284	15	_	
58-29	11285-11292	ordered	_	
58-30	11293-11298	words	_	
58-31	11299-11302	per	_	
58-32	11303-11307	list	_	
58-33	11307-11308	.	_	

#Text=Intrusions were defined as the number of words named that did not appear on the current word list, and perseverations were defined as the number of words repeated within the same trial.
59-1	11309-11319	Intrusions	_	
59-2	11320-11324	were	_	
59-3	11325-11332	defined	_	
59-4	11333-11335	as	_	
59-5	11336-11339	the	_	
59-6	11340-11346	number	_	
59-7	11347-11349	of	_	
59-8	11350-11355	words	_	
59-9	11356-11361	named	_	
59-10	11362-11366	that	_	
59-11	11367-11370	did	_	
59-12	11371-11374	not	_	
59-13	11375-11381	appear	_	
59-14	11382-11384	on	_	
59-15	11385-11388	the	_	
59-16	11389-11396	current	_	
59-17	11397-11401	word	_	
59-18	11402-11406	list	_	
59-19	11406-11407	,	_	
59-20	11408-11411	and	_	
59-21	11412-11426	perseverations	_	
59-22	11427-11431	were	_	
59-23	11432-11439	defined	_	
59-24	11440-11442	as	_	
59-25	11443-11446	the	_	
59-26	11447-11453	number	_	
59-27	11454-11456	of	_	
59-28	11457-11462	words	_	
59-29	11463-11471	repeated	_	
59-30	11472-11478	within	_	
59-31	11479-11482	the	_	
59-32	11483-11487	same	_	
59-33	11488-11493	trial	_	
59-34	11493-11494	.	_	

#Text=T1-weighted MR images were acquired using a 1.5T Signa 5× scanner (GE Medical Systems) with a 3D-SPGR sequence (TR=24 msec, TE=5 msec, flip angle=40°, matrix size=256×256, field of view=23 cm, slice thickness=1.2 mm, total slices=128, NEX=1).
60-1	11495-11497	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[26]	
60-2	11497-11498	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[26]	
60-3	11498-11506	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[26]	
60-4	11507-11509	MR	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[27]	
60-5	11510-11516	images	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[27]	
60-6	11517-11521	were	_	
60-7	11522-11530	acquired	_	
60-8	11531-11536	using	_	
60-9	11537-11538	a	_	
60-10	11539-11543	1.5T	_	
60-11	11544-11549	Signa	_	
60-12	11550-11551	5	_	
60-13	11551-11552	×	_	
60-14	11553-11560	scanner	_	
60-15	11561-11562	(	_	
60-16	11562-11564	GE	_	
60-17	11565-11572	Medical	_	
60-18	11573-11580	Systems	_	
60-19	11580-11581	)	_	
60-20	11582-11586	with	_	
60-21	11587-11588	a	_	
60-22	11589-11596	3D-SPGR	_	
60-23	11597-11605	sequence	_	
60-24	11606-11607	(	_	
60-25	11607-11609	TR	_	
60-26	11609-11610	=	_	
60-27	11610-11612	24	_	
60-28	11613-11617	msec	_	
60-29	11617-11618	,	_	
60-30	11619-11621	TE	_	
60-31	11621-11622	=	_	
60-32	11622-11623	5	_	
60-33	11624-11628	msec	_	
60-34	11628-11629	,	_	
60-35	11630-11634	flip	_	
60-36	11635-11640	angle	_	
60-37	11640-11641	=	_	
60-38	11641-11643	40	_	
60-39	11643-11644	°	_	
60-40	11644-11645	,	_	
60-41	11646-11652	matrix	_	
60-42	11653-11657	size	_	
60-43	11657-11658	=	_	
60-44	11658-11661	256	_	
60-45	11661-11662	×	_	
60-46	11662-11665	256	_	
60-47	11665-11666	,	_	
60-48	11667-11672	field	_	
60-49	11673-11675	of	_	
60-50	11676-11680	view	_	
60-51	11680-11681	=	_	
60-52	11681-11683	23	_	
60-53	11684-11686	cm	_	
60-54	11686-11687	,	_	
60-55	11688-11693	slice	_	
60-56	11694-11703	thickness	_	
60-57	11703-11704	=	_	
60-58	11704-11707	1.2	_	
60-59	11708-11710	mm	_	
60-60	11710-11711	,	_	
60-61	11712-11717	total	_	
60-62	11718-11724	slices	_	
60-63	11724-11725	=	_	
60-64	11725-11728	128	_	
60-65	11728-11729	,	_	
60-66	11730-11733	NEX	_	
60-67	11733-11734	=	_	
60-68	11734-11735	1	_	
60-69	11735-11736	)	_	
60-70	11736-11737	.	_	

#Text=Anatomical SPGR MR images were resectioned to standard Talairach-Tournoux position using the protocol of and a 6-parameter rigid-body transformation.
61-1	11738-11748	Anatomical	_	
61-2	11749-11753	SPGR	_	
61-3	11754-11756	MR	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[28]	
61-4	11757-11763	images	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[28]	
61-5	11764-11768	were	_	
61-6	11769-11780	resectioned	_	
61-7	11781-11783	to	_	
61-8	11784-11792	standard	_	
61-9	11793-11811	Talairach-Tournoux	_	
61-10	11812-11820	position	_	
61-11	11821-11826	using	_	
61-12	11827-11830	the	_	
61-13	11831-11839	protocol	_	
61-14	11840-11842	of	_	
61-15	11843-11846	and	_	
61-16	11847-11848	a	_	
61-17	11849-11850	6	_	
61-18	11850-11851	-	_	
61-19	11851-11860	parameter	_	
61-20	11861-11871	rigid-body	_	
61-21	11872-11886	transformation	_	
61-22	11886-11887	.	_	

#Text=For analyses of 42 cortical Brodmann areas and subcortical structures we obtained FDG uptake values using the AFNI regions of interest.
62-1	11888-11891	For	_	
62-2	11892-11900	analyses	_	
62-3	11901-11903	of	_	
62-4	11904-11906	42	_	
62-5	11907-11915	cortical	_	
62-6	11916-11924	Brodmann	_	
62-7	11925-11930	areas	_	
62-8	11931-11934	and	_	
62-9	11935-11946	subcortical	_	
62-10	11947-11957	structures	_	
62-11	11958-11960	we	_	
62-12	11961-11969	obtained	_	
62-13	11970-11973	FDG	_	
62-14	11974-11980	uptake	_	
62-15	11981-11987	values	_	
62-16	11988-11993	using	_	
62-17	11994-11997	the	_	
62-18	11998-12002	AFNI	_	
62-19	12003-12010	regions	_	
62-20	12011-12013	of	_	
62-21	12014-12022	interest	_	
62-22	12022-12023	.	_	

#Text=Only the structures featured in published literature on ASD and schizophrenia were chosen for analyses.
63-1	12024-12028	Only	_	
63-2	12029-12032	the	_	
63-3	12033-12043	structures	_	
63-4	12044-12052	featured	_	
63-5	12053-12055	in	_	
63-6	12056-12065	published	_	
63-7	12066-12076	literature	_	
63-8	12077-12079	on	_	
63-9	12080-12083	ASD	http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder	
63-10	12084-12087	and	_	
63-11	12088-12101	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
63-12	12102-12106	were	_	
63-13	12107-12113	chosen	_	
63-14	12114-12117	for	_	
63-15	12118-12126	analyses	_	
63-16	12126-12127	.	_	

#Text=These included the amygdala, hippocampus, cerebellar subregions (tonsil, culmen, declive, tuber, and pyramis of the vermis), basal ganglia associates structures (head, body and tail of the caudate, putamen, lateral globus pallidus, medial globus pallidus, red nucleus, substantia nigra, claustrum), mammillary body, hypothalamus, whole thalamus and thalamic nuclei (pulvinar, anteroventral, lateral dorsal, ventral lateral, ventral posteromedial, lateral posterior, ventroposterior lateral, mediodorsal, as well as the anterior and midline nuclear groups).
64-1	12128-12133	These	_	
64-2	12134-12142	included	_	
64-3	12143-12146	the	_	
64-4	12147-12155	amygdala	_	
64-5	12155-12156	,	_	
64-6	12157-12168	hippocampus	_	
64-7	12168-12169	,	_	
64-8	12170-12180	cerebellar	_	
64-9	12181-12191	subregions	_	
64-10	12192-12193	(	_	
64-11	12193-12199	tonsil	_	
64-12	12199-12200	,	_	
64-13	12201-12207	culmen	_	
64-14	12207-12208	,	_	
64-15	12209-12216	declive	_	
64-16	12216-12217	,	_	
64-17	12218-12223	tuber	_	
64-18	12223-12224	,	_	
64-19	12225-12228	and	_	
64-20	12229-12236	pyramis	_	
64-21	12237-12239	of	_	
64-22	12240-12243	the	_	
64-23	12244-12250	vermis	_	
64-24	12250-12251	)	_	
64-25	12251-12252	,	_	
64-26	12253-12258	basal	_	
64-27	12259-12266	ganglia	_	
64-28	12267-12277	associates	_	
64-29	12278-12288	structures	_	
64-30	12289-12290	(	_	
64-31	12290-12294	head	_	
64-32	12294-12295	,	_	
64-33	12296-12300	body	_	
64-34	12301-12304	and	_	
64-35	12305-12309	tail	_	
64-36	12310-12312	of	_	
64-37	12313-12316	the	_	
64-38	12317-12324	caudate	_	
64-39	12324-12325	,	_	
64-40	12326-12333	putamen	_	
64-41	12333-12334	,	_	
64-42	12335-12342	lateral	_	
64-43	12343-12349	globus	_	
64-44	12350-12358	pallidus	_	
64-45	12358-12359	,	_	
64-46	12360-12366	medial	_	
64-47	12367-12373	globus	_	
64-48	12374-12382	pallidus	_	
64-49	12382-12383	,	_	
64-50	12384-12387	red	_	
64-51	12388-12395	nucleus	_	
64-52	12395-12396	,	_	
64-53	12397-12407	substantia	_	
64-54	12408-12413	nigra	_	
64-55	12413-12414	,	_	
64-56	12415-12424	claustrum	_	
64-57	12424-12425	)	_	
64-58	12425-12426	,	_	
64-59	12427-12437	mammillary	_	
64-60	12438-12442	body	_	
64-61	12442-12443	,	_	
64-62	12444-12456	hypothalamus	_	
64-63	12456-12457	,	_	
64-64	12458-12463	whole	_	
64-65	12464-12472	thalamus	_	
64-66	12473-12476	and	_	
64-67	12477-12485	thalamic	_	
64-68	12486-12492	nuclei	_	
64-69	12493-12494	(	_	
64-70	12494-12502	pulvinar	_	
64-71	12502-12503	,	_	
64-72	12504-12517	anteroventral	_	
64-73	12517-12518	,	_	
64-74	12519-12526	lateral	_	
64-75	12527-12533	dorsal	_	
64-76	12533-12534	,	_	
64-77	12535-12542	ventral	_	
64-78	12543-12550	lateral	_	
64-79	12550-12551	,	_	
64-80	12552-12559	ventral	_	
64-81	12560-12573	posteromedial	_	
64-82	12573-12574	,	_	
64-83	12575-12582	lateral	_	
64-84	12583-12592	posterior	_	
64-85	12592-12593	,	_	
64-86	12594-12609	ventroposterior	_	
64-87	12610-12617	lateral	_	
64-88	12617-12618	,	_	
64-89	12619-12630	mediodorsal	_	
64-90	12630-12631	,	_	
64-91	12632-12634	as	_	
64-92	12635-12639	well	_	
64-93	12640-12642	as	_	
64-94	12643-12646	the	_	
64-95	12647-12655	anterior	_	
64-96	12656-12659	and	_	
64-97	12660-12667	midline	_	
64-98	12668-12675	nuclear	_	
64-99	12676-12682	groups	_	
64-100	12682-12683	)	_	
64-101	12683-12684	.	_	

#Text=We normalized the images by dividing each voxel value by the mean value of the whole brain, masked with the MNI brain and using slices above MNI z=-53.
65-1	12685-12687	We	_	
65-2	12688-12698	normalized	_	
65-3	12699-12702	the	_	
65-4	12703-12709	images	_	
65-5	12710-12712	by	_	
65-6	12713-12721	dividing	_	
65-7	12722-12726	each	_	
65-8	12727-12732	voxel	_	
65-9	12733-12738	value	_	
65-10	12739-12741	by	_	
65-11	12742-12745	the	_	
65-12	12746-12750	mean	_	
65-13	12751-12756	value	_	
65-14	12757-12759	of	_	
65-15	12760-12763	the	_	
65-16	12764-12769	whole	_	
65-17	12770-12775	brain	_	
65-18	12775-12776	,	_	
65-19	12777-12783	masked	_	
65-20	12784-12788	with	_	
65-21	12789-12792	the	_	
65-22	12793-12796	MNI	_	
65-23	12797-12802	brain	_	
65-24	12803-12806	and	_	
65-25	12807-12812	using	_	
65-26	12813-12819	slices	_	
65-27	12820-12825	above	_	
65-28	12826-12829	MNI	_	
65-29	12830-12831	z	_	
65-30	12831-12832	=	_	
65-31	12832-12833	-	_	
65-32	12833-12835	53	_	
65-33	12835-12836	.	_	

#Text=A restricted vertical range was chosen to minimize errors in the brain extraction routine at low slice levels.
66-1	12837-12838	A	_	
66-2	12839-12849	restricted	_	
66-3	12850-12858	vertical	_	
66-4	12859-12864	range	_	
66-5	12865-12868	was	_	
66-6	12869-12875	chosen	_	
66-7	12876-12878	to	_	
66-8	12879-12887	minimize	_	
66-9	12888-12894	errors	_	
66-10	12895-12897	in	_	
66-11	12898-12901	the	_	
66-12	12902-12907	brain	_	
66-13	12908-12918	extraction	_	
66-14	12919-12926	routine	_	
66-15	12927-12929	at	_	
66-16	12930-12933	low	_	
66-17	12934-12939	slice	_	
66-18	12940-12946	levels	_	
66-19	12946-12947	.	_	

#Text=These relative metabolic rates were used in all analyses.
67-1	12948-12953	These	_	
67-2	12954-12962	relative	_	
67-3	12963-12972	metabolic	_	
67-4	12973-12978	rates	_	
67-5	12979-12983	were	_	
67-6	12984-12988	used	_	
67-7	12989-12991	in	_	
67-8	12992-12995	all	_	
67-9	12996-13004	analyses	_	
67-10	13004-13005	.	_	

#Text=Statistical analyses
#Text=Repeated-measures ANCOVA (with subjects’ age as a covariate) was used to ascertain significant patterns of differences in glucose metabolic rates among the three diagnostic groups and then for two-group comparisons (subjects with schizophrenia vs. subjects with ASD, subjects with schizophrenia vs. healthy controls, subjects with ASD vs. healthy controls).
68-1	13006-13017	Statistical	_	
68-2	13018-13026	analyses	_	
68-3	13027-13044	Repeated-measures	_	
68-4	13045-13051	ANCOVA	_	
68-5	13052-13053	(	_	
68-6	13053-13057	with	_	
68-7	13058-13066	subjects	_	
68-8	13066-13067	’	_	
68-9	13068-13071	age	_	
68-10	13072-13074	as	_	
68-11	13075-13076	a	_	
68-12	13077-13086	covariate	_	
68-13	13086-13087	)	_	
68-14	13088-13091	was	_	
68-15	13092-13096	used	_	
68-16	13097-13099	to	_	
68-17	13100-13109	ascertain	_	
68-18	13110-13121	significant	_	
68-19	13122-13130	patterns	_	
68-20	13131-13133	of	_	
68-21	13134-13145	differences	_	
68-22	13146-13148	in	_	
68-23	13149-13156	glucose	_	
68-24	13157-13166	metabolic	_	
68-25	13167-13172	rates	_	
68-26	13173-13178	among	_	
68-27	13179-13182	the	_	
68-28	13183-13188	three	_	
68-29	13189-13199	diagnostic	_	
68-30	13200-13206	groups	_	
68-31	13207-13210	and	_	
68-32	13211-13215	then	_	
68-33	13216-13219	for	_	
68-34	13220-13229	two-group	_	
68-35	13230-13241	comparisons	_	
68-36	13242-13243	(	_	
68-37	13243-13251	subjects	_	
68-38	13252-13256	with	_	
68-39	13257-13270	schizophrenia	_	
68-40	13271-13273	vs	_	
68-41	13273-13274	.	_	
68-42	13275-13283	subjects	_	
68-43	13284-13288	with	_	
68-44	13289-13292	ASD	_	
68-45	13292-13293	,	_	
68-46	13294-13302	subjects	_	
68-47	13303-13307	with	_	
68-48	13308-13321	schizophrenia	_	
68-49	13322-13324	vs	_	
68-50	13324-13325	.	_	
68-51	13326-13333	healthy	_	
68-52	13334-13342	controls	_	
68-53	13342-13343	,	_	
68-54	13344-13352	subjects	_	
68-55	13353-13357	with	_	
68-56	13358-13361	ASD	_	
68-57	13362-13364	vs	_	
68-58	13364-13365	.	_	
68-59	13366-13373	healthy	_	
68-60	13374-13382	controls	_	
68-61	13382-13383	)	_	
68-62	13383-13384	.	_	

#Text=For cortical analyses, metabolic rates for each of the 42 Brodmann areas were entered into an ANCOVA with repeated measures of hemisphere and Brodmann areas.
69-1	13385-13388	For	_	
69-2	13389-13397	cortical	_	
69-3	13398-13406	analyses	_	
69-4	13406-13407	,	_	
69-5	13408-13417	metabolic	_	
69-6	13418-13423	rates	_	
69-7	13424-13427	for	_	
69-8	13428-13432	each	_	
69-9	13433-13435	of	_	
69-10	13436-13439	the	_	
69-11	13440-13442	42	_	
69-12	13443-13451	Brodmann	_	
69-13	13452-13457	areas	_	
69-14	13458-13462	were	_	
69-15	13463-13470	entered	_	
69-16	13471-13475	into	_	
69-17	13476-13478	an	_	
69-18	13479-13485	ANCOVA	_	
69-19	13486-13490	with	_	
69-20	13491-13499	repeated	_	
69-21	13500-13508	measures	_	
69-22	13509-13511	of	_	
69-23	13512-13522	hemisphere	_	
69-24	13523-13526	and	_	
69-25	13527-13535	Brodmann	_	
69-26	13536-13541	areas	_	
69-27	13541-13542	.	_	

#Text=Main effects of diagnosis, as well as higher-order group-by-hemisphere and group-by-Brodmann area interactions were assessed for hemispheric and localized intergroup differences in metabolic rates.
70-1	13543-13547	Main	_	
70-2	13548-13555	effects	_	
70-3	13556-13558	of	_	
70-4	13559-13568	diagnosis	_	
70-5	13568-13569	,	_	
70-6	13570-13572	as	_	
70-7	13573-13577	well	_	
70-8	13578-13580	as	_	
70-9	13581-13593	higher-order	_	
70-10	13594-13613	group-by-hemisphere	_	
70-11	13614-13617	and	_	
70-12	13618-13635	group-by-Brodmann	_	
70-13	13636-13640	area	_	
70-14	13641-13653	interactions	_	
70-15	13654-13658	were	_	
70-16	13659-13667	assessed	_	
70-17	13668-13671	for	_	
70-18	13672-13683	hemispheric	_	
70-19	13684-13687	and	_	
70-20	13688-13697	localized	_	
70-21	13698-13708	intergroup	_	
70-22	13709-13720	differences	_	
70-23	13721-13723	in	_	
70-24	13724-13733	metabolic	_	
70-25	13734-13739	rates	_	
70-26	13739-13740	.	_	

#Text=These analyses of the whole cortex were followed by separate lobar analyses for constellations of Brodmann areas in each of the lobes, as well as the cingulate arch: 11 areas in the frontal lobe (4, 6, 8, 9, 10, 11, 12, 44, 45, 46, 47), 12 areas in the temporal lobe (20, 21, 22, 27, 28, 34, 35, 36, 37, 38, 41, 42), 8 areas in the parietal lobe (1, 2, 3, 5, 7, 39, 40, 43), 3 areas in the occipital lobe (17, 18, 19), and 8 areas in the cingulate (23, 24, 25, 29, 30, 31, 32, 33).
71-1	13741-13746	These	_	
71-2	13747-13755	analyses	_	
71-3	13756-13758	of	_	
71-4	13759-13762	the	_	
71-5	13763-13768	whole	_	
71-6	13769-13775	cortex	_	
71-7	13776-13780	were	_	
71-8	13781-13789	followed	_	
71-9	13790-13792	by	_	
71-10	13793-13801	separate	_	
71-11	13802-13807	lobar	_	
71-12	13808-13816	analyses	_	
71-13	13817-13820	for	_	
71-14	13821-13835	constellations	_	
71-15	13836-13838	of	_	
71-16	13839-13847	Brodmann	_	
71-17	13848-13853	areas	_	
71-18	13854-13856	in	_	
71-19	13857-13861	each	_	
71-20	13862-13864	of	_	
71-21	13865-13868	the	_	
71-22	13869-13874	lobes	_	
71-23	13874-13875	,	_	
71-24	13876-13878	as	_	
71-25	13879-13883	well	_	
71-26	13884-13886	as	_	
71-27	13887-13890	the	_	
71-28	13891-13900	cingulate	_	
71-29	13901-13905	arch	_	
71-30	13905-13906	:	_	
71-31	13907-13909	11	_	
71-32	13910-13915	areas	_	
71-33	13916-13918	in	_	
71-34	13919-13922	the	_	
71-35	13923-13930	frontal	_	
71-36	13931-13935	lobe	_	
71-37	13936-13937	(	_	
71-38	13937-13938	4	_	
71-39	13938-13939	,	_	
71-40	13940-13941	6	_	
71-41	13941-13942	,	_	
71-42	13943-13944	8	_	
71-43	13944-13945	,	_	
71-44	13946-13947	9	_	
71-45	13947-13948	,	_	
71-46	13949-13951	10	_	
71-47	13951-13952	,	_	
71-48	13953-13955	11	_	
71-49	13955-13956	,	_	
71-50	13957-13959	12	_	
71-51	13959-13960	,	_	
71-52	13961-13963	44	_	
71-53	13963-13964	,	_	
71-54	13965-13967	45	_	
71-55	13967-13968	,	_	
71-56	13969-13971	46	_	
71-57	13971-13972	,	_	
71-58	13973-13975	47	_	
71-59	13975-13976	)	_	
71-60	13976-13977	,	_	
71-61	13978-13980	12	_	
71-62	13981-13986	areas	_	
71-63	13987-13989	in	_	
71-64	13990-13993	the	_	
71-65	13994-14002	temporal	_	
71-66	14003-14007	lobe	_	
71-67	14008-14009	(	_	
71-68	14009-14011	20	_	
71-69	14011-14012	,	_	
71-70	14013-14015	21	_	
71-71	14015-14016	,	_	
71-72	14017-14019	22	_	
71-73	14019-14020	,	_	
71-74	14021-14023	27	_	
71-75	14023-14024	,	_	
71-76	14025-14027	28	_	
71-77	14027-14028	,	_	
71-78	14029-14031	34	_	
71-79	14031-14032	,	_	
71-80	14033-14035	35	_	
71-81	14035-14036	,	_	
71-82	14037-14039	36	_	
71-83	14039-14040	,	_	
71-84	14041-14043	37	_	
71-85	14043-14044	,	_	
71-86	14045-14047	38	_	
71-87	14047-14048	,	_	
71-88	14049-14051	41	_	
71-89	14051-14052	,	_	
71-90	14053-14055	42	_	
71-91	14055-14056	)	_	
71-92	14056-14057	,	_	
71-93	14058-14059	8	_	
71-94	14060-14065	areas	_	
71-95	14066-14068	in	_	
71-96	14069-14072	the	_	
71-97	14073-14081	parietal	_	
71-98	14082-14086	lobe	_	
71-99	14087-14088	(	_	
71-100	14088-14089	1	_	
71-101	14089-14090	,	_	
71-102	14091-14092	2	_	
71-103	14092-14093	,	_	
71-104	14094-14095	3	_	
71-105	14095-14096	,	_	
71-106	14097-14098	5	_	
71-107	14098-14099	,	_	
71-108	14100-14101	7	_	
71-109	14101-14102	,	_	
71-110	14103-14105	39	_	
71-111	14105-14106	,	_	
71-112	14107-14109	40	_	
71-113	14109-14110	,	_	
71-114	14111-14113	43	_	
71-115	14113-14114	)	_	
71-116	14114-14115	,	_	
71-117	14116-14117	3	_	
71-118	14118-14123	areas	_	
71-119	14124-14126	in	_	
71-120	14127-14130	the	_	
71-121	14131-14140	occipital	_	
71-122	14141-14145	lobe	_	
71-123	14146-14147	(	_	
71-124	14147-14149	17	_	
71-125	14149-14150	,	_	
71-126	14151-14153	18	_	
71-127	14153-14154	,	_	
71-128	14155-14157	19	_	
71-129	14157-14158	)	_	
71-130	14158-14159	,	_	
71-131	14160-14163	and	_	
71-132	14164-14165	8	_	
71-133	14166-14171	areas	_	
71-134	14172-14174	in	_	
71-135	14175-14178	the	_	
71-136	14179-14188	cingulate	_	
71-137	14189-14190	(	_	
71-138	14190-14192	23	_	
71-139	14192-14193	,	_	
71-140	14194-14196	24	_	
71-141	14196-14197	,	_	
71-142	14198-14200	25	_	
71-143	14200-14201	,	_	
71-144	14202-14204	29	_	
71-145	14204-14205	,	_	
71-146	14206-14208	30	_	
71-147	14208-14209	,	_	
71-148	14210-14212	31	_	
71-149	14212-14213	,	_	
71-150	14214-14216	32	_	
71-151	14216-14217	,	_	
71-152	14218-14220	33	_	
71-153	14220-14221	)	_	
71-154	14221-14222	.	_	

#Text=In addition to univariate F, multivariate Wilks’ λ statistics were documented for all higher-order (i.e. other than main effects) interactions.
72-1	14223-14225	In	_	
72-2	14226-14234	addition	_	
72-3	14235-14237	to	_	
72-4	14238-14248	univariate	_	
72-5	14249-14250	F	_	
72-6	14250-14251	,	_	
72-7	14252-14264	multivariate	_	
72-8	14265-14270	Wilks	_	
72-9	14270-14271	’	_	
72-10	14272-14273	λ	_	
72-11	14274-14284	statistics	_	
72-12	14285-14289	were	_	
72-13	14290-14300	documented	_	
72-14	14301-14304	for	_	
72-15	14305-14308	all	_	
72-16	14309-14321	higher-order	_	
72-17	14322-14323	(	_	
72-18	14323-14326	i.e	_	
72-19	14326-14327	.	_	
72-20	14328-14333	other	_	
72-21	14334-14338	than	_	
72-22	14339-14343	main	_	
72-23	14344-14351	effects	_	
72-24	14351-14352	)	_	
72-25	14353-14365	interactions	_	
72-26	14365-14366	.	_	

#Text=We selected the use of repeated measures MANOVA as our strategy to counteract the problem of multiple comparisons since it reduced their number to a single group-by-Brodmann area interaction, with visual assessment of the graphed patterns.
73-1	14367-14369	We	_	
73-2	14370-14378	selected	_	
73-3	14379-14382	the	_	
73-4	14383-14386	use	_	
73-5	14387-14389	of	_	
73-6	14390-14398	repeated	_	
73-7	14399-14407	measures	_	
73-8	14408-14414	MANOVA	_	
73-9	14415-14417	as	_	
73-10	14418-14421	our	_	
73-11	14422-14430	strategy	_	
73-12	14431-14433	to	_	
73-13	14434-14444	counteract	_	
73-14	14445-14448	the	_	
73-15	14449-14456	problem	_	
73-16	14457-14459	of	_	
73-17	14460-14468	multiple	_	
73-18	14469-14480	comparisons	_	
73-19	14481-14486	since	_	
73-20	14487-14489	it	_	
73-21	14490-14497	reduced	_	
73-22	14498-14503	their	_	
73-23	14504-14510	number	_	
73-24	14511-14513	to	_	
73-25	14514-14515	a	_	
73-26	14516-14522	single	_	
73-27	14523-14540	group-by-Brodmann	_	
73-28	14541-14545	area	_	
73-29	14546-14557	interaction	_	
73-30	14557-14558	,	_	
73-31	14559-14563	with	_	
73-32	14564-14570	visual	_	
73-33	14571-14581	assessment	_	
73-34	14582-14584	of	_	
73-35	14585-14588	the	_	
73-36	14589-14596	graphed	_	
73-37	14597-14605	patterns	_	
73-38	14605-14606	.	_	

#Text=For reference in the future replication studies, we do, however, report significant F statistics for follow-up three-group ANCOVAs on each of the individual Brodmann areas that emerge as differential in the inspection of the graphed patterns.
74-1	14607-14610	For	_	
74-2	14611-14620	reference	_	
74-3	14621-14623	in	_	
74-4	14624-14627	the	_	
74-5	14628-14634	future	_	
74-6	14635-14646	replication	_	
74-7	14647-14654	studies	_	
74-8	14654-14655	,	_	
74-9	14656-14658	we	_	
74-10	14659-14661	do	_	
74-11	14661-14662	,	_	
74-12	14663-14670	however	_	
74-13	14670-14671	,	_	
74-14	14672-14678	report	_	
74-15	14679-14690	significant	_	
74-16	14691-14692	F	_	
74-17	14693-14703	statistics	_	
74-18	14704-14707	for	_	
74-19	14708-14717	follow-up	_	
74-20	14718-14729	three-group	_	
74-21	14730-14737	ANCOVAs	_	
74-22	14738-14740	on	_	
74-23	14741-14745	each	_	
74-24	14746-14748	of	_	
74-25	14749-14752	the	_	
74-26	14753-14763	individual	_	
74-27	14764-14772	Brodmann	_	
74-28	14773-14778	areas	_	
74-29	14779-14783	that	_	
74-30	14784-14790	emerge	_	
74-31	14791-14793	as	_	
74-32	14794-14806	differential	_	
74-33	14807-14809	in	_	
74-34	14810-14813	the	_	
74-35	14814-14824	inspection	_	
74-36	14825-14827	of	_	
74-37	14828-14831	the	_	
74-38	14832-14839	graphed	_	
74-39	14840-14848	patterns	_	
74-40	14848-14849	.	_	

#Text=Similar analyses were used for comparisons of relevant subcortical structures, with evaluation of main effects of diagnosis for all of them and also diagnostic group-by-region interaction for subregions of the caudate.
75-1	14850-14857	Similar	_	
75-2	14858-14866	analyses	_	
75-3	14867-14871	were	_	
75-4	14872-14876	used	_	
75-5	14877-14880	for	_	
75-6	14881-14892	comparisons	_	
75-7	14893-14895	of	_	
75-8	14896-14904	relevant	_	
75-9	14905-14916	subcortical	_	
75-10	14917-14927	structures	_	
75-11	14927-14928	,	_	
75-12	14929-14933	with	_	
75-13	14934-14944	evaluation	_	
75-14	14945-14947	of	_	
75-15	14948-14952	main	_	
75-16	14953-14960	effects	_	
75-17	14961-14963	of	_	
75-18	14964-14973	diagnosis	_	
75-19	14974-14977	for	_	
75-20	14978-14981	all	_	
75-21	14982-14984	of	_	
75-22	14985-14989	them	_	
75-23	14990-14993	and	_	
75-24	14994-14998	also	_	
75-25	14999-15009	diagnostic	_	
75-26	15010-15025	group-by-region	_	
75-27	15026-15037	interaction	_	
75-28	15038-15041	for	_	
75-29	15042-15052	subregions	_	
75-30	15053-15055	of	_	
75-31	15056-15059	the	_	
75-32	15060-15067	caudate	_	
75-33	15067-15068	.	_	

#Text=Age was used as a covariate due to significant age differences among three groups of participants (ANOVA F2, 118=3.47, p=0.034).
76-1	15069-15072	Age	_	
76-2	15073-15076	was	_	
76-3	15077-15081	used	_	
76-4	15082-15084	as	_	
76-5	15085-15086	a	_	
76-6	15087-15096	covariate	_	
76-7	15097-15100	due	_	
76-8	15101-15103	to	_	
76-9	15104-15115	significant	_	
76-10	15116-15119	age	_	
76-11	15120-15131	differences	_	
76-12	15132-15137	among	_	
76-13	15138-15143	three	_	
76-14	15144-15150	groups	_	
76-15	15151-15153	of	_	
76-16	15154-15166	participants	_	
76-17	15167-15168	(	_	
76-18	15168-15173	ANOVA	_	
76-19	15174-15176	F2	_	
76-20	15176-15177	,	_	
76-21	15178-15181	118	_	
76-22	15181-15182	=	_	
76-23	15182-15186	3.47	_	
76-24	15186-15187	,	_	
76-25	15188-15189	p	_	
76-26	15189-15190	=	_	
76-27	15190-15195	0.034	_	
76-28	15195-15196	)	_	
76-29	15196-15197	.	_	

#Text=We supplement these results (Tables 1 and 2) with ANOVAs without controlling for age as illustrated in Figures 1–4, because different age trajectories of ASD and schizophrenia may potentially render ANCOVA correction confounded.
77-1	15198-15200	We	_	
77-2	15201-15211	supplement	_	
77-3	15212-15217	these	_	
77-4	15218-15225	results	_	
77-5	15226-15227	(	_	
77-6	15227-15233	Tables	_	
77-7	15234-15235	1	_	
77-8	15236-15239	and	_	
77-9	15240-15241	2	_	
77-10	15241-15242	)	_	
77-11	15243-15247	with	_	
77-12	15248-15254	ANOVAs	_	
77-13	15255-15262	without	_	
77-14	15263-15274	controlling	_	
77-15	15275-15278	for	_	
77-16	15279-15282	age	_	
77-17	15283-15285	as	_	
77-18	15286-15297	illustrated	_	
77-19	15298-15300	in	_	
77-20	15301-15308	Figures	_	
77-21	15309-15310	1	_	
77-22	15310-15311	–	_	
77-23	15311-15312	4	_	
77-24	15312-15313	,	_	
77-25	15314-15321	because	_	
77-26	15322-15331	different	_	
77-27	15332-15335	age	_	
77-28	15336-15348	trajectories	_	
77-29	15349-15351	of	_	
77-30	15352-15355	ASD	_	
77-31	15356-15359	and	_	
77-32	15360-15373	schizophrenia	_	
77-33	15374-15377	may	_	
77-34	15378-15389	potentially	_	
77-35	15390-15396	render	_	
77-36	15397-15403	ANCOVA	_	
77-37	15404-15414	correction	_	
77-38	15415-15425	confounded	_	
77-39	15425-15426	.	_	

#Text=We report all 42 Brodmann areas and 16 subcortical structures to provide a systematic database (Table 1).
78-1	15427-15429	We	_	
78-2	15430-15436	report	_	
78-3	15437-15440	all	_	
78-4	15441-15443	42	_	
78-5	15444-15452	Brodmann	_	
78-6	15453-15458	areas	_	
78-7	15459-15462	and	_	
78-8	15463-15465	16	_	
78-9	15466-15477	subcortical	_	
78-10	15478-15488	structures	_	
78-11	15489-15491	to	_	
78-12	15492-15499	provide	_	
78-13	15500-15501	a	_	
78-14	15502-15512	systematic	_	
78-15	15513-15521	database	_	
78-16	15522-15523	(	_	
78-17	15523-15528	Table	_	
78-18	15529-15530	1	_	
78-19	15530-15531	)	_	
78-20	15531-15532	.	_	

#Text=Since earlier studies have tended to emphasize frontal, thalamic and striatal differences in subjects with schizophrenia and cingulate, parietal and cerebellar differences in ASD, a wide region of interest selection was important for the three-group analyses.
79-1	15533-15538	Since	_	
79-2	15539-15546	earlier	_	
79-3	15547-15554	studies	_	
79-4	15555-15559	have	_	
79-5	15560-15566	tended	_	
79-6	15567-15569	to	_	
79-7	15570-15579	emphasize	_	
79-8	15580-15587	frontal	_	
79-9	15587-15588	,	_	
79-10	15589-15597	thalamic	_	
79-11	15598-15601	and	_	
79-12	15602-15610	striatal	_	
79-13	15611-15622	differences	_	
79-14	15623-15625	in	_	
79-15	15626-15634	subjects	_	
79-16	15635-15639	with	_	
79-17	15640-15653	schizophrenia	_	
79-18	15654-15657	and	_	
79-19	15658-15667	cingulate	_	
79-20	15667-15668	,	_	
79-21	15669-15677	parietal	_	
79-22	15678-15681	and	_	
79-23	15682-15692	cerebellar	_	
79-24	15693-15704	differences	_	
79-25	15705-15707	in	_	
79-26	15708-15711	ASD	_	
79-27	15711-15712	,	_	
79-28	15713-15714	a	_	
79-29	15715-15719	wide	_	
79-30	15720-15726	region	_	
79-31	15727-15729	of	_	
79-32	15730-15738	interest	_	
79-33	15739-15748	selection	_	
79-34	15749-15752	was	_	
79-35	15753-15762	important	_	
79-36	15763-15766	for	_	
79-37	15767-15770	the	_	
79-38	15771-15782	three-group	_	
79-39	15783-15791	analyses	_	
79-40	15791-15792	.	_	

#Text=Since a number of studies have reported multiple regions of significant differences in two-group analyses, we have reported uncorrected, Bonferroni corrected, and MANOVA repeated measures interactions to provide control of Type I and II error.
80-1	15793-15798	Since	_	
80-2	15799-15800	a	_	
80-3	15801-15807	number	_	
80-4	15808-15810	of	_	
80-5	15811-15818	studies	_	
80-6	15819-15823	have	_	
80-7	15824-15832	reported	_	
80-8	15833-15841	multiple	_	
80-9	15842-15849	regions	_	
80-10	15850-15852	of	_	
80-11	15853-15864	significant	_	
80-12	15865-15876	differences	_	
80-13	15877-15879	in	_	
80-14	15880-15889	two-group	_	
80-15	15890-15898	analyses	_	
80-16	15898-15899	,	_	
80-17	15900-15902	we	_	
80-18	15903-15907	have	_	
80-19	15908-15916	reported	_	
80-20	15917-15928	uncorrected	_	
80-21	15928-15929	,	_	
80-22	15930-15940	Bonferroni	_	
80-23	15941-15950	corrected	_	
80-24	15950-15951	,	_	
80-25	15952-15955	and	_	
80-26	15956-15962	MANOVA	_	
80-27	15963-15971	repeated	_	
80-28	15972-15980	measures	_	
80-29	15981-15993	interactions	_	
80-30	15994-15996	to	_	
80-31	15997-16004	provide	_	
80-32	16005-16012	control	_	
80-33	16013-16015	of	_	
80-34	16016-16020	Type	_	
80-35	16021-16022	I	_	
80-36	16023-16026	and	_	
80-37	16027-16029	II	_	
80-38	16030-16035	error	_	
80-39	16035-16036	.	_	

#Text=We applied two strategies in correcting for multiple region testing and the problem of type I error.
81-1	16037-16039	We	_	
81-2	16040-16047	applied	_	
81-3	16048-16051	two	_	
81-4	16052-16062	strategies	_	
81-5	16063-16065	in	_	
81-6	16066-16076	correcting	_	
81-7	16077-16080	for	_	
81-8	16081-16089	multiple	_	
81-9	16090-16096	region	_	
81-10	16097-16104	testing	_	
81-11	16105-16108	and	_	
81-12	16109-16112	the	_	
81-13	16113-16120	problem	_	
81-14	16121-16123	of	_	
81-15	16124-16128	type	_	
81-16	16129-16130	I	_	
81-17	16131-16136	error	_	
81-18	16136-16137	.	_	

#Text=First, we entered the entire cortical dataset into an all-data ANOVA (42 Brodmann areas × three diagnostic groups × two hemispheres).
82-1	16138-16143	First	_	
82-2	16143-16144	,	_	
82-3	16145-16147	we	_	
82-4	16148-16155	entered	_	
82-5	16156-16159	the	_	
82-6	16160-16166	entire	_	
82-7	16167-16175	cortical	_	
82-8	16176-16183	dataset	_	
82-9	16184-16188	into	_	
82-10	16189-16191	an	_	
82-11	16192-16200	all-data	_	
82-12	16201-16206	ANOVA	_	
82-13	16207-16208	(	_	
82-14	16208-16210	42	_	
82-15	16211-16219	Brodmann	_	
82-16	16220-16225	areas	_	
82-17	16226-16227	×	_	
82-18	16228-16233	three	_	
82-19	16234-16244	diagnostic	_	
82-20	16245-16251	groups	_	
82-21	16252-16253	×	_	
82-22	16254-16257	two	_	
82-23	16258-16269	hemispheres	_	
82-24	16269-16270	)	_	
82-25	16270-16271	.	_	

#Text=If this was significant at the p<0.05 level, we then examined follow-up ANOVA for specific brain lobes considering main effect of group and group×Brodmann area interaction (two tests).
83-1	16272-16274	If	_	
83-2	16275-16279	this	_	
83-3	16280-16283	was	_	
83-4	16284-16295	significant	_	
83-5	16296-16298	at	_	
83-6	16299-16302	the	_	
83-7	16303-16304	p	_	
83-8	16304-16305	<	_	
83-9	16305-16309	0.05	_	
83-10	16310-16315	level	_	
83-11	16315-16316	,	_	
83-12	16317-16319	we	_	
83-13	16320-16324	then	_	
83-14	16325-16333	examined	_	
83-15	16334-16343	follow-up	_	
83-16	16344-16349	ANOVA	_	
83-17	16350-16353	for	_	
83-18	16354-16362	specific	_	
83-19	16363-16368	brain	_	
83-20	16369-16374	lobes	_	
83-21	16375-16386	considering	_	
83-22	16387-16391	main	_	
83-23	16392-16398	effect	_	
83-24	16399-16401	of	_	
83-25	16402-16407	group	_	
83-26	16408-16411	and	_	
83-27	16412-16417	group	_	
83-28	16417-16418	×	_	
83-29	16418-16426	Brodmann	_	
83-30	16427-16431	area	_	
83-31	16432-16443	interaction	_	
83-32	16444-16445	(	_	
83-33	16445-16448	two	_	
83-34	16449-16454	tests	_	
83-35	16454-16455	)	_	
83-36	16455-16456	.	_	

#Text=However, since individual t-tests are most commonly reported in the literature we also examined follow-up group–pair ANOVA and t-tests.
84-1	16457-16464	However	_	
84-2	16464-16465	,	_	
84-3	16466-16471	since	_	
84-4	16472-16482	individual	_	
84-5	16483-16490	t-tests	_	
84-6	16491-16494	are	_	
84-7	16495-16499	most	_	
84-8	16500-16508	commonly	_	
84-9	16509-16517	reported	_	
84-10	16518-16520	in	_	
84-11	16521-16524	the	_	
84-12	16525-16535	literature	_	
84-13	16536-16538	we	_	
84-14	16539-16543	also	_	
84-15	16544-16552	examined	_	
84-16	16553-16562	follow-up	_	
84-17	16563-16573	group–pair	_	
84-18	16574-16579	ANOVA	_	
84-19	16580-16583	and	_	
84-20	16584-16591	t-tests	_	
84-21	16591-16592	.	_	

#Text=For patients vs. healthy controls comparison we computed the Bonferroni correction based on the number of variables in the cortex and subcortical regions separately because published literature values have been reported for single structures and single hemispheres, typically in separate reports.
85-1	16593-16596	For	_	
85-2	16597-16605	patients	_	
85-3	16606-16608	vs	_	
85-4	16608-16609	.	_	
85-5	16610-16617	healthy	_	
85-6	16618-16626	controls	_	
85-7	16627-16637	comparison	_	
85-8	16638-16640	we	_	
85-9	16641-16649	computed	_	
85-10	16650-16653	the	_	
85-11	16654-16664	Bonferroni	_	
85-12	16665-16675	correction	_	
85-13	16676-16681	based	_	
85-14	16682-16684	on	_	
85-15	16685-16688	the	_	
85-16	16689-16695	number	_	
85-17	16696-16698	of	_	
85-18	16699-16708	variables	_	
85-19	16709-16711	in	_	
85-20	16712-16715	the	_	
85-21	16716-16722	cortex	_	
85-22	16723-16726	and	_	
85-23	16727-16738	subcortical	_	
85-24	16739-16746	regions	_	
85-25	16747-16757	separately	_	
85-26	16758-16765	because	_	
85-27	16766-16775	published	_	
85-28	16776-16786	literature	_	
85-29	16787-16793	values	_	
85-30	16794-16798	have	_	
85-31	16799-16803	been	_	
85-32	16804-16812	reported	_	
85-33	16813-16816	for	_	
85-34	16817-16823	single	_	
85-35	16824-16834	structures	_	
85-36	16835-16838	and	_	
85-37	16839-16845	single	_	
85-38	16846-16857	hemispheres	_	
85-39	16857-16858	,	_	
85-40	16859-16868	typically	_	
85-41	16869-16871	in	_	
85-42	16872-16880	separate	_	
85-43	16881-16888	reports	_	
85-44	16888-16889	.	_	

#Text=An alternative was to compute the denominator based on the three-group comparison and the three two-group comparisons (variables×4).
86-1	16890-16892	An	_	
86-2	16893-16904	alternative	_	
86-3	16905-16908	was	_	
86-4	16909-16911	to	_	
86-5	16912-16919	compute	_	
86-6	16920-16923	the	_	
86-7	16924-16935	denominator	_	
86-8	16936-16941	based	_	
86-9	16942-16944	on	_	
86-10	16945-16948	the	_	
86-11	16949-16960	three-group	_	
86-12	16961-16971	comparison	_	
86-13	16972-16975	and	_	
86-14	16976-16979	the	_	
86-15	16980-16985	three	_	
86-16	16986-16995	two-group	_	
86-17	16996-17007	comparisons	_	
86-18	17008-17009	(	_	
86-19	17009-17018	variables	_	
86-20	17018-17019	×	_	
86-21	17019-17020	4	_	
86-22	17020-17021	)	_	
86-23	17021-17022	.	_	

#Text=However, this strategy could have been considered spuriously conservative since it would be associated with a false failure to replicate published findings.
87-1	17023-17030	However	_	
87-2	17030-17031	,	_	
87-3	17032-17036	this	_	
87-4	17037-17045	strategy	_	
87-5	17046-17051	could	_	
87-6	17052-17056	have	_	
87-7	17057-17061	been	_	
87-8	17062-17072	considered	_	
87-9	17073-17083	spuriously	_	
87-10	17084-17096	conservative	_	
87-11	17097-17102	since	_	
87-12	17103-17105	it	_	
87-13	17106-17111	would	_	
87-14	17112-17114	be	_	
87-15	17115-17125	associated	_	
87-16	17126-17130	with	_	
87-17	17131-17132	a	_	
87-18	17133-17138	false	_	
87-19	17139-17146	failure	_	
87-20	17147-17149	to	_	
87-21	17150-17159	replicate	_	
87-22	17160-17169	published	_	
87-23	17170-17178	findings	_	
87-24	17178-17179	.	_	

#Text=Therefore, we present all data both as p<0.05 as replication and Bonferroni corrected for multiple structures.
88-1	17180-17189	Therefore	_	
88-2	17189-17190	,	_	
88-3	17191-17193	we	_	
88-4	17194-17201	present	_	
88-5	17202-17205	all	_	
88-6	17206-17210	data	_	
88-7	17211-17215	both	_	
88-8	17216-17218	as	_	
88-9	17219-17220	p	_	
88-10	17220-17221	<	_	
88-11	17221-17225	0.05	_	
88-12	17226-17228	as	_	
88-13	17229-17240	replication	_	
88-14	17241-17244	and	_	
88-15	17245-17255	Bonferroni	_	
88-16	17256-17265	corrected	_	
88-17	17266-17269	for	_	
88-18	17270-17278	multiple	_	
88-19	17279-17289	structures	_	
88-20	17289-17290	.	_	

#Text=Results
#Text=Subjects with ASD and schizophrenia vs. healthy controls
#Text=Based on the three-group MANCOVA with repeated measures of hemisphere and Brodmann areas, comparing FDG metabolic rates across all 42 Brodmann areas in subjects with ASD, schizophrenia and healthy controls, there emerged a divergent pattern of greater-than-normal rates in those with schizophrenia and lower-than-normal rates in those with ASD in the precentral/postcentral region comprising areas 2, 3, 4, and 5 (Tables 1 and 2, Fig. 1).
89-1	17291-17298	Results	_	
89-2	17299-17307	Subjects	_	
89-3	17308-17312	with	_	
89-4	17313-17316	ASD	_	
89-5	17317-17320	and	_	
89-6	17321-17334	schizophrenia	_	
89-7	17335-17337	vs	_	
89-8	17337-17338	.	_	
89-9	17339-17346	healthy	_	
89-10	17347-17355	controls	_	
89-11	17356-17361	Based	_	
89-12	17362-17364	on	_	
89-13	17365-17368	the	_	
89-14	17369-17380	three-group	_	
89-15	17381-17388	MANCOVA	_	
89-16	17389-17393	with	_	
89-17	17394-17402	repeated	_	
89-18	17403-17411	measures	_	
89-19	17412-17414	of	_	
89-20	17415-17425	hemisphere	_	
89-21	17426-17429	and	_	
89-22	17430-17438	Brodmann	_	
89-23	17439-17444	areas	_	
89-24	17444-17445	,	_	
89-25	17446-17455	comparing	_	
89-26	17456-17459	FDG	_	
89-27	17460-17469	metabolic	_	
89-28	17470-17475	rates	_	
89-29	17476-17482	across	_	
89-30	17483-17486	all	_	
89-31	17487-17489	42	_	
89-32	17490-17498	Brodmann	_	
89-33	17499-17504	areas	_	
89-34	17505-17507	in	_	
89-35	17508-17516	subjects	_	
89-36	17517-17521	with	_	
89-37	17522-17525	ASD	_	
89-38	17525-17526	,	_	
89-39	17527-17540	schizophrenia	_	
89-40	17541-17544	and	_	
89-41	17545-17552	healthy	_	
89-42	17553-17561	controls	_	
89-43	17561-17562	,	_	
89-44	17563-17568	there	_	
89-45	17569-17576	emerged	_	
89-46	17577-17578	a	_	
89-47	17579-17588	divergent	_	
89-48	17589-17596	pattern	_	
89-49	17597-17599	of	_	
89-50	17600-17619	greater-than-normal	_	
89-51	17620-17625	rates	_	
89-52	17626-17628	in	_	
89-53	17629-17634	those	_	
89-54	17635-17639	with	_	
89-55	17640-17653	schizophrenia	_	
89-56	17654-17657	and	_	
89-57	17658-17675	lower-than-normal	_	
89-58	17676-17681	rates	_	
89-59	17682-17684	in	_	
89-60	17685-17690	those	_	
89-61	17691-17695	with	_	
89-62	17696-17699	ASD	_	
89-63	17700-17702	in	_	
89-64	17703-17706	the	_	
89-65	17707-17717	precentral	_	
89-66	17717-17718	/	_	
89-67	17718-17729	postcentral	_	
89-68	17730-17736	region	_	
89-69	17737-17747	comprising	_	
89-70	17748-17753	areas	_	
89-71	17754-17755	2	_	
89-72	17755-17756	,	_	
89-73	17757-17758	3	_	
89-74	17758-17759	,	_	
89-75	17760-17761	4	_	
89-76	17761-17762	,	_	
89-77	17763-17766	and	_	
89-78	17767-17768	5	_	
89-79	17769-17770	(	_	
89-80	17770-17776	Tables	_	
89-81	17777-17778	1	_	
89-82	17779-17782	and	_	
89-83	17783-17784	2	_	
89-84	17784-17785	,	_	
89-85	17786-17789	Fig	_	
89-86	17789-17790	.	_	
89-87	17791-17792	1	_	
89-88	17792-17793	)	_	
89-89	17793-17794	.	_	

#Text=Follow-up analysis of the precentral/postcentral region confirmed significant intergroup differences (Fig. 2).
90-1	17795-17804	Follow-up	_	
90-2	17805-17813	analysis	_	
90-3	17814-17816	of	_	
90-4	17817-17820	the	_	
90-5	17821-17831	precentral	_	
90-6	17831-17832	/	_	
90-7	17832-17843	postcentral	_	
90-8	17844-17850	region	_	
90-9	17851-17860	confirmed	_	
90-10	17861-17872	significant	_	
90-11	17873-17883	intergroup	_	
90-12	17884-17895	differences	_	
90-13	17896-17897	(	_	
90-14	17897-17900	Fig	_	
90-15	17900-17901	.	_	
90-16	17902-17903	2	_	
90-17	17903-17904	)	_	
90-18	17904-17905	.	_	

#Text=The reversed pattern of greater-than-normal rates in ASD and lower-than-normal rates in schizophrenia was observed in the anterior cingulate (contiguous areas 33 and 32), to a lesser degree frontal area 9.
91-1	17906-17909	The	_	
91-2	17910-17918	reversed	_	
91-3	17919-17926	pattern	_	
91-4	17927-17929	of	_	
91-5	17930-17949	greater-than-normal	_	
91-6	17950-17955	rates	_	
91-7	17956-17958	in	_	
91-8	17959-17962	ASD	_	
91-9	17963-17966	and	_	
91-10	17967-17984	lower-than-normal	_	
91-11	17985-17990	rates	_	
91-12	17991-17993	in	_	
91-13	17994-18007	schizophrenia	_	
91-14	18008-18011	was	_	
91-15	18012-18020	observed	_	
91-16	18021-18023	in	_	
91-17	18024-18027	the	_	
91-18	18028-18036	anterior	_	
91-19	18037-18046	cingulate	_	
91-20	18047-18048	(	_	
91-21	18048-18058	contiguous	_	
91-22	18059-18064	areas	_	
91-23	18065-18067	33	_	
91-24	18068-18071	and	_	
91-25	18072-18074	32	_	
91-26	18074-18075	)	_	
91-27	18075-18076	,	_	
91-28	18077-18079	to	_	
91-29	18080-18081	a	_	
91-30	18082-18088	lesser	_	
91-31	18089-18095	degree	_	
91-32	18096-18103	frontal	_	
91-33	18104-18108	area	_	
91-34	18109-18110	9	_	
91-35	18110-18111	.	_	

#Text=Both subjects with schizophrenia and ASD showed lower-than-normal metabolic rates in a vast frontal region comprising areas 8, 10, 11, 45, 46, and 47 (more pronounced in those with schizophrenia), as well as contiguous parietal areas 39 and 40 (more pronounced in those with ASD).
92-1	18112-18116	Both	_	
92-2	18117-18125	subjects	_	
92-3	18126-18130	with	_	
92-4	18131-18144	schizophrenia	_	
92-5	18145-18148	and	_	
92-6	18149-18152	ASD	_	
92-7	18153-18159	showed	_	
92-8	18160-18177	lower-than-normal	_	
92-9	18178-18187	metabolic	_	
92-10	18188-18193	rates	_	
92-11	18194-18196	in	_	
92-12	18197-18198	a	_	
92-13	18199-18203	vast	_	
92-14	18204-18211	frontal	_	
92-15	18212-18218	region	_	
92-16	18219-18229	comprising	_	
92-17	18230-18235	areas	_	
92-18	18236-18237	8	_	
92-19	18237-18238	,	_	
92-20	18239-18241	10	_	
92-21	18241-18242	,	_	
92-22	18243-18245	11	_	
92-23	18245-18246	,	_	
92-24	18247-18249	45	_	
92-25	18249-18250	,	_	
92-26	18251-18253	46	_	
92-27	18253-18254	,	_	
92-28	18255-18258	and	_	
92-29	18259-18261	47	_	
92-30	18262-18263	(	_	
92-31	18263-18267	more	_	
92-32	18268-18278	pronounced	_	
92-33	18279-18281	in	_	
92-34	18282-18287	those	_	
92-35	18288-18292	with	_	
92-36	18293-18306	schizophrenia	_	
92-37	18306-18307	)	_	
92-38	18307-18308	,	_	
92-39	18309-18311	as	_	
92-40	18312-18316	well	_	
92-41	18317-18319	as	_	
92-42	18320-18330	contiguous	_	
92-43	18331-18339	parietal	_	
92-44	18340-18345	areas	_	
92-45	18346-18348	39	_	
92-46	18349-18352	and	_	
92-47	18353-18355	40	_	
92-48	18356-18357	(	_	
92-49	18357-18361	more	_	
92-50	18362-18372	pronounced	_	
92-51	18373-18375	in	_	
92-52	18376-18381	those	_	
92-53	18382-18386	with	_	
92-54	18387-18390	ASD	_	
92-55	18390-18391	)	_	
92-56	18391-18392	.	_	

#Text=Both patient groups had higher-than-normal metabolic rates in occipital areas 17 and 18.
93-1	18393-18397	Both	_	
93-2	18398-18405	patient	_	
93-3	18406-18412	groups	_	
93-4	18413-18416	had	_	
93-5	18417-18435	higher-than-normal	_	
93-6	18436-18445	metabolic	_	
93-7	18446-18451	rates	_	
93-8	18452-18454	in	_	
93-9	18455-18464	occipital	_	
93-10	18465-18470	areas	_	
93-11	18471-18473	17	_	
93-12	18474-18477	and	_	
93-13	18478-18480	18	_	
93-14	18480-18481	.	_	

#Text=Metabolic rates in postcentral areas 1 and 7 were decreased only in subjects with ASD and not in those with schizophrenia.
94-1	18482-18491	Metabolic	_	
94-2	18492-18497	rates	_	
94-3	18498-18500	in	_	
94-4	18501-18512	postcentral	_	
94-5	18513-18518	areas	_	
94-6	18519-18520	1	_	
94-7	18521-18524	and	_	
94-8	18525-18526	7	_	
94-9	18527-18531	were	_	
94-10	18532-18541	decreased	_	
94-11	18542-18546	only	_	
94-12	18547-18549	in	_	
94-13	18550-18558	subjects	_	
94-14	18559-18563	with	_	
94-15	18564-18567	ASD	_	
94-16	18568-18571	and	_	
94-17	18572-18575	not	_	
94-18	18576-18578	in	_	
94-19	18579-18584	those	_	
94-20	18585-18589	with	_	
94-21	18590-18603	schizophrenia	_	
94-22	18603-18604	.	_	

#Text=This overarching MANCOVA was followed by lobar analyses, which produced two significant main effects of diagnosis.
95-1	18605-18609	This	_	
95-2	18610-18621	overarching	_	
95-3	18622-18629	MANCOVA	_	
95-4	18630-18633	was	_	
95-5	18634-18642	followed	_	
95-6	18643-18645	by	_	
95-7	18646-18651	lobar	_	
95-8	18652-18660	analyses	_	
95-9	18660-18661	,	_	
95-10	18662-18667	which	_	
95-11	18668-18676	produced	_	
95-12	18677-18680	two	_	
95-13	18681-18692	significant	_	
95-14	18693-18697	main	_	
95-15	18698-18705	effects	_	
95-16	18706-18708	of	_	
95-17	18709-18718	diagnosis	_	
95-18	18718-18719	.	_	

#Text=In the frontal lobe (average for all 11 Brodmann areas), these results indicated lower metabolic rates in subjects with schizophrenia than in those with ASD and healthy controls (with no appreciable differences between the latter two groups).
96-1	18720-18722	In	_	
96-2	18723-18726	the	_	
96-3	18727-18734	frontal	_	
96-4	18735-18739	lobe	_	
96-5	18740-18741	(	_	
96-6	18741-18748	average	_	
96-7	18749-18752	for	_	
96-8	18753-18756	all	_	
96-9	18757-18759	11	_	
96-10	18760-18768	Brodmann	_	
96-11	18769-18774	areas	_	
96-12	18774-18775	)	_	
96-13	18775-18776	,	_	
96-14	18777-18782	these	_	
96-15	18783-18790	results	_	
96-16	18791-18800	indicated	_	
96-17	18801-18806	lower	_	
96-18	18807-18816	metabolic	_	
96-19	18817-18822	rates	_	
96-20	18823-18825	in	_	
96-21	18826-18834	subjects	_	
96-22	18835-18839	with	_	
96-23	18840-18853	schizophrenia	_	
96-24	18854-18858	than	_	
96-25	18859-18861	in	_	
96-26	18862-18867	those	_	
96-27	18868-18872	with	_	
96-28	18873-18876	ASD	_	
96-29	18877-18880	and	_	
96-30	18881-18888	healthy	_	
96-31	18889-18897	controls	_	
96-32	18898-18899	(	_	
96-33	18899-18903	with	_	
96-34	18904-18906	no	_	
96-35	18907-18918	appreciable	_	
96-36	18919-18930	differences	_	
96-37	18931-18938	between	_	
96-38	18939-18942	the	_	
96-39	18943-18949	latter	_	
96-40	18950-18953	two	_	
96-41	18954-18960	groups	_	
96-42	18960-18961	)	_	
96-43	18961-18962	.	_	

#Text=In the parietal lobe (average for all 8 Brodmann areas), significant main effect indicated lower metabolic rates in subjects with ASD than in those with schizophrenia and healthy controls (with no differences between the latter two groups).
97-1	18963-18965	In	_	
97-2	18966-18969	the	_	
97-3	18970-18978	parietal	_	
97-4	18979-18983	lobe	_	
97-5	18984-18985	(	_	
97-6	18985-18992	average	_	
97-7	18993-18996	for	_	
97-8	18997-19000	all	_	
97-9	19001-19002	8	_	
97-10	19003-19011	Brodmann	_	
97-11	19012-19017	areas	_	
97-12	19017-19018	)	_	
97-13	19018-19019	,	_	
97-14	19020-19031	significant	_	
97-15	19032-19036	main	_	
97-16	19037-19043	effect	_	
97-17	19044-19053	indicated	_	
97-18	19054-19059	lower	_	
97-19	19060-19069	metabolic	_	
97-20	19070-19075	rates	_	
97-21	19076-19078	in	_	
97-22	19079-19087	subjects	_	
97-23	19088-19092	with	_	
97-24	19093-19096	ASD	_	
97-25	19097-19101	than	_	
97-26	19102-19104	in	_	
97-27	19105-19110	those	_	
97-28	19111-19115	with	_	
97-29	19116-19129	schizophrenia	_	
97-30	19130-19133	and	_	
97-31	19134-19141	healthy	_	
97-32	19142-19150	controls	_	
97-33	19151-19152	(	_	
97-34	19152-19156	with	_	
97-35	19157-19159	no	_	
97-36	19160-19171	differences	_	
97-37	19172-19179	between	_	
97-38	19180-19183	the	_	
97-39	19184-19190	latter	_	
97-40	19191-19194	two	_	
97-41	19195-19201	groups	_	
97-42	19201-19202	)	_	
97-43	19202-19203	.	_	

#Text=Diagnostic group-by-Brodmann area interactions confirmed patterns observed in the whole-cortex analysis for the frontal, parietal, and occipital lobes.
98-1	19204-19214	Diagnostic	_	
98-2	19215-19232	group-by-Brodmann	_	
98-3	19233-19237	area	_	
98-4	19238-19250	interactions	_	
98-5	19251-19260	confirmed	_	
98-6	19261-19269	patterns	_	
98-7	19270-19278	observed	_	
98-8	19279-19281	in	_	
98-9	19282-19285	the	_	
98-10	19286-19298	whole-cortex	_	
98-11	19299-19307	analysis	_	
98-12	19308-19311	for	_	
98-13	19312-19315	the	_	
98-14	19316-19323	frontal	_	
98-15	19323-19324	,	_	
98-16	19325-19333	parietal	_	
98-17	19333-19334	,	_	
98-18	19335-19338	and	_	
98-19	19339-19348	occipital	_	
98-20	19349-19354	lobes	_	
98-21	19354-19355	.	_	

#Text=In the frontal lobe, metabolic rates in subjects with schizophrenia were the lowest of three groups in all Brodmann areas, except area 4 (see Figures 3 and 4 for detailed analyses of the frontal lobe).
99-1	19356-19358	In	_	
99-2	19359-19362	the	_	
99-3	19363-19370	frontal	_	
99-4	19371-19375	lobe	_	
99-5	19375-19376	,	_	
99-6	19377-19386	metabolic	_	
99-7	19387-19392	rates	_	
99-8	19393-19395	in	_	
99-9	19396-19404	subjects	_	
99-10	19405-19409	with	_	
99-11	19410-19423	schizophrenia	_	
99-12	19424-19428	were	_	
99-13	19429-19432	the	_	
99-14	19433-19439	lowest	_	
99-15	19440-19442	of	_	
99-16	19443-19448	three	_	
99-17	19449-19455	groups	_	
99-18	19456-19458	in	_	
99-19	19459-19462	all	_	
99-20	19463-19471	Brodmann	_	
99-21	19472-19477	areas	_	
99-22	19477-19478	,	_	
99-23	19479-19485	except	_	
99-24	19486-19490	area	_	
99-25	19491-19492	4	_	
99-26	19493-19494	(	_	
99-27	19494-19497	see	_	
99-28	19498-19505	Figures	_	
99-29	19506-19507	3	_	
99-30	19508-19511	and	_	
99-31	19512-19513	4	_	
99-32	19514-19517	for	_	
99-33	19518-19526	detailed	_	
99-34	19527-19535	analyses	_	
99-35	19536-19538	of	_	
99-36	19539-19542	the	_	
99-37	19543-19550	frontal	_	
99-38	19551-19555	lobe	_	
99-39	19555-19556	)	_	
99-40	19556-19557	.	_	

#Text=In the parietal lobe, metabolic rates in subjects with ASD were the lowest of three groups in all areas, except area 43.
100-1	19558-19560	In	_	
100-2	19561-19564	the	_	
100-3	19565-19573	parietal	_	
100-4	19574-19578	lobe	_	
100-5	19578-19579	,	_	
100-6	19580-19589	metabolic	_	
100-7	19590-19595	rates	_	
100-8	19596-19598	in	_	
100-9	19599-19607	subjects	_	
100-10	19608-19612	with	_	
100-11	19613-19616	ASD	_	
100-12	19617-19621	were	_	
100-13	19622-19625	the	_	
100-14	19626-19632	lowest	_	
100-15	19633-19635	of	_	
100-16	19636-19641	three	_	
100-17	19642-19648	groups	_	
100-18	19649-19651	in	_	
100-19	19652-19655	all	_	
100-20	19656-19661	areas	_	
100-21	19661-19662	,	_	
100-22	19663-19669	except	_	
100-23	19670-19674	area	_	
100-24	19675-19677	43	_	
100-25	19677-19678	.	_	

#Text=Temporal lobe and cingulate gyrus analyses yielded no significant group-by-Brodmann area interactions.
101-1	19679-19687	Temporal	_	
101-2	19688-19692	lobe	_	
101-3	19693-19696	and	_	
101-4	19697-19706	cingulate	_	
101-5	19707-19712	gyrus	_	
101-6	19713-19721	analyses	_	
101-7	19722-19729	yielded	_	
101-8	19730-19732	no	_	
101-9	19733-19744	significant	_	
101-10	19745-19762	group-by-Brodmann	_	
101-11	19763-19767	area	_	
101-12	19768-19780	interactions	_	
101-13	19780-19781	.	_	

#Text=In analyses of subcortical structures, a pattern of greater-than-normal rates in subjects with ASD and lower-than-normal rates in those with schizophrenia was observed only in the hypothalamus.
102-1	19782-19784	In	_	
102-2	19785-19793	analyses	_	
102-3	19794-19796	of	_	
102-4	19797-19808	subcortical	_	
102-5	19809-19819	structures	_	
102-6	19819-19820	,	_	
102-7	19821-19822	a	_	
102-8	19823-19830	pattern	_	
102-9	19831-19833	of	_	
102-10	19834-19853	greater-than-normal	_	
102-11	19854-19859	rates	_	
102-12	19860-19862	in	_	
102-13	19863-19871	subjects	_	
102-14	19872-19876	with	_	
102-15	19877-19880	ASD	_	
102-16	19881-19884	and	_	
102-17	19885-19902	lower-than-normal	_	
102-18	19903-19908	rates	_	
102-19	19909-19911	in	_	
102-20	19912-19917	those	_	
102-21	19918-19922	with	_	
102-22	19923-19936	schizophrenia	_	
102-23	19937-19940	was	_	
102-24	19941-19949	observed	_	
102-25	19950-19954	only	_	
102-26	19955-19957	in	_	
102-27	19958-19961	the	_	
102-28	19962-19974	hypothalamus	_	
102-29	19974-19975	.	_	

#Text=A reverse pattern was not observed in any of the analyses.
103-1	19976-19977	A	_	
103-2	19978-19985	reverse	_	
103-3	19986-19993	pattern	_	
103-4	19994-19997	was	_	
103-5	19998-20001	not	_	
103-6	20002-20010	observed	_	
103-7	20011-20013	in	_	
103-8	20014-20017	any	_	
103-9	20018-20020	of	_	
103-10	20021-20024	the	_	
103-11	20025-20033	analyses	_	
103-12	20033-20034	.	_	

#Text=Both subjects with schizophrenia and ASD showed lower-than-normal metabolic rates in the amygdala, claustrum, and ventral posteromedial nucleus of the thalamus (in the latter more pronounced in subjects with schizophrenia).
104-1	20035-20039	Both	_	
104-2	20040-20048	subjects	_	
104-3	20049-20053	with	_	
104-4	20054-20067	schizophrenia	_	
104-5	20068-20071	and	_	
104-6	20072-20075	ASD	_	
104-7	20076-20082	showed	_	
104-8	20083-20100	lower-than-normal	_	
104-9	20101-20110	metabolic	_	
104-10	20111-20116	rates	_	
104-11	20117-20119	in	_	
104-12	20120-20123	the	_	
104-13	20124-20132	amygdala	_	
104-14	20132-20133	,	_	
104-15	20134-20143	claustrum	_	
104-16	20143-20144	,	_	
104-17	20145-20148	and	_	
104-18	20149-20156	ventral	_	
104-19	20157-20170	posteromedial	_	
104-20	20171-20178	nucleus	_	
104-21	20179-20181	of	_	
104-22	20182-20185	the	_	
104-23	20186-20194	thalamus	_	
104-24	20195-20196	(	_	
104-25	20196-20198	in	_	
104-26	20199-20202	the	_	
104-27	20203-20209	latter	_	
104-28	20210-20214	more	_	
104-29	20215-20225	pronounced	_	
104-30	20226-20228	in	_	
104-31	20229-20237	subjects	_	
104-32	20238-20242	with	_	
104-33	20243-20256	schizophrenia	_	
104-34	20256-20257	)	_	
104-35	20257-20258	.	_	

#Text=Both subjects with schizophrenia and ASD showed higher-than-normal metabolic rates in the lateral globus pallidus, putamen and pulvinar (more pronounced in those with schizophrenia); medial globus pallidus (more pronounced in those with ASD); tail of the caudate and hippocampus (equal increases in both groups).
105-1	20259-20263	Both	_	
105-2	20264-20272	subjects	_	
105-3	20273-20277	with	_	
105-4	20278-20291	schizophrenia	_	
105-5	20292-20295	and	_	
105-6	20296-20299	ASD	_	
105-7	20300-20306	showed	_	
105-8	20307-20325	higher-than-normal	_	
105-9	20326-20335	metabolic	_	
105-10	20336-20341	rates	_	
105-11	20342-20344	in	_	
105-12	20345-20348	the	_	
105-13	20349-20356	lateral	_	
105-14	20357-20363	globus	_	
105-15	20364-20372	pallidus	_	
105-16	20372-20373	,	_	
105-17	20374-20381	putamen	_	
105-18	20382-20385	and	_	
105-19	20386-20394	pulvinar	_	
105-20	20395-20396	(	_	
105-21	20396-20400	more	_	
105-22	20401-20411	pronounced	_	
105-23	20412-20414	in	_	
105-24	20415-20420	those	_	
105-25	20421-20425	with	_	
105-26	20426-20439	schizophrenia	_	
105-27	20439-20440	)	_	
105-28	20440-20441	;	_	
105-29	20442-20448	medial	_	
105-30	20449-20455	globus	_	
105-31	20456-20464	pallidus	_	
105-32	20465-20466	(	_	
105-33	20466-20470	more	_	
105-34	20471-20481	pronounced	_	
105-35	20482-20484	in	_	
105-36	20485-20490	those	_	
105-37	20491-20495	with	_	
105-38	20496-20499	ASD	_	
105-39	20499-20500	)	_	
105-40	20500-20501	;	_	
105-41	20502-20506	tail	_	
105-42	20507-20509	of	_	
105-43	20510-20513	the	_	
105-44	20514-20521	caudate	_	
105-45	20522-20525	and	_	
105-46	20526-20537	hippocampus	_	
105-47	20538-20539	(	_	
105-48	20539-20544	equal	_	
105-49	20545-20554	increases	_	
105-50	20555-20557	in	_	
105-51	20558-20562	both	_	
105-52	20563-20569	groups	_	
105-53	20569-20570	)	_	
105-54	20570-20571	.	_	

#Text=Only subjects with schizophrenia showed increased metabolic rates in the lateral posterior and ventroposterior lateral nuclei of the thalamus, and decreased metabolic rates in the head and body of the caudate (Fig. 5), and at a trend level also in the mediodorsal nucleus of the thalamus.
106-1	20572-20576	Only	_	
106-2	20577-20585	subjects	_	
106-3	20586-20590	with	_	
106-4	20591-20604	schizophrenia	_	
106-5	20605-20611	showed	_	
106-6	20612-20621	increased	_	
106-7	20622-20631	metabolic	_	
106-8	20632-20637	rates	_	
106-9	20638-20640	in	_	
106-10	20641-20644	the	_	
106-11	20645-20652	lateral	_	
106-12	20653-20662	posterior	_	
106-13	20663-20666	and	_	
106-14	20667-20682	ventroposterior	_	
106-15	20683-20690	lateral	_	
106-16	20691-20697	nuclei	_	
106-17	20698-20700	of	_	
106-18	20701-20704	the	_	
106-19	20705-20713	thalamus	_	
106-20	20713-20714	,	_	
106-21	20715-20718	and	_	
106-22	20719-20728	decreased	_	
106-23	20729-20738	metabolic	_	
106-24	20739-20744	rates	_	
106-25	20745-20747	in	_	
106-26	20748-20751	the	_	
106-27	20752-20756	head	_	
106-28	20757-20760	and	_	
106-29	20761-20765	body	_	
106-30	20766-20768	of	_	
106-31	20769-20772	the	_	
106-32	20773-20780	caudate	_	
106-33	20781-20782	(	_	
106-34	20782-20785	Fig	_	
106-35	20785-20786	.	_	
106-36	20787-20788	5	_	
106-37	20788-20789	)	_	
106-38	20789-20790	,	_	
106-39	20791-20794	and	_	
106-40	20795-20797	at	_	
106-41	20798-20799	a	_	
106-42	20800-20805	trend	_	
106-43	20806-20811	level	_	
106-44	20812-20816	also	_	
106-45	20817-20819	in	_	
106-46	20820-20823	the	_	
106-47	20824-20835	mediodorsal	_	
106-48	20836-20843	nucleus	_	
106-49	20844-20846	of	_	
106-50	20847-20850	the	_	
106-51	20851-20859	thalamus	_	
106-52	20859-20860	.	_	

#Text=There were no significant interactions in three-group or any of the two-group analyses of the red nucleus, substantia nigra, cerebellar subregions (tonsil, culmen, declive, tuber, and pyramis of the vermis), whole thalamus and the following thalamic nuclei: anteroventral, lateral dorsal, ventral lateral, anterior and midline nuclear groups.
107-1	20861-20866	There	_	
107-2	20867-20871	were	_	
107-3	20872-20874	no	_	
107-4	20875-20886	significant	_	
107-5	20887-20899	interactions	_	
107-6	20900-20902	in	_	
107-7	20903-20914	three-group	_	
107-8	20915-20917	or	_	
107-9	20918-20921	any	_	
107-10	20922-20924	of	_	
107-11	20925-20928	the	_	
107-12	20929-20938	two-group	_	
107-13	20939-20947	analyses	_	
107-14	20948-20950	of	_	
107-15	20951-20954	the	_	
107-16	20955-20958	red	_	
107-17	20959-20966	nucleus	_	
107-18	20966-20967	,	_	
107-19	20968-20978	substantia	_	
107-20	20979-20984	nigra	_	
107-21	20984-20985	,	_	
107-22	20986-20996	cerebellar	_	
107-23	20997-21007	subregions	_	
107-24	21008-21009	(	_	
107-25	21009-21015	tonsil	_	
107-26	21015-21016	,	_	
107-27	21017-21023	culmen	_	
107-28	21023-21024	,	_	
107-29	21025-21032	declive	_	
107-30	21032-21033	,	_	
107-31	21034-21039	tuber	_	
107-32	21039-21040	,	_	
107-33	21041-21044	and	_	
107-34	21045-21052	pyramis	_	
107-35	21053-21055	of	_	
107-36	21056-21059	the	_	
107-37	21060-21066	vermis	_	
107-38	21066-21067	)	_	
107-39	21067-21068	,	_	
107-40	21069-21074	whole	_	
107-41	21075-21083	thalamus	_	
107-42	21084-21087	and	_	
107-43	21088-21091	the	_	
107-44	21092-21101	following	_	
107-45	21102-21110	thalamic	_	
107-46	21111-21117	nuclei	_	
107-47	21117-21118	:	_	
107-48	21119-21132	anteroventral	_	
107-49	21132-21133	,	_	
107-50	21134-21141	lateral	_	
107-51	21142-21148	dorsal	_	
107-52	21148-21149	,	_	
107-53	21150-21157	ventral	_	
107-54	21158-21165	lateral	_	
107-55	21165-21166	,	_	
107-56	21167-21175	anterior	_	
107-57	21176-21179	and	_	
107-58	21180-21187	midline	_	
107-59	21188-21195	nuclear	_	
107-60	21196-21202	groups	_	
107-61	21202-21203	.	_	

#Text=Direct two-group comparison of all 42 Brodmann areas in subjects with ASD and schizophrenia produced a trend-level group-by-area interaction, indicating a pattern of lower metabolic rates in subjects with ASD in the contiguous pericentral region (areas 1, 2, 3, 4, 5, 6, 7) and at the parieto-occipital junction (areas 39 and 40), and higher rates across the rest of the cortex; none of the lobar analyses yielded significant main effects of diagnosis.
108-1	21204-21210	Direct	_	
108-2	21211-21220	two-group	_	
108-3	21221-21231	comparison	_	
108-4	21232-21234	of	_	
108-5	21235-21238	all	_	
108-6	21239-21241	42	_	
108-7	21242-21250	Brodmann	_	
108-8	21251-21256	areas	_	
108-9	21257-21259	in	_	
108-10	21260-21268	subjects	_	
108-11	21269-21273	with	_	
108-12	21274-21277	ASD	_	
108-13	21278-21281	and	_	
108-14	21282-21295	schizophrenia	_	
108-15	21296-21304	produced	_	
108-16	21305-21306	a	_	
108-17	21307-21318	trend-level	_	
108-18	21319-21332	group-by-area	_	
108-19	21333-21344	interaction	_	
108-20	21344-21345	,	_	
108-21	21346-21356	indicating	_	
108-22	21357-21358	a	_	
108-23	21359-21366	pattern	_	
108-24	21367-21369	of	_	
108-25	21370-21375	lower	_	
108-26	21376-21385	metabolic	_	
108-27	21386-21391	rates	_	
108-28	21392-21394	in	_	
108-29	21395-21403	subjects	_	
108-30	21404-21408	with	_	
108-31	21409-21412	ASD	_	
108-32	21413-21415	in	_	
108-33	21416-21419	the	_	
108-34	21420-21430	contiguous	_	
108-35	21431-21442	pericentral	_	
108-36	21443-21449	region	_	
108-37	21450-21451	(	_	
108-38	21451-21456	areas	_	
108-39	21457-21458	1	_	
108-40	21458-21459	,	_	
108-41	21460-21461	2	_	
108-42	21461-21462	,	_	
108-43	21463-21464	3	_	
108-44	21464-21465	,	_	
108-45	21466-21467	4	_	
108-46	21467-21468	,	_	
108-47	21469-21470	5	_	
108-48	21470-21471	,	_	
108-49	21472-21473	6	_	
108-50	21473-21474	,	_	
108-51	21475-21476	7	_	
108-52	21476-21477	)	_	
108-53	21478-21481	and	_	
108-54	21482-21484	at	_	
108-55	21485-21488	the	_	
108-56	21489-21506	parieto-occipital	_	
108-57	21507-21515	junction	_	
108-58	21516-21517	(	_	
108-59	21517-21522	areas	_	
108-60	21523-21525	39	_	
108-61	21526-21529	and	_	
108-62	21530-21532	40	_	
108-63	21532-21533	)	_	
108-64	21533-21534	,	_	
108-65	21535-21538	and	_	
108-66	21539-21545	higher	_	
108-67	21546-21551	rates	_	
108-68	21552-21558	across	_	
108-69	21559-21562	the	_	
108-70	21563-21567	rest	_	
108-71	21568-21570	of	_	
108-72	21571-21574	the	_	
108-73	21575-21581	cortex	_	
108-74	21581-21582	;	_	
108-75	21583-21587	none	_	
108-76	21588-21590	of	_	
108-77	21591-21594	the	_	
108-78	21595-21600	lobar	_	
108-79	21601-21609	analyses	_	
108-80	21610-21617	yielded	_	
108-81	21618-21629	significant	_	
108-82	21630-21634	main	_	
108-83	21635-21642	effects	_	
108-84	21643-21645	of	_	
108-85	21646-21655	diagnosis	_	
108-86	21655-21656	.	_	

#Text=In subcortical analyses, only three structures yielded significant effects: in the hypothalamus and adjacent mammillary bodies rates were higher in subjects with ASD, in the lateral posterior nucleus of the thalamus rates were higher in those with schizophrenia.
109-1	21657-21659	In	_	
109-2	21660-21671	subcortical	_	
109-3	21672-21680	analyses	_	
109-4	21680-21681	,	_	
109-5	21682-21686	only	_	
109-6	21687-21692	three	_	
109-7	21693-21703	structures	_	
109-8	21704-21711	yielded	_	
109-9	21712-21723	significant	_	
109-10	21724-21731	effects	_	
109-11	21731-21732	:	_	
109-12	21733-21735	in	_	
109-13	21736-21739	the	_	
109-14	21740-21752	hypothalamus	_	
109-15	21753-21756	and	_	
109-16	21757-21765	adjacent	_	
109-17	21766-21776	mammillary	_	
109-18	21777-21783	bodies	_	
109-19	21784-21789	rates	_	
109-20	21790-21794	were	_	
109-21	21795-21801	higher	_	
109-22	21802-21804	in	_	
109-23	21805-21813	subjects	_	
109-24	21814-21818	with	_	
109-25	21819-21822	ASD	_	
109-26	21822-21823	,	_	
109-27	21824-21826	in	_	
109-28	21827-21830	the	_	
109-29	21831-21838	lateral	_	
109-30	21839-21848	posterior	_	
109-31	21849-21856	nucleus	_	
109-32	21857-21859	of	_	
109-33	21860-21863	the	_	
109-34	21864-21872	thalamus	_	
109-35	21873-21878	rates	_	
109-36	21879-21883	were	_	
109-37	21884-21890	higher	_	
109-38	21891-21893	in	_	
109-39	21894-21899	those	_	
109-40	21900-21904	with	_	
109-41	21905-21918	schizophrenia	_	
109-42	21918-21919	.	_	

#Text=A significant group-by-hemisphere interaction for the amygdala pointed to higher metabolic rates in left than right hemisphere in subjects with schizophrenia, whereas there was an opposite pattern in those with ASD (F1, 66 =6.29, p=0.015).
110-1	21920-21921	A	_	
110-2	21922-21933	significant	_	
110-3	21934-21953	group-by-hemisphere	_	
110-4	21954-21965	interaction	_	
110-5	21966-21969	for	_	
110-6	21970-21973	the	_	
110-7	21974-21982	amygdala	_	
110-8	21983-21990	pointed	_	
110-9	21991-21993	to	_	
110-10	21994-22000	higher	_	
110-11	22001-22010	metabolic	_	
110-12	22011-22016	rates	_	
110-13	22017-22019	in	_	
110-14	22020-22024	left	_	
110-15	22025-22029	than	_	
110-16	22030-22035	right	_	
110-17	22036-22046	hemisphere	_	
110-18	22047-22049	in	_	
110-19	22050-22058	subjects	_	
110-20	22059-22063	with	_	
110-21	22064-22077	schizophrenia	_	
110-22	22077-22078	,	_	
110-23	22079-22086	whereas	_	
110-24	22087-22092	there	_	
110-25	22093-22096	was	_	
110-26	22097-22099	an	_	
110-27	22100-22108	opposite	_	
110-28	22109-22116	pattern	_	
110-29	22117-22119	in	_	
110-30	22120-22125	those	_	
110-31	22126-22130	with	_	
110-32	22131-22134	ASD	_	
110-33	22135-22136	(	_	
110-34	22136-22138	F1	_	
110-35	22138-22139	,	_	
110-36	22140-22142	66	_	
110-37	22143-22144	=	_	
110-38	22144-22148	6.29	_	
110-39	22148-22149	,	_	
110-40	22150-22151	p	_	
110-41	22151-22152	=	_	
110-42	22152-22157	0.015	_	
110-43	22157-22158	)	_	
110-44	22158-22159	.	_	

#Text=Subjects with ASD vs. healthy controls
#Text=The MANCOVA with all 42 Brodmann areas comparing subjects with ASD and healthy controls yielded a significant group-by-area interaction, indicating lower metabolic rates in subjects with ASD in most of parietal areas, as well as frontal areas 6, 8, and 11.
111-1	22160-22168	Subjects	_	
111-2	22169-22173	with	_	
111-3	22174-22177	ASD	_	
111-4	22178-22180	vs	_	
111-5	22180-22181	.	_	
111-6	22182-22189	healthy	_	
111-7	22190-22198	controls	_	
111-8	22199-22202	The	_	
111-9	22203-22210	MANCOVA	_	
111-10	22211-22215	with	_	
111-11	22216-22219	all	_	
111-12	22220-22222	42	_	
111-13	22223-22231	Brodmann	_	
111-14	22232-22237	areas	_	
111-15	22238-22247	comparing	_	
111-16	22248-22256	subjects	_	
111-17	22257-22261	with	_	
111-18	22262-22265	ASD	_	
111-19	22266-22269	and	_	
111-20	22270-22277	healthy	_	
111-21	22278-22286	controls	_	
111-22	22287-22294	yielded	_	
111-23	22295-22296	a	_	
111-24	22297-22308	significant	_	
111-25	22309-22322	group-by-area	_	
111-26	22323-22334	interaction	_	
111-27	22334-22335	,	_	
111-28	22336-22346	indicating	_	
111-29	22347-22352	lower	_	
111-30	22353-22362	metabolic	_	
111-31	22363-22368	rates	_	
111-32	22369-22371	in	_	
111-33	22372-22380	subjects	_	
111-34	22381-22385	with	_	
111-35	22386-22389	ASD	_	
111-36	22390-22392	in	_	
111-37	22393-22397	most	_	
111-38	22398-22400	of	_	
111-39	22401-22409	parietal	_	
111-40	22410-22415	areas	_	
111-41	22415-22416	,	_	
111-42	22417-22419	as	_	
111-43	22420-22424	well	_	
111-44	22425-22427	as	_	
111-45	22428-22435	frontal	_	
111-46	22436-22441	areas	_	
111-47	22442-22443	6	_	
111-48	22443-22444	,	_	
111-49	22445-22446	8	_	
111-50	22446-22447	,	_	
111-51	22448-22451	and	_	
111-52	22452-22454	11	_	
111-53	22454-22455	.	_	

#Text=Metabolic rates were higher in subjects with ASD in the posterior and pregenual cingulate (23, 29, 30, 33), occipital (17, 18) and inferior frontal cortices (area 12), and to a lesser degree in the medial temporal cortex (contiguous areas 27, 28, 34, 35, 36, 37, 38).
112-1	22456-22465	Metabolic	_	
112-2	22466-22471	rates	_	
112-3	22472-22476	were	_	
112-4	22477-22483	higher	_	
112-5	22484-22486	in	_	
112-6	22487-22495	subjects	_	
112-7	22496-22500	with	_	
112-8	22501-22504	ASD	_	
112-9	22505-22507	in	_	
112-10	22508-22511	the	_	
112-11	22512-22521	posterior	_	
112-12	22522-22525	and	_	
112-13	22526-22535	pregenual	_	
112-14	22536-22545	cingulate	_	
112-15	22546-22547	(	_	
112-16	22547-22549	23	_	
112-17	22549-22550	,	_	
112-18	22551-22553	29	_	
112-19	22553-22554	,	_	
112-20	22555-22557	30	_	
112-21	22557-22558	,	_	
112-22	22559-22561	33	_	
112-23	22561-22562	)	_	
112-24	22562-22563	,	_	
112-25	22564-22573	occipital	_	
112-26	22574-22575	(	_	
112-27	22575-22577	17	_	
112-28	22577-22578	,	_	
112-29	22579-22581	18	_	
112-30	22581-22582	)	_	
112-31	22583-22586	and	_	
112-32	22587-22595	inferior	_	
112-33	22596-22603	frontal	_	
112-34	22604-22612	cortices	_	
112-35	22613-22614	(	_	
112-36	22614-22618	area	_	
112-37	22619-22621	12	_	
112-38	22621-22622	)	_	
112-39	22622-22623	,	_	
112-40	22624-22627	and	_	
112-41	22628-22630	to	_	
112-42	22631-22632	a	_	
112-43	22633-22639	lesser	_	
112-44	22640-22646	degree	_	
112-45	22647-22649	in	_	
112-46	22650-22653	the	_	
112-47	22654-22660	medial	_	
112-48	22661-22669	temporal	_	
112-49	22670-22676	cortex	_	
112-50	22677-22678	(	_	
112-51	22678-22688	contiguous	_	
112-52	22689-22694	areas	_	
112-53	22695-22697	27	_	
112-54	22697-22698	,	_	
112-55	22699-22701	28	_	
112-56	22701-22702	,	_	
112-57	22703-22705	34	_	
112-58	22705-22706	,	_	
112-59	22707-22709	35	_	
112-60	22709-22710	,	_	
112-61	22711-22713	36	_	
112-62	22713-22714	,	_	
112-63	22715-22717	37	_	
112-64	22717-22718	,	_	
112-65	22719-22721	38	_	
112-66	22721-22722	)	_	
112-67	22722-22723	.	_	

#Text=Differential metabolic patterns on the lobar level were confirmed only in the parietal lobe analysis (main effect of diagnosis), with lower metabolic rates in subjects with ASD across all areas, except area 43.
113-1	22724-22736	Differential	_	
113-2	22737-22746	metabolic	_	
113-3	22747-22755	patterns	_	
113-4	22756-22758	on	_	
113-5	22759-22762	the	_	
113-6	22763-22768	lobar	_	
113-7	22769-22774	level	_	
113-8	22775-22779	were	_	
113-9	22780-22789	confirmed	_	
113-10	22790-22794	only	_	
113-11	22795-22797	in	_	
113-12	22798-22801	the	_	
113-13	22802-22810	parietal	_	
113-14	22811-22815	lobe	_	
113-15	22816-22824	analysis	_	
113-16	22825-22826	(	_	
113-17	22826-22830	main	_	
113-18	22831-22837	effect	_	
113-19	22838-22840	of	_	
113-20	22841-22850	diagnosis	_	
113-21	22850-22851	)	_	
113-22	22851-22852	,	_	
113-23	22853-22857	with	_	
113-24	22858-22863	lower	_	
113-25	22864-22873	metabolic	_	
113-26	22874-22879	rates	_	
113-27	22880-22882	in	_	
113-28	22883-22891	subjects	_	
113-29	22892-22896	with	_	
113-30	22897-22900	ASD	_	
113-31	22901-22907	across	_	
113-32	22908-22911	all	_	
113-33	22912-22917	areas	_	
113-34	22917-22918	,	_	
113-35	22919-22925	except	_	
113-36	22926-22930	area	_	
113-37	22931-22933	43	_	
113-38	22933-22934	.	_	

#Text=In subcortical analyses, subjects with ASD showed increased metabolic rates in the putamen, medial and lateral globi pallidi, tail of the caudate, claustrum, and hippocampus.
114-1	22935-22937	In	_	
114-2	22938-22949	subcortical	_	
114-3	22950-22958	analyses	_	
114-4	22958-22959	,	_	
114-5	22960-22968	subjects	_	
114-6	22969-22973	with	_	
114-7	22974-22977	ASD	_	
114-8	22978-22984	showed	_	
114-9	22985-22994	increased	_	
114-10	22995-23004	metabolic	_	
114-11	23005-23010	rates	_	
114-12	23011-23013	in	_	
114-13	23014-23017	the	_	
114-14	23018-23025	putamen	_	
114-15	23025-23026	,	_	
114-16	23027-23033	medial	_	
114-17	23034-23037	and	_	
114-18	23038-23045	lateral	_	
114-19	23046-23051	globi	_	
114-20	23052-23059	pallidi	_	
114-21	23059-23060	,	_	
114-22	23061-23065	tail	_	
114-23	23066-23068	of	_	
114-24	23069-23072	the	_	
114-25	23073-23080	caudate	_	
114-26	23080-23081	,	_	
114-27	23082-23091	claustrum	_	
114-28	23091-23092	,	_	
114-29	23093-23096	and	_	
114-30	23097-23108	hippocampus	_	
114-31	23108-23109	.	_	

#Text=In comparison to healthy controls, metabolic rates were decreased only in the amygdala.
115-1	23110-23112	In	_	
115-2	23113-23123	comparison	_	
115-3	23124-23126	to	_	
115-4	23127-23134	healthy	_	
115-5	23135-23143	controls	_	
115-6	23143-23144	,	_	
115-7	23145-23154	metabolic	_	
115-8	23155-23160	rates	_	
115-9	23161-23165	were	_	
115-10	23166-23175	decreased	_	
115-11	23176-23180	only	_	
115-12	23181-23183	in	_	
115-13	23184-23187	the	_	
115-14	23188-23196	amygdala	_	
115-15	23196-23197	.	_	

#Text=Subjects with schizophrenia vs. healthy controls
#Text=In comparisons of subjects with schizophrenia and healthy controls, significant group-by-Brodmann area interactions were obtained for the overarching 42 Brodmann area MANCOVA and in analyses of the frontal, parietal and occipital lobes.
116-1	23198-23206	Subjects	_	
116-2	23207-23211	with	_	
116-3	23212-23225	schizophrenia	_	
116-4	23226-23228	vs	_	
116-5	23228-23229	.	_	
116-6	23230-23237	healthy	_	
116-7	23238-23246	controls	_	
116-8	23247-23249	In	_	
116-9	23250-23261	comparisons	_	
116-10	23262-23264	of	_	
116-11	23265-23273	subjects	_	
116-12	23274-23278	with	_	
116-13	23279-23292	schizophrenia	_	
116-14	23293-23296	and	_	
116-15	23297-23304	healthy	_	
116-16	23305-23313	controls	_	
116-17	23313-23314	,	_	
116-18	23315-23326	significant	_	
116-19	23327-23344	group-by-Brodmann	_	
116-20	23345-23349	area	_	
116-21	23350-23362	interactions	_	
116-22	23363-23367	were	_	
116-23	23368-23376	obtained	_	
116-24	23377-23380	for	_	
116-25	23381-23384	the	_	
116-26	23385-23396	overarching	_	
116-27	23397-23399	42	_	
116-28	23400-23408	Brodmann	_	
116-29	23409-23413	area	_	
116-30	23414-23421	MANCOVA	_	
116-31	23422-23425	and	_	
116-32	23426-23428	in	_	
116-33	23429-23437	analyses	_	
116-34	23438-23440	of	_	
116-35	23441-23444	the	_	
116-36	23445-23452	frontal	_	
116-37	23452-23453	,	_	
116-38	23454-23462	parietal	_	
116-39	23463-23466	and	_	
116-40	23467-23476	occipital	_	
116-41	23477-23482	lobes	_	
116-42	23482-23483	.	_	

#Text=These indicated lower metabolic rates in subjects with schizophrenia in all frontal areas, except precentral area 4, and in the parietal area 40 (supramarginal gyrus), superior temporal gyrus (area 22), and in the primarily anterior cingulate gyrus (areas 25, 32, 33, to lesser degree 23 and 24).
117-1	23484-23489	These	_	
117-2	23490-23499	indicated	_	
117-3	23500-23505	lower	_	
117-4	23506-23515	metabolic	_	
117-5	23516-23521	rates	_	
117-6	23522-23524	in	_	
117-7	23525-23533	subjects	_	
117-8	23534-23538	with	_	
117-9	23539-23552	schizophrenia	_	
117-10	23553-23555	in	_	
117-11	23556-23559	all	_	
117-12	23560-23567	frontal	_	
117-13	23568-23573	areas	_	
117-14	23573-23574	,	_	
117-15	23575-23581	except	_	
117-16	23582-23592	precentral	_	
117-17	23593-23597	area	_	
117-18	23598-23599	4	_	
117-19	23599-23600	,	_	
117-20	23601-23604	and	_	
117-21	23605-23607	in	_	
117-22	23608-23611	the	_	
117-23	23612-23620	parietal	_	
117-24	23621-23625	area	_	
117-25	23626-23628	40	_	
117-26	23629-23630	(	_	
117-27	23630-23643	supramarginal	_	
117-28	23644-23649	gyrus	_	
117-29	23649-23650	)	_	
117-30	23650-23651	,	_	
117-31	23652-23660	superior	_	
117-32	23661-23669	temporal	_	
117-33	23670-23675	gyrus	_	
117-34	23676-23677	(	_	
117-35	23677-23681	area	_	
117-36	23682-23684	22	_	
117-37	23684-23685	)	_	
117-38	23685-23686	,	_	
117-39	23687-23690	and	_	
117-40	23691-23693	in	_	
117-41	23694-23697	the	_	
117-42	23698-23707	primarily	_	
117-43	23708-23716	anterior	_	
117-44	23717-23726	cingulate	_	
117-45	23727-23732	gyrus	_	
117-46	23733-23734	(	_	
117-47	23734-23739	areas	_	
117-48	23740-23742	25	_	
117-49	23742-23743	,	_	
117-50	23744-23746	32	_	
117-51	23746-23747	,	_	
117-52	23748-23750	33	_	
117-53	23750-23751	,	_	
117-54	23752-23754	to	_	
117-55	23755-23761	lesser	_	
117-56	23762-23768	degree	_	
117-57	23769-23771	23	_	
117-58	23772-23775	and	_	
117-59	23776-23778	24	_	
117-60	23778-23779	)	_	
117-61	23779-23780	.	_	

#Text=Significant main effect of diagnosis confirmed lower metabolic rates in those with schizophrenia in the whole frontal lobe.
118-1	23781-23792	Significant	_	
118-2	23793-23797	main	_	
118-3	23798-23804	effect	_	
118-4	23805-23807	of	_	
118-5	23808-23817	diagnosis	_	
118-6	23818-23827	confirmed	_	
118-7	23828-23833	lower	_	
118-8	23834-23843	metabolic	_	
118-9	23844-23849	rates	_	
118-10	23850-23852	in	_	
118-11	23853-23858	those	_	
118-12	23859-23863	with	_	
118-13	23864-23877	schizophrenia	_	
118-14	23878-23880	in	_	
118-15	23881-23884	the	_	
118-16	23885-23890	whole	_	
118-17	23891-23898	frontal	_	
118-18	23899-23903	lobe	_	
118-19	23903-23904	.	_	

#Text=Higher-than-normal rates in subjects with schizophrenia were seen in the occipital areas 17 and 18.
119-1	23905-23923	Higher-than-normal	_	
119-2	23924-23929	rates	_	
119-3	23930-23932	in	_	
119-4	23933-23941	subjects	_	
119-5	23942-23946	with	_	
119-6	23947-23960	schizophrenia	_	
119-7	23961-23965	were	_	
119-8	23966-23970	seen	_	
119-9	23971-23973	in	_	
119-10	23974-23977	the	_	
119-11	23978-23987	occipital	_	
119-12	23988-23993	areas	_	
119-13	23994-23996	17	_	
119-14	23997-24000	and	_	
119-15	24001-24003	18	_	
119-16	24003-24004	.	_	

#Text=In subcortical analyses, subjects with schizophrenia showed increased metabolic rates in the lateral globus pallidus, putamen, tail of the caudate, claustrum, hippocampus, as well as the pulvinar, ventroposterior lateral and lateral posterior nuclei of the thalamus.
120-1	24005-24007	In	_	
120-2	24008-24019	subcortical	_	
120-3	24020-24028	analyses	_	
120-4	24028-24029	,	_	
120-5	24030-24038	subjects	_	
120-6	24039-24043	with	_	
120-7	24044-24057	schizophrenia	_	
120-8	24058-24064	showed	_	
120-9	24065-24074	increased	_	
120-10	24075-24084	metabolic	_	
120-11	24085-24090	rates	_	
120-12	24091-24093	in	_	
120-13	24094-24097	the	_	
120-14	24098-24105	lateral	_	
120-15	24106-24112	globus	_	
120-16	24113-24121	pallidus	_	
120-17	24121-24122	,	_	
120-18	24123-24130	putamen	_	
120-19	24130-24131	,	_	
120-20	24132-24136	tail	_	
120-21	24137-24139	of	_	
120-22	24140-24143	the	_	
120-23	24144-24151	caudate	_	
120-24	24151-24152	,	_	
120-25	24153-24162	claustrum	_	
120-26	24162-24163	,	_	
120-27	24164-24175	hippocampus	_	
120-28	24175-24176	,	_	
120-29	24177-24179	as	_	
120-30	24180-24184	well	_	
120-31	24185-24187	as	_	
120-32	24188-24191	the	_	
120-33	24192-24200	pulvinar	_	
120-34	24200-24201	,	_	
120-35	24202-24217	ventroposterior	_	
120-36	24218-24225	lateral	_	
120-37	24226-24229	and	_	
120-38	24230-24237	lateral	_	
120-39	24238-24247	posterior	_	
120-40	24248-24254	nuclei	_	
120-41	24255-24257	of	_	
120-42	24258-24261	the	_	
120-43	24262-24270	thalamus	_	
120-44	24270-24271	.	_	

#Text=Metabolic rates were decreased in the hippocampus, amygdala, head of the caudate, and in the mediodorsal and ventral posteromedial nuclei of the thalamus.
121-1	24272-24281	Metabolic	_	
121-2	24282-24287	rates	_	
121-3	24288-24292	were	_	
121-4	24293-24302	decreased	_	
121-5	24303-24305	in	_	
121-6	24306-24309	the	_	
121-7	24310-24321	hippocampus	_	
121-8	24321-24322	,	_	
121-9	24323-24331	amygdala	_	
121-10	24331-24332	,	_	
121-11	24333-24337	head	_	
121-12	24338-24340	of	_	
121-13	24341-24344	the	_	
121-14	24345-24352	caudate	_	
121-15	24352-24353	,	_	
121-16	24354-24357	and	_	
121-17	24358-24360	in	_	
121-18	24361-24364	the	_	
121-19	24365-24376	mediodorsal	_	
121-20	24377-24380	and	_	
121-21	24381-24388	ventral	_	
121-22	24389-24402	posteromedial	_	
121-23	24403-24409	nuclei	_	
121-24	24410-24412	of	_	
121-25	24413-24416	the	_	
121-26	24417-24425	thalamus	_	
121-27	24425-24426	.	_	

#Text=In t-tests on 42 individual Brodmann areas for right and left hemispheres, areas 10L, 10R, 44R, 45R, 47R and 47L met the Bonferroni criterion (0.05/84=0.00060) in schizophrenia vs. healthy controls comparisons; only area 1R met this criterion in ASD vs. healthy controls comparisons.
122-1	24427-24429	In	_	
122-2	24430-24437	t-tests	_	
122-3	24438-24440	on	_	
122-4	24441-24443	42	_	
122-5	24444-24454	individual	_	
122-6	24455-24463	Brodmann	_	
122-7	24464-24469	areas	_	
122-8	24470-24473	for	_	
122-9	24474-24479	right	_	
122-10	24480-24483	and	_	
122-11	24484-24488	left	_	
122-12	24489-24500	hemispheres	_	
122-13	24500-24501	,	_	
122-14	24502-24507	areas	_	
122-15	24508-24511	10L	_	
122-16	24511-24512	,	_	
122-17	24513-24516	10R	_	
122-18	24516-24517	,	_	
122-19	24518-24521	44R	_	
122-20	24521-24522	,	_	
122-21	24523-24526	45R	_	
122-22	24526-24527	,	_	
122-23	24528-24531	47R	_	
122-24	24532-24535	and	_	
122-25	24536-24539	47L	_	
122-26	24540-24543	met	_	
122-27	24544-24547	the	_	
122-28	24548-24558	Bonferroni	_	
122-29	24559-24568	criterion	_	
122-30	24569-24570	(	_	
122-31	24570-24574	0.05	_	
122-32	24574-24575	/	_	
122-33	24575-24577	84	_	
122-34	24577-24578	=	_	
122-35	24578-24585	0.00060	_	
122-36	24585-24586	)	_	
122-37	24587-24589	in	_	
122-38	24590-24603	schizophrenia	_	
122-39	24604-24606	vs	_	
122-40	24606-24607	.	_	
122-41	24608-24615	healthy	_	
122-42	24616-24624	controls	_	
122-43	24625-24636	comparisons	_	
122-44	24636-24637	;	_	
122-45	24638-24642	only	_	
122-46	24643-24647	area	_	
122-47	24648-24650	1R	_	
122-48	24651-24654	met	_	
122-49	24655-24659	this	_	
122-50	24660-24669	criterion	_	
122-51	24670-24672	in	_	
122-52	24673-24676	ASD	_	
122-53	24677-24679	vs	_	
122-54	24679-24680	.	_	
122-55	24681-24688	healthy	_	
122-56	24689-24697	controls	_	
122-57	24698-24709	comparisons	_	
122-58	24709-24710	.	_	

#Text=The largest effect size for any Brodmann area metabolic rates for healthy controls vs. schizophrenia comparisons was in right area 44 (t94=4.20, effect size=0.86, p=0.000061; schizophrenia 1.23±0.087, healthy controls 1.29±0.070).
123-1	24711-24714	The	_	
123-2	24715-24722	largest	_	
123-3	24723-24729	effect	_	
123-4	24730-24734	size	_	
123-5	24735-24738	for	_	
123-6	24739-24742	any	_	
123-7	24743-24751	Brodmann	_	
123-8	24752-24756	area	_	
123-9	24757-24766	metabolic	_	
123-10	24767-24772	rates	_	
123-11	24773-24776	for	_	
123-12	24777-24784	healthy	_	
123-13	24785-24793	controls	_	
123-14	24794-24796	vs	_	
123-15	24796-24797	.	_	
123-16	24798-24811	schizophrenia	_	
123-17	24812-24823	comparisons	_	
123-18	24824-24827	was	_	
123-19	24828-24830	in	_	
123-20	24831-24836	right	_	
123-21	24837-24841	area	_	
123-22	24842-24844	44	_	
123-23	24845-24846	(	_	
123-24	24846-24849	t94	_	
123-25	24849-24850	=	_	
123-26	24850-24854	4.20	_	
123-27	24854-24855	,	_	
123-28	24856-24862	effect	_	
123-29	24863-24867	size	_	
123-30	24867-24868	=	_	
123-31	24868-24872	0.86	_	
123-32	24872-24873	,	_	
123-33	24874-24875	p	_	
123-34	24875-24876	=	_	
123-35	24876-24884	0.000061	_	
123-36	24884-24885	;	_	
123-37	24886-24899	schizophrenia	_	
123-38	24900-24904	1.23	_	
123-39	24904-24905	±	_	
123-40	24905-24910	0.087	_	
123-41	24910-24911	,	_	
123-42	24912-24919	healthy	_	
123-43	24920-24928	controls	_	
123-44	24929-24933	1.29	_	
123-45	24933-24934	±	_	
123-46	24934-24939	0.070	_	
123-47	24939-24940	)	_	
123-48	24940-24941	.	_	

#Text=This area met Bonferroni criterion (0.05/84, p=0.00060) for subjects with schizophrenia, but it was not significant (p<0.05) in ASD vs. healthy controls comparison.
124-1	24942-24946	This	_	
124-2	24947-24951	area	_	
124-3	24952-24955	met	_	
124-4	24956-24966	Bonferroni	_	
124-5	24967-24976	criterion	_	
124-6	24977-24978	(	_	
124-7	24978-24982	0.05	_	
124-8	24982-24983	/	_	
124-9	24983-24985	84	_	
124-10	24985-24986	,	_	
124-11	24987-24988	p	_	
124-12	24988-24989	=	_	
124-13	24989-24996	0.00060	_	
124-14	24996-24997	)	_	
124-15	24998-25001	for	_	
124-16	25002-25010	subjects	_	
124-17	25011-25015	with	_	
124-18	25016-25029	schizophrenia	_	
124-19	25029-25030	,	_	
124-20	25031-25034	but	_	
124-21	25035-25037	it	_	
124-22	25038-25041	was	_	
124-23	25042-25045	not	_	
124-24	25046-25057	significant	_	
124-25	25058-25059	(	_	
124-26	25059-25060	p	_	
124-27	25060-25061	<	_	
124-28	25061-25065	0.05	_	
124-29	25065-25066	)	_	
124-30	25067-25069	in	_	
124-31	25070-25073	ASD	_	
124-32	25074-25076	vs	_	
124-33	25076-25077	.	_	
124-34	25078-25085	healthy	_	
124-35	25086-25094	controls	_	
124-36	25095-25105	comparison	_	
124-37	25105-25106	.	_	

#Text=Serial Verbal Learning Test
#Text=Based on Student’s t-tests, subjects with schizophrenia showed worse performance than healthy controls in total number of correctly memorized words (t89=11.18, p<0.0000001) and in their semantic clustering (t89=9.57, p<0.0000001), and they expressed more intrusions (t89=3.53, p=0.0007) and perseverations (t89=3.10, p=0.003), with no significant differences in serial ordering (Fig. 6).
125-1	25107-25113	Serial	_	
125-2	25114-25120	Verbal	_	
125-3	25121-25129	Learning	_	
125-4	25130-25134	Test	_	
125-5	25135-25140	Based	_	
125-6	25141-25143	on	_	
125-7	25144-25151	Student	_	
125-8	25151-25152	’	_	
125-9	25152-25153	s	_	
125-10	25154-25161	t-tests	_	
125-11	25161-25162	,	_	
125-12	25163-25171	subjects	_	
125-13	25172-25176	with	_	
125-14	25177-25190	schizophrenia	_	
125-15	25191-25197	showed	_	
125-16	25198-25203	worse	_	
125-17	25204-25215	performance	_	
125-18	25216-25220	than	_	
125-19	25221-25228	healthy	_	
125-20	25229-25237	controls	_	
125-21	25238-25240	in	_	
125-22	25241-25246	total	_	
125-23	25247-25253	number	_	
125-24	25254-25256	of	_	
125-25	25257-25266	correctly	_	
125-26	25267-25276	memorized	_	
125-27	25277-25282	words	_	
125-28	25283-25284	(	_	
125-29	25284-25287	t89	_	
125-30	25287-25288	=	_	
125-31	25288-25293	11.18	_	
125-32	25293-25294	,	_	
125-33	25295-25296	p	_	
125-34	25296-25297	<	_	
125-35	25297-25306	0.0000001	_	
125-36	25306-25307	)	_	
125-37	25308-25311	and	_	
125-38	25312-25314	in	_	
125-39	25315-25320	their	_	
125-40	25321-25329	semantic	_	
125-41	25330-25340	clustering	_	
125-42	25341-25342	(	_	
125-43	25342-25345	t89	_	
125-44	25345-25346	=	_	
125-45	25346-25350	9.57	_	
125-46	25350-25351	,	_	
125-47	25352-25353	p	_	
125-48	25353-25354	<	_	
125-49	25354-25363	0.0000001	_	
125-50	25363-25364	)	_	
125-51	25364-25365	,	_	
125-52	25366-25369	and	_	
125-53	25370-25374	they	_	
125-54	25375-25384	expressed	_	
125-55	25385-25389	more	_	
125-56	25390-25400	intrusions	_	
125-57	25401-25402	(	_	
125-58	25402-25405	t89	_	
125-59	25405-25406	=	_	
125-60	25406-25410	3.53	_	
125-61	25410-25411	,	_	
125-62	25412-25413	p	_	
125-63	25413-25414	=	_	
125-64	25414-25420	0.0007	_	
125-65	25420-25421	)	_	
125-66	25422-25425	and	_	
125-67	25426-25440	perseverations	_	
125-68	25441-25442	(	_	
125-69	25442-25445	t89	_	
125-70	25445-25446	=	_	
125-71	25446-25450	3.10	_	
125-72	25450-25451	,	_	
125-73	25452-25453	p	_	
125-74	25453-25454	=	_	
125-75	25454-25459	0.003	_	
125-76	25459-25460	)	_	
125-77	25460-25461	,	_	
125-78	25462-25466	with	_	
125-79	25467-25469	no	_	
125-80	25470-25481	significant	_	
125-81	25482-25493	differences	_	
125-82	25494-25496	in	_	
125-83	25497-25503	serial	_	
125-84	25504-25512	ordering	_	
125-85	25513-25514	(	_	
125-86	25514-25517	Fig	_	
125-87	25517-25518	.	_	
125-88	25519-25520	6	_	
125-89	25520-25521	)	_	
125-90	25521-25522	.	_	

#Text=Subjects with ASD showed worse performance than healthy controls in semantic clustering (t60=2.32, p=0.02) and more intrusions (t61=3.50, p=0.0009) and perseverations (t61=2.30, p=0.025), but their performance was numerically intermediate to that of healthy controls and subjects with schizophrenia.
126-1	25523-25531	Subjects	_	
126-2	25532-25536	with	_	
126-3	25537-25540	ASD	_	
126-4	25541-25547	showed	_	
126-5	25548-25553	worse	_	
126-6	25554-25565	performance	_	
126-7	25566-25570	than	_	
126-8	25571-25578	healthy	_	
126-9	25579-25587	controls	_	
126-10	25588-25590	in	_	
126-11	25591-25599	semantic	_	
126-12	25600-25610	clustering	_	
126-13	25611-25612	(	_	
126-14	25612-25615	t60	_	
126-15	25615-25616	=	_	
126-16	25616-25620	2.32	_	
126-17	25620-25621	,	_	
126-18	25622-25623	p	_	
126-19	25623-25624	=	_	
126-20	25624-25628	0.02	_	
126-21	25628-25629	)	_	
126-22	25630-25633	and	_	
126-23	25634-25638	more	_	
126-24	25639-25649	intrusions	_	
126-25	25650-25651	(	_	
126-26	25651-25654	t61	_	
126-27	25654-25655	=	_	
126-28	25655-25659	3.50	_	
126-29	25659-25660	,	_	
126-30	25661-25662	p	_	
126-31	25662-25663	=	_	
126-32	25663-25669	0.0009	_	
126-33	25669-25670	)	_	
126-34	25671-25674	and	_	
126-35	25675-25689	perseverations	_	
126-36	25690-25691	(	_	
126-37	25691-25694	t61	_	
126-38	25694-25695	=	_	
126-39	25695-25699	2.30	_	
126-40	25699-25700	,	_	
126-41	25701-25702	p	_	
126-42	25702-25703	=	_	
126-43	25703-25708	0.025	_	
126-44	25708-25709	)	_	
126-45	25709-25710	,	_	
126-46	25711-25714	but	_	
126-47	25715-25720	their	_	
126-48	25721-25732	performance	_	
126-49	25733-25736	was	_	
126-50	25737-25748	numerically	_	
126-51	25749-25761	intermediate	_	
126-52	25762-25764	to	_	
126-53	25765-25769	that	_	
126-54	25770-25772	of	_	
126-55	25773-25780	healthy	_	
126-56	25781-25789	controls	_	
126-57	25790-25793	and	_	
126-58	25794-25802	subjects	_	
126-59	25803-25807	with	_	
126-60	25808-25821	schizophrenia	_	
126-61	25821-25822	.	_	

#Text=In direct comparison of subjects with ASD and schizophrenia, the latter showed worse performance in total number of correctly memorized words (t43=3.74, p=0.0005) and in their semantic clustering (t43=2.38, p=0.02).
127-1	25823-25825	In	_	
127-2	25826-25832	direct	_	
127-3	25833-25843	comparison	_	
127-4	25844-25846	of	_	
127-5	25847-25855	subjects	_	
127-6	25856-25860	with	_	
127-7	25861-25864	ASD	_	
127-8	25865-25868	and	_	
127-9	25869-25882	schizophrenia	_	
127-10	25882-25883	,	_	
127-11	25884-25887	the	_	
127-12	25888-25894	latter	_	
127-13	25895-25901	showed	_	
127-14	25902-25907	worse	_	
127-15	25908-25919	performance	_	
127-16	25920-25922	in	_	
127-17	25923-25928	total	_	
127-18	25929-25935	number	_	
127-19	25936-25938	of	_	
127-20	25939-25948	correctly	_	
127-21	25949-25958	memorized	_	
127-22	25959-25964	words	_	
127-23	25965-25966	(	_	
127-24	25966-25969	t43	_	
127-25	25969-25970	=	_	
127-26	25970-25974	3.74	_	
127-27	25974-25975	,	_	
127-28	25976-25977	p	_	
127-29	25977-25978	=	_	
127-30	25978-25984	0.0005	_	
127-31	25984-25985	)	_	
127-32	25986-25989	and	_	
127-33	25990-25992	in	_	
127-34	25993-25998	their	_	
127-35	25999-26007	semantic	_	
127-36	26008-26018	clustering	_	
127-37	26019-26020	(	_	
127-38	26020-26023	t43	_	
127-39	26023-26024	=	_	
127-40	26024-26028	2.38	_	
127-41	26028-26029	,	_	
127-42	26030-26031	p	_	
127-43	26031-26032	=	_	
127-44	26032-26036	0.02	_	
127-45	26036-26037	)	_	
127-46	26037-26038	.	_	

#Text=In order to test whether between-group differences in metabolic rates were primarily related to differential activation under task performance, we ran three-group and two-group ANCOVAs controlling for performance on the two SVLT subtests that showed significant differences between subjects with schizophrenia and ASD (number of correctly memorized words and semantic clustering).
128-1	26039-26041	In	_	
128-2	26042-26047	order	_	
128-3	26048-26050	to	_	
128-4	26051-26055	test	_	
128-5	26056-26063	whether	_	
128-6	26064-26077	between-group	_	
128-7	26078-26089	differences	_	
128-8	26090-26092	in	_	
128-9	26093-26102	metabolic	_	
128-10	26103-26108	rates	_	
128-11	26109-26113	were	_	
128-12	26114-26123	primarily	_	
128-13	26124-26131	related	_	
128-14	26132-26134	to	_	
128-15	26135-26147	differential	_	
128-16	26148-26158	activation	_	
128-17	26159-26164	under	_	
128-18	26165-26169	task	_	
128-19	26170-26181	performance	_	
128-20	26181-26182	,	_	
128-21	26183-26185	we	_	
128-22	26186-26189	ran	_	
128-23	26190-26201	three-group	_	
128-24	26202-26205	and	_	
128-25	26206-26215	two-group	_	
128-26	26216-26223	ANCOVAs	_	
128-27	26224-26235	controlling	_	
128-28	26236-26239	for	_	
128-29	26240-26251	performance	_	
128-30	26252-26254	on	_	
128-31	26255-26258	the	_	
128-32	26259-26262	two	_	
128-33	26263-26267	SVLT	_	
128-34	26268-26276	subtests	_	
128-35	26277-26281	that	_	
128-36	26282-26288	showed	_	
128-37	26289-26300	significant	_	
128-38	26301-26312	differences	_	
128-39	26313-26320	between	_	
128-40	26321-26329	subjects	_	
128-41	26330-26334	with	_	
128-42	26335-26348	schizophrenia	_	
128-43	26349-26352	and	_	
128-44	26353-26356	ASD	_	
128-45	26357-26358	(	_	
128-46	26358-26364	number	_	
128-47	26365-26367	of	_	
128-48	26368-26377	correctly	_	
128-49	26378-26387	memorized	_	
128-50	26388-26393	words	_	
128-51	26394-26397	and	_	
128-52	26398-26406	semantic	_	
128-53	26407-26417	clustering	_	
128-54	26417-26418	)	_	
128-55	26418-26419	.	_	

#Text=This was expected to render metabolic differences related to task-induced activations less or nonsignificant while leaving the regional differences in basal metabolic rates intact.
129-1	26420-26424	This	_	
129-2	26425-26428	was	_	
129-3	26429-26437	expected	_	
129-4	26438-26440	to	_	
129-5	26441-26447	render	_	
129-6	26448-26457	metabolic	_	
129-7	26458-26469	differences	_	
129-8	26470-26477	related	_	
129-9	26478-26480	to	_	
129-10	26481-26493	task-induced	_	
129-11	26494-26505	activations	_	
129-12	26506-26510	less	_	
129-13	26511-26513	or	_	
129-14	26514-26528	nonsignificant	_	
129-15	26529-26534	while	_	
129-16	26535-26542	leaving	_	
129-17	26543-26546	the	_	
129-18	26547-26555	regional	_	
129-19	26556-26567	differences	_	
129-20	26568-26570	in	_	
129-21	26571-26576	basal	_	
129-22	26577-26586	metabolic	_	
129-23	26587-26592	rates	_	
129-24	26593-26599	intact	_	
129-25	26599-26600	.	_	

#Text=After controlling for test performance in three-group analyses (schizophrenia, ASD, healthy controls) statistically significant, albeit diminished differences remained in the group-by-Brodmann area interaction for all 42 cortical Brodmann areas (F82, 4059=1.60, p=0.0055, Wilks’ λ p=0.006), as well as in main effects of diagnostic group for the hippocampus (F2, 99= 6.89, p=0.002), claustrum (F2, 99= 5.95, p=0.004), tail of the caudate nucleus (F2, 99=9.10, p=0.0002), putamen (F2, 99=3.75, p=0.03), lateral globus pallidus (F2, 99 =3.33, p=0.04), and the thalamic nuclei: lateral posterior (F2, 99=7.17, p=0.001), pulvinar (F2, 99=5.26, p=0.007), and ventral posterolateral (F2, 99=2.95, p=0.057, trend level).
130-1	26601-26606	After	_	
130-2	26607-26618	controlling	_	
130-3	26619-26622	for	_	
130-4	26623-26627	test	_	
130-5	26628-26639	performance	_	
130-6	26640-26642	in	_	
130-7	26643-26654	three-group	_	
130-8	26655-26663	analyses	_	
130-9	26664-26665	(	_	
130-10	26665-26678	schizophrenia	_	
130-11	26678-26679	,	_	
130-12	26680-26683	ASD	_	
130-13	26683-26684	,	_	
130-14	26685-26692	healthy	_	
130-15	26693-26701	controls	_	
130-16	26701-26702	)	_	
130-17	26703-26716	statistically	_	
130-18	26717-26728	significant	_	
130-19	26728-26729	,	_	
130-20	26730-26736	albeit	_	
130-21	26737-26747	diminished	_	
130-22	26748-26759	differences	_	
130-23	26760-26768	remained	_	
130-24	26769-26771	in	_	
130-25	26772-26775	the	_	
130-26	26776-26793	group-by-Brodmann	_	
130-27	26794-26798	area	_	
130-28	26799-26810	interaction	_	
130-29	26811-26814	for	_	
130-30	26815-26818	all	_	
130-31	26819-26821	42	_	
130-32	26822-26830	cortical	_	
130-33	26831-26839	Brodmann	_	
130-34	26840-26845	areas	_	
130-35	26846-26847	(	_	
130-36	26847-26850	F82	_	
130-37	26850-26851	,	_	
130-38	26852-26856	4059	_	
130-39	26856-26857	=	_	
130-40	26857-26861	1.60	_	
130-41	26861-26862	,	_	
130-42	26863-26864	p	_	
130-43	26864-26865	=	_	
130-44	26865-26871	0.0055	_	
130-45	26871-26872	,	_	
130-46	26873-26878	Wilks	_	
130-47	26878-26879	’	_	
130-48	26880-26881	λ	_	
130-49	26882-26883	p	_	
130-50	26883-26884	=	_	
130-51	26884-26889	0.006	_	
130-52	26889-26890	)	_	
130-53	26890-26891	,	_	
130-54	26892-26894	as	_	
130-55	26895-26899	well	_	
130-56	26900-26902	as	_	
130-57	26903-26905	in	_	
130-58	26906-26910	main	_	
130-59	26911-26918	effects	_	
130-60	26919-26921	of	_	
130-61	26922-26932	diagnostic	_	
130-62	26933-26938	group	_	
130-63	26939-26942	for	_	
130-64	26943-26946	the	_	
130-65	26947-26958	hippocampus	_	
130-66	26959-26960	(	_	
130-67	26960-26962	F2	_	
130-68	26962-26963	,	_	
130-69	26964-26966	99	_	
130-70	26966-26967	=	_	
130-71	26968-26972	6.89	_	
130-72	26972-26973	,	_	
130-73	26974-26975	p	_	
130-74	26975-26976	=	_	
130-75	26976-26981	0.002	_	
130-76	26981-26982	)	_	
130-77	26982-26983	,	_	
130-78	26984-26993	claustrum	_	
130-79	26994-26995	(	_	
130-80	26995-26997	F2	_	
130-81	26997-26998	,	_	
130-82	26999-27001	99	_	
130-83	27001-27002	=	_	
130-84	27003-27007	5.95	_	
130-85	27007-27008	,	_	
130-86	27009-27010	p	_	
130-87	27010-27011	=	_	
130-88	27011-27016	0.004	_	
130-89	27016-27017	)	_	
130-90	27017-27018	,	_	
130-91	27019-27023	tail	_	
130-92	27024-27026	of	_	
130-93	27027-27030	the	_	
130-94	27031-27038	caudate	_	
130-95	27039-27046	nucleus	_	
130-96	27047-27048	(	_	
130-97	27048-27050	F2	_	
130-98	27050-27051	,	_	
130-99	27052-27054	99	_	
130-100	27054-27055	=	_	
130-101	27055-27059	9.10	_	
130-102	27059-27060	,	_	
130-103	27061-27062	p	_	
130-104	27062-27063	=	_	
130-105	27063-27069	0.0002	_	
130-106	27069-27070	)	_	
130-107	27070-27071	,	_	
130-108	27072-27079	putamen	_	
130-109	27080-27081	(	_	
130-110	27081-27083	F2	_	
130-111	27083-27084	,	_	
130-112	27085-27087	99	_	
130-113	27087-27088	=	_	
130-114	27088-27092	3.75	_	
130-115	27092-27093	,	_	
130-116	27094-27095	p	_	
130-117	27095-27096	=	_	
130-118	27096-27100	0.03	_	
130-119	27100-27101	)	_	
130-120	27101-27102	,	_	
130-121	27103-27110	lateral	_	
130-122	27111-27117	globus	_	
130-123	27118-27126	pallidus	_	
130-124	27127-27128	(	_	
130-125	27128-27130	F2	_	
130-126	27130-27131	,	_	
130-127	27132-27134	99	_	
130-128	27135-27136	=	_	
130-129	27136-27140	3.33	_	
130-130	27140-27141	,	_	
130-131	27142-27143	p	_	
130-132	27143-27144	=	_	
130-133	27144-27148	0.04	_	
130-134	27148-27149	)	_	
130-135	27149-27150	,	_	
130-136	27151-27154	and	_	
130-137	27155-27158	the	_	
130-138	27159-27167	thalamic	_	
130-139	27168-27174	nuclei	_	
130-140	27174-27175	:	_	
130-141	27176-27183	lateral	_	
130-142	27184-27193	posterior	_	
130-143	27194-27195	(	_	
130-144	27195-27197	F2	_	
130-145	27197-27198	,	_	
130-146	27199-27201	99	_	
130-147	27201-27202	=	_	
130-148	27202-27206	7.17	_	
130-149	27206-27207	,	_	
130-150	27208-27209	p	_	
130-151	27209-27210	=	_	
130-152	27210-27215	0.001	_	
130-153	27215-27216	)	_	
130-154	27216-27217	,	_	
130-155	27218-27226	pulvinar	_	
130-156	27227-27228	(	_	
130-157	27228-27230	F2	_	
130-158	27230-27231	,	_	
130-159	27232-27234	99	_	
130-160	27234-27235	=	_	
130-161	27235-27239	5.26	_	
130-162	27239-27240	,	_	
130-163	27241-27242	p	_	
130-164	27242-27243	=	_	
130-165	27243-27248	0.007	_	
130-166	27248-27249	)	_	
130-167	27249-27250	,	_	
130-168	27251-27254	and	_	
130-169	27255-27262	ventral	_	
130-170	27263-27277	posterolateral	_	
130-171	27278-27279	(	_	
130-172	27279-27281	F2	_	
130-173	27281-27282	,	_	
130-174	27283-27285	99	_	
130-175	27285-27286	=	_	
130-176	27286-27290	2.95	_	
130-177	27290-27291	,	_	
130-178	27292-27293	p	_	
130-179	27293-27294	=	_	
130-180	27294-27299	0.057	_	
130-181	27299-27300	,	_	
130-182	27301-27306	trend	_	
130-183	27307-27312	level	_	
130-184	27312-27313	)	_	
130-185	27313-27314	.	_	

#Text=Differences in the hypothalamus and amygdala were reduced to the trend level of significance (F2, 99=2.51, p=0.09 and F2, 99=2.45, p=0.09, respectively).
131-1	27315-27326	Differences	_	
131-2	27327-27329	in	_	
131-3	27330-27333	the	_	
131-4	27334-27346	hypothalamus	_	
131-5	27347-27350	and	_	
131-6	27351-27359	amygdala	_	
131-7	27360-27364	were	_	
131-8	27365-27372	reduced	_	
131-9	27373-27375	to	_	
131-10	27376-27379	the	_	
131-11	27380-27385	trend	_	
131-12	27386-27391	level	_	
131-13	27392-27394	of	_	
131-14	27395-27407	significance	_	
131-15	27408-27409	(	_	
131-16	27409-27411	F2	_	
131-17	27411-27412	,	_	
131-18	27413-27415	99	_	
131-19	27415-27416	=	_	
131-20	27416-27420	2.51	_	
131-21	27420-27421	,	_	
131-22	27422-27423	p	_	
131-23	27423-27424	=	_	
131-24	27424-27428	0.09	_	
131-25	27429-27432	and	_	
131-26	27433-27435	F2	_	
131-27	27435-27436	,	_	
131-28	27437-27439	99	_	
131-29	27439-27440	=	_	
131-30	27440-27444	2.45	_	
131-31	27444-27445	,	_	
131-32	27446-27447	p	_	
131-33	27447-27448	=	_	
131-34	27448-27452	0.09	_	
131-35	27452-27453	,	_	
131-36	27454-27466	respectively	_	
131-37	27466-27467	)	_	
131-38	27467-27468	.	_	

#Text=In two-group analyses (schizophrenia vs ASD) significant differences remained in the hypothalamus (F1, 46=5.80, p=0.02) and posterolateral nucleus of the thalamus (F1, 46=6.86, p=0.01), with trend level reached in the pulvinar (F1, 46=3.24, p=0.08).
132-1	27469-27471	In	_	
132-2	27472-27481	two-group	_	
132-3	27482-27490	analyses	_	
132-4	27491-27492	(	_	
132-5	27492-27505	schizophrenia	_	
132-6	27506-27508	vs	_	
132-7	27509-27512	ASD	_	
132-8	27512-27513	)	_	
132-9	27514-27525	significant	_	
132-10	27526-27537	differences	_	
132-11	27538-27546	remained	_	
132-12	27547-27549	in	_	
132-13	27550-27553	the	_	
132-14	27554-27566	hypothalamus	_	
132-15	27567-27568	(	_	
132-16	27568-27570	F1	_	
132-17	27570-27571	,	_	
132-18	27572-27574	46	_	
132-19	27574-27575	=	_	
132-20	27575-27579	5.80	_	
132-21	27579-27580	,	_	
132-22	27581-27582	p	_	
132-23	27582-27583	=	_	
132-24	27583-27587	0.02	_	
132-25	27587-27588	)	_	
132-26	27589-27592	and	_	
132-27	27593-27607	posterolateral	_	
132-28	27608-27615	nucleus	_	
132-29	27616-27618	of	_	
132-30	27619-27622	the	_	
132-31	27623-27631	thalamus	_	
132-32	27632-27633	(	_	
132-33	27633-27635	F1	_	
132-34	27635-27636	,	_	
132-35	27637-27639	46	_	
132-36	27639-27640	=	_	
132-37	27640-27644	6.86	_	
132-38	27644-27645	,	_	
132-39	27646-27647	p	_	
132-40	27647-27648	=	_	
132-41	27648-27652	0.01	_	
132-42	27652-27653	)	_	
132-43	27653-27654	,	_	
132-44	27655-27659	with	_	
132-45	27660-27665	trend	_	
132-46	27666-27671	level	_	
132-47	27672-27679	reached	_	
132-48	27680-27682	in	_	
132-49	27683-27686	the	_	
132-50	27687-27695	pulvinar	_	
132-51	27696-27697	(	_	
132-52	27697-27699	F1	_	
132-53	27699-27700	,	_	
132-54	27701-27703	46	_	
132-55	27703-27704	=	_	
132-56	27704-27708	3.24	_	
132-57	27708-27709	,	_	
132-58	27710-27711	p	_	
132-59	27711-27712	=	_	
132-60	27712-27716	0.08	_	
132-61	27716-27717	)	_	
132-62	27717-27718	.	_	

#Text=Cortical Brodmann area ANCOVAs with SVLT scores as the covariates also produced significant group-by-hemisphere interactions (F2, 99=3.56, p=0.03 for three groups and F1, 46=4.96, p=0.03 for two groups).
133-1	27719-27727	Cortical	_	
133-2	27728-27736	Brodmann	_	
133-3	27737-27741	area	_	
133-4	27742-27749	ANCOVAs	_	
133-5	27750-27754	with	_	
133-6	27755-27759	SVLT	_	
133-7	27760-27766	scores	_	
133-8	27767-27769	as	_	
133-9	27770-27773	the	_	
133-10	27774-27784	covariates	_	
133-11	27785-27789	also	_	
133-12	27790-27798	produced	_	
133-13	27799-27810	significant	_	
133-14	27811-27830	group-by-hemisphere	_	
133-15	27831-27843	interactions	_	
133-16	27844-27845	(	_	
133-17	27845-27847	F2	_	
133-18	27847-27848	,	_	
133-19	27849-27851	99	_	
133-20	27851-27852	=	_	
133-21	27852-27856	3.56	_	
133-22	27856-27857	,	_	
133-23	27858-27859	p	_	
133-24	27859-27860	=	_	
133-25	27860-27864	0.03	_	
133-26	27865-27868	for	_	
133-27	27869-27874	three	_	
133-28	27875-27881	groups	_	
133-29	27882-27885	and	_	
133-30	27886-27888	F1	_	
133-31	27888-27889	,	_	
133-32	27890-27892	46	_	
133-33	27892-27893	=	_	
133-34	27893-27897	4.96	_	
133-35	27897-27898	,	_	
133-36	27899-27900	p	_	
133-37	27900-27901	=	_	
133-38	27901-27905	0.03	_	
133-39	27906-27909	for	_	
133-40	27910-27913	two	_	
133-41	27914-27920	groups	_	
133-42	27920-27921	)	_	
133-43	27921-27922	.	_	

#Text=These hemispheric effects pointed to greater-than-normal basal cortical metabolic rates in subjects with ASD and markedly lower-than-normal rates in those with schizophrenia in the right hemisphere, with much smaller between-group differences in the left hemisphere.
134-1	27923-27928	These	_	
134-2	27929-27940	hemispheric	_	
134-3	27941-27948	effects	_	
134-4	27949-27956	pointed	_	
134-5	27957-27959	to	_	
134-6	27960-27979	greater-than-normal	_	
134-7	27980-27985	basal	_	
134-8	27986-27994	cortical	_	
134-9	27995-28004	metabolic	_	
134-10	28005-28010	rates	_	
134-11	28011-28013	in	_	
134-12	28014-28022	subjects	_	
134-13	28023-28027	with	_	
134-14	28028-28031	ASD	_	
134-15	28032-28035	and	_	
134-16	28036-28044	markedly	_	
134-17	28045-28062	lower-than-normal	_	
134-18	28063-28068	rates	_	
134-19	28069-28071	in	_	
134-20	28072-28077	those	_	
134-21	28078-28082	with	_	
134-22	28083-28096	schizophrenia	_	
134-23	28097-28099	in	_	
134-24	28100-28103	the	_	
134-25	28104-28109	right	_	
134-26	28110-28120	hemisphere	_	
134-27	28120-28121	,	_	
134-28	28122-28126	with	_	
134-29	28127-28131	much	_	
134-30	28132-28139	smaller	_	
134-31	28140-28153	between-group	_	
134-32	28154-28165	differences	_	
134-33	28166-28168	in	_	
134-34	28169-28172	the	_	
134-35	28173-28177	left	_	
134-36	28178-28188	hemisphere	_	
134-37	28188-28189	.	_	

#Text=Of the differences remaining statistically significant after controlling for task performance, all but the putamen and lateral globus pallidus survived the Bonferroni correction in three-group analyses, while none of the differences survived the procedure in two-group schizophrenia vs.
135-1	28190-28192	Of	_	
135-2	28193-28196	the	_	
135-3	28197-28208	differences	_	
135-4	28209-28218	remaining	_	
135-5	28219-28232	statistically	_	
135-6	28233-28244	significant	_	
135-7	28245-28250	after	_	
135-8	28251-28262	controlling	_	
135-9	28263-28266	for	_	
135-10	28267-28271	task	_	
135-11	28272-28283	performance	_	
135-12	28283-28284	,	_	
135-13	28285-28288	all	_	
135-14	28289-28292	but	_	
135-15	28293-28296	the	_	
135-16	28297-28304	putamen	_	
135-17	28305-28308	and	_	
135-18	28309-28316	lateral	_	
135-19	28317-28323	globus	_	
135-20	28324-28332	pallidus	_	
135-21	28333-28341	survived	_	
135-22	28342-28345	the	_	
135-23	28346-28356	Bonferroni	_	
135-24	28357-28367	correction	_	
135-25	28368-28370	in	_	
135-26	28371-28382	three-group	_	
135-27	28383-28391	analyses	_	
135-28	28391-28392	,	_	
135-29	28393-28398	while	_	
135-30	28399-28403	none	_	
135-31	28404-28406	of	_	
135-32	28407-28410	the	_	
135-33	28411-28422	differences	_	
135-34	28423-28431	survived	_	
135-35	28432-28435	the	_	
135-36	28436-28445	procedure	_	
135-37	28446-28448	in	_	
135-38	28449-28458	two-group	_	
135-39	28459-28472	schizophrenia	_	
135-40	28473-28475	vs	_	
135-41	28475-28476	.	_	

#Text=ASD analyses (see footnotes to Table 1 for the Bonferroni criteria).
136-1	28477-28480	ASD	_	
136-2	28481-28489	analyses	_	
136-3	28490-28491	(	_	
136-4	28491-28494	see	_	
136-5	28495-28504	footnotes	_	
136-6	28505-28507	to	_	
136-7	28508-28513	Table	_	
136-8	28514-28515	1	_	
136-9	28516-28519	for	_	
136-10	28520-28523	the	_	
136-11	28524-28534	Bonferroni	_	
136-12	28535-28543	criteria	_	
136-13	28543-28544	)	_	
136-14	28544-28545	.	_	

#Text=Exploratory analysis of correlation patterns between the subjects’ performance on total number of correctly memorized words and their semantic clustering with metabolic rates across the regions of interest in each group of participants revealed the following intergroup differences.
137-1	28546-28557	Exploratory	_	
137-2	28558-28566	analysis	_	
137-3	28567-28569	of	_	
137-4	28570-28581	correlation	_	
137-5	28582-28590	patterns	_	
137-6	28591-28598	between	_	
137-7	28599-28602	the	_	
137-8	28603-28611	subjects	_	
137-9	28611-28612	’	_	
137-10	28613-28624	performance	_	
137-11	28625-28627	on	_	
137-12	28628-28633	total	_	
137-13	28634-28640	number	_	
137-14	28641-28643	of	_	
137-15	28644-28653	correctly	_	
137-16	28654-28663	memorized	_	
137-17	28664-28669	words	_	
137-18	28670-28673	and	_	
137-19	28674-28679	their	_	
137-20	28680-28688	semantic	_	
137-21	28689-28699	clustering	_	
137-22	28700-28704	with	_	
137-23	28705-28714	metabolic	_	
137-24	28715-28720	rates	_	
137-25	28721-28727	across	_	
137-26	28728-28731	the	_	
137-27	28732-28739	regions	_	
137-28	28740-28742	of	_	
137-29	28743-28751	interest	_	
137-30	28752-28754	in	_	
137-31	28755-28759	each	_	
137-32	28760-28765	group	_	
137-33	28766-28768	of	_	
137-34	28769-28781	participants	_	
137-35	28782-28790	revealed	_	
137-36	28791-28794	the	_	
137-37	28795-28804	following	_	
137-38	28805-28815	intergroup	_	
137-39	28816-28827	differences	_	
137-40	28827-28828	.	_	

#Text=In healthy controls, significant positive correlations (p<0.05) for the total number of correctly memorized words were observed with the widespread cortical Brodmann areas in the left hemisphere (frontal areas 9, 10, 32; temporal areas 21, 22, 41; occipital area 19); negative correlations were recorded for the bilateral cerebellar subregions (uvula, tuber, pyramis) and right medial and lateral globi pallidi.
138-1	28829-28831	In	_	
138-2	28832-28839	healthy	_	
138-3	28840-28848	controls	_	
138-4	28848-28849	,	_	
138-5	28850-28861	significant	_	
138-6	28862-28870	positive	_	
138-7	28871-28883	correlations	_	
138-8	28884-28885	(	_	
138-9	28885-28886	p	_	
138-10	28886-28887	<	_	
138-11	28887-28891	0.05	_	
138-12	28891-28892	)	_	
138-13	28893-28896	for	_	
138-14	28897-28900	the	_	
138-15	28901-28906	total	_	
138-16	28907-28913	number	_	
138-17	28914-28916	of	_	
138-18	28917-28926	correctly	_	
138-19	28927-28936	memorized	_	
138-20	28937-28942	words	_	
138-21	28943-28947	were	_	
138-22	28948-28956	observed	_	
138-23	28957-28961	with	_	
138-24	28962-28965	the	_	
138-25	28966-28976	widespread	_	
138-26	28977-28985	cortical	_	
138-27	28986-28994	Brodmann	_	
138-28	28995-29000	areas	_	
138-29	29001-29003	in	_	
138-30	29004-29007	the	_	
138-31	29008-29012	left	_	
138-32	29013-29023	hemisphere	_	
138-33	29024-29025	(	_	
138-34	29025-29032	frontal	_	
138-35	29033-29038	areas	_	
138-36	29039-29040	9	_	
138-37	29040-29041	,	_	
138-38	29042-29044	10	_	
138-39	29044-29045	,	_	
138-40	29046-29048	32	_	
138-41	29048-29049	;	_	
138-42	29050-29058	temporal	_	
138-43	29059-29064	areas	_	
138-44	29065-29067	21	_	
138-45	29067-29068	,	_	
138-46	29069-29071	22	_	
138-47	29071-29072	,	_	
138-48	29073-29075	41	_	
138-49	29075-29076	;	_	
138-50	29077-29086	occipital	_	
138-51	29087-29091	area	_	
138-52	29092-29094	19	_	
138-53	29094-29095	)	_	
138-54	29095-29096	;	_	
138-55	29097-29105	negative	_	
138-56	29106-29118	correlations	_	
138-57	29119-29123	were	_	
138-58	29124-29132	recorded	_	
138-59	29133-29136	for	_	
138-60	29137-29140	the	_	
138-61	29141-29150	bilateral	_	
138-62	29151-29161	cerebellar	_	
138-63	29162-29172	subregions	_	
138-64	29173-29174	(	_	
138-65	29174-29179	uvula	_	
138-66	29179-29180	,	_	
138-67	29181-29186	tuber	_	
138-68	29186-29187	,	_	
138-69	29188-29195	pyramis	_	
138-70	29195-29196	)	_	
138-71	29197-29200	and	_	
138-72	29201-29206	right	_	
138-73	29207-29213	medial	_	
138-74	29214-29217	and	_	
138-75	29218-29225	lateral	_	
138-76	29226-29231	globi	_	
138-77	29232-29239	pallidi	_	
138-78	29239-29240	.	_	

#Text=Semantic clustering scores were positively correlated with metabolic rates in the left hemisphere Brodmann areas 9, 44 (frontal lobe) and 21, 22 (temporal lobe); negative correlations were recorded with the bilateral cerebellar subregions (tuber, pyramis, declive, culmen) and right medial and lateral globi pallidi.
139-1	29241-29249	Semantic	_	
139-2	29250-29260	clustering	_	
139-3	29261-29267	scores	_	
139-4	29268-29272	were	_	
139-5	29273-29283	positively	_	
139-6	29284-29294	correlated	_	
139-7	29295-29299	with	_	
139-8	29300-29309	metabolic	_	
139-9	29310-29315	rates	_	
139-10	29316-29318	in	_	
139-11	29319-29322	the	_	
139-12	29323-29327	left	_	
139-13	29328-29338	hemisphere	_	
139-14	29339-29347	Brodmann	_	
139-15	29348-29353	areas	_	
139-16	29354-29355	9	_	
139-17	29355-29356	,	_	
139-18	29357-29359	44	_	
139-19	29360-29361	(	_	
139-20	29361-29368	frontal	_	
139-21	29369-29373	lobe	_	
139-22	29373-29374	)	_	
139-23	29375-29378	and	_	
139-24	29379-29381	21	_	
139-25	29381-29382	,	_	
139-26	29383-29385	22	_	
139-27	29386-29387	(	_	
139-28	29387-29395	temporal	_	
139-29	29396-29400	lobe	_	
139-30	29400-29401	)	_	
139-31	29401-29402	;	_	
139-32	29403-29411	negative	_	
139-33	29412-29424	correlations	_	
139-34	29425-29429	were	_	
139-35	29430-29438	recorded	_	
139-36	29439-29443	with	_	
139-37	29444-29447	the	_	
139-38	29448-29457	bilateral	_	
139-39	29458-29468	cerebellar	_	
139-40	29469-29479	subregions	_	
139-41	29480-29481	(	_	
139-42	29481-29486	tuber	_	
139-43	29486-29487	,	_	
139-44	29488-29495	pyramis	_	
139-45	29495-29496	,	_	
139-46	29497-29504	declive	_	
139-47	29504-29505	,	_	
139-48	29506-29512	culmen	_	
139-49	29512-29513	)	_	
139-50	29514-29517	and	_	
139-51	29518-29523	right	_	
139-52	29524-29530	medial	_	
139-53	29531-29534	and	_	
139-54	29535-29542	lateral	_	
139-55	29543-29548	globi	_	
139-56	29549-29556	pallidi	_	
139-57	29556-29557	.	_	

#Text=In subjects with schizophrenia, the total number of correctly memorized words yielded a single positive (left area 11) and negative (right cerebellar uvula) correlation; semantic clustering yielded positive correlations with bilateral area 11 and left area 25 (frontal lobe), and negative correlations with cerebellar subregions (right uvula and pyramis, left culmen) and right mediodorsal nucleus of the thalamus.
140-1	29558-29560	In	_	
140-2	29561-29569	subjects	_	
140-3	29570-29574	with	_	
140-4	29575-29588	schizophrenia	_	
140-5	29588-29589	,	_	
140-6	29590-29593	the	_	
140-7	29594-29599	total	_	
140-8	29600-29606	number	_	
140-9	29607-29609	of	_	
140-10	29610-29619	correctly	_	
140-11	29620-29629	memorized	_	
140-12	29630-29635	words	_	
140-13	29636-29643	yielded	_	
140-14	29644-29645	a	_	
140-15	29646-29652	single	_	
140-16	29653-29661	positive	_	
140-17	29662-29663	(	_	
140-18	29663-29667	left	_	
140-19	29668-29672	area	_	
140-20	29673-29675	11	_	
140-21	29675-29676	)	_	
140-22	29677-29680	and	_	
140-23	29681-29689	negative	_	
140-24	29690-29691	(	_	
140-25	29691-29696	right	_	
140-26	29697-29707	cerebellar	_	
140-27	29708-29713	uvula	_	
140-28	29713-29714	)	_	
140-29	29715-29726	correlation	_	
140-30	29726-29727	;	_	
140-31	29728-29736	semantic	_	
140-32	29737-29747	clustering	_	
140-33	29748-29755	yielded	_	
140-34	29756-29764	positive	_	
140-35	29765-29777	correlations	_	
140-36	29778-29782	with	_	
140-37	29783-29792	bilateral	_	
140-38	29793-29797	area	_	
140-39	29798-29800	11	_	
140-40	29801-29804	and	_	
140-41	29805-29809	left	_	
140-42	29810-29814	area	_	
140-43	29815-29817	25	_	
140-44	29818-29819	(	_	
140-45	29819-29826	frontal	_	
140-46	29827-29831	lobe	_	
140-47	29831-29832	)	_	
140-48	29832-29833	,	_	
140-49	29834-29837	and	_	
140-50	29838-29846	negative	_	
140-51	29847-29859	correlations	_	
140-52	29860-29864	with	_	
140-53	29865-29875	cerebellar	_	
140-54	29876-29886	subregions	_	
140-55	29887-29888	(	_	
140-56	29888-29893	right	_	
140-57	29894-29899	uvula	_	
140-58	29900-29903	and	_	
140-59	29904-29911	pyramis	_	
140-60	29911-29912	,	_	
140-61	29913-29917	left	_	
140-62	29918-29924	culmen	_	
140-63	29924-29925	)	_	
140-64	29926-29929	and	_	
140-65	29930-29935	right	_	
140-66	29936-29947	mediodorsal	_	
140-67	29948-29955	nucleus	_	
140-68	29956-29958	of	_	
140-69	29959-29962	the	_	
140-70	29963-29971	thalamus	_	
140-71	29971-29972	.	_	

#Text=In subjects with ASD, the total number of correctly memorized words was positively correlated with the left hemisphere areas 22, 37 (temporal lobe), bilateral areas 39, 42, 43 (parietal lobe and auditory cortex), as well as bilateral caudate (tail and body) and thalamic nuclei (right midline and pulvinar, left lateral dorsal); negative correlations were registered with the left cerebellar pyramis, temporal pole (area 38) and bilateral hypothalamus.
141-1	29973-29975	In	_	
141-2	29976-29984	subjects	_	
141-3	29985-29989	with	_	
141-4	29990-29993	ASD	_	
141-5	29993-29994	,	_	
141-6	29995-29998	the	_	
141-7	29999-30004	total	_	
141-8	30005-30011	number	_	
141-9	30012-30014	of	_	
141-10	30015-30024	correctly	_	
141-11	30025-30034	memorized	_	
141-12	30035-30040	words	_	
141-13	30041-30044	was	_	
141-14	30045-30055	positively	_	
141-15	30056-30066	correlated	_	
141-16	30067-30071	with	_	
141-17	30072-30075	the	_	
141-18	30076-30080	left	_	
141-19	30081-30091	hemisphere	_	
141-20	30092-30097	areas	_	
141-21	30098-30100	22	_	
141-22	30100-30101	,	_	
141-23	30102-30104	37	_	
141-24	30105-30106	(	_	
141-25	30106-30114	temporal	_	
141-26	30115-30119	lobe	_	
141-27	30119-30120	)	_	
141-28	30120-30121	,	_	
141-29	30122-30131	bilateral	_	
141-30	30132-30137	areas	_	
141-31	30138-30140	39	_	
141-32	30140-30141	,	_	
141-33	30142-30144	42	_	
141-34	30144-30145	,	_	
141-35	30146-30148	43	_	
141-36	30149-30150	(	_	
141-37	30150-30158	parietal	_	
141-38	30159-30163	lobe	_	
141-39	30164-30167	and	_	
141-40	30168-30176	auditory	_	
141-41	30177-30183	cortex	_	
141-42	30183-30184	)	_	
141-43	30184-30185	,	_	
141-44	30186-30188	as	_	
141-45	30189-30193	well	_	
141-46	30194-30196	as	_	
141-47	30197-30206	bilateral	_	
141-48	30207-30214	caudate	_	
141-49	30215-30216	(	_	
141-50	30216-30220	tail	_	
141-51	30221-30224	and	_	
141-52	30225-30229	body	_	
141-53	30229-30230	)	_	
141-54	30231-30234	and	_	
141-55	30235-30243	thalamic	_	
141-56	30244-30250	nuclei	_	
141-57	30251-30252	(	_	
141-58	30252-30257	right	_	
141-59	30258-30265	midline	_	
141-60	30266-30269	and	_	
141-61	30270-30278	pulvinar	_	
141-62	30278-30279	,	_	
141-63	30280-30284	left	_	
141-64	30285-30292	lateral	_	
141-65	30293-30299	dorsal	_	
141-66	30299-30300	)	_	
141-67	30300-30301	;	_	
141-68	30302-30310	negative	_	
141-69	30311-30323	correlations	_	
141-70	30324-30328	were	_	
141-71	30329-30339	registered	_	
141-72	30340-30344	with	_	
141-73	30345-30348	the	_	
141-74	30349-30353	left	_	
141-75	30354-30364	cerebellar	_	
141-76	30365-30372	pyramis	_	
141-77	30372-30373	,	_	
141-78	30374-30382	temporal	_	
141-79	30383-30387	pole	_	
141-80	30388-30389	(	_	
141-81	30389-30393	area	_	
141-82	30394-30396	38	_	
141-83	30396-30397	)	_	
141-84	30398-30401	and	_	
141-85	30402-30411	bilateral	_	
141-86	30412-30424	hypothalamus	_	
141-87	30424-30425	.	_	

#Text=Semantic clustering was positively correlated with the left hemisphere areas 8 (frontal lobe), 22, 42 (temporal lobe) and 43 (parietal lobe), bilateral caudate (tail and body), and thalamic nuclei (right lateral posterior and pulvinar, left midline); negative correlations were registered with the left temporal pole (area 38) and mammillary body, bilateral hypothalamus, and right substantia nigra.
142-1	30426-30434	Semantic	_	
142-2	30435-30445	clustering	_	
142-3	30446-30449	was	_	
142-4	30450-30460	positively	_	
142-5	30461-30471	correlated	_	
142-6	30472-30476	with	_	
142-7	30477-30480	the	_	
142-8	30481-30485	left	_	
142-9	30486-30496	hemisphere	_	
142-10	30497-30502	areas	_	
142-11	30503-30504	8	_	
142-12	30505-30506	(	_	
142-13	30506-30513	frontal	_	
142-14	30514-30518	lobe	_	
142-15	30518-30519	)	_	
142-16	30519-30520	,	_	
142-17	30521-30523	22	_	
142-18	30523-30524	,	_	
142-19	30525-30527	42	_	
142-20	30528-30529	(	_	
142-21	30529-30537	temporal	_	
142-22	30538-30542	lobe	_	
142-23	30542-30543	)	_	
142-24	30544-30547	and	_	
142-25	30548-30550	43	_	
142-26	30551-30552	(	_	
142-27	30552-30560	parietal	_	
142-28	30561-30565	lobe	_	
142-29	30565-30566	)	_	
142-30	30566-30567	,	_	
142-31	30568-30577	bilateral	_	
142-32	30578-30585	caudate	_	
142-33	30586-30587	(	_	
142-34	30587-30591	tail	_	
142-35	30592-30595	and	_	
142-36	30596-30600	body	_	
142-37	30600-30601	)	_	
142-38	30601-30602	,	_	
142-39	30603-30606	and	_	
142-40	30607-30615	thalamic	_	
142-41	30616-30622	nuclei	_	
142-42	30623-30624	(	_	
142-43	30624-30629	right	_	
142-44	30630-30637	lateral	_	
142-45	30638-30647	posterior	_	
142-46	30648-30651	and	_	
142-47	30652-30660	pulvinar	_	
142-48	30660-30661	,	_	
142-49	30662-30666	left	_	
142-50	30667-30674	midline	_	
142-51	30674-30675	)	_	
142-52	30675-30676	;	_	
142-53	30677-30685	negative	_	
142-54	30686-30698	correlations	_	
142-55	30699-30703	were	_	
142-56	30704-30714	registered	_	
142-57	30715-30719	with	_	
142-58	30720-30723	the	_	
142-59	30724-30728	left	_	
142-60	30729-30737	temporal	_	
142-61	30738-30742	pole	_	
142-62	30743-30744	(	_	
142-63	30744-30748	area	_	
142-64	30749-30751	38	_	
142-65	30751-30752	)	_	
142-66	30753-30756	and	_	
142-67	30757-30767	mammillary	_	
142-68	30768-30772	body	_	
142-69	30772-30773	,	_	
142-70	30774-30783	bilateral	_	
142-71	30784-30796	hypothalamus	_	
142-72	30796-30797	,	_	
142-73	30798-30801	and	_	
142-74	30802-30807	right	_	
142-75	30808-30818	substantia	_	
142-76	30819-30824	nigra	_	
142-77	30824-30825	.	_	

#Text=Discussion
#Text=The main findings of this study, as pertains to direct comparison of subjects with schizophrenia and ASD, are twofold: 1) both groups displayed comparable deviations from the normal metabolic patterns in most of the regions generally associated with the so-called social brain; 2) divergent metabolic patterns, that are compatible with the hypothesis of ASD and schizophrenia as diametrical trade-off diseases, were confined to a much more limited assortment of structures, of which only the anterior cingulate, somatosensory and motor regions are tentatively accorded roles in social cognition.
143-1	30826-30836	Discussion	_	
143-2	30837-30840	The	_	
143-3	30841-30845	main	_	
143-4	30846-30854	findings	_	
143-5	30855-30857	of	_	
143-6	30858-30862	this	_	
143-7	30863-30868	study	_	
143-8	30868-30869	,	_	
143-9	30870-30872	as	_	
143-10	30873-30881	pertains	_	
143-11	30882-30884	to	_	
143-12	30885-30891	direct	_	
143-13	30892-30902	comparison	_	
143-14	30903-30905	of	_	
143-15	30906-30914	subjects	_	
143-16	30915-30919	with	_	
143-17	30920-30933	schizophrenia	_	
143-18	30934-30937	and	_	
143-19	30938-30941	ASD	_	
143-20	30941-30942	,	_	
143-21	30943-30946	are	_	
143-22	30947-30954	twofold	_	
143-23	30954-30955	:	_	
143-24	30956-30957	1	_	
143-25	30957-30958	)	_	
143-26	30959-30963	both	_	
143-27	30964-30970	groups	_	
143-28	30971-30980	displayed	_	
143-29	30981-30991	comparable	_	
143-30	30992-31002	deviations	_	
143-31	31003-31007	from	_	
143-32	31008-31011	the	_	
143-33	31012-31018	normal	_	
143-34	31019-31028	metabolic	_	
143-35	31029-31037	patterns	_	
143-36	31038-31040	in	_	
143-37	31041-31045	most	_	
143-38	31046-31048	of	_	
143-39	31049-31052	the	_	
143-40	31053-31060	regions	_	
143-41	31061-31070	generally	_	
143-42	31071-31081	associated	_	
143-43	31082-31086	with	_	
143-44	31087-31090	the	_	
143-45	31091-31100	so-called	_	
143-46	31101-31107	social	_	
143-47	31108-31113	brain	_	
143-48	31113-31114	;	_	
143-49	31115-31116	2	_	
143-50	31116-31117	)	_	
143-51	31118-31127	divergent	_	
143-52	31128-31137	metabolic	_	
143-53	31138-31146	patterns	_	
143-54	31146-31147	,	_	
143-55	31148-31152	that	_	
143-56	31153-31156	are	_	
143-57	31157-31167	compatible	_	
143-58	31168-31172	with	_	
143-59	31173-31176	the	_	
143-60	31177-31187	hypothesis	_	
143-61	31188-31190	of	_	
143-62	31191-31194	ASD	_	
143-63	31195-31198	and	_	
143-64	31199-31212	schizophrenia	_	
143-65	31213-31215	as	_	
143-66	31216-31227	diametrical	_	
143-67	31228-31237	trade-off	_	
143-68	31238-31246	diseases	_	
143-69	31246-31247	,	_	
143-70	31248-31252	were	_	
143-71	31253-31261	confined	_	
143-72	31262-31264	to	_	
143-73	31265-31266	a	_	
143-74	31267-31271	much	_	
143-75	31272-31276	more	_	
143-76	31277-31284	limited	_	
143-77	31285-31295	assortment	_	
143-78	31296-31298	of	_	
143-79	31299-31309	structures	_	
143-80	31309-31310	,	_	
143-81	31311-31313	of	_	
143-82	31314-31319	which	_	
143-83	31320-31324	only	_	
143-84	31325-31328	the	_	
143-85	31329-31337	anterior	_	
143-86	31338-31347	cingulate	_	
143-87	31347-31348	,	_	
143-88	31349-31362	somatosensory	_	
143-89	31363-31366	and	_	
143-90	31367-31372	motor	_	
143-91	31373-31380	regions	_	
143-92	31381-31384	are	_	
143-93	31385-31396	tentatively	_	
143-94	31397-31405	accorded	_	
143-95	31406-31411	roles	_	
143-96	31412-31414	in	_	
143-97	31415-31421	social	_	
143-98	31422-31431	cognition	_	
143-99	31431-31432	.	_	

#Text=Subjects with schizophrenia and ASD showed similar changes in metabolic rates in the prefrontal cortex, including the frontopolar, dorsolateral and orbitofrontal regions (areas 8, 10, 11, 44, 45, 46, 47), inferior parietal lobule at the temporoparietal junction (39, 40), primary and accessory visual areas in the occipital cortex (17, 18), amygdala, hippocampus, as well as two thalamic nuclei (pulvinar, ventral posteromedial) and basal ganglia associated structures (tail of the caudate, lateral and medial globi pallidi, claustrum, putamen).
144-1	31433-31441	Subjects	_	
144-2	31442-31446	with	_	
144-3	31447-31460	schizophrenia	_	
144-4	31461-31464	and	_	
144-5	31465-31468	ASD	_	
144-6	31469-31475	showed	_	
144-7	31476-31483	similar	_	
144-8	31484-31491	changes	_	
144-9	31492-31494	in	_	
144-10	31495-31504	metabolic	_	
144-11	31505-31510	rates	_	
144-12	31511-31513	in	_	
144-13	31514-31517	the	_	
144-14	31518-31528	prefrontal	_	
144-15	31529-31535	cortex	_	
144-16	31535-31536	,	_	
144-17	31537-31546	including	_	
144-18	31547-31550	the	_	
144-19	31551-31562	frontopolar	_	
144-20	31562-31563	,	_	
144-21	31564-31576	dorsolateral	_	
144-22	31577-31580	and	_	
144-23	31581-31594	orbitofrontal	_	
144-24	31595-31602	regions	_	
144-25	31603-31604	(	_	
144-26	31604-31609	areas	_	
144-27	31610-31611	8	_	
144-28	31611-31612	,	_	
144-29	31613-31615	10	_	
144-30	31615-31616	,	_	
144-31	31617-31619	11	_	
144-32	31619-31620	,	_	
144-33	31621-31623	44	_	
144-34	31623-31624	,	_	
144-35	31625-31627	45	_	
144-36	31627-31628	,	_	
144-37	31629-31631	46	_	
144-38	31631-31632	,	_	
144-39	31633-31635	47	_	
144-40	31635-31636	)	_	
144-41	31636-31637	,	_	
144-42	31638-31646	inferior	_	
144-43	31647-31655	parietal	_	
144-44	31656-31662	lobule	_	
144-45	31663-31665	at	_	
144-46	31666-31669	the	_	
144-47	31670-31685	temporoparietal	_	
144-48	31686-31694	junction	_	
144-49	31695-31696	(	_	
144-50	31696-31698	39	_	
144-51	31698-31699	,	_	
144-52	31700-31702	40	_	
144-53	31702-31703	)	_	
144-54	31703-31704	,	_	
144-55	31705-31712	primary	_	
144-56	31713-31716	and	_	
144-57	31717-31726	accessory	_	
144-58	31727-31733	visual	_	
144-59	31734-31739	areas	_	
144-60	31740-31742	in	_	
144-61	31743-31746	the	_	
144-62	31747-31756	occipital	_	
144-63	31757-31763	cortex	_	
144-64	31764-31765	(	_	
144-65	31765-31767	17	_	
144-66	31767-31768	,	_	
144-67	31769-31771	18	_	
144-68	31771-31772	)	_	
144-69	31772-31773	,	_	
144-70	31774-31782	amygdala	_	
144-71	31782-31783	,	_	
144-72	31784-31795	hippocampus	_	
144-73	31795-31796	,	_	
144-74	31797-31799	as	_	
144-75	31800-31804	well	_	
144-76	31805-31807	as	_	
144-77	31808-31811	two	_	
144-78	31812-31820	thalamic	_	
144-79	31821-31827	nuclei	_	
144-80	31828-31829	(	_	
144-81	31829-31837	pulvinar	_	
144-82	31837-31838	,	_	
144-83	31839-31846	ventral	_	
144-84	31847-31860	posteromedial	_	
144-85	31860-31861	)	_	
144-86	31862-31865	and	_	
144-87	31866-31871	basal	_	
144-88	31872-31879	ganglia	_	
144-89	31880-31890	associated	_	
144-90	31891-31901	structures	_	
144-91	31902-31903	(	_	
144-92	31903-31907	tail	_	
144-93	31908-31910	of	_	
144-94	31911-31914	the	_	
144-95	31915-31922	caudate	_	
144-96	31922-31923	,	_	
144-97	31924-31931	lateral	_	
144-98	31932-31935	and	_	
144-99	31936-31942	medial	_	
144-100	31943-31948	globi	_	
144-101	31949-31956	pallidi	_	
144-102	31956-31957	,	_	
144-103	31958-31967	claustrum	_	
144-104	31967-31968	,	_	
144-105	31969-31976	putamen	_	
144-106	31976-31977	)	_	
144-107	31977-31978	.	_	

#Text=Most of these regions are viewed as major components of the social brain owing to such socially relevant functions as value assignment and more specifically emotion recognition (amygdala), theory of mind and perspective taking (temporoparietal junction, dorsolateral and ventromedial prefrontal cortex), mentalizing (medial prefrontal cortex), social reward (striatum).
145-1	31979-31983	Most	_	
145-2	31984-31986	of	_	
145-3	31987-31992	these	_	
145-4	31993-32000	regions	_	
145-5	32001-32004	are	_	
145-6	32005-32011	viewed	_	
145-7	32012-32014	as	_	
145-8	32015-32020	major	_	
145-9	32021-32031	components	_	
145-10	32032-32034	of	_	
145-11	32035-32038	the	_	
145-12	32039-32045	social	_	
145-13	32046-32051	brain	_	
145-14	32052-32057	owing	_	
145-15	32058-32060	to	_	
145-16	32061-32065	such	_	
145-17	32066-32074	socially	_	
145-18	32075-32083	relevant	_	
145-19	32084-32093	functions	_	
145-20	32094-32096	as	_	
145-21	32097-32102	value	_	
145-22	32103-32113	assignment	_	
145-23	32114-32117	and	_	
145-24	32118-32122	more	_	
145-25	32123-32135	specifically	_	
145-26	32136-32143	emotion	_	
145-27	32144-32155	recognition	_	
145-28	32156-32157	(	_	
145-29	32157-32165	amygdala	_	
145-30	32165-32166	)	_	
145-31	32166-32167	,	_	
145-32	32168-32174	theory	_	
145-33	32175-32177	of	_	
145-34	32178-32182	mind	_	
145-35	32183-32186	and	_	
145-36	32187-32198	perspective	_	
145-37	32199-32205	taking	_	
145-38	32206-32207	(	_	
145-39	32207-32222	temporoparietal	_	
145-40	32223-32231	junction	_	
145-41	32231-32232	,	_	
145-42	32233-32245	dorsolateral	_	
145-43	32246-32249	and	_	
145-44	32250-32262	ventromedial	_	
145-45	32263-32273	prefrontal	_	
145-46	32274-32280	cortex	_	
145-47	32280-32281	)	_	
145-48	32281-32282	,	_	
145-49	32283-32294	mentalizing	_	
145-50	32295-32296	(	_	
145-51	32296-32302	medial	_	
145-52	32303-32313	prefrontal	_	
145-53	32314-32320	cortex	_	
145-54	32320-32321	)	_	
145-55	32321-32322	,	_	
145-56	32323-32329	social	_	
145-57	32330-32336	reward	_	
145-58	32337-32338	(	_	
145-59	32338-32346	striatum	_	
145-60	32346-32347	)	_	
145-61	32347-32348	.	_	

#Text=Other shared regions point to similar impairments in visual information processing (occipital lobes), memory formation and retrieval (hippocampus), perseverative and stereotypical behaviors (basal ganglia).
146-1	32349-32354	Other	_	
146-2	32355-32361	shared	_	
146-3	32362-32369	regions	_	
146-4	32370-32375	point	_	
146-5	32376-32378	to	_	
146-6	32379-32386	similar	_	
146-7	32387-32398	impairments	_	
146-8	32399-32401	in	_	
146-9	32402-32408	visual	_	
146-10	32409-32420	information	_	
146-11	32421-32431	processing	_	
146-12	32432-32433	(	_	
146-13	32433-32442	occipital	_	
146-14	32443-32448	lobes	_	
146-15	32448-32449	)	_	
146-16	32449-32450	,	_	
146-17	32451-32457	memory	_	
146-18	32458-32467	formation	_	
146-19	32468-32471	and	_	
146-20	32472-32481	retrieval	_	
146-21	32482-32483	(	_	
146-22	32483-32494	hippocampus	_	
146-23	32494-32495	)	_	
146-24	32495-32496	,	_	
146-25	32497-32510	perseverative	_	
146-26	32511-32514	and	_	
146-27	32515-32528	stereotypical	_	
146-28	32529-32538	behaviors	_	
146-29	32539-32540	(	_	
146-30	32540-32545	basal	_	
146-31	32546-32553	ganglia	_	
146-32	32553-32554	)	_	
146-33	32554-32555	.	_	

#Text=Diametrically different changes in subjects with schizophrenia and ASD were found in the pericentral somatosensory and motor cortex (areas 2, 3, 4, 5), anterior cingulate (areas 32, 33), frontal area 9, and hypothalamus.
147-1	32556-32569	Diametrically	_	
147-2	32570-32579	different	_	
147-3	32580-32587	changes	_	
147-4	32588-32590	in	_	
147-5	32591-32599	subjects	_	
147-6	32600-32604	with	_	
147-7	32605-32618	schizophrenia	_	
147-8	32619-32622	and	_	
147-9	32623-32626	ASD	_	
147-10	32627-32631	were	_	
147-11	32632-32637	found	_	
147-12	32638-32640	in	_	
147-13	32641-32644	the	_	
147-14	32645-32656	pericentral	_	
147-15	32657-32670	somatosensory	_	
147-16	32671-32674	and	_	
147-17	32675-32680	motor	_	
147-18	32681-32687	cortex	_	
147-19	32688-32689	(	_	
147-20	32689-32694	areas	_	
147-21	32695-32696	2	_	
147-22	32696-32697	,	_	
147-23	32698-32699	3	_	
147-24	32699-32700	,	_	
147-25	32701-32702	4	_	
147-26	32702-32703	,	_	
147-27	32704-32705	5	_	
147-28	32705-32706	)	_	
147-29	32706-32707	,	_	
147-30	32708-32716	anterior	_	
147-31	32717-32726	cingulate	_	
147-32	32727-32728	(	_	
147-33	32728-32733	areas	_	
147-34	32734-32736	32	_	
147-35	32736-32737	,	_	
147-36	32738-32740	33	_	
147-37	32740-32741	)	_	
147-38	32741-32742	,	_	
147-39	32743-32750	frontal	_	
147-40	32751-32755	area	_	
147-41	32756-32757	9	_	
147-42	32757-32758	,	_	
147-43	32759-32762	and	_	
147-44	32763-32775	hypothalamus	_	
147-45	32775-32776	.	_	

#Text=Although still debated, motivational mechanisms and reward anticipation in the anterior cingulate and mirroring functions (empathy) of the motor and somatosensory cortices are often deemed relevant to social cognition and thus considered a part of the social brain.
148-1	32777-32785	Although	_	
148-2	32786-32791	still	_	
148-3	32792-32799	debated	_	
148-4	32799-32800	,	_	
148-5	32801-32813	motivational	_	
148-6	32814-32824	mechanisms	_	
148-7	32825-32828	and	_	
148-8	32829-32835	reward	_	
148-9	32836-32848	anticipation	_	
148-10	32849-32851	in	_	
148-11	32852-32855	the	_	
148-12	32856-32864	anterior	_	
148-13	32865-32874	cingulate	_	
148-14	32875-32878	and	_	
148-15	32879-32888	mirroring	_	
148-16	32889-32898	functions	_	
148-17	32899-32900	(	_	
148-18	32900-32907	empathy	_	
148-19	32907-32908	)	_	
148-20	32909-32911	of	_	
148-21	32912-32915	the	_	
148-22	32916-32921	motor	_	
148-23	32922-32925	and	_	
148-24	32926-32939	somatosensory	_	
148-25	32940-32948	cortices	_	
148-26	32949-32952	are	_	
148-27	32953-32958	often	_	
148-28	32959-32965	deemed	_	
148-29	32966-32974	relevant	_	
148-30	32975-32977	to	_	
148-31	32978-32984	social	_	
148-32	32985-32994	cognition	_	
148-33	32995-32998	and	_	
148-34	32999-33003	thus	_	
148-35	33004-33014	considered	_	
148-36	33015-33016	a	_	
148-37	33017-33021	part	_	
148-38	33022-33024	of	_	
148-39	33025-33028	the	_	
148-40	33029-33035	social	_	
148-41	33036-33041	brain	_	
148-42	33041-33042	.	_	

#Text=Medial portion of Brodmann area 9 may be relevant to reasoning, including social reasoning and mentalizing.
149-1	33043-33049	Medial	_	
149-2	33050-33057	portion	_	
149-3	33058-33060	of	_	
149-4	33061-33069	Brodmann	_	
149-5	33070-33074	area	_	
149-6	33075-33076	9	_	
149-7	33077-33080	may	_	
149-8	33081-33083	be	_	
149-9	33084-33092	relevant	_	
149-10	33093-33095	to	_	
149-11	33096-33105	reasoning	_	
149-12	33105-33106	,	_	
149-13	33107-33116	including	_	
149-14	33117-33123	social	_	
149-15	33124-33133	reasoning	_	
149-16	33134-33137	and	_	
149-17	33138-33149	mentalizing	_	
149-18	33149-33150	.	_	

#Text=In line with the diametrical hypothesis of, our present finding of higher-than-normal metabolic rates in the somatosensory and motor cortex in schizophrenia may underlie its position at the empathizing extreme of the systemizing-empathizing axis.
150-1	33151-33153	In	_	
150-2	33154-33158	line	_	
150-3	33159-33163	with	_	
150-4	33164-33167	the	_	
150-5	33168-33179	diametrical	_	
150-6	33180-33190	hypothesis	_	
150-7	33191-33193	of	_	
150-8	33193-33194	,	_	
150-9	33195-33198	our	_	
150-10	33199-33206	present	_	
150-11	33207-33214	finding	_	
150-12	33215-33217	of	_	
150-13	33218-33236	higher-than-normal	_	
150-14	33237-33246	metabolic	_	
150-15	33247-33252	rates	_	
150-16	33253-33255	in	_	
150-17	33256-33259	the	_	
150-18	33260-33273	somatosensory	_	
150-19	33274-33277	and	_	
150-20	33278-33283	motor	_	
150-21	33284-33290	cortex	_	
150-22	33291-33293	in	_	
150-23	33294-33307	schizophrenia	_	
150-24	33308-33311	may	_	
150-25	33312-33320	underlie	_	
150-26	33321-33324	its	_	
150-27	33325-33333	position	_	
150-28	33334-33336	at	_	
150-29	33337-33340	the	_	
150-30	33341-33352	empathizing	_	
150-31	33353-33360	extreme	_	
150-32	33361-33363	of	_	
150-33	33364-33367	the	_	
150-34	33368-33391	systemizing-empathizing	_	
150-35	33392-33396	axis	_	
150-36	33396-33397	.	_	

#Text=The finding of higher-than-normal metabolic rates in the medial prefrontal cortex (area 9) in ASD may then underlie its position at the systemizing (over-reasoning) extreme.
151-1	33398-33401	The	_	
151-2	33402-33409	finding	_	
151-3	33410-33412	of	_	
151-4	33413-33431	higher-than-normal	_	
151-5	33432-33441	metabolic	_	
151-6	33442-33447	rates	_	
151-7	33448-33450	in	_	
151-8	33451-33454	the	_	
151-9	33455-33461	medial	_	
151-10	33462-33472	prefrontal	_	
151-11	33473-33479	cortex	_	
151-12	33480-33481	(	_	
151-13	33481-33485	area	_	
151-14	33486-33487	9	_	
151-15	33487-33488	)	_	
151-16	33489-33491	in	_	
151-17	33492-33495	ASD	_	
151-18	33496-33499	may	_	
151-19	33500-33504	then	_	
151-20	33505-33513	underlie	_	
151-21	33514-33517	its	_	
151-22	33518-33526	position	_	
151-23	33527-33529	at	_	
151-24	33530-33533	the	_	
151-25	33534-33545	systemizing	_	
151-26	33546-33547	(	_	
151-27	33547-33561	over-reasoning	_	
151-28	33561-33562	)	_	
151-29	33563-33570	extreme	_	
151-30	33570-33571	.	_	

#Text=Another intriguing possibility may arise if the regions with diametrical changes in metabolic rates in subjects with ASD and schizophrenia are considered as a network.
152-1	33572-33579	Another	_	
152-2	33580-33590	intriguing	_	
152-3	33591-33602	possibility	_	
152-4	33603-33606	may	_	
152-5	33607-33612	arise	_	
152-6	33613-33615	if	_	
152-7	33616-33619	the	_	
152-8	33620-33627	regions	_	
152-9	33628-33632	with	_	
152-10	33633-33644	diametrical	_	
152-11	33645-33652	changes	_	
152-12	33653-33655	in	_	
152-13	33656-33665	metabolic	_	
152-14	33666-33671	rates	_	
152-15	33672-33674	in	_	
152-16	33675-33683	subjects	_	
152-17	33684-33688	with	_	
152-18	33689-33692	ASD	_	
152-19	33693-33696	and	_	
152-20	33697-33710	schizophrenia	_	
152-21	33711-33714	are	_	
152-22	33715-33725	considered	_	
152-23	33726-33728	as	_	
152-24	33729-33730	a	_	
152-25	33731-33738	network	_	
152-26	33738-33739	.	_	

#Text=Indeed, recent meta-analyses of PET imaging studies of dimorphism in male and female sexual behaviors include premotor and supplementary motor areas in their cognitive component, primary and secondary somatosensory areas – in the emotional component, anterior cingulate and hypothalamus – in the motivational component.
153-1	33740-33746	Indeed	_	
153-2	33746-33747	,	_	
153-3	33748-33754	recent	_	
153-4	33755-33768	meta-analyses	_	
153-5	33769-33771	of	_	
153-6	33772-33775	PET	_	
153-7	33776-33783	imaging	_	
153-8	33784-33791	studies	_	
153-9	33792-33794	of	_	
153-10	33795-33805	dimorphism	_	
153-11	33806-33808	in	_	
153-12	33809-33813	male	_	
153-13	33814-33817	and	_	
153-14	33818-33824	female	_	
153-15	33825-33831	sexual	_	
153-16	33832-33841	behaviors	_	
153-17	33842-33849	include	_	
153-18	33850-33858	premotor	_	
153-19	33859-33862	and	_	
153-20	33863-33876	supplementary	_	
153-21	33877-33882	motor	_	
153-22	33883-33888	areas	_	
153-23	33889-33891	in	_	
153-24	33892-33897	their	_	
153-25	33898-33907	cognitive	_	
153-26	33908-33917	component	_	
153-27	33917-33918	,	_	
153-28	33919-33926	primary	_	
153-29	33927-33930	and	_	
153-30	33931-33940	secondary	_	
153-31	33941-33954	somatosensory	_	
153-32	33955-33960	areas	_	
153-33	33961-33962	–	_	
153-34	33963-33965	in	_	
153-35	33966-33969	the	_	
153-36	33970-33979	emotional	_	
153-37	33980-33989	component	_	
153-38	33989-33990	,	_	
153-39	33991-33999	anterior	_	
153-40	34000-34009	cingulate	_	
153-41	34010-34013	and	_	
153-42	34014-34026	hypothalamus	_	
153-43	34027-34028	–	_	
153-44	34029-34031	in	_	
153-45	34032-34035	the	_	
153-46	34036-34048	motivational	_	
153-47	34049-34058	component	_	
153-48	34058-34059	.	_	

#Text=Of these, increased metabolic rates in the hypothalamus appear exclusively correlated with male sexual response.
154-1	34060-34062	Of	_	
154-2	34063-34068	these	_	
154-3	34068-34069	,	_	
154-4	34070-34079	increased	_	
154-5	34080-34089	metabolic	_	
154-6	34090-34095	rates	_	
154-7	34096-34098	in	_	
154-8	34099-34102	the	_	
154-9	34103-34115	hypothalamus	_	
154-10	34116-34122	appear	_	
154-11	34123-34134	exclusively	_	
154-12	34135-34145	correlated	_	
154-13	34146-34150	with	_	
154-14	34151-34155	male	_	
154-15	34156-34162	sexual	_	
154-16	34163-34171	response	_	
154-17	34171-34172	.	_	

#Text=The extreme male brain theory of autism posits the systemizing–empathizing axis of cognitive styles as a function of the dimensional distribution of psychological correlates of sexual dimorphism in population.
155-1	34173-34176	The	_	
155-2	34177-34184	extreme	_	
155-3	34185-34189	male	_	
155-4	34190-34195	brain	_	
155-5	34196-34202	theory	_	
155-6	34203-34205	of	_	
155-7	34206-34212	autism	_	
155-8	34213-34219	posits	_	
155-9	34220-34223	the	_	
155-10	34224-34247	systemizing–empathizing	_	
155-11	34248-34252	axis	_	
155-12	34253-34255	of	_	
155-13	34256-34265	cognitive	_	
155-14	34266-34272	styles	_	
155-15	34273-34275	as	_	
155-16	34276-34277	a	_	
155-17	34278-34286	function	_	
155-18	34287-34289	of	_	
155-19	34290-34293	the	_	
155-20	34294-34305	dimensional	_	
155-21	34306-34318	distribution	_	
155-22	34319-34321	of	_	
155-23	34322-34335	psychological	_	
155-24	34336-34346	correlates	_	
155-25	34347-34349	of	_	
155-26	34350-34356	sexual	_	
155-27	34357-34367	dimorphism	_	
155-28	34368-34370	in	_	
155-29	34371-34381	population	_	
155-30	34381-34382	.	_	

#Text=Herein reported higher-than-normal metabolic rates in the hypothalamus in subjects with ASD, as predicted by the extreme male brain theory, would place them at the male brain extreme, and reverse would be true of those with schizophrenia.
156-1	34383-34389	Herein	_	
156-2	34390-34398	reported	_	
156-3	34399-34417	higher-than-normal	_	
156-4	34418-34427	metabolic	_	
156-5	34428-34433	rates	_	
156-6	34434-34436	in	_	
156-7	34437-34440	the	_	
156-8	34441-34453	hypothalamus	_	
156-9	34454-34456	in	_	
156-10	34457-34465	subjects	_	
156-11	34466-34470	with	_	
156-12	34471-34474	ASD	_	
156-13	34474-34475	,	_	
156-14	34476-34478	as	_	
156-15	34479-34488	predicted	_	
156-16	34489-34491	by	_	
156-17	34492-34495	the	_	
156-18	34496-34503	extreme	_	
156-19	34504-34508	male	_	
156-20	34509-34514	brain	_	
156-21	34515-34521	theory	_	
156-22	34521-34522	,	_	
156-23	34523-34528	would	_	
156-24	34529-34534	place	_	
156-25	34535-34539	them	_	
156-26	34540-34542	at	_	
156-27	34543-34546	the	_	
156-28	34547-34551	male	_	
156-29	34552-34557	brain	_	
156-30	34558-34565	extreme	_	
156-31	34565-34566	,	_	
156-32	34567-34570	and	_	
156-33	34571-34578	reverse	_	
156-34	34579-34584	would	_	
156-35	34585-34587	be	_	
156-36	34588-34592	true	_	
156-37	34593-34595	of	_	
156-38	34596-34601	those	_	
156-39	34602-34606	with	_	
156-40	34607-34620	schizophrenia	_	
156-41	34620-34621	.	_	

#Text=Intergroup differences in the motor, somatosensory, medial frontal and anterior cingulate areas may be interpreted in the same vein, with diametrical cognitive styles of the two disorders viewed as secondary to their positions along the axis of distribution of sex differences in brain morphology in the general population.
157-1	34622-34632	Intergroup	_	
157-2	34633-34644	differences	_	
157-3	34645-34647	in	_	
157-4	34648-34651	the	_	
157-5	34652-34657	motor	_	
157-6	34657-34658	,	_	
157-7	34659-34672	somatosensory	_	
157-8	34672-34673	,	_	
157-9	34674-34680	medial	_	
157-10	34681-34688	frontal	_	
157-11	34689-34692	and	_	
157-12	34693-34701	anterior	_	
157-13	34702-34711	cingulate	_	
157-14	34712-34717	areas	_	
157-15	34718-34721	may	_	
157-16	34722-34724	be	_	
157-17	34725-34736	interpreted	_	
157-18	34737-34739	in	_	
157-19	34740-34743	the	_	
157-20	34744-34748	same	_	
157-21	34749-34753	vein	_	
157-22	34753-34754	,	_	
157-23	34755-34759	with	_	
157-24	34760-34771	diametrical	_	
157-25	34772-34781	cognitive	_	
157-26	34782-34788	styles	_	
157-27	34789-34791	of	_	
157-28	34792-34795	the	_	
157-29	34796-34799	two	_	
157-30	34800-34809	disorders	_	
157-31	34810-34816	viewed	_	
157-32	34817-34819	as	_	
157-33	34820-34829	secondary	_	
157-34	34830-34832	to	_	
157-35	34833-34838	their	_	
157-36	34839-34848	positions	_	
157-37	34849-34854	along	_	
157-38	34855-34858	the	_	
157-39	34859-34863	axis	_	
157-40	34864-34866	of	_	
157-41	34867-34879	distribution	_	
157-42	34880-34882	of	_	
157-43	34883-34886	sex	_	
157-44	34887-34898	differences	_	
157-45	34899-34901	in	_	
157-46	34902-34907	brain	_	
157-47	34908-34918	morphology	_	
157-48	34919-34921	in	_	
157-49	34922-34925	the	_	
157-50	34926-34933	general	_	
157-51	34934-34944	population	_	
157-52	34944-34945	.	_	

#Text=Finally, regions where only one of the diagnostic groups showed differential metabolic patterns included the superior parietal lobule, caudate head and body, and 3 thalamic nuclei (lateral posterior, ventroposterior lateral, and mediodorsal).
158-1	34946-34953	Finally	_	
158-2	34953-34954	,	_	
158-3	34955-34962	regions	_	
158-4	34963-34968	where	_	
158-5	34969-34973	only	_	
158-6	34974-34977	one	_	
158-7	34978-34980	of	_	
158-8	34981-34984	the	_	
158-9	34985-34995	diagnostic	_	
158-10	34996-35002	groups	_	
158-11	35003-35009	showed	_	
158-12	35010-35022	differential	_	
158-13	35023-35032	metabolic	_	
158-14	35033-35041	patterns	_	
158-15	35042-35050	included	_	
158-16	35051-35054	the	_	
158-17	35055-35063	superior	_	
158-18	35064-35072	parietal	_	
158-19	35073-35079	lobule	_	
158-20	35079-35080	,	_	
158-21	35081-35088	caudate	_	
158-22	35089-35093	head	_	
158-23	35094-35097	and	_	
158-24	35098-35102	body	_	
158-25	35102-35103	,	_	
158-26	35104-35107	and	_	
158-27	35108-35109	3	_	
158-28	35110-35118	thalamic	_	
158-29	35119-35125	nuclei	_	
158-30	35126-35127	(	_	
158-31	35127-35134	lateral	_	
158-32	35135-35144	posterior	_	
158-33	35144-35145	,	_	
158-34	35146-35161	ventroposterior	_	
158-35	35162-35169	lateral	_	
158-36	35169-35170	,	_	
158-37	35171-35174	and	_	
158-38	35175-35186	mediodorsal	_	
158-39	35186-35187	)	_	
158-40	35187-35188	.	_	

#Text=These structures may therefore underlie unique clinical features of each of the disorders.
159-1	35189-35194	These	_	
159-2	35195-35205	structures	_	
159-3	35206-35209	may	_	
159-4	35210-35219	therefore	_	
159-5	35220-35228	underlie	_	
159-6	35229-35235	unique	_	
159-7	35236-35244	clinical	_	
159-8	35245-35253	features	_	
159-9	35254-35256	of	_	
159-10	35257-35261	each	_	
159-11	35262-35264	of	_	
159-12	35265-35268	the	_	
159-13	35269-35278	disorders	_	
159-14	35278-35279	.	_	

#Text=Other findings in this study point to hemispheric differences between subjects with ASD and schizophrenia in the amygdalar activation and the more pronounced right than left hemisphere differences in basal cortical metabolic rates.
160-1	35280-35285	Other	_	
160-2	35286-35294	findings	_	
160-3	35295-35297	in	_	
160-4	35298-35302	this	_	
160-5	35303-35308	study	_	
160-6	35309-35314	point	_	
160-7	35315-35317	to	_	
160-8	35318-35329	hemispheric	_	
160-9	35330-35341	differences	_	
160-10	35342-35349	between	_	
160-11	35350-35358	subjects	_	
160-12	35359-35363	with	_	
160-13	35364-35367	ASD	_	
160-14	35368-35371	and	_	
160-15	35372-35385	schizophrenia	_	
160-16	35386-35388	in	_	
160-17	35389-35392	the	_	
160-18	35393-35402	amygdalar	_	
160-19	35403-35413	activation	_	
160-20	35414-35417	and	_	
160-21	35418-35421	the	_	
160-22	35422-35426	more	_	
160-23	35427-35437	pronounced	_	
160-24	35438-35443	right	_	
160-25	35444-35448	than	_	
160-26	35449-35453	left	_	
160-27	35454-35464	hemisphere	_	
160-28	35465-35476	differences	_	
160-29	35477-35479	in	_	
160-30	35480-35485	basal	_	
160-31	35486-35494	cortical	_	
160-32	35495-35504	metabolic	_	
160-33	35505-35510	rates	_	
160-34	35510-35511	.	_	

#Text=Our previous morphometric investigation on an overlapping cohort of participants allows for a comparison of changes in gray matter volumes (adjusted for total brain volume) and co-territorial glucose metabolism.
161-1	35512-35515	Our	_	
161-2	35516-35524	previous	_	
161-3	35525-35537	morphometric	_	
161-4	35538-35551	investigation	_	
161-5	35552-35554	on	_	
161-6	35555-35557	an	_	
161-7	35558-35569	overlapping	_	
161-8	35570-35576	cohort	_	
161-9	35577-35579	of	_	
161-10	35580-35592	participants	_	
161-11	35593-35599	allows	_	
161-12	35600-35603	for	_	
161-13	35604-35605	a	_	
161-14	35606-35616	comparison	_	
161-15	35617-35619	of	_	
161-16	35620-35627	changes	_	
161-17	35628-35630	in	_	
161-18	35631-35635	gray	_	
161-19	35636-35642	matter	_	
161-20	35643-35650	volumes	_	
161-21	35651-35652	(	_	
161-22	35652-35660	adjusted	_	
161-23	35661-35664	for	_	
161-24	35665-35670	total	_	
161-25	35671-35676	brain	_	
161-26	35677-35683	volume	_	
161-27	35683-35684	)	_	
161-28	35685-35688	and	_	
161-29	35689-35703	co-territorial	_	
161-30	35704-35711	glucose	_	
161-31	35712-35722	metabolism	_	
161-32	35722-35723	.	_	

#Text=While in the anterior cingulate cortex and frontal Brodmann area 9 both the volumes and metabolic rates where greater-than-normal in subjects with ASD and lower-than-normal in those with schizophrenia, an inverse relationship between volumes and metabolism was seen in the precentral/postcentral (motor and somatosensory) region.
162-1	35724-35729	While	_	
162-2	35730-35732	in	_	
162-3	35733-35736	the	_	
162-4	35737-35745	anterior	_	
162-5	35746-35755	cingulate	_	
162-6	35756-35762	cortex	_	
162-7	35763-35766	and	_	
162-8	35767-35774	frontal	_	
162-9	35775-35783	Brodmann	_	
162-10	35784-35788	area	_	
162-11	35789-35790	9	_	
162-12	35791-35795	both	_	
162-13	35796-35799	the	_	
162-14	35800-35807	volumes	_	
162-15	35808-35811	and	_	
162-16	35812-35821	metabolic	_	
162-17	35822-35827	rates	_	
162-18	35828-35833	where	_	
162-19	35834-35853	greater-than-normal	_	
162-20	35854-35856	in	_	
162-21	35857-35865	subjects	_	
162-22	35866-35870	with	_	
162-23	35871-35874	ASD	_	
162-24	35875-35878	and	_	
162-25	35879-35896	lower-than-normal	_	
162-26	35897-35899	in	_	
162-27	35900-35905	those	_	
162-28	35906-35910	with	_	
162-29	35911-35924	schizophrenia	_	
162-30	35924-35925	,	_	
162-31	35926-35928	an	_	
162-32	35929-35936	inverse	_	
162-33	35937-35949	relationship	_	
162-34	35950-35957	between	_	
162-35	35958-35965	volumes	_	
162-36	35966-35969	and	_	
162-37	35970-35980	metabolism	_	
162-38	35981-35984	was	_	
162-39	35985-35989	seen	_	
162-40	35990-35992	in	_	
162-41	35993-35996	the	_	
162-42	35997-36007	precentral	_	
162-43	36007-36008	/	_	
162-44	36008-36019	postcentral	_	
162-45	36020-36021	(	_	
162-46	36021-36026	motor	_	
162-47	36027-36030	and	_	
162-48	36031-36044	somatosensory	_	
162-49	36044-36045	)	_	
162-50	36046-36052	region	_	
162-51	36052-36053	.	_	

#Text=In this latter region, volumes were greater-than-normal in ASD and lower-than-normal in schizophrenia, but metabolic rates were lower-than-normal in ASD and greater-than-normal in schizophrenia.
163-1	36054-36056	In	_	
163-2	36057-36061	this	_	
163-3	36062-36068	latter	_	
163-4	36069-36075	region	_	
163-5	36075-36076	,	_	
163-6	36077-36084	volumes	_	
163-7	36085-36089	were	_	
163-8	36090-36109	greater-than-normal	_	
163-9	36110-36112	in	_	
163-10	36113-36116	ASD	_	
163-11	36117-36120	and	_	
163-12	36121-36138	lower-than-normal	_	
163-13	36139-36141	in	_	
163-14	36142-36155	schizophrenia	_	
163-15	36155-36156	,	_	
163-16	36157-36160	but	_	
163-17	36161-36170	metabolic	_	
163-18	36171-36176	rates	_	
163-19	36177-36181	were	_	
163-20	36182-36199	lower-than-normal	_	
163-21	36200-36202	in	_	
163-22	36203-36206	ASD	_	
163-23	36207-36210	and	_	
163-24	36211-36230	greater-than-normal	_	
163-25	36231-36233	in	_	
163-26	36234-36247	schizophrenia	_	
163-27	36247-36248	.	_	

#Text=This suggests that direction of changes in cerebral metabolism cannot be reliably predicted from concurrent changes in cerebral volumes.
164-1	36249-36253	This	_	
164-2	36254-36262	suggests	_	
164-3	36263-36267	that	_	
164-4	36268-36277	direction	_	
164-5	36278-36280	of	_	
164-6	36281-36288	changes	_	
164-7	36289-36291	in	_	
164-8	36292-36300	cerebral	_	
164-9	36301-36311	metabolism	_	
164-10	36312-36318	cannot	_	
164-11	36319-36321	be	_	
164-12	36322-36330	reliably	_	
164-13	36331-36340	predicted	_	
164-14	36341-36345	from	_	
164-15	36346-36356	concurrent	_	
164-16	36357-36364	changes	_	
164-17	36365-36367	in	_	
164-18	36368-36376	cerebral	_	
164-19	36377-36384	volumes	_	
164-20	36384-36385	.	_	

#Text=Larger regional volumes may still have the same number of neurons in a less dense array resulting in a lower relative metabolic rate.
165-1	36386-36392	Larger	_	
165-2	36393-36401	regional	_	
165-3	36402-36409	volumes	_	
165-4	36410-36413	may	_	
165-5	36414-36419	still	_	
165-6	36420-36424	have	_	
165-7	36425-36428	the	_	
165-8	36429-36433	same	_	
165-9	36434-36440	number	_	
165-10	36441-36443	of	_	
165-11	36444-36451	neurons	_	
165-12	36452-36454	in	_	
165-13	36455-36456	a	_	
165-14	36457-36461	less	_	
165-15	36462-36467	dense	_	
165-16	36468-36473	array	_	
165-17	36474-36483	resulting	_	
165-18	36484-36486	in	_	
165-19	36487-36488	a	_	
165-20	36489-36494	lower	_	
165-21	36495-36503	relative	_	
165-22	36504-36513	metabolic	_	
165-23	36514-36518	rate	_	
165-24	36518-36519	.	_	

#Text=Schizophrenia
#Text=Compared to healthy controls, subjects with schizophrenia displayed a pattern of hypofrontality, with decreased glucose metabolism in the whole frontal lobe, as well as superior temporal gyrus, anterior cingulate cortex and amygdala.
166-1	36520-36533	Schizophrenia	_	
166-2	36534-36542	Compared	_	
166-3	36543-36545	to	_	
166-4	36546-36553	healthy	_	
166-5	36554-36562	controls	_	
166-6	36562-36563	,	_	
166-7	36564-36572	subjects	_	
166-8	36573-36577	with	_	
166-9	36578-36591	schizophrenia	_	
166-10	36592-36601	displayed	_	
166-11	36602-36603	a	_	
166-12	36604-36611	pattern	_	
166-13	36612-36614	of	_	
166-14	36615-36629	hypofrontality	_	
166-15	36629-36630	,	_	
166-16	36631-36635	with	_	
166-17	36636-36645	decreased	_	
166-18	36646-36653	glucose	_	
166-19	36654-36664	metabolism	_	
166-20	36665-36667	in	_	
166-21	36668-36671	the	_	
166-22	36672-36677	whole	_	
166-23	36678-36685	frontal	_	
166-24	36686-36690	lobe	_	
166-25	36690-36691	,	_	
166-26	36692-36694	as	_	
166-27	36695-36699	well	_	
166-28	36700-36702	as	_	
166-29	36703-36711	superior	_	
166-30	36712-36720	temporal	_	
166-31	36721-36726	gyrus	_	
166-32	36726-36727	,	_	
166-33	36728-36736	anterior	_	
166-34	36737-36746	cingulate	_	
166-35	36747-36753	cortex	_	
166-36	36754-36757	and	_	
166-37	36758-36766	amygdala	_	
166-38	36766-36767	.	_	

#Text=Increased metabolic rates were seen in the occipital visual cortex, basal ganglia associated structures (lateral globus pallidus, tail of the caudate, putamen, claustrum), as well as the hippocampus, where many studies have previously found basal hyperperfusion in schizophrenia (reviewed in).
167-1	36768-36777	Increased	_	
167-2	36778-36787	metabolic	_	
167-3	36788-36793	rates	_	
167-4	36794-36798	were	_	
167-5	36799-36803	seen	_	
167-6	36804-36806	in	_	
167-7	36807-36810	the	_	
167-8	36811-36820	occipital	_	
167-9	36821-36827	visual	_	
167-10	36828-36834	cortex	_	
167-11	36834-36835	,	_	
167-12	36836-36841	basal	_	
167-13	36842-36849	ganglia	_	
167-14	36850-36860	associated	_	
167-15	36861-36871	structures	_	
167-16	36872-36873	(	_	
167-17	36873-36880	lateral	_	
167-18	36881-36887	globus	_	
167-19	36888-36896	pallidus	_	
167-20	36896-36897	,	_	
167-21	36898-36902	tail	_	
167-22	36903-36905	of	_	
167-23	36906-36909	the	_	
167-24	36910-36917	caudate	_	
167-25	36917-36918	,	_	
167-26	36919-36926	putamen	_	
167-27	36926-36927	,	_	
167-28	36928-36937	claustrum	_	
167-29	36937-36938	)	_	
167-30	36938-36939	,	_	
167-31	36940-36942	as	_	
167-32	36943-36947	well	_	
167-33	36948-36950	as	_	
167-34	36951-36954	the	_	
167-35	36955-36966	hippocampus	_	
167-36	36966-36967	,	_	
167-37	36968-36973	where	_	
167-38	36974-36978	many	_	
167-39	36979-36986	studies	_	
167-40	36987-36991	have	_	
167-41	36992-37002	previously	_	
167-42	37003-37008	found	_	
167-43	37009-37014	basal	_	
167-44	37015-37029	hyperperfusion	_	
167-45	37030-37032	in	_	
167-46	37033-37046	schizophrenia	_	
167-47	37047-37048	(	_	
167-48	37048-37056	reviewed	_	
167-49	37057-37059	in	_	
167-50	37059-37060	)	_	
167-51	37060-37061	.	_	

#Text=A gradient of metabolic activity was observed in the caudate (decreased rates in the head, increased rates in the tail, and normal rates in the body), as well as the thalamus, where rates were decreased in two medial thalamic nuclei (mediodorsal and ventral posteromedial) and increased in lateral nuclei (ventroposterior lateral, lateral posterior and pulvinar).
168-1	37062-37063	A	_	
168-2	37064-37072	gradient	_	
168-3	37073-37075	of	_	
168-4	37076-37085	metabolic	_	
168-5	37086-37094	activity	_	
168-6	37095-37098	was	_	
168-7	37099-37107	observed	_	
168-8	37108-37110	in	_	
168-9	37111-37114	the	_	
168-10	37115-37122	caudate	_	
168-11	37123-37124	(	_	
168-12	37124-37133	decreased	_	
168-13	37134-37139	rates	_	
168-14	37140-37142	in	_	
168-15	37143-37146	the	_	
168-16	37147-37151	head	_	
168-17	37151-37152	,	_	
168-18	37153-37162	increased	_	
168-19	37163-37168	rates	_	
168-20	37169-37171	in	_	
168-21	37172-37175	the	_	
168-22	37176-37180	tail	_	
168-23	37180-37181	,	_	
168-24	37182-37185	and	_	
168-25	37186-37192	normal	_	
168-26	37193-37198	rates	_	
168-27	37199-37201	in	_	
168-28	37202-37205	the	_	
168-29	37206-37210	body	_	
168-30	37210-37211	)	_	
168-31	37211-37212	,	_	
168-32	37213-37215	as	_	
168-33	37216-37220	well	_	
168-34	37221-37223	as	_	
168-35	37224-37227	the	_	
168-36	37228-37236	thalamus	_	
168-37	37236-37237	,	_	
168-38	37238-37243	where	_	
168-39	37244-37249	rates	_	
168-40	37250-37254	were	_	
168-41	37255-37264	decreased	_	
168-42	37265-37267	in	_	
168-43	37268-37271	two	_	
168-44	37272-37278	medial	_	
168-45	37279-37287	thalamic	_	
168-46	37288-37294	nuclei	_	
168-47	37295-37296	(	_	
168-48	37296-37307	mediodorsal	_	
168-49	37308-37311	and	_	
168-50	37312-37319	ventral	_	
168-51	37320-37333	posteromedial	_	
168-52	37333-37334	)	_	
168-53	37335-37338	and	_	
168-54	37339-37348	increased	_	
168-55	37349-37351	in	_	
168-56	37352-37359	lateral	_	
168-57	37360-37366	nuclei	_	
168-58	37367-37368	(	_	
168-59	37368-37383	ventroposterior	_	
168-60	37384-37391	lateral	_	
168-61	37391-37392	,	_	
168-62	37393-37400	lateral	_	
168-63	37401-37410	posterior	_	
168-64	37411-37414	and	_	
168-65	37415-37423	pulvinar	_	
168-66	37423-37424	)	_	
168-67	37424-37425	.	_	

#Text=Other PET studies have similarly reported decreased metabolic rates in the mediodorsal and centromedian nuclei, and increased rates in the pulvinar, as well as abnormal connectivity patterns of these structures, but no gradient of metabolic activity within the thalamus has previously been suggested.
169-1	37426-37431	Other	_	
169-2	37432-37435	PET	_	
169-3	37436-37443	studies	_	
169-4	37444-37448	have	_	
169-5	37449-37458	similarly	_	
169-6	37459-37467	reported	_	
169-7	37468-37477	decreased	_	
169-8	37478-37487	metabolic	_	
169-9	37488-37493	rates	_	
169-10	37494-37496	in	_	
169-11	37497-37500	the	_	
169-12	37501-37512	mediodorsal	_	
169-13	37513-37516	and	_	
169-14	37517-37529	centromedian	_	
169-15	37530-37536	nuclei	_	
169-16	37536-37537	,	_	
169-17	37538-37541	and	_	
169-18	37542-37551	increased	_	
169-19	37552-37557	rates	_	
169-20	37558-37560	in	_	
169-21	37561-37564	the	_	
169-22	37565-37573	pulvinar	_	
169-23	37573-37574	,	_	
169-24	37575-37577	as	_	
169-25	37578-37582	well	_	
169-26	37583-37585	as	_	
169-27	37586-37594	abnormal	_	
169-28	37595-37607	connectivity	_	
169-29	37608-37616	patterns	_	
169-30	37617-37619	of	_	
169-31	37620-37625	these	_	
169-32	37626-37636	structures	_	
169-33	37636-37637	,	_	
169-34	37638-37641	but	_	
169-35	37642-37644	no	_	
169-36	37645-37653	gradient	_	
169-37	37654-37656	of	_	
169-38	37657-37666	metabolic	_	
169-39	37667-37675	activity	_	
169-40	37676-37682	within	_	
169-41	37683-37686	the	_	
169-42	37687-37695	thalamus	_	
169-43	37696-37699	has	_	
169-44	37700-37710	previously	_	
169-45	37711-37715	been	_	
169-46	37716-37725	suggested	_	
169-47	37725-37726	.	_	

#Text=An upward rostrocaudal gradient of glucose metabolism in the caudate in schizophrenia may be evidence of an accentuation of the normally occurring rostrocaudal increment in the density of D2 receptors and dopamine uptake sites in this nucleus.
170-1	37727-37729	An	_	
170-2	37730-37736	upward	_	
170-3	37737-37749	rostrocaudal	_	
170-4	37750-37758	gradient	_	
170-5	37759-37761	of	_	
170-6	37762-37769	glucose	_	
170-7	37770-37780	metabolism	_	
170-8	37781-37783	in	_	
170-9	37784-37787	the	_	
170-10	37788-37795	caudate	_	
170-11	37796-37798	in	_	
170-12	37799-37812	schizophrenia	_	
170-13	37813-37816	may	_	
170-14	37817-37819	be	_	
170-15	37820-37828	evidence	_	
170-16	37829-37831	of	_	
170-17	37832-37834	an	_	
170-18	37835-37847	accentuation	_	
170-19	37848-37850	of	_	
170-20	37851-37854	the	_	
170-21	37855-37863	normally	_	
170-22	37864-37873	occurring	_	
170-23	37874-37886	rostrocaudal	_	
170-24	37887-37896	increment	_	
170-25	37897-37899	in	_	
170-26	37900-37903	the	_	
170-27	37904-37911	density	_	
170-28	37912-37914	of	_	
170-29	37915-37917	D2	_	
170-30	37918-37927	receptors	_	
170-31	37928-37931	and	_	
170-32	37932-37940	dopamine	_	
170-33	37941-37947	uptake	_	
170-34	37948-37953	sites	_	
170-35	37954-37956	in	_	
170-36	37957-37961	this	_	
170-37	37962-37969	nucleus	_	
170-38	37969-37970	.	_	

#Text=Autism
#Text=As compared to healthy controls, subjects with ASD displayed lower metabolic rates in the whole parietal lobe, as well as the frontal premotor/supplementary motor and eye-fields areas, rostral orbitofrontal cortex, and amygdala.
171-1	37971-37977	Autism	_	
171-2	37978-37980	As	_	
171-3	37981-37989	compared	_	
171-4	37990-37992	to	_	
171-5	37993-38000	healthy	_	
171-6	38001-38009	controls	_	
171-7	38009-38010	,	_	
171-8	38011-38019	subjects	_	
171-9	38020-38024	with	_	
171-10	38025-38028	ASD	_	
171-11	38029-38038	displayed	_	
171-12	38039-38044	lower	_	
171-13	38045-38054	metabolic	_	
171-14	38055-38060	rates	_	
171-15	38061-38063	in	_	
171-16	38064-38067	the	_	
171-17	38068-38073	whole	_	
171-18	38074-38082	parietal	_	
171-19	38083-38087	lobe	_	
171-20	38087-38088	,	_	
171-21	38089-38091	as	_	
171-22	38092-38096	well	_	
171-23	38097-38099	as	_	
171-24	38100-38103	the	_	
171-25	38104-38111	frontal	_	
171-26	38112-38120	premotor	_	
171-27	38120-38121	/	_	
171-28	38121-38134	supplementary	_	
171-29	38135-38140	motor	_	
171-30	38141-38144	and	_	
171-31	38145-38155	eye-fields	_	
171-32	38156-38161	areas	_	
171-33	38161-38162	,	_	
171-34	38163-38170	rostral	_	
171-35	38171-38184	orbitofrontal	_	
171-36	38185-38191	cortex	_	
171-37	38191-38192	,	_	
171-38	38193-38196	and	_	
171-39	38197-38205	amygdala	_	
171-40	38205-38206	.	_	

#Text=Increased metabolic rates were found in the posterior cingulate and occipital visual cortices, orbitofrontal area 12, and medial temporal cortex, as well as the hippocampus and basal ganglia associated structures (medial and lateral globi pallidi, tail of the caudate, claustrum and putamen).
172-1	38207-38216	Increased	_	
172-2	38217-38226	metabolic	_	
172-3	38227-38232	rates	_	
172-4	38233-38237	were	_	
172-5	38238-38243	found	_	
172-6	38244-38246	in	_	
172-7	38247-38250	the	_	
172-8	38251-38260	posterior	_	
172-9	38261-38270	cingulate	_	
172-10	38271-38274	and	_	
172-11	38275-38284	occipital	_	
172-12	38285-38291	visual	_	
172-13	38292-38300	cortices	_	
172-14	38300-38301	,	_	
172-15	38302-38315	orbitofrontal	_	
172-16	38316-38320	area	_	
172-17	38321-38323	12	_	
172-18	38323-38324	,	_	
172-19	38325-38328	and	_	
172-20	38329-38335	medial	_	
172-21	38336-38344	temporal	_	
172-22	38345-38351	cortex	_	
172-23	38351-38352	,	_	
172-24	38353-38355	as	_	
172-25	38356-38360	well	_	
172-26	38361-38363	as	_	
172-27	38364-38367	the	_	
172-28	38368-38379	hippocampus	_	
172-29	38380-38383	and	_	
172-30	38384-38389	basal	_	
172-31	38390-38397	ganglia	_	
172-32	38398-38408	associated	_	
172-33	38409-38419	structures	_	
172-34	38420-38421	(	_	
172-35	38421-38427	medial	_	
172-36	38428-38431	and	_	
172-37	38432-38439	lateral	_	
172-38	38440-38445	globi	_	
172-39	38446-38453	pallidi	_	
172-40	38453-38454	,	_	
172-41	38455-38459	tail	_	
172-42	38460-38462	of	_	
172-43	38463-38466	the	_	
172-44	38467-38474	caudate	_	
172-45	38474-38475	,	_	
172-46	38476-38485	claustrum	_	
172-47	38486-38489	and	_	
172-48	38490-38497	putamen	_	
172-49	38497-38498	)	_	
172-50	38498-38499	.	_	

#Text=In contrast to some prior reports, we found no metabolic changes in the cerebellum or any of its subdivisions.
173-1	38500-38502	In	_	
173-2	38503-38511	contrast	_	
173-3	38512-38514	to	_	
173-4	38515-38519	some	_	
173-5	38520-38525	prior	_	
173-6	38526-38533	reports	_	
173-7	38533-38534	,	_	
173-8	38535-38537	we	_	
173-9	38538-38543	found	_	
173-10	38544-38546	no	_	
173-11	38547-38556	metabolic	_	
173-12	38557-38564	changes	_	
173-13	38565-38567	in	_	
173-14	38568-38571	the	_	
173-15	38572-38582	cerebellum	_	
173-16	38583-38585	or	_	
173-17	38586-38589	any	_	
173-18	38590-38592	of	_	
173-19	38593-38596	its	_	
173-20	38597-38609	subdivisions	_	
173-21	38609-38610	.	_	

#Text=Similar to our present findings, amygdalar hypoactivation has been a common thread in recent fMRI investigations in ASD.
174-1	38611-38618	Similar	_	
174-2	38619-38621	to	_	
174-3	38622-38625	our	_	
174-4	38626-38633	present	_	
174-5	38634-38642	findings	_	
174-6	38642-38643	,	_	
174-7	38644-38653	amygdalar	_	
174-8	38654-38668	hypoactivation	_	
174-9	38669-38672	has	_	
174-10	38673-38677	been	_	
174-11	38678-38679	a	_	
174-12	38680-38686	common	_	
174-13	38687-38693	thread	_	
174-14	38694-38696	in	_	
174-15	38697-38703	recent	_	
174-16	38704-38708	fMRI	_	
174-17	38709-38723	investigations	_	
174-18	38724-38726	in	_	
174-19	38727-38730	ASD	_	
174-20	38730-38731	.	_	

#Text=Caudate and lentiform nuclei impairments, among other structures, were found in an early 18FDG PET intercorrelations study and caudate hyperactivation emerged as the most robust finding in a meta-analysis of fMRI studies with emotional face processing tasks.
175-1	38732-38739	Caudate	_	
175-2	38740-38743	and	_	
175-3	38744-38753	lentiform	_	
175-4	38754-38760	nuclei	_	
175-5	38761-38772	impairments	_	
175-6	38772-38773	,	_	
175-7	38774-38779	among	_	
175-8	38780-38785	other	_	
175-9	38786-38796	structures	_	
175-10	38796-38797	,	_	
175-11	38798-38802	were	_	
175-12	38803-38808	found	_	
175-13	38809-38811	in	_	
175-14	38812-38814	an	_	
175-15	38815-38820	early	_	
175-16	38821-38826	18FDG	_	
175-17	38827-38830	PET	_	
175-18	38831-38848	intercorrelations	_	
175-19	38849-38854	study	_	
175-20	38855-38858	and	_	
175-21	38859-38866	caudate	_	
175-22	38867-38882	hyperactivation	_	
175-23	38883-38890	emerged	_	
175-24	38891-38893	as	_	
175-25	38894-38897	the	_	
175-26	38898-38902	most	_	
175-27	38903-38909	robust	_	
175-28	38910-38917	finding	_	
175-29	38918-38920	in	_	
175-30	38921-38922	a	_	
175-31	38923-38936	meta-analysis	_	
175-32	38937-38939	of	_	
175-33	38940-38944	fMRI	_	
175-34	38945-38952	studies	_	
175-35	38953-38957	with	_	
175-36	38958-38967	emotional	_	
175-37	38968-38972	face	_	
175-38	38973-38983	processing	_	
175-39	38984-38989	tasks	_	
175-40	38989-38990	.	_	

#Text=A small [1-11C]butanol PET study likewise observed hyperperfusion in the caudate and putamen, as well as the posterior cingulate gyrus.
176-1	38991-38992	A	_	
176-2	38993-38998	small	_	
176-3	38999-39000	[	_	
176-4	39000-39001	1	_	
176-5	39001-39002	-	_	
176-6	39002-39005	11C	_	
176-7	39005-39006	]	_	
176-8	39006-39013	butanol	_	
176-9	39014-39017	PET	_	
176-10	39018-39023	study	_	
176-11	39024-39032	likewise	_	
176-12	39033-39041	observed	_	
176-13	39042-39056	hyperperfusion	_	
176-14	39057-39059	in	_	
176-15	39060-39063	the	_	
176-16	39064-39071	caudate	_	
176-17	39072-39075	and	_	
176-18	39076-39083	putamen	_	
176-19	39083-39084	,	_	
176-20	39085-39087	as	_	
176-21	39088-39092	well	_	
176-22	39093-39095	as	_	
176-23	39096-39099	the	_	
176-24	39100-39109	posterior	_	
176-25	39110-39119	cingulate	_	
176-26	39120-39125	gyrus	_	
176-27	39125-39126	.	_	

#Text=In contrast, decreased metabolic rates in the ventral caudate and putamen were found in one 18FDG PET study and in the left posterior putamen only in another 18FDG PET study.
177-1	39127-39129	In	_	
177-2	39130-39138	contrast	_	
177-3	39138-39139	,	_	
177-4	39140-39149	decreased	_	
177-5	39150-39159	metabolic	_	
177-6	39160-39165	rates	_	
177-7	39166-39168	in	_	
177-8	39169-39172	the	_	
177-9	39173-39180	ventral	_	
177-10	39181-39188	caudate	_	
177-11	39189-39192	and	_	
177-12	39193-39200	putamen	_	
177-13	39201-39205	were	_	
177-14	39206-39211	found	_	
177-15	39212-39214	in	_	
177-16	39215-39218	one	_	
177-17	39219-39224	18FDG	_	
177-18	39225-39228	PET	_	
177-19	39229-39234	study	_	
177-20	39235-39238	and	_	
177-21	39239-39241	in	_	
177-22	39242-39245	the	_	
177-23	39246-39250	left	_	
177-24	39251-39260	posterior	_	
177-25	39261-39268	putamen	_	
177-26	39269-39273	only	_	
177-27	39274-39276	in	_	
177-28	39277-39284	another	_	
177-29	39285-39290	18FDG	_	
177-30	39291-39294	PET	_	
177-31	39295-39300	study	_	
177-32	39300-39301	.	_	

#Text=Increased metabolic rates in the posterior cingulate cortex could reflect diminished cognitive task engagement of subjects with ASD, which in healthy participants typically leads to lowered metabolic activity in this region – central to the default mode network (Leech and Sharp 2013).
178-1	39302-39311	Increased	_	
178-2	39312-39321	metabolic	_	
178-3	39322-39327	rates	_	
178-4	39328-39330	in	_	
178-5	39331-39334	the	_	
178-6	39335-39344	posterior	_	
178-7	39345-39354	cingulate	_	
178-8	39355-39361	cortex	_	
178-9	39362-39367	could	_	
178-10	39368-39375	reflect	_	
178-11	39376-39386	diminished	_	
178-12	39387-39396	cognitive	_	
178-13	39397-39401	task	_	
178-14	39402-39412	engagement	_	
178-15	39413-39415	of	_	
178-16	39416-39424	subjects	_	
178-17	39425-39429	with	_	
178-18	39430-39433	ASD	_	
178-19	39433-39434	,	_	
178-20	39435-39440	which	_	
178-21	39441-39443	in	_	
178-22	39444-39451	healthy	_	
178-23	39452-39464	participants	_	
178-24	39465-39474	typically	_	
178-25	39475-39480	leads	_	
178-26	39481-39483	to	_	
178-27	39484-39491	lowered	_	
178-28	39492-39501	metabolic	_	
178-29	39502-39510	activity	_	
178-30	39511-39513	in	_	
178-31	39514-39518	this	_	
178-32	39519-39525	region	_	
178-33	39526-39527	–	_	
178-34	39528-39535	central	_	
178-35	39536-39538	to	_	
178-36	39539-39542	the	_	
178-37	39543-39550	default	_	
178-38	39551-39555	mode	_	
178-39	39556-39563	network	_	
178-40	39564-39565	(	_	
178-41	39565-39570	Leech	_	
178-42	39571-39574	and	_	
178-43	39575-39580	Sharp	_	
178-44	39581-39585	2013	_	
178-45	39585-39586	)	_	
178-46	39586-39587	.	_	

#Text=However, while altered task-related deactivation of the posterior cingulate cortex has been previously shown using fMRI in schizophrenia, our findings are confined to ASD and not schizophrenia.
179-1	39588-39595	However	_	
179-2	39595-39596	,	_	
179-3	39597-39602	while	_	
179-4	39603-39610	altered	_	
179-5	39611-39623	task-related	_	
179-6	39624-39636	deactivation	_	
179-7	39637-39639	of	_	
179-8	39640-39643	the	_	
179-9	39644-39653	posterior	_	
179-10	39654-39663	cingulate	_	
179-11	39664-39670	cortex	_	
179-12	39671-39674	has	_	
179-13	39675-39679	been	_	
179-14	39680-39690	previously	_	
179-15	39691-39696	shown	_	
179-16	39697-39702	using	_	
179-17	39703-39707	fMRI	_	
179-18	39708-39710	in	_	
179-19	39711-39724	schizophrenia	_	
179-20	39724-39725	,	_	
179-21	39726-39729	our	_	
179-22	39730-39738	findings	_	
179-23	39739-39742	are	_	
179-24	39743-39751	confined	_	
179-25	39752-39754	to	_	
179-26	39755-39758	ASD	_	
179-27	39759-39762	and	_	
179-28	39763-39766	not	_	
179-29	39767-39780	schizophrenia	_	
179-30	39780-39781	.	_	

#Text=It is therefore likely that rather than being due to diminished cognitive task engagement metabolic hyperactivity of the posterior cingulate connotes an inefficient overall functioning of the default network in ASD.
180-1	39782-39784	It	_	
180-2	39785-39787	is	_	
180-3	39788-39797	therefore	_	
180-4	39798-39804	likely	_	
180-5	39805-39809	that	_	
180-6	39810-39816	rather	_	
180-7	39817-39821	than	_	
180-8	39822-39827	being	_	
180-9	39828-39831	due	_	
180-10	39832-39834	to	_	
180-11	39835-39845	diminished	_	
180-12	39846-39855	cognitive	_	
180-13	39856-39860	task	_	
180-14	39861-39871	engagement	_	
180-15	39872-39881	metabolic	_	
180-16	39882-39895	hyperactivity	_	
180-17	39896-39898	of	_	
180-18	39899-39902	the	_	
180-19	39903-39912	posterior	_	
180-20	39913-39922	cingulate	_	
180-21	39923-39931	connotes	_	
180-22	39932-39934	an	_	
180-23	39935-39946	inefficient	_	
180-24	39947-39954	overall	_	
180-25	39955-39966	functioning	_	
180-26	39967-39969	of	_	
180-27	39970-39973	the	_	
180-28	39974-39981	default	_	
180-29	39982-39989	network	_	
180-30	39990-39992	in	_	
180-31	39993-39996	ASD	_	
180-32	39996-39997	.	_	

#Text=In particular, greater metabolic resources are devoted to the maintenance of a cohesive sense of self (functionally attributed to the posterior cingulate cortex, see), which some theorists view as the central impairment in the phenomenology of autism.
181-1	39998-40000	In	_	
181-2	40001-40011	particular	_	
181-3	40011-40012	,	_	
181-4	40013-40020	greater	_	
181-5	40021-40030	metabolic	_	
181-6	40031-40040	resources	_	
181-7	40041-40044	are	_	
181-8	40045-40052	devoted	_	
181-9	40053-40055	to	_	
181-10	40056-40059	the	_	
181-11	40060-40071	maintenance	_	
181-12	40072-40074	of	_	
181-13	40075-40076	a	_	
181-14	40077-40085	cohesive	_	
181-15	40086-40091	sense	_	
181-16	40092-40094	of	_	
181-17	40095-40099	self	_	
181-18	40100-40101	(	_	
181-19	40101-40113	functionally	_	
181-20	40114-40124	attributed	_	
181-21	40125-40127	to	_	
181-22	40128-40131	the	_	
181-23	40132-40141	posterior	_	
181-24	40142-40151	cingulate	_	
181-25	40152-40158	cortex	_	
181-26	40158-40159	,	_	
181-27	40160-40163	see	_	
181-28	40163-40164	)	_	
181-29	40164-40165	,	_	
181-30	40166-40171	which	_	
181-31	40172-40176	some	_	
181-32	40177-40186	theorists	_	
181-33	40187-40191	view	_	
181-34	40192-40194	as	_	
181-35	40195-40198	the	_	
181-36	40199-40206	central	_	
181-37	40207-40217	impairment	_	
181-38	40218-40220	in	_	
181-39	40221-40224	the	_	
181-40	40225-40238	phenomenology	_	
181-41	40239-40241	of	_	
181-42	40242-40248	autism	_	
181-43	40248-40249	.	_	

#Text=Cognitive task performance
#Text=Subjects with schizophrenia and ASD differed in their performance on two of the administered cognitive tasks (total number of correctly memorized words and their semantic clustering), and controlling for these subscores in main analyses of variance showed that the between-group patterns of regional differences reported in this study were due to the combination of differences in both the task-induced activations and basal metabolic rates.
182-1	40250-40259	Cognitive	_	
182-2	40260-40264	task	_	
182-3	40265-40276	performance	_	
182-4	40277-40285	Subjects	_	
182-5	40286-40290	with	_	
182-6	40291-40304	schizophrenia	_	
182-7	40305-40308	and	_	
182-8	40309-40312	ASD	_	
182-9	40313-40321	differed	_	
182-10	40322-40324	in	_	
182-11	40325-40330	their	_	
182-12	40331-40342	performance	_	
182-13	40343-40345	on	_	
182-14	40346-40349	two	_	
182-15	40350-40352	of	_	
182-16	40353-40356	the	_	
182-17	40357-40369	administered	_	
182-18	40370-40379	cognitive	_	
182-19	40380-40385	tasks	_	
182-20	40386-40387	(	_	
182-21	40387-40392	total	_	
182-22	40393-40399	number	_	
182-23	40400-40402	of	_	
182-24	40403-40412	correctly	_	
182-25	40413-40422	memorized	_	
182-26	40423-40428	words	_	
182-27	40429-40432	and	_	
182-28	40433-40438	their	_	
182-29	40439-40447	semantic	_	
182-30	40448-40458	clustering	_	
182-31	40458-40459	)	_	
182-32	40459-40460	,	_	
182-33	40461-40464	and	_	
182-34	40465-40476	controlling	_	
182-35	40477-40480	for	_	
182-36	40481-40486	these	_	
182-37	40487-40496	subscores	_	
182-38	40497-40499	in	_	
182-39	40500-40504	main	_	
182-40	40505-40513	analyses	_	
182-41	40514-40516	of	_	
182-42	40517-40525	variance	_	
182-43	40526-40532	showed	_	
182-44	40533-40537	that	_	
182-45	40538-40541	the	_	
182-46	40542-40555	between-group	_	
182-47	40556-40564	patterns	_	
182-48	40565-40567	of	_	
182-49	40568-40576	regional	_	
182-50	40577-40588	differences	_	
182-51	40589-40597	reported	_	
182-52	40598-40600	in	_	
182-53	40601-40605	this	_	
182-54	40606-40611	study	_	
182-55	40612-40616	were	_	
182-56	40617-40620	due	_	
182-57	40621-40623	to	_	
182-58	40624-40627	the	_	
182-59	40628-40639	combination	_	
182-60	40640-40642	of	_	
182-61	40643-40654	differences	_	
182-62	40655-40657	in	_	
182-63	40658-40662	both	_	
182-64	40663-40666	the	_	
182-65	40667-40679	task-induced	_	
182-66	40680-40691	activations	_	
182-67	40692-40695	and	_	
182-68	40696-40701	basal	_	
182-69	40702-40711	metabolic	_	
182-70	40712-40717	rates	_	
182-71	40717-40718	.	_	

#Text=Exploratory correlation analyses suggested that while in healthy controls better task performance was associated with greater activations across the wide network of cortical regions in the left hemisphere and suppression of the cerebellar and pallidal metabolism, these patterns were disturbed in both patient groups.
183-1	40719-40730	Exploratory	_	
183-2	40731-40742	correlation	_	
183-3	40743-40751	analyses	_	
183-4	40752-40761	suggested	_	
183-5	40762-40766	that	_	
183-6	40767-40772	while	_	
183-7	40773-40775	in	_	
183-8	40776-40783	healthy	_	
183-9	40784-40792	controls	_	
183-10	40793-40799	better	_	
183-11	40800-40804	task	_	
183-12	40805-40816	performance	_	
183-13	40817-40820	was	_	
183-14	40821-40831	associated	_	
183-15	40832-40836	with	_	
183-16	40837-40844	greater	_	
183-17	40845-40856	activations	_	
183-18	40857-40863	across	_	
183-19	40864-40867	the	_	
183-20	40868-40872	wide	_	
183-21	40873-40880	network	_	
183-22	40881-40883	of	_	
183-23	40884-40892	cortical	_	
183-24	40893-40900	regions	_	
183-25	40901-40903	in	_	
183-26	40904-40907	the	_	
183-27	40908-40912	left	_	
183-28	40913-40923	hemisphere	_	
183-29	40924-40927	and	_	
183-30	40928-40939	suppression	_	
183-31	40940-40942	of	_	
183-32	40943-40946	the	_	
183-33	40947-40957	cerebellar	_	
183-34	40958-40961	and	_	
183-35	40962-40970	pallidal	_	
183-36	40971-40981	metabolism	_	
183-37	40981-40982	,	_	
183-38	40983-40988	these	_	
183-39	40989-40997	patterns	_	
183-40	40998-41002	were	_	
183-41	41003-41012	disturbed	_	
183-42	41013-41015	in	_	
183-43	41016-41020	both	_	
183-44	41021-41028	patient	_	
183-45	41029-41035	groups	_	
183-46	41035-41036	.	_	

#Text=We observed a paucity of both positive and negative significant correlations of metabolic rates and task performance in subjects with schizophrenia in the cortical and subcortical structures.
184-1	41037-41039	We	_	
184-2	41040-41048	observed	_	
184-3	41049-41050	a	_	
184-4	41051-41058	paucity	_	
184-5	41059-41061	of	_	
184-6	41062-41066	both	_	
184-7	41067-41075	positive	_	
184-8	41076-41079	and	_	
184-9	41080-41088	negative	_	
184-10	41089-41100	significant	_	
184-11	41101-41113	correlations	_	
184-12	41114-41116	of	_	
184-13	41117-41126	metabolic	_	
184-14	41127-41132	rates	_	
184-15	41133-41136	and	_	
184-16	41137-41141	task	_	
184-17	41142-41153	performance	_	
184-18	41154-41156	in	_	
184-19	41157-41165	subjects	_	
184-20	41166-41170	with	_	
184-21	41171-41184	schizophrenia	_	
184-22	41185-41187	in	_	
184-23	41188-41191	the	_	
184-24	41192-41200	cortical	_	
184-25	41201-41204	and	_	
184-26	41205-41216	subcortical	_	
184-27	41217-41227	structures	_	
184-28	41227-41228	.	_	

#Text=In subjects with ASD, on the other hand, we saw a diminished association of better task performance with cortical activations, with involvement of the subcortical structures (nuclei of the thalamus and caudate) instead, as well a conspicuous reliance on metabolic suppression of the hypothalamus and adjacent mammillary bodies rather than the globus pallidus and cerebellum as in healthy controls.
185-1	41229-41231	In	_	
185-2	41232-41240	subjects	_	
185-3	41241-41245	with	_	
185-4	41246-41249	ASD	_	
185-5	41249-41250	,	_	
185-6	41251-41253	on	_	
185-7	41254-41257	the	_	
185-8	41258-41263	other	_	
185-9	41264-41268	hand	_	
185-10	41268-41269	,	_	
185-11	41270-41272	we	_	
185-12	41273-41276	saw	_	
185-13	41277-41278	a	_	
185-14	41279-41289	diminished	_	
185-15	41290-41301	association	_	
185-16	41302-41304	of	_	
185-17	41305-41311	better	_	
185-18	41312-41316	task	_	
185-19	41317-41328	performance	_	
185-20	41329-41333	with	_	
185-21	41334-41342	cortical	_	
185-22	41343-41354	activations	_	
185-23	41354-41355	,	_	
185-24	41356-41360	with	_	
185-25	41361-41372	involvement	_	
185-26	41373-41375	of	_	
185-27	41376-41379	the	_	
185-28	41380-41391	subcortical	_	
185-29	41392-41402	structures	_	
185-30	41403-41404	(	_	
185-31	41404-41410	nuclei	_	
185-32	41411-41413	of	_	
185-33	41414-41417	the	_	
185-34	41418-41426	thalamus	_	
185-35	41427-41430	and	_	
185-36	41431-41438	caudate	_	
185-37	41438-41439	)	_	
185-38	41440-41447	instead	_	
185-39	41447-41448	,	_	
185-40	41449-41451	as	_	
185-41	41452-41456	well	_	
185-42	41457-41458	a	_	
185-43	41459-41470	conspicuous	_	
185-44	41471-41479	reliance	_	
185-45	41480-41482	on	_	
185-46	41483-41492	metabolic	_	
185-47	41493-41504	suppression	_	
185-48	41505-41507	of	_	
185-49	41508-41511	the	_	
185-50	41512-41524	hypothalamus	_	
185-51	41525-41528	and	_	
185-52	41529-41537	adjacent	_	
185-53	41538-41548	mammillary	_	
185-54	41549-41555	bodies	_	
185-55	41556-41562	rather	_	
185-56	41563-41567	than	_	
185-57	41568-41571	the	_	
185-58	41572-41578	globus	_	
185-59	41579-41587	pallidus	_	
185-60	41588-41591	and	_	
185-61	41592-41602	cerebellum	_	
185-62	41603-41605	as	_	
185-63	41606-41608	in	_	
185-64	41609-41616	healthy	_	
185-65	41617-41625	controls	_	
185-66	41625-41626	.	_	

#Text=Limitations
#Text=The following limitations and caveats of this study have to be considered in interpretation of its results.
186-1	41627-41638	Limitations	_	
186-2	41639-41642	The	_	
186-3	41643-41652	following	_	
186-4	41653-41664	limitations	_	
186-5	41665-41668	and	_	
186-6	41669-41676	caveats	_	
186-7	41677-41679	of	_	
186-8	41680-41684	this	_	
186-9	41685-41690	study	_	
186-10	41691-41695	have	_	
186-11	41696-41698	to	_	
186-12	41699-41701	be	_	
186-13	41702-41712	considered	_	
186-14	41713-41715	in	_	
186-15	41716-41730	interpretation	_	
186-16	41731-41733	of	_	
186-17	41734-41737	its	_	
186-18	41738-41745	results	_	
186-19	41745-41746	.	_	

#Text=Schizophrenia subjects in this cohort reflect a wide gamut of illness severity, chronicity and social functioning, comprising inpatient and outpatient, as well as good-outcome and poor-outcome participants.
187-1	41747-41760	Schizophrenia	_	
187-2	41761-41769	subjects	_	
187-3	41770-41772	in	_	
187-4	41773-41777	this	_	
187-5	41778-41784	cohort	_	
187-6	41785-41792	reflect	_	
187-7	41793-41794	a	_	
187-8	41795-41799	wide	_	
187-9	41800-41805	gamut	_	
187-10	41806-41808	of	_	
187-11	41809-41816	illness	_	
187-12	41817-41825	severity	_	
187-13	41825-41826	,	_	
187-14	41827-41837	chronicity	_	
187-15	41838-41841	and	_	
187-16	41842-41848	social	_	
187-17	41849-41860	functioning	_	
187-18	41860-41861	,	_	
187-19	41862-41872	comprising	_	
187-20	41873-41882	inpatient	_	
187-21	41883-41886	and	_	
187-22	41887-41897	outpatient	_	
187-23	41897-41898	,	_	
187-24	41899-41901	as	_	
187-25	41902-41906	well	_	
187-26	41907-41909	as	_	
187-27	41910-41922	good-outcome	_	
187-28	41923-41926	and	_	
187-29	41927-41939	poor-outcome	_	
187-30	41940-41952	participants	_	
187-31	41952-41953	.	_	

#Text=In contrast, subjects with ASD are invariably high-functioning, with no concurrent intellectual disability or pharmacological anamnesis, i.e. clearly a minority of those within the spectrum and nowhere near its more severe extreme.
188-1	41954-41956	In	_	
188-2	41957-41965	contrast	_	
188-3	41965-41966	,	_	
188-4	41967-41975	subjects	_	
188-5	41976-41980	with	_	
188-6	41981-41984	ASD	_	
188-7	41985-41988	are	_	
188-8	41989-41999	invariably	_	
188-9	42000-42016	high-functioning	_	
188-10	42016-42017	,	_	
188-11	42018-42022	with	_	
188-12	42023-42025	no	_	
188-13	42026-42036	concurrent	_	
188-14	42037-42049	intellectual	_	
188-15	42050-42060	disability	_	
188-16	42061-42063	or	_	
188-17	42064-42079	pharmacological	_	
188-18	42080-42089	anamnesis	_	
188-19	42089-42090	,	_	
188-20	42091-42094	i.e	_	
188-21	42094-42095	.	_	
188-22	42096-42103	clearly	_	
188-23	42104-42105	a	_	
188-24	42106-42114	minority	_	
188-25	42115-42117	of	_	
188-26	42118-42123	those	_	
188-27	42124-42130	within	_	
188-28	42131-42134	the	_	
188-29	42135-42143	spectrum	_	
188-30	42144-42147	and	_	
188-31	42148-42155	nowhere	_	
188-32	42156-42160	near	_	
188-33	42161-42164	its	_	
188-34	42165-42169	more	_	
188-35	42170-42176	severe	_	
188-36	42177-42184	extreme	_	
188-37	42184-42185	.	_	

#Text=This may potentially efface some of the diametrical differences in metabolic rates, but is not expected to impact on their similarities and topological overlaps.
189-1	42186-42190	This	_	
189-2	42191-42194	may	_	
189-3	42195-42206	potentially	_	
189-4	42207-42213	efface	_	
189-5	42214-42218	some	_	
189-6	42219-42221	of	_	
189-7	42222-42225	the	_	
189-8	42226-42237	diametrical	_	
189-9	42238-42249	differences	_	
189-10	42250-42252	in	_	
189-11	42253-42262	metabolic	_	
189-12	42263-42268	rates	_	
189-13	42268-42269	,	_	
189-14	42270-42273	but	_	
189-15	42274-42276	is	_	
189-16	42277-42280	not	_	
189-17	42281-42289	expected	_	
189-18	42290-42292	to	_	
189-19	42293-42299	impact	_	
189-20	42300-42302	on	_	
189-21	42303-42308	their	_	
189-22	42309-42321	similarities	_	
189-23	42322-42325	and	_	
189-24	42326-42337	topological	_	
189-25	42338-42346	overlaps	_	
189-26	42346-42347	.	_	

#Text=Secondly, functional neuroimaging activation patterns are inherently influenced by a choice of cognitive tasks, in this case the modified California Verbal Learning Test.
190-1	42348-42356	Secondly	_	
190-2	42356-42357	,	_	
190-3	42358-42368	functional	_	
190-4	42369-42381	neuroimaging	_	
190-5	42382-42392	activation	_	
190-6	42393-42401	patterns	_	
190-7	42402-42405	are	_	
190-8	42406-42416	inherently	_	
190-9	42417-42427	influenced	_	
190-10	42428-42430	by	_	
190-11	42431-42432	a	_	
190-12	42433-42439	choice	_	
190-13	42440-42442	of	_	
190-14	42443-42452	cognitive	_	
190-15	42453-42458	tasks	_	
190-16	42458-42459	,	_	
190-17	42460-42462	in	_	
190-18	42463-42467	this	_	
190-19	42468-42472	case	_	
190-20	42473-42476	the	_	
190-21	42477-42485	modified	_	
190-22	42486-42496	California	_	
190-23	42497-42503	Verbal	_	
190-24	42504-42512	Learning	_	
190-25	42513-42517	Test	_	
190-26	42517-42518	.	_	

#Text=The latter invokes a broad range of cognitive demands, including memory, learning, comprehension of both verbal and written language, as well as auditory and visual information processing, but it’s not specifically geared towards emotion recognition and processing, face perception, elicitation of empathic responses, mental state attribution and theory of mind, – all prominent in the semiotics of both disorders.
191-1	42519-42522	The	_	
191-2	42523-42529	latter	_	
191-3	42530-42537	invokes	_	
191-4	42538-42539	a	_	
191-5	42540-42545	broad	_	
191-6	42546-42551	range	_	
191-7	42552-42554	of	_	
191-8	42555-42564	cognitive	_	
191-9	42565-42572	demands	_	
191-10	42572-42573	,	_	
191-11	42574-42583	including	_	
191-12	42584-42590	memory	_	
191-13	42590-42591	,	_	
191-14	42592-42600	learning	_	
191-15	42600-42601	,	_	
191-16	42602-42615	comprehension	_	
191-17	42616-42618	of	_	
191-18	42619-42623	both	_	
191-19	42624-42630	verbal	_	
191-20	42631-42634	and	_	
191-21	42635-42642	written	_	
191-22	42643-42651	language	_	
191-23	42651-42652	,	_	
191-24	42653-42655	as	_	
191-25	42656-42660	well	_	
191-26	42661-42663	as	_	
191-27	42664-42672	auditory	_	
191-28	42673-42676	and	_	
191-29	42677-42683	visual	_	
191-30	42684-42695	information	_	
191-31	42696-42706	processing	_	
191-32	42706-42707	,	_	
191-33	42708-42711	but	_	
191-34	42712-42714	it	_	
191-35	42714-42715	’	_	
191-36	42715-42716	s	_	
191-37	42717-42720	not	_	
191-38	42721-42733	specifically	_	
191-39	42734-42740	geared	_	
191-40	42741-42748	towards	_	
191-41	42749-42756	emotion	_	
191-42	42757-42768	recognition	_	
191-43	42769-42772	and	_	
191-44	42773-42783	processing	_	
191-45	42783-42784	,	_	
191-46	42785-42789	face	_	
191-47	42790-42800	perception	_	
191-48	42800-42801	,	_	
191-49	42802-42813	elicitation	_	
191-50	42814-42816	of	_	
191-51	42817-42825	empathic	_	
191-52	42826-42835	responses	_	
191-53	42835-42836	,	_	
191-54	42837-42843	mental	_	
191-55	42844-42849	state	_	
191-56	42850-42861	attribution	_	
191-57	42862-42865	and	_	
191-58	42866-42872	theory	_	
191-59	42873-42875	of	_	
191-60	42876-42880	mind	_	
191-61	42880-42881	,	_	
191-62	42882-42883	–	_	
191-63	42884-42887	all	_	
191-64	42888-42897	prominent	_	
191-65	42898-42900	in	_	
191-66	42901-42904	the	_	
191-67	42905-42914	semiotics	_	
191-68	42915-42917	of	_	
191-69	42918-42922	both	_	
191-70	42923-42932	disorders	_	
191-71	42932-42933	.	_	

#Text=This may potentially de-emphasize such pertinent regions as the fusiform gyrus, amygdala–orbitofrontal network and mirroring system, but – of all functional imaging techniques – the long tracer uptake period of 18FDG PET tends to mitigate this problem by averaging the 30 minute task-induced changes in metabolic rates and thus shifting emphasis to the basal metabolic activity.
192-1	42934-42938	This	_	
192-2	42939-42942	may	_	
192-3	42943-42954	potentially	_	
192-4	42955-42967	de-emphasize	_	
192-5	42968-42972	such	_	
192-6	42973-42982	pertinent	_	
192-7	42983-42990	regions	_	
192-8	42991-42993	as	_	
192-9	42994-42997	the	_	
192-10	42998-43006	fusiform	_	
192-11	43007-43012	gyrus	_	
192-12	43012-43013	,	_	
192-13	43014-43036	amygdala–orbitofrontal	_	
192-14	43037-43044	network	_	
192-15	43045-43048	and	_	
192-16	43049-43058	mirroring	_	
192-17	43059-43065	system	_	
192-18	43065-43066	,	_	
192-19	43067-43070	but	_	
192-20	43071-43072	–	_	
192-21	43073-43075	of	_	
192-22	43076-43079	all	_	
192-23	43080-43090	functional	_	
192-24	43091-43098	imaging	_	
192-25	43099-43109	techniques	_	
192-26	43110-43111	–	_	
192-27	43112-43115	the	_	
192-28	43116-43120	long	_	
192-29	43121-43127	tracer	_	
192-30	43128-43134	uptake	_	
192-31	43135-43141	period	_	
192-32	43142-43144	of	_	
192-33	43145-43150	18FDG	_	
192-34	43151-43154	PET	_	
192-35	43155-43160	tends	_	
192-36	43161-43163	to	_	
192-37	43164-43172	mitigate	_	
192-38	43173-43177	this	_	
192-39	43178-43185	problem	_	
192-40	43186-43188	by	_	
192-41	43189-43198	averaging	_	
192-42	43199-43202	the	_	
192-43	43203-43205	30	_	
192-44	43206-43212	minute	_	
192-45	43213-43225	task-induced	_	
192-46	43226-43233	changes	_	
192-47	43234-43236	in	_	
192-48	43237-43246	metabolic	_	
192-49	43247-43252	rates	_	
192-50	43253-43256	and	_	
192-51	43257-43261	thus	_	
192-52	43262-43270	shifting	_	
192-53	43271-43279	emphasis	_	
192-54	43280-43282	to	_	
192-55	43283-43286	the	_	
192-56	43287-43292	basal	_	
192-57	43293-43302	metabolic	_	
192-58	43303-43311	activity	_	
192-59	43311-43312	.	_	

#Text=Compliance and ethical standards         
#Text=Author Serge A.
193-1	43324-43334	Compliance	_	
193-2	43335-43338	and	_	
193-3	43339-43346	ethical	_	
193-4	43347-43356	standards	_	
193-5	43366-43372	Author	_	
193-6	43373-43378	Serge	_	
193-7	43379-43380	A	_	
193-8	43380-43381	.	_	

#Text=Mitelman declares that he has no conflict of interest to report.
194-1	43382-43390	Mitelman	_	
194-2	43391-43399	declares	_	
194-3	43400-43404	that	_	
194-4	43405-43407	he	_	
194-5	43408-43411	has	_	
194-6	43412-43414	no	_	
194-7	43415-43423	conflict	_	
194-8	43424-43426	of	_	
194-9	43427-43435	interest	_	
194-10	43436-43438	to	_	
194-11	43439-43445	report	_	
194-12	43445-43446	.	_	

#Text=Author Marie-Cecile Bralet declares that she has no conflict of interest to report.
195-1	43447-43453	Author	_	
195-2	43454-43466	Marie-Cecile	_	
195-3	43467-43473	Bralet	_	
195-4	43474-43482	declares	_	
195-5	43483-43487	that	_	
195-6	43488-43491	she	_	
195-7	43492-43495	has	_	
195-8	43496-43498	no	_	
195-9	43499-43507	conflict	_	
195-10	43508-43510	of	_	
195-11	43511-43519	interest	_	
195-12	43520-43522	to	_	
195-13	43523-43529	report	_	
195-14	43529-43530	.	_	

#Text=Author M.
196-1	43531-43537	Author	_	
196-2	43538-43539	M	_	
196-3	43539-43540	.	_	

#Text=Mehmet Haznedar declares that he has no conflict of interest to report.
197-1	43541-43547	Mehmet	_	
197-2	43548-43556	Haznedar	_	
197-3	43557-43565	declares	_	
197-4	43566-43570	that	_	
197-5	43571-43573	he	_	
197-6	43574-43577	has	_	
197-7	43578-43580	no	_	
197-8	43581-43589	conflict	_	
197-9	43590-43592	of	_	
197-10	43593-43601	interest	_	
197-11	43602-43604	to	_	
197-12	43605-43611	report	_	
197-13	43611-43612	.	_	

#Text=Author Eric Hollander has received consultation fees from Transceit, Neuropharm, and Nastech.
198-1	43613-43619	Author	_	
198-2	43620-43624	Eric	_	
198-3	43625-43634	Hollander	_	
198-4	43635-43638	has	_	
198-5	43639-43647	received	_	
198-6	43648-43660	consultation	_	
198-7	43661-43665	fees	_	
198-8	43666-43670	from	_	
198-9	43671-43680	Transceit	_	
198-10	43680-43681	,	_	
198-11	43682-43692	Neuropharm	_	
198-12	43692-43693	,	_	
198-13	43694-43697	and	_	
198-14	43698-43705	Nastech	_	
198-15	43705-43706	.	_	

#Text=Author Lina Shihabuddin declares that she has no conflict of interest to report.
199-1	43707-43713	Author	_	
199-2	43714-43718	Lina	_	
199-3	43719-43730	Shihabuddin	_	
199-4	43731-43739	declares	_	
199-5	43740-43744	that	_	
199-6	43745-43748	she	_	
199-7	43749-43752	has	_	
199-8	43753-43755	no	_	
199-9	43756-43764	conflict	_	
199-10	43765-43767	of	_	
199-11	43768-43776	interest	_	
199-12	43777-43779	to	_	
199-13	43780-43786	report	_	
199-14	43786-43787	.	_	

#Text=Author Erin A.
200-1	43788-43794	Author	_	
200-2	43795-43799	Erin	_	
200-3	43800-43801	A	_	
200-4	43801-43802	.	_	

#Text=Hazlett declares that she has no conflict of interest to report.
201-1	43803-43810	Hazlett	_	
201-2	43811-43819	declares	_	
201-3	43820-43824	that	_	
201-4	43825-43828	she	_	
201-5	43829-43832	has	_	
201-6	43833-43835	no	_	
201-7	43836-43844	conflict	_	
201-8	43845-43847	of	_	
201-9	43848-43856	interest	_	
201-10	43857-43859	to	_	
201-11	43860-43866	report	_	
201-12	43866-43867	.	_	

#Text=Author Monte S.
202-1	43868-43874	Author	_	
202-2	43875-43880	Monte	_	
202-3	43881-43882	S	_	
202-4	43882-43883	.	_	

#Text=Buchsbaum declares that he has no conflict of interest to report.
203-1	43884-43893	Buchsbaum	_	
203-2	43894-43902	declares	_	
203-3	43903-43907	that	_	
203-4	43908-43910	he	_	
203-5	43911-43914	has	_	
203-6	43915-43917	no	_	
203-7	43918-43926	conflict	_	
203-8	43927-43929	of	_	
203-9	43930-43938	interest	_	
203-10	43939-43941	to	_	
203-11	43942-43948	report	_	
203-12	43948-43949	.	_	

#Text=All procedures performed in this study were in accordance with the ethical standards of the Mount Sinai institutional research committee, as well as with the 1964 Helsinki declaration and its later amendments.
204-1	43950-43953	All	_	
204-2	43954-43964	procedures	_	
204-3	43965-43974	performed	_	
204-4	43975-43977	in	_	
204-5	43978-43982	this	_	
204-6	43983-43988	study	_	
204-7	43989-43993	were	_	
204-8	43994-43996	in	_	
204-9	43997-44007	accordance	_	
204-10	44008-44012	with	_	
204-11	44013-44016	the	_	
204-12	44017-44024	ethical	_	
204-13	44025-44034	standards	_	
204-14	44035-44037	of	_	
204-15	44038-44041	the	_	
204-16	44042-44047	Mount	_	
204-17	44048-44053	Sinai	_	
204-18	44054-44067	institutional	_	
204-19	44068-44076	research	_	
204-20	44077-44086	committee	_	
204-21	44086-44087	,	_	
204-22	44088-44090	as	_	
204-23	44091-44095	well	_	
204-24	44096-44098	as	_	
204-25	44099-44103	with	_	
204-26	44104-44107	the	_	
204-27	44108-44112	1964	_	
204-28	44113-44121	Helsinki	_	
204-29	44122-44133	declaration	_	
204-30	44134-44137	and	_	
204-31	44138-44141	its	_	
204-32	44142-44147	later	_	
204-33	44148-44158	amendments	_	
204-34	44158-44159	.	_	

#Text=The project was approved by the institutional review board of The Icahn School of Medicine at Mount Sinai.
205-1	44160-44163	The	_	
205-2	44164-44171	project	_	
205-3	44172-44175	was	_	
205-4	44176-44184	approved	_	
205-5	44185-44187	by	_	
205-6	44188-44191	the	_	
205-7	44192-44205	institutional	_	
205-8	44206-44212	review	_	
205-9	44213-44218	board	_	
205-10	44219-44221	of	_	
205-11	44222-44225	The	_	
205-12	44226-44231	Icahn	_	
205-13	44232-44238	School	_	
205-14	44239-44241	of	_	
205-15	44242-44250	Medicine	_	
205-16	44251-44253	at	_	
205-17	44254-44259	Mount	_	
205-18	44260-44265	Sinai	_	
205-19	44265-44266	.	_	

#Text=Informed consent was obtained from all individual participants in the study.
206-1	44267-44275	Informed	_	
206-2	44276-44283	consent	_	
206-3	44284-44287	was	_	
206-4	44288-44296	obtained	_	
206-5	44297-44301	from	_	
206-6	44302-44305	all	_	
206-7	44306-44316	individual	_	
206-8	44317-44329	participants	_	
206-9	44330-44332	in	_	
206-10	44333-44336	the	_	
206-11	44337-44342	study	_	
206-12	44342-44343	.	_	

#Text=Autism and psychosis expressions diametrically modulate the right temporoparietal junction
#Text=The social brain: neural basis of social knowledge
#Text=Neural bases of atypical emotional face processing in autism: a meta-analysis of fMRI studies
#Text=The anterior cingulate gyrus and social cognition: tracking the motivation of others
#Text=The role of the striatum in social behavior
#Text=Autism: the empathizing-systemizing (E-S) theory
#Text=Empathizing, systemizing, and the extreme male brain theory of autism
#Text=Sex differences in the brain: implications for explaining autism
#Text=Autism and schizophrenia: Similar perceptual consequence, different neurobiological etiology?
207-1	44344-44350	Autism	_	
207-2	44351-44354	and	_	
207-3	44355-44364	psychosis	_	
207-4	44365-44376	expressions	_	
207-5	44377-44390	diametrically	_	
207-6	44391-44399	modulate	_	
207-7	44400-44403	the	_	
207-8	44404-44409	right	_	
207-9	44410-44425	temporoparietal	_	
207-10	44426-44434	junction	_	
207-11	44435-44438	The	_	
207-12	44439-44445	social	_	
207-13	44446-44451	brain	_	
207-14	44451-44452	:	_	
207-15	44453-44459	neural	_	
207-16	44460-44465	basis	_	
207-17	44466-44468	of	_	
207-18	44469-44475	social	_	
207-19	44476-44485	knowledge	_	
207-20	44486-44492	Neural	_	
207-21	44493-44498	bases	_	
207-22	44499-44501	of	_	
207-23	44502-44510	atypical	_	
207-24	44511-44520	emotional	_	
207-25	44521-44525	face	_	
207-26	44526-44536	processing	_	
207-27	44537-44539	in	_	
207-28	44540-44546	autism	_	
207-29	44546-44547	:	_	
207-30	44548-44549	a	_	
207-31	44550-44563	meta-analysis	_	
207-32	44564-44566	of	_	
207-33	44567-44571	fMRI	_	
207-34	44572-44579	studies	_	
207-35	44580-44583	The	_	
207-36	44584-44592	anterior	_	
207-37	44593-44602	cingulate	_	
207-38	44603-44608	gyrus	_	
207-39	44609-44612	and	_	
207-40	44613-44619	social	_	
207-41	44620-44629	cognition	_	
207-42	44629-44630	:	_	
207-43	44631-44639	tracking	_	
207-44	44640-44643	the	_	
207-45	44644-44654	motivation	_	
207-46	44655-44657	of	_	
207-47	44658-44664	others	_	
207-48	44665-44668	The	_	
207-49	44669-44673	role	_	
207-50	44674-44676	of	_	
207-51	44677-44680	the	_	
207-52	44681-44689	striatum	_	
207-53	44690-44692	in	_	
207-54	44693-44699	social	_	
207-55	44700-44708	behavior	_	
207-56	44709-44715	Autism	_	
207-57	44715-44716	:	_	
207-58	44717-44720	the	_	
207-59	44721-44744	empathizing-systemizing	_	
207-60	44745-44746	(	_	
207-61	44746-44749	E-S	_	
207-62	44749-44750	)	_	
207-63	44751-44757	theory	_	
207-64	44758-44769	Empathizing	_	
207-65	44769-44770	,	_	
207-66	44771-44782	systemizing	_	
207-67	44782-44783	,	_	
207-68	44784-44787	and	_	
207-69	44788-44791	the	_	
207-70	44792-44799	extreme	_	
207-71	44800-44804	male	_	
207-72	44805-44810	brain	_	
207-73	44811-44817	theory	_	
207-74	44818-44820	of	_	
207-75	44821-44827	autism	_	
207-76	44828-44831	Sex	_	
207-77	44832-44843	differences	_	
207-78	44844-44846	in	_	
207-79	44847-44850	the	_	
207-80	44851-44856	brain	_	
207-81	44856-44857	:	_	
207-82	44858-44870	implications	_	
207-83	44871-44874	for	_	
207-84	44875-44885	explaining	_	
207-85	44886-44892	autism	_	
207-86	44893-44899	Autism	_	
207-87	44900-44903	and	_	
207-88	44904-44917	schizophrenia	_	
207-89	44917-44918	:	_	
207-90	44919-44926	Similar	_	
207-91	44927-44937	perceptual	_	
207-92	44938-44949	consequence	_	
207-93	44949-44950	,	_	
207-94	44951-44960	different	_	
207-95	44961-44976	neurobiological	_	
207-96	44977-44985	etiology	_	
207-97	44985-44986	?	_	

#Text=FDG-PET scans in patients with Kraepelinian and non-Kraepelinian schizophrenia
#Text=Reasoning on the autism spectrum: a dual process theory account
#Text=Positron emission tomography studies of abnormal glucose metabolism in schizophrenia
#Text=Schizophrenia and autism as contrasting minds: neural evidence for the hypo-hyper-intentionality hypothesis
#Text=AFNI: software for analysis and visualization of functional magnetic resonance neuroimages
#Text=Psychosis and autism as diametrical disorders of the social brain
#Text=Diametrical diseases reflect evolutionary-genetic tradeoffs: Evidence from psychiatry, neurology, rheumatology, oncology and immunology
#Text=Comparative genomics of autism and schizophrenia
#Text=Mapping the self in the brain’s default mode network
#Text=
#Text=Functional magnetic resonance imaging of autism spectrum disorders
#Text=Autism and the social brain: the first-year puzzle
#Text=The social brain?
208-1	44987-44994	FDG-PET	_	
208-2	44995-45000	scans	_	
208-3	45001-45003	in	_	
208-4	45004-45012	patients	_	
208-5	45013-45017	with	_	
208-6	45018-45030	Kraepelinian	_	
208-7	45031-45034	and	_	
208-8	45035-45051	non-Kraepelinian	_	
208-9	45052-45065	schizophrenia	_	
208-10	45066-45075	Reasoning	_	
208-11	45076-45078	on	_	
208-12	45079-45082	the	_	
208-13	45083-45089	autism	_	
208-14	45090-45098	spectrum	_	
208-15	45098-45099	:	_	
208-16	45100-45101	a	_	
208-17	45102-45106	dual	_	
208-18	45107-45114	process	_	
208-19	45115-45121	theory	_	
208-20	45122-45129	account	_	
208-21	45130-45138	Positron	_	
208-22	45139-45147	emission	_	
208-23	45148-45158	tomography	_	
208-24	45159-45166	studies	_	
208-25	45167-45169	of	_	
208-26	45170-45178	abnormal	_	
208-27	45179-45186	glucose	_	
208-28	45187-45197	metabolism	_	
208-29	45198-45200	in	_	
208-30	45201-45214	schizophrenia	_	
208-31	45215-45228	Schizophrenia	_	
208-32	45229-45232	and	_	
208-33	45233-45239	autism	_	
208-34	45240-45242	as	_	
208-35	45243-45254	contrasting	_	
208-36	45255-45260	minds	_	
208-37	45260-45261	:	_	
208-38	45262-45268	neural	_	
208-39	45269-45277	evidence	_	
208-40	45278-45281	for	_	
208-41	45282-45285	the	_	
208-42	45286-45311	hypo-hyper-intentionality	_	
208-43	45312-45322	hypothesis	_	
208-44	45323-45327	AFNI	_	
208-45	45327-45328	:	_	
208-46	45329-45337	software	_	
208-47	45338-45341	for	_	
208-48	45342-45350	analysis	_	
208-49	45351-45354	and	_	
208-50	45355-45368	visualization	_	
208-51	45369-45371	of	_	
208-52	45372-45382	functional	_	
208-53	45383-45391	magnetic	_	
208-54	45392-45401	resonance	_	
208-55	45402-45413	neuroimages	_	
208-56	45414-45423	Psychosis	_	
208-57	45424-45427	and	_	
208-58	45428-45434	autism	_	
208-59	45435-45437	as	_	
208-60	45438-45449	diametrical	_	
208-61	45450-45459	disorders	_	
208-62	45460-45462	of	_	
208-63	45463-45466	the	_	
208-64	45467-45473	social	_	
208-65	45474-45479	brain	_	
208-66	45480-45491	Diametrical	_	
208-67	45492-45500	diseases	_	
208-68	45501-45508	reflect	_	
208-69	45509-45529	evolutionary-genetic	_	
208-70	45530-45539	tradeoffs	_	
208-71	45539-45540	:	_	
208-72	45541-45549	Evidence	_	
208-73	45550-45554	from	_	
208-74	45555-45565	psychiatry	_	
208-75	45565-45566	,	_	
208-76	45567-45576	neurology	_	
208-77	45576-45577	,	_	
208-78	45578-45590	rheumatology	_	
208-79	45590-45591	,	_	
208-80	45592-45600	oncology	_	
208-81	45601-45604	and	_	
208-82	45605-45615	immunology	_	
208-83	45616-45627	Comparative	_	
208-84	45628-45636	genomics	_	
208-85	45637-45639	of	_	
208-86	45640-45646	autism	_	
208-87	45647-45650	and	_	
208-88	45651-45664	schizophrenia	_	
208-89	45665-45672	Mapping	_	
208-90	45673-45676	the	_	
208-91	45677-45681	self	_	
208-92	45682-45684	in	_	
208-93	45685-45688	the	_	
208-94	45689-45694	brain	_	
208-95	45694-45695	’	_	
208-96	45695-45696	s	_	
208-97	45697-45704	default	_	
208-98	45705-45709	mode	_	
208-99	45710-45717	network	_	
208-100	45719-45729	Functional	_	
208-101	45730-45738	magnetic	_	
208-102	45739-45748	resonance	_	
208-103	45749-45756	imaging	_	
208-104	45757-45759	of	_	
208-105	45760-45766	autism	_	
208-106	45767-45775	spectrum	_	
208-107	45776-45785	disorders	_	
208-108	45786-45792	Autism	_	
208-109	45793-45796	and	_	
208-110	45797-45800	the	_	
208-111	45801-45807	social	_	
208-112	45808-45813	brain	_	
208-113	45813-45814	:	_	
208-114	45815-45818	the	_	
208-115	45819-45829	first-year	_	
208-116	45830-45836	puzzle	_	
208-117	45837-45840	The	_	
208-118	45841-45847	social	_	
208-119	45848-45853	brain	_	
208-120	45853-45854	?	_	

#Text=Task-induced deactivation of midline cortical regions in schizophrenia assessed with fMRI
#Text=Representation, control, or reasoning?
209-1	45856-45868	Task-induced	_	
209-2	45869-45881	deactivation	_	
209-3	45882-45884	of	_	
209-4	45885-45892	midline	_	
209-5	45893-45901	cortical	_	
209-6	45902-45909	regions	_	
209-7	45910-45912	in	_	
209-8	45913-45926	schizophrenia	_	
209-9	45927-45935	assessed	_	
209-10	45936-45940	with	_	
209-11	45941-45945	fMRI	_	
209-12	45946-45960	Representation	_	
209-13	45960-45961	,	_	
209-14	45962-45969	control	_	
209-15	45969-45970	,	_	
209-16	45971-45973	or	_	
209-17	45974-45983	reasoning	_	
209-18	45983-45984	?	_	

#Text=Distinct functions for theory of mind within the medial prefrontal cortex
#Text=Regional glucose metabolism within cortical Brodmann areas in healthy individuals and autistic patients
#Text=Abnormal glucose metabolism in the mediodorsal nucleus of the thalamus in schizophrenia
#Text=Effects of sex and normal aging on regional brain activation during verbal memory performance
#Text=Volumetric analysis and three-dimensional glucose metabolic mapping of the striatum and thalamus in patients with autism spectrum disorders
#Text=Schizophrenia and autism – related disorders
#Text=The cerebral metabolic landscape in autism.
210-1	45985-45993	Distinct	_	
210-2	45994-46003	functions	_	
210-3	46004-46007	for	_	
210-4	46008-46014	theory	_	
210-5	46015-46017	of	_	
210-6	46018-46022	mind	_	
210-7	46023-46029	within	_	
210-8	46030-46033	the	_	
210-9	46034-46040	medial	_	
210-10	46041-46051	prefrontal	_	
210-11	46052-46058	cortex	_	
210-12	46059-46067	Regional	_	
210-13	46068-46075	glucose	_	
210-14	46076-46086	metabolism	_	
210-15	46087-46093	within	_	
210-16	46094-46102	cortical	_	
210-17	46103-46111	Brodmann	_	
210-18	46112-46117	areas	_	
210-19	46118-46120	in	_	
210-20	46121-46128	healthy	_	
210-21	46129-46140	individuals	_	
210-22	46141-46144	and	_	
210-23	46145-46153	autistic	_	
210-24	46154-46162	patients	_	
210-25	46163-46171	Abnormal	_	
210-26	46172-46179	glucose	_	
210-27	46180-46190	metabolism	_	
210-28	46191-46193	in	_	
210-29	46194-46197	the	_	
210-30	46198-46209	mediodorsal	_	
210-31	46210-46217	nucleus	_	
210-32	46218-46220	of	_	
210-33	46221-46224	the	_	
210-34	46225-46233	thalamus	_	
210-35	46234-46236	in	_	
210-36	46237-46250	schizophrenia	_	
210-37	46251-46258	Effects	_	
210-38	46259-46261	of	_	
210-39	46262-46265	sex	_	
210-40	46266-46269	and	_	
210-41	46270-46276	normal	_	
210-42	46277-46282	aging	_	
210-43	46283-46285	on	_	
210-44	46286-46294	regional	_	
210-45	46295-46300	brain	_	
210-46	46301-46311	activation	_	
210-47	46312-46318	during	_	
210-48	46319-46325	verbal	_	
210-49	46326-46332	memory	_	
210-50	46333-46344	performance	_	
210-51	46345-46355	Volumetric	_	
210-52	46356-46364	analysis	_	
210-53	46365-46368	and	_	
210-54	46369-46386	three-dimensional	_	
210-55	46387-46394	glucose	_	
210-56	46395-46404	metabolic	_	
210-57	46405-46412	mapping	_	
210-58	46413-46415	of	_	
210-59	46416-46419	the	_	
210-60	46420-46428	striatum	_	
210-61	46429-46432	and	_	
210-62	46433-46441	thalamus	_	
210-63	46442-46444	in	_	
210-64	46445-46453	patients	_	
210-65	46454-46458	with	_	
210-66	46459-46465	autism	_	
210-67	46466-46474	spectrum	_	
210-68	46475-46484	disorders	_	
210-69	46485-46498	Schizophrenia	_	
210-70	46499-46502	and	_	
210-71	46503-46509	autism	_	
210-72	46510-46511	–	_	
210-73	46512-46519	related	_	
210-74	46520-46529	disorders	_	
210-75	46530-46533	The	_	
210-76	46534-46542	cerebral	_	
210-77	46543-46552	metabolic	_	
210-78	46553-46562	landscape	_	
210-79	46563-46565	in	_	
210-80	46566-46572	autism	_	
210-81	46572-46573	.	_	

#Text=Intercorrelations of regional glucose utilization
#Text=Similar white matter but opposite grey matter changes in schizophrenia and high-functioning autism
#Text=Characteristics of very poor outcome schizophrenia
#Text=Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs
#Text=The role of the posterior cingulate cortex in cognition and disease
#Text=Thalamic and prefrontal FDG uptake in never medicated patients with schizophrenia
#Text=Diametrical relationship between gray and white matter volumes in autism spectrum disorder and schizophrenia
#Text=Metabolic disconnection between the mediodorsal nucleus of the thalamus and cortical Brodmann’s areas of the left hemisphere in schizophrenia
#Text=Is the medial prefrontal cortex necessary for theory of mind?
211-1	46574-46591	Intercorrelations	_	
211-2	46592-46594	of	_	
211-3	46595-46603	regional	_	
211-4	46604-46611	glucose	_	
211-5	46612-46623	utilization	_	
211-6	46624-46631	Similar	_	
211-7	46632-46637	white	_	
211-8	46638-46644	matter	_	
211-9	46645-46648	but	_	
211-10	46649-46657	opposite	_	
211-11	46658-46662	grey	_	
211-12	46663-46669	matter	_	
211-13	46670-46677	changes	_	
211-14	46678-46680	in	_	
211-15	46681-46694	schizophrenia	_	
211-16	46695-46698	and	_	
211-17	46699-46715	high-functioning	_	
211-18	46716-46722	autism	_	
211-19	46723-46738	Characteristics	_	
211-20	46739-46741	of	_	
211-21	46742-46746	very	_	
211-22	46747-46751	poor	_	
211-23	46752-46759	outcome	_	
211-24	46760-46773	schizophrenia	_	
211-25	46774-46781	Genetic	_	
211-26	46782-46794	relationship	_	
211-27	46795-46802	between	_	
211-28	46803-46807	five	_	
211-29	46808-46819	psychiatric	_	
211-30	46820-46829	disorders	_	
211-31	46830-46839	estimated	_	
211-32	46840-46844	from	_	
211-33	46845-46856	genome-wide	_	
211-34	46857-46861	SNPs	_	
211-35	46862-46865	The	_	
211-36	46866-46870	role	_	
211-37	46871-46873	of	_	
211-38	46874-46877	the	_	
211-39	46878-46887	posterior	_	
211-40	46888-46897	cingulate	_	
211-41	46898-46904	cortex	_	
211-42	46905-46907	in	_	
211-43	46908-46917	cognition	_	
211-44	46918-46921	and	_	
211-45	46922-46929	disease	_	
211-46	46930-46938	Thalamic	_	
211-47	46939-46942	and	_	
211-48	46943-46953	prefrontal	_	
211-49	46954-46957	FDG	_	
211-50	46958-46964	uptake	_	
211-51	46965-46967	in	_	
211-52	46968-46973	never	_	
211-53	46974-46983	medicated	_	
211-54	46984-46992	patients	_	
211-55	46993-46997	with	_	
211-56	46998-47011	schizophrenia	_	
211-57	47012-47023	Diametrical	_	
211-58	47024-47036	relationship	_	
211-59	47037-47044	between	_	
211-60	47045-47049	gray	_	
211-61	47050-47053	and	_	
211-62	47054-47059	white	_	
211-63	47060-47066	matter	_	
211-64	47067-47074	volumes	_	
211-65	47075-47077	in	_	
211-66	47078-47084	autism	_	
211-67	47085-47093	spectrum	_	
211-68	47094-47102	disorder	_	
211-69	47103-47106	and	_	
211-70	47107-47120	schizophrenia	_	
211-71	47121-47130	Metabolic	_	
211-72	47131-47144	disconnection	_	
211-73	47145-47152	between	_	
211-74	47153-47156	the	_	
211-75	47157-47168	mediodorsal	_	
211-76	47169-47176	nucleus	_	
211-77	47177-47179	of	_	
211-78	47180-47183	the	_	
211-79	47184-47192	thalamus	_	
211-80	47193-47196	and	_	
211-81	47197-47205	cortical	_	
211-82	47206-47214	Brodmann	_	
211-83	47214-47215	’	_	
211-84	47215-47216	s	_	
211-85	47217-47222	areas	_	
211-86	47223-47225	of	_	
211-87	47226-47229	the	_	
211-88	47230-47234	left	_	
211-89	47235-47245	hemisphere	_	
211-90	47246-47248	in	_	
211-91	47249-47262	schizophrenia	_	
211-92	47263-47265	Is	_	
211-93	47266-47269	the	_	
211-94	47270-47276	medial	_	
211-95	47277-47287	prefrontal	_	
211-96	47288-47294	cortex	_	
211-97	47295-47304	necessary	_	
211-98	47305-47308	for	_	
211-99	47309-47315	theory	_	
211-100	47316-47318	of	_	
211-101	47319-47323	mind	_	
211-102	47323-47324	?	_	

#Text=Brief report: alterations in cerebral blood flow as assessed by PET/CT in adults with autism spectrum disorder with normal IQ
#Text=Cerebral blood flow in posterior cortical nodes of the default mode network decreases with task engagement but remains higher in most brain regions
#Text=Dopaminergic activities in the human striatum: rostrocaudal gradients of uptake sites and of D1 and D2 but not of D3 receptor binding or dopamine
#Text=The neural basis of sex differences in sexual behavior: a quantitative meta-analysis
#Text=Neurodevelopmental model of schizophrenia: update 2012
#Text=Fluorodeoxyglucose PET in neurology and psychiatry
#Text=Regional cerebral glucose metabolism and attention in adults with a history of childhood autism
#Text=Glucose metabolic correlates of continuous performance test performance in adults with a history of infantile autism, schizophrenia, and controls
#Text=Abstract spatial reasoning as an autistic strength
#Text=Functional neuroimaging studies of sexual arousal and orgasm in healthy men and women: a review and meta-analysis
#Text=The hippocampal formation in schizophrenia
#Text=A dissociation between social mentalizing and general reasoning
#Text=Hyperactivity and hyperconnectivity of the default network in schizophrenia and in first-degree relatives of persons with schizophrenia
#Text=MRI-PET registration with automated algorithm
#Text=A small number of abnormal brain connections predicts adult autism spectrum disorder
#Text=A systematic review of molecular imaging (PET and SPECT) in autism spectrum disorder: current state and future research opportunities
#Text=Relative 18fluorodeoxyglucose uptake in subjects with schizophrenia, subjects with ASD and healthy controls.
212-1	47325-47330	Brief	_	
212-2	47331-47337	report	_	
212-3	47337-47338	:	_	
212-4	47339-47350	alterations	_	
212-5	47351-47353	in	_	
212-6	47354-47362	cerebral	_	
212-7	47363-47368	blood	_	
212-8	47369-47373	flow	_	
212-9	47374-47376	as	_	
212-10	47377-47385	assessed	_	
212-11	47386-47388	by	_	
212-12	47389-47392	PET	_	
212-13	47392-47393	/	_	
212-14	47393-47395	CT	_	
212-15	47396-47398	in	_	
212-16	47399-47405	adults	_	
212-17	47406-47410	with	_	
212-18	47411-47417	autism	_	
212-19	47418-47426	spectrum	_	
212-20	47427-47435	disorder	_	
212-21	47436-47440	with	_	
212-22	47441-47447	normal	_	
212-23	47448-47450	IQ	_	
212-24	47451-47459	Cerebral	_	
212-25	47460-47465	blood	_	
212-26	47466-47470	flow	_	
212-27	47471-47473	in	_	
212-28	47474-47483	posterior	_	
212-29	47484-47492	cortical	_	
212-30	47493-47498	nodes	_	
212-31	47499-47501	of	_	
212-32	47502-47505	the	_	
212-33	47506-47513	default	_	
212-34	47514-47518	mode	_	
212-35	47519-47526	network	_	
212-36	47527-47536	decreases	_	
212-37	47537-47541	with	_	
212-38	47542-47546	task	_	
212-39	47547-47557	engagement	_	
212-40	47558-47561	but	_	
212-41	47562-47569	remains	_	
212-42	47570-47576	higher	_	
212-43	47577-47579	in	_	
212-44	47580-47584	most	_	
212-45	47585-47590	brain	_	
212-46	47591-47598	regions	_	
212-47	47599-47611	Dopaminergic	_	
212-48	47612-47622	activities	_	
212-49	47623-47625	in	_	
212-50	47626-47629	the	_	
212-51	47630-47635	human	_	
212-52	47636-47644	striatum	_	
212-53	47644-47645	:	_	
212-54	47646-47658	rostrocaudal	_	
212-55	47659-47668	gradients	_	
212-56	47669-47671	of	_	
212-57	47672-47678	uptake	_	
212-58	47679-47684	sites	_	
212-59	47685-47688	and	_	
212-60	47689-47691	of	_	
212-61	47692-47694	D1	_	
212-62	47695-47698	and	_	
212-63	47699-47701	D2	_	
212-64	47702-47705	but	_	
212-65	47706-47709	not	_	
212-66	47710-47712	of	_	
212-67	47713-47715	D3	_	
212-68	47716-47724	receptor	_	
212-69	47725-47732	binding	_	
212-70	47733-47735	or	_	
212-71	47736-47744	dopamine	_	
212-72	47745-47748	The	_	
212-73	47749-47755	neural	_	
212-74	47756-47761	basis	_	
212-75	47762-47764	of	_	
212-76	47765-47768	sex	_	
212-77	47769-47780	differences	_	
212-78	47781-47783	in	_	
212-79	47784-47790	sexual	_	
212-80	47791-47799	behavior	_	
212-81	47799-47800	:	_	
212-82	47801-47802	a	_	
212-83	47803-47815	quantitative	_	
212-84	47816-47829	meta-analysis	_	
212-85	47830-47848	Neurodevelopmental	_	
212-86	47849-47854	model	_	
212-87	47855-47857	of	_	
212-88	47858-47871	schizophrenia	_	
212-89	47871-47872	:	_	
212-90	47873-47879	update	_	
212-91	47880-47884	2012	_	
212-92	47885-47903	Fluorodeoxyglucose	_	
212-93	47904-47907	PET	_	
212-94	47908-47910	in	_	
212-95	47911-47920	neurology	_	
212-96	47921-47924	and	_	
212-97	47925-47935	psychiatry	_	
212-98	47936-47944	Regional	_	
212-99	47945-47953	cerebral	_	
212-100	47954-47961	glucose	_	
212-101	47962-47972	metabolism	_	
212-102	47973-47976	and	_	
212-103	47977-47986	attention	_	
212-104	47987-47989	in	_	
212-105	47990-47996	adults	_	
212-106	47997-48001	with	_	
212-107	48002-48003	a	_	
212-108	48004-48011	history	_	
212-109	48012-48014	of	_	
212-110	48015-48024	childhood	_	
212-111	48025-48031	autism	_	
212-112	48032-48039	Glucose	_	
212-113	48040-48049	metabolic	_	
212-114	48050-48060	correlates	_	
212-115	48061-48063	of	_	
212-116	48064-48074	continuous	_	
212-117	48075-48086	performance	_	
212-118	48087-48091	test	_	
212-119	48092-48103	performance	_	
212-120	48104-48106	in	_	
212-121	48107-48113	adults	_	
212-122	48114-48118	with	_	
212-123	48119-48120	a	_	
212-124	48121-48128	history	_	
212-125	48129-48131	of	_	
212-126	48132-48141	infantile	_	
212-127	48142-48148	autism	_	
212-128	48148-48149	,	_	
212-129	48150-48163	schizophrenia	_	
212-130	48163-48164	,	_	
212-131	48165-48168	and	_	
212-132	48169-48177	controls	_	
212-133	48178-48186	Abstract	_	
212-134	48187-48194	spatial	_	
212-135	48195-48204	reasoning	_	
212-136	48205-48207	as	_	
212-137	48208-48210	an	_	
212-138	48211-48219	autistic	_	
212-139	48220-48228	strength	_	
212-140	48229-48239	Functional	_	
212-141	48240-48252	neuroimaging	_	
212-142	48253-48260	studies	_	
212-143	48261-48263	of	_	
212-144	48264-48270	sexual	_	
212-145	48271-48278	arousal	_	
212-146	48279-48282	and	_	
212-147	48283-48289	orgasm	_	
212-148	48290-48292	in	_	
212-149	48293-48300	healthy	_	
212-150	48301-48304	men	_	
212-151	48305-48308	and	_	
212-152	48309-48314	women	_	
212-153	48314-48315	:	_	
212-154	48316-48317	a	_	
212-155	48318-48324	review	_	
212-156	48325-48328	and	_	
212-157	48329-48342	meta-analysis	_	
212-158	48343-48346	The	_	
212-159	48347-48358	hippocampal	_	
212-160	48359-48368	formation	_	
212-161	48369-48371	in	_	
212-162	48372-48385	schizophrenia	_	
212-163	48386-48387	A	_	
212-164	48388-48400	dissociation	_	
212-165	48401-48408	between	_	
212-166	48409-48415	social	_	
212-167	48416-48427	mentalizing	_	
212-168	48428-48431	and	_	
212-169	48432-48439	general	_	
212-170	48440-48449	reasoning	_	
212-171	48450-48463	Hyperactivity	_	
212-172	48464-48467	and	_	
212-173	48468-48485	hyperconnectivity	_	
212-174	48486-48488	of	_	
212-175	48489-48492	the	_	
212-176	48493-48500	default	_	
212-177	48501-48508	network	_	
212-178	48509-48511	in	_	
212-179	48512-48525	schizophrenia	_	
212-180	48526-48529	and	_	
212-181	48530-48532	in	_	
212-182	48533-48545	first-degree	_	
212-183	48546-48555	relatives	_	
212-184	48556-48558	of	_	
212-185	48559-48566	persons	_	
212-186	48567-48571	with	_	
212-187	48572-48585	schizophrenia	_	
212-188	48586-48593	MRI-PET	_	
212-189	48594-48606	registration	_	
212-190	48607-48611	with	_	
212-191	48612-48621	automated	_	
212-192	48622-48631	algorithm	_	
212-193	48632-48633	A	_	
212-194	48634-48639	small	_	
212-195	48640-48646	number	_	
212-196	48647-48649	of	_	
212-197	48650-48658	abnormal	_	
212-198	48659-48664	brain	_	
212-199	48665-48676	connections	_	
212-200	48677-48685	predicts	_	
212-201	48686-48691	adult	_	
212-202	48692-48698	autism	_	
212-203	48699-48707	spectrum	_	
212-204	48708-48716	disorder	_	
212-205	48717-48718	A	_	
212-206	48719-48729	systematic	_	
212-207	48730-48736	review	_	
212-208	48737-48739	of	_	
212-209	48740-48749	molecular	_	
212-210	48750-48757	imaging	_	
212-211	48758-48759	(	_	
212-212	48759-48762	PET	_	
212-213	48763-48766	and	_	
212-214	48767-48772	SPECT	_	
212-215	48772-48773	)	_	
212-216	48774-48776	in	_	
212-217	48777-48783	autism	_	
212-218	48784-48792	spectrum	_	
212-219	48793-48801	disorder	_	
212-220	48801-48802	:	_	
212-221	48803-48810	current	_	
212-222	48811-48816	state	_	
212-223	48817-48820	and	_	
212-224	48821-48827	future	_	
212-225	48828-48836	research	_	
212-226	48837-48850	opportunities	_	
212-227	48851-48859	Relative	_	
212-228	48860-48880	18fluorodeoxyglucose	_	
212-229	48881-48887	uptake	_	
212-230	48888-48890	in	_	
212-231	48891-48899	subjects	_	
212-232	48900-48904	with	_	
212-233	48905-48918	schizophrenia	_	
212-234	48918-48919	,	_	
212-235	48920-48928	subjects	_	
212-236	48929-48933	with	_	
212-237	48934-48937	ASD	_	
212-238	48938-48941	and	_	
212-239	48942-48949	healthy	_	
212-240	48950-48958	controls	_	
212-241	48958-48959	.	_	

#Text=This graph is based on the diagnostic group-by-Brodmann area interaction in ANOVA with three diagnostic groups and 42 Brodmann areas.
213-1	48960-48964	This	_	
213-2	48965-48970	graph	_	
213-3	48971-48973	is	_	
213-4	48974-48979	based	_	
213-5	48980-48982	on	_	
213-6	48983-48986	the	_	
213-7	48987-48997	diagnostic	_	
213-8	48998-49015	group-by-Brodmann	_	
213-9	49016-49020	area	_	
213-10	49021-49032	interaction	_	
213-11	49033-49035	in	_	
213-12	49036-49041	ANOVA	_	
213-13	49042-49046	with	_	
213-14	49047-49052	three	_	
213-15	49053-49063	diagnostic	_	
213-16	49064-49070	groups	_	
213-17	49071-49074	and	_	
213-18	49075-49077	42	_	
213-19	49078-49086	Brodmann	_	
213-20	49087-49092	areas	_	
213-21	49092-49093	.	_	

#Text=Orange and green bars represent metabolic rates in healthy controls subtracted from metabolic rates in subjects with autism and schizophrenia respectively, so that each patient group is plotted against the zero axis line of healthy controls.
214-1	49094-49100	Orange	_	
214-2	49101-49104	and	_	
214-3	49105-49110	green	_	
214-4	49111-49115	bars	_	
214-5	49116-49125	represent	_	
214-6	49126-49135	metabolic	_	
214-7	49136-49141	rates	_	
214-8	49142-49144	in	_	
214-9	49145-49152	healthy	_	
214-10	49153-49161	controls	_	
214-11	49162-49172	subtracted	_	
214-12	49173-49177	from	_	
214-13	49178-49187	metabolic	_	
214-14	49188-49193	rates	_	
214-15	49194-49196	in	_	
214-16	49197-49205	subjects	_	
214-17	49206-49210	with	_	
214-18	49211-49217	autism	_	
214-19	49218-49221	and	_	
214-20	49222-49235	schizophrenia	_	
214-21	49236-49248	respectively	_	
214-22	49248-49249	,	_	
214-23	49250-49252	so	_	
214-24	49253-49257	that	_	
214-25	49258-49262	each	_	
214-26	49263-49270	patient	_	
214-27	49271-49276	group	_	
214-28	49277-49279	is	_	
214-29	49280-49287	plotted	_	
214-30	49288-49295	against	_	
214-31	49296-49299	the	_	
214-32	49300-49304	zero	_	
214-33	49305-49309	axis	_	
214-34	49310-49314	line	_	
214-35	49315-49317	of	_	
214-36	49318-49325	healthy	_	
214-37	49326-49334	controls	_	
214-38	49334-49335	.	_	

#Text=Follow-up three-group ANOVA for a precentral/postcentral region comprising primary motor and somatosensory Brodmann areas 1, 2, 3, 4, and 5.
215-1	49336-49345	Follow-up	_	
215-2	49346-49357	three-group	_	
215-3	49358-49363	ANOVA	_	
215-4	49364-49367	for	_	
215-5	49368-49369	a	_	
215-6	49370-49380	precentral	_	
215-7	49380-49381	/	_	
215-8	49381-49392	postcentral	_	
215-9	49393-49399	region	_	
215-10	49400-49410	comprising	_	
215-11	49411-49418	primary	_	
215-12	49419-49424	motor	_	
215-13	49425-49428	and	_	
215-14	49429-49442	somatosensory	_	
215-15	49443-49451	Brodmann	_	
215-16	49452-49457	areas	_	
215-17	49458-49459	1	_	
215-18	49459-49460	,	_	
215-19	49461-49462	2	_	
215-20	49462-49463	,	_	
215-21	49464-49465	3	_	
215-22	49465-49466	,	_	
215-23	49467-49468	4	_	
215-24	49468-49469	,	_	
215-25	49470-49473	and	_	
215-26	49474-49475	5	_	
215-27	49475-49476	.	_	

#Text=This figure illustrates the main effect of diagnostic group (upper panel) and group-by-Brodmann area interaction (lower panel) for the region where diametric differences between subjects with schizophrenia and ASD were observed in the overarching analysis of all 42 Brodmann areas.
216-1	49477-49481	This	_	
216-2	49482-49488	figure	_	
216-3	49489-49500	illustrates	_	
216-4	49501-49504	the	_	
216-5	49505-49509	main	_	
216-6	49510-49516	effect	_	
216-7	49517-49519	of	_	
216-8	49520-49530	diagnostic	_	
216-9	49531-49536	group	_	
216-10	49537-49538	(	_	
216-11	49538-49543	upper	_	
216-12	49544-49549	panel	_	
216-13	49549-49550	)	_	
216-14	49551-49554	and	_	
216-15	49555-49572	group-by-Brodmann	_	
216-16	49573-49577	area	_	
216-17	49578-49589	interaction	_	
216-18	49590-49591	(	_	
216-19	49591-49596	lower	_	
216-20	49597-49602	panel	_	
216-21	49602-49603	)	_	
216-22	49604-49607	for	_	
216-23	49608-49611	the	_	
216-24	49612-49618	region	_	
216-25	49619-49624	where	_	
216-26	49625-49634	diametric	_	
216-27	49635-49646	differences	_	
216-28	49647-49654	between	_	
216-29	49655-49663	subjects	_	
216-30	49664-49668	with	_	
216-31	49669-49682	schizophrenia	_	
216-32	49683-49686	and	_	
216-33	49687-49690	ASD	_	
216-34	49691-49695	were	_	
216-35	49696-49704	observed	_	
216-36	49705-49707	in	_	
216-37	49708-49711	the	_	
216-38	49712-49723	overarching	_	
216-39	49724-49732	analysis	_	
216-40	49733-49735	of	_	
216-41	49736-49739	all	_	
216-42	49740-49742	42	_	
216-43	49743-49751	Brodmann	_	
216-44	49752-49757	areas	_	
216-45	49757-49758	.	_	

#Text=There were also significant main effects in two-group ANOVA for schizophrenia vs. healthy control (F1, 94=6.86, p=0.01) and schizophrenia vs.
217-1	49759-49764	There	_	
217-2	49765-49769	were	_	
217-3	49770-49774	also	_	
217-4	49775-49786	significant	_	
217-5	49787-49791	main	_	
217-6	49792-49799	effects	_	
217-7	49800-49802	in	_	
217-8	49803-49812	two-group	_	
217-9	49813-49818	ANOVA	_	
217-10	49819-49822	for	_	
217-11	49823-49836	schizophrenia	_	
217-12	49837-49839	vs	_	
217-13	49839-49840	.	_	
217-14	49841-49848	healthy	_	
217-15	49849-49856	control	_	
217-16	49857-49858	(	_	
217-17	49858-49860	F1	_	
217-18	49860-49861	,	_	
217-19	49862-49864	94	_	
217-20	49864-49865	=	_	
217-21	49865-49869	6.86	_	
217-22	49869-49870	,	_	
217-23	49871-49872	p	_	
217-24	49872-49873	=	_	
217-25	49873-49877	0.01	_	
217-26	49877-49878	)	_	
217-27	49879-49882	and	_	
217-28	49883-49896	schizophrenia	_	
217-29	49897-49899	vs	_	
217-30	49899-49900	.	_	

#Text=ASD (F1, 64=4.87, p=0.03) comparisons.
218-1	49901-49904	ASD	_	
218-2	49905-49906	(	_	
218-3	49906-49908	F1	_	
218-4	49908-49909	,	_	
218-5	49910-49912	64	_	
218-6	49912-49913	=	_	
218-7	49913-49917	4.87	_	
218-8	49917-49918	,	_	
218-9	49919-49920	p	_	
218-10	49920-49921	=	_	
218-11	49921-49925	0.03	_	
218-12	49925-49926	)	_	
218-13	49927-49938	comparisons	_	
218-14	49938-49939	.	_	

#Text=Three-group ANOVA comparison of 18fluorodeoxyglucose uptake in the prefrontal cortex.
219-1	49940-49951	Three-group	_	
219-2	49952-49957	ANOVA	_	
219-3	49958-49968	comparison	_	
219-4	49969-49971	of	_	
219-5	49972-49992	18fluorodeoxyglucose	_	
219-6	49993-49999	uptake	_	
219-7	50000-50002	in	_	
219-8	50003-50006	the	_	
219-9	50007-50017	prefrontal	_	
219-10	50018-50024	cortex	_	
219-11	50024-50025	.	_	

#Text=Prefrontal cortex was divided into 4 regions, each containing 3 Brodmann areas.
220-1	50026-50036	Prefrontal	_	
220-2	50037-50043	cortex	_	
220-3	50044-50047	was	_	
220-4	50048-50055	divided	_	
220-5	50056-50060	into	_	
220-6	50061-50062	4	_	
220-7	50063-50070	regions	_	
220-8	50070-50071	,	_	
220-9	50072-50076	each	_	
220-10	50077-50087	containing	_	
220-11	50088-50089	3	_	
220-12	50090-50098	Brodmann	_	
220-13	50099-50104	areas	_	
220-14	50104-50105	.	_	

#Text=The upper panel illustrates the group-by-hemisphere-by-prefrontal region interaction (F6, 354=3.74, p=0.001; Wilks’ λ =0.87, multivariate F6, 232=2.75, p=0.001), the lower panel illustrates the group-by-region-by-Brodmann area interaction (F12, 708=1.86, p=0.036; Wilks’ λ =0.87, multivariate F2, 117=2.75, p=0.033).
221-1	50106-50109	The	_	
221-2	50110-50115	upper	_	
221-3	50116-50121	panel	_	
221-4	50122-50133	illustrates	_	
221-5	50134-50137	the	_	
221-6	50138-50171	group-by-hemisphere-by-prefrontal	_	
221-7	50172-50178	region	_	
221-8	50179-50190	interaction	_	
221-9	50191-50192	(	_	
221-10	50192-50194	F6	_	
221-11	50194-50195	,	_	
221-12	50196-50199	354	_	
221-13	50199-50200	=	_	
221-14	50200-50204	3.74	_	
221-15	50204-50205	,	_	
221-16	50206-50207	p	_	
221-17	50207-50208	=	_	
221-18	50208-50213	0.001	_	
221-19	50213-50214	;	_	
221-20	50215-50220	Wilks	_	
221-21	50220-50221	’	_	
221-22	50222-50223	λ	_	
221-23	50224-50225	=	_	
221-24	50225-50229	0.87	_	
221-25	50229-50230	,	_	
221-26	50231-50243	multivariate	_	
221-27	50244-50246	F6	_	
221-28	50246-50247	,	_	
221-29	50248-50251	232	_	
221-30	50251-50252	=	_	
221-31	50252-50256	2.75	_	
221-32	50256-50257	,	_	
221-33	50258-50259	p	_	
221-34	50259-50260	=	_	
221-35	50260-50265	0.001	_	
221-36	50265-50266	)	_	
221-37	50266-50267	,	_	
221-38	50268-50271	the	_	
221-39	50272-50277	lower	_	
221-40	50278-50283	panel	_	
221-41	50284-50295	illustrates	_	
221-42	50296-50299	the	_	
221-43	50300-50327	group-by-region-by-Brodmann	_	
221-44	50328-50332	area	_	
221-45	50333-50344	interaction	_	
221-46	50345-50346	(	_	
221-47	50346-50349	F12	_	
221-48	50349-50350	,	_	
221-49	50351-50354	708	_	
221-50	50354-50355	=	_	
221-51	50355-50359	1.86	_	
221-52	50359-50360	,	_	
221-53	50361-50362	p	_	
221-54	50362-50363	=	_	
221-55	50363-50368	0.036	_	
221-56	50368-50369	;	_	
221-57	50370-50375	Wilks	_	
221-58	50375-50376	’	_	
221-59	50377-50378	λ	_	
221-60	50379-50380	=	_	
221-61	50380-50384	0.87	_	
221-62	50384-50385	,	_	
221-63	50386-50398	multivariate	_	
221-64	50399-50401	F2	_	
221-65	50401-50402	,	_	
221-66	50403-50406	117	_	
221-67	50406-50407	=	_	
221-68	50407-50411	2.75	_	
221-69	50411-50412	,	_	
221-70	50413-50414	p	_	
221-71	50414-50415	=	_	
221-72	50415-50420	0.033	_	
221-73	50420-50421	)	_	
221-74	50421-50422	.	_	

#Text=The Bonferroni testing (p<0.01) confirmed the main effect of diagnostic group.
222-1	50423-50426	The	_	
222-2	50427-50437	Bonferroni	_	
222-3	50438-50445	testing	_	
222-4	50446-50447	(	_	
222-5	50447-50448	p	_	
222-6	50448-50449	<	_	
222-7	50449-50453	0.01	_	
222-8	50453-50454	)	_	
222-9	50455-50464	confirmed	_	
222-10	50465-50468	the	_	
222-11	50469-50473	main	_	
222-12	50474-50480	effect	_	
222-13	50481-50483	of	_	
222-14	50484-50494	diagnostic	_	
222-15	50495-50500	group	_	
222-16	50500-50501	.	_	

#Text=Individual t-tests on the 24 areas (12 in each hemisphere) yielded 14 schizophrenia/healthy control differences at p<0.05 uncorrected; Brodmann areas 10 (left and right), 44 (right), and 45 (right) were significant with the Bonferroni criterion of 0.002.
223-1	50502-50512	Individual	_	
223-2	50513-50520	t-tests	_	
223-3	50521-50523	on	_	
223-4	50524-50527	the	_	
223-5	50528-50530	24	_	
223-6	50531-50536	areas	_	
223-7	50537-50538	(	_	
223-8	50538-50540	12	_	
223-9	50541-50543	in	_	
223-10	50544-50548	each	_	
223-11	50549-50559	hemisphere	_	
223-12	50559-50560	)	_	
223-13	50561-50568	yielded	_	
223-14	50569-50571	14	_	
223-15	50572-50585	schizophrenia	_	
223-16	50585-50586	/	_	
223-17	50586-50593	healthy	_	
223-18	50594-50601	control	_	
223-19	50602-50613	differences	_	
223-20	50614-50616	at	_	
223-21	50617-50618	p	_	
223-22	50618-50619	<	_	
223-23	50619-50623	0.05	_	
223-24	50624-50635	uncorrected	_	
223-25	50635-50636	;	_	
223-26	50637-50645	Brodmann	_	
223-27	50646-50651	areas	_	
223-28	50652-50654	10	_	
223-29	50655-50656	(	_	
223-30	50656-50660	left	_	
223-31	50661-50664	and	_	
223-32	50665-50670	right	_	
223-33	50670-50671	)	_	
223-34	50671-50672	,	_	
223-35	50673-50675	44	_	
223-36	50676-50677	(	_	
223-37	50677-50682	right	_	
223-38	50682-50683	)	_	
223-39	50683-50684	,	_	
223-40	50685-50688	and	_	
223-41	50689-50691	45	_	
223-42	50692-50693	(	_	
223-43	50693-50698	right	_	
223-44	50698-50699	)	_	
223-45	50700-50704	were	_	
223-46	50705-50716	significant	_	
223-47	50717-50721	with	_	
223-48	50722-50725	the	_	
223-49	50726-50736	Bonferroni	_	
223-50	50737-50746	criterion	_	
223-51	50747-50749	of	_	
223-52	50750-50755	0.002	_	
223-53	50755-50756	.	_	

#Text=Hemispheric asymmetry of metabolic rates in the prefrontal cortex.
224-1	50757-50768	Hemispheric	_	
224-2	50769-50778	asymmetry	_	
224-3	50779-50781	of	_	
224-4	50782-50791	metabolic	_	
224-5	50792-50797	rates	_	
224-6	50798-50800	in	_	
224-7	50801-50804	the	_	
224-8	50805-50815	prefrontal	_	
224-9	50816-50822	cortex	_	
224-10	50822-50823	.	_	

#Text=This figure is based on the significant group-by-hemisphere-by-prefrontal region interaction (F6, 354=3.74, p=0.001), confirmed with the Bonferroni correction.
225-1	50824-50828	This	_	
225-2	50829-50835	figure	_	
225-3	50836-50838	is	_	
225-4	50839-50844	based	_	
225-5	50845-50847	on	_	
225-6	50848-50851	the	_	
225-7	50852-50863	significant	_	
225-8	50864-50897	group-by-hemisphere-by-prefrontal	_	
225-9	50898-50904	region	_	
225-10	50905-50916	interaction	_	
225-11	50917-50918	(	_	
225-12	50918-50920	F6	_	
225-13	50920-50921	,	_	
225-14	50922-50925	354	_	
225-15	50925-50926	=	_	
225-16	50926-50930	3.74	_	
225-17	50930-50931	,	_	
225-18	50932-50933	p	_	
225-19	50933-50934	=	_	
225-20	50934-50939	0.001	_	
225-21	50939-50940	)	_	
225-22	50940-50941	,	_	
225-23	50942-50951	confirmed	_	
225-24	50952-50956	with	_	
225-25	50957-50960	the	_	
225-26	50961-50971	Bonferroni	_	
225-27	50972-50982	correction	_	
225-28	50982-50983	.	_	

#Text=The left panel shows the difference in asymmetry in the patient groups compared to healthy controls.
226-1	50984-50987	The	_	
226-2	50988-50992	left	_	
226-3	50993-50998	panel	_	
226-4	50999-51004	shows	_	
226-5	51005-51008	the	_	
226-6	51009-51019	difference	_	
226-7	51020-51022	in	_	
226-8	51023-51032	asymmetry	_	
226-9	51033-51035	in	_	
226-10	51036-51039	the	_	
226-11	51040-51047	patient	_	
226-12	51048-51054	groups	_	
226-13	51055-51063	compared	_	
226-14	51064-51066	to	_	
226-15	51067-51074	healthy	_	
226-16	51075-51083	controls	_	
226-17	51083-51084	.	_	

#Text=The right panel shows the left-minus-right difference in asymmetry in the patient groups (orange and green) compared to healthy controls (zero axis).
227-1	51085-51088	The	_	
227-2	51089-51094	right	_	
227-3	51095-51100	panel	_	
227-4	51101-51106	shows	_	
227-5	51107-51110	the	_	
227-6	51111-51127	left-minus-right	_	
227-7	51128-51138	difference	_	
227-8	51139-51141	in	_	
227-9	51142-51151	asymmetry	_	
227-10	51152-51154	in	_	
227-11	51155-51158	the	_	
227-12	51159-51166	patient	_	
227-13	51167-51173	groups	_	
227-14	51174-51175	(	_	
227-15	51175-51181	orange	_	
227-16	51182-51185	and	_	
227-17	51186-51191	green	_	
227-18	51191-51192	)	_	
227-19	51193-51201	compared	_	
227-20	51202-51204	to	_	
227-21	51205-51212	healthy	_	
227-22	51213-51221	controls	_	
227-23	51222-51223	(	_	
227-24	51223-51227	zero	_	
227-25	51228-51232	axis	_	
227-26	51232-51233	)	_	
227-27	51233-51234	.	_	

#Text=Bars above zero indicate higher left-minus-right differences in comparison to healthy controls and bars below zero indicate lower left-minus-right differences in comparison to healthy controls.
228-1	51235-51239	Bars	_	
228-2	51240-51245	above	_	
228-3	51246-51250	zero	_	
228-4	51251-51259	indicate	_	
228-5	51260-51266	higher	_	
228-6	51267-51283	left-minus-right	_	
228-7	51284-51295	differences	_	
228-8	51296-51298	in	_	
228-9	51299-51309	comparison	_	
228-10	51310-51312	to	_	
228-11	51313-51320	healthy	_	
228-12	51321-51329	controls	_	
228-13	51330-51333	and	_	
228-14	51334-51338	bars	_	
228-15	51339-51344	below	_	
228-16	51345-51349	zero	_	
228-17	51350-51358	indicate	_	
228-18	51359-51364	lower	_	
228-19	51365-51381	left-minus-right	_	
228-20	51382-51393	differences	_	
228-21	51394-51396	in	_	
228-22	51397-51407	comparison	_	
228-23	51408-51410	to	_	
228-24	51411-51418	healthy	_	
228-25	51419-51427	controls	_	
228-26	51427-51428	.	_	

#Text=Three-group ANOVA for the caudate nucleus subregions.
229-1	51429-51440	Three-group	_	
229-2	51441-51446	ANOVA	_	
229-3	51447-51450	for	_	
229-4	51451-51454	the	_	
229-5	51455-51462	caudate	_	
229-6	51463-51470	nucleus	_	
229-7	51471-51481	subregions	_	
229-8	51481-51482	.	_	

#Text=Three-group ANOVA for the serial verbal learning test performance.
230-1	51483-51494	Three-group	_	
230-2	51495-51500	ANOVA	_	
230-3	51501-51504	for	_	
230-4	51505-51508	the	_	
230-5	51509-51515	serial	_	
230-6	51516-51522	verbal	_	
230-7	51523-51531	learning	_	
230-8	51532-51536	test	_	
230-9	51537-51548	performance	_	
230-10	51548-51549	.	_	

#Text=Significant ANCOVA interactions for between-group differences in FDG metabolic rates
#Text=\t\tASD vs. schizophrenia vs. normal controls\tASD vs. schizophrenia\tASD vs. normal controls\tSchizophrenia vs. normal controls\t \tWhole brain\tg×BA\tF82, 4797=2.20, p<0.0000001 (0.0005)*\tF41, 2583=1.57, p<0.01 (0.35)\tF41, 3157=2.23, p=0.00001 (0.005)*\tF41, 3813=2.60, p<0.0000001 (0.01)\t \tFrontal lobe\tME\tF2, 117=4.91, p=0.009\t\t\tF1, 93=9.88, p=0.002*\t \tg×BA\tF20, 1170=2.54, p=0.0002 (0.002)*\t\t\tF10, 930=5.38, p<0.0000001 (0.0036)*\t \tParietal lobe\tME\tF2, 117=3.36, p=0.04\t\tF1, 77=4.51, p=0.037\t\t \tg×BA\tF14, 819=3.47, p=0.000002 (0.000005)*\tF7, 441=1.99, p=0.055 (0.09)\tF7, 539=3.43, p=0.001 (0.000009)*\tF7, 651=5.70, p=0.000002 (0.00015)*\t \tOccipital lobe\tg×BA\tF4, 234=2.52, p=0.04 (0.05)\t\t\tF2, 186=3.90, p=0.02 (0.09)\t \tHippocampus\tME\tF2, 117=9.71, p=0.0001*\t\tF1, 77=13.76, p=0.0004*\tF1, 93=18.22, p=0.00005*\t \tHypothalamus\tME\tF2, 117=4.08, p=0.02\tF1, 63=7.05, p=0.01\t\tF1, 93=6.26, p=0.007\t \tMammilary bodies\t\t\tF1, 63=4.38, p=0.04\t\t\t \tThalamic nuclei\t \t Lateral posterior\tME\tF2, 117=6.35, p=0.002*\tF1, 63=3.84, p=0.055\t\tF1, 93=10.85, p=0.001*\t \t Ventral posteromedial\tME\tF2, 117=2.59, p=0.08\t\t\tF1, 93=5.10, p=0.026\t \t Ventral posterolateral\tME\tF2, 117=4.34, p=0.015\t\t\tF1, 93=7.93, p=0.006\t \t Pulvinar\tME\tF2, 117=4.06, p=0.02\t\t\tF1, 93=7.62, p=0.007\t \t Mediodorsal\tME\tF2, 117=2.50, p=0.09\t\t\tF1, 93=4.07, p=0.047\t \tCaudate subdivisions\tg×R\tF4, 234=10.15, p<0.0000001 (0.000035)*\t\tF2, 154=6.41, p=0.002 (0.01)\tF2, 186=18.64, p<0.00000001 (0.000007)*\t \t Head of the caudate\tME\tF2, 117=2.64, p=0.08\t\t\tF1, 93=4.92, p=0.03\t \t Tail of the caudate\tME\tF2, 117=10.87, p=0.00005*\t\tF1, 77=9.69, p=0.003*\tF1, 93=25.79, p=0.000002*\t \tPutamen\tME\tF2, 117=6.18, p=0.003*\t\tF1, 77=5.76, p=0.02\tF1, 93=11.62, p=0.001*\t \tMedial globus pallidus\tME\tF2, 117=4.18, p=0.02\t\tF1, 77=7.80, p=0.007\t\t \tLateral globus pallidus\tME\tF2, 117=4.83, p=0.01\t\tF1, 77=8.52, p=0.005\tF1, 93=4.67, p=0.03\t \tClaustrum\tME\tF2, 117=10.36, p=0.00007*\t\tF1, 77=13.14, p=0.0005*\tF1, 93=16.86, p=0.00009*\t \tAmygdala\tME\tF2, 117=4.87, p=0.009\t\tF1, 77=7.48, p=0.008\tF1, 93=8.09, p=0.0055\t \t
#Text=For all higher-order ANCOVA interactions (i.e. other than the main effects) univariate p-values are followed by multivariate Wilks’ λ p-values in parentheses; p-values at trend level of significance (<0.1) are italicized.
231-1	51550-51561	Significant	_	
231-2	51562-51568	ANCOVA	_	
231-3	51569-51581	interactions	_	
231-4	51582-51585	for	_	
231-5	51586-51599	between-group	_	
231-6	51600-51611	differences	_	
231-7	51612-51614	in	_	
231-8	51615-51618	FDG	_	
231-9	51619-51628	metabolic	_	
231-10	51629-51634	rates	_	
231-11	51637-51640	ASD	_	
231-12	51641-51643	vs	_	
231-13	51643-51644	.	_	
231-14	51645-51658	schizophrenia	_	
231-15	51659-51661	vs	_	
231-16	51661-51662	.	_	
231-17	51663-51669	normal	_	
231-18	51670-51678	controls	_	
231-19	51679-51682	ASD	_	
231-20	51683-51685	vs	_	
231-21	51685-51686	.	_	
231-22	51687-51700	schizophrenia	_	
231-23	51701-51704	ASD	_	
231-24	51705-51707	vs	_	
231-25	51707-51708	.	_	
231-26	51709-51715	normal	_	
231-27	51716-51724	controls	_	
231-28	51725-51738	Schizophrenia	_	
231-29	51739-51741	vs	_	
231-30	51741-51742	.	_	
231-31	51743-51749	normal	_	
231-32	51750-51758	controls	_	
231-33	51761-51766	Whole	_	
231-34	51767-51772	brain	_	
231-35	51773-51774	g	_	
231-36	51774-51775	×	_	
231-37	51775-51777	BA	_	
231-38	51778-51781	F82	_	
231-39	51781-51782	,	_	
231-40	51783-51787	4797	_	
231-41	51787-51788	=	_	
231-42	51788-51792	2.20	_	
231-43	51792-51793	,	_	
231-44	51794-51795	p	_	
231-45	51795-51796	<	_	
231-46	51796-51805	0.0000001	_	
231-47	51806-51807	(	_	
231-48	51807-51813	0.0005	_	
231-49	51813-51814	)	_	
231-50	51814-51815	*	_	
231-51	51816-51819	F41	_	
231-52	51819-51820	,	_	
231-53	51821-51825	2583	_	
231-54	51825-51826	=	_	
231-55	51826-51830	1.57	_	
231-56	51830-51831	,	_	
231-57	51832-51833	p	_	
231-58	51833-51834	<	_	
231-59	51834-51838	0.01	_	
231-60	51839-51840	(	_	
231-61	51840-51844	0.35	_	
231-62	51844-51845	)	_	
231-63	51846-51849	F41	_	
231-64	51849-51850	,	_	
231-65	51851-51855	3157	_	
231-66	51855-51856	=	_	
231-67	51856-51860	2.23	_	
231-68	51860-51861	,	_	
231-69	51862-51863	p	_	
231-70	51863-51864	=	_	
231-71	51864-51871	0.00001	_	
231-72	51872-51873	(	_	
231-73	51873-51878	0.005	_	
231-74	51878-51879	)	_	
231-75	51879-51880	*	_	
231-76	51881-51884	F41	_	
231-77	51884-51885	,	_	
231-78	51886-51890	3813	_	
231-79	51890-51891	=	_	
231-80	51891-51895	2.60	_	
231-81	51895-51896	,	_	
231-82	51897-51898	p	_	
231-83	51898-51899	<	_	
231-84	51899-51908	0.0000001	_	
231-85	51909-51910	(	_	
231-86	51910-51914	0.01	_	
231-87	51914-51915	)	_	
231-88	51918-51925	Frontal	_	
231-89	51926-51930	lobe	_	
231-90	51931-51933	ME	_	
231-91	51934-51936	F2	_	
231-92	51936-51937	,	_	
231-93	51938-51941	117	_	
231-94	51941-51942	=	_	
231-95	51942-51946	4.91	_	
231-96	51946-51947	,	_	
231-97	51948-51949	p	_	
231-98	51949-51950	=	_	
231-99	51950-51955	0.009	_	
231-100	51958-51960	F1	_	
231-101	51960-51961	,	_	
231-102	51962-51964	93	_	
231-103	51964-51965	=	_	
231-104	51965-51969	9.88	_	
231-105	51969-51970	,	_	
231-106	51971-51972	p	_	
231-107	51972-51973	=	_	
231-108	51973-51978	0.002	_	
231-109	51978-51979	*	_	
231-110	51982-51983	g	_	
231-111	51983-51984	×	_	
231-112	51984-51986	BA	_	
231-113	51987-51990	F20	_	
231-114	51990-51991	,	_	
231-115	51992-51996	1170	_	
231-116	51996-51997	=	_	
231-117	51997-52001	2.54	_	
231-118	52001-52002	,	_	
231-119	52003-52004	p	_	
231-120	52004-52005	=	_	
231-121	52005-52011	0.0002	_	
231-122	52012-52013	(	_	
231-123	52013-52018	0.002	_	
231-124	52018-52019	)	_	
231-125	52019-52020	*	_	
231-126	52023-52026	F10	_	
231-127	52026-52027	,	_	
231-128	52028-52031	930	_	
231-129	52031-52032	=	_	
231-130	52032-52036	5.38	_	
231-131	52036-52037	,	_	
231-132	52038-52039	p	_	
231-133	52039-52040	<	_	
231-134	52040-52049	0.0000001	_	
231-135	52050-52051	(	_	
231-136	52051-52057	0.0036	_	
231-137	52057-52058	)	_	
231-138	52058-52059	*	_	
231-139	52062-52070	Parietal	_	
231-140	52071-52075	lobe	_	
231-141	52076-52078	ME	_	
231-142	52079-52081	F2	_	
231-143	52081-52082	,	_	
231-144	52083-52086	117	_	
231-145	52086-52087	=	_	
231-146	52087-52091	3.36	_	
231-147	52091-52092	,	_	
231-148	52093-52094	p	_	
231-149	52094-52095	=	_	
231-150	52095-52099	0.04	_	
231-151	52101-52103	F1	_	
231-152	52103-52104	,	_	
231-153	52105-52107	77	_	
231-154	52107-52108	=	_	
231-155	52108-52112	4.51	_	
231-156	52112-52113	,	_	
231-157	52114-52115	p	_	
231-158	52115-52116	=	_	
231-159	52116-52121	0.037	_	
231-160	52125-52126	g	_	
231-161	52126-52127	×	_	
231-162	52127-52129	BA	_	
231-163	52130-52133	F14	_	
231-164	52133-52134	,	_	
231-165	52135-52138	819	_	
231-166	52138-52139	=	_	
231-167	52139-52143	3.47	_	
231-168	52143-52144	,	_	
231-169	52145-52146	p	_	
231-170	52146-52147	=	_	
231-171	52147-52155	0.000002	_	
231-172	52156-52157	(	_	
231-173	52157-52165	0.000005	_	
231-174	52165-52166	)	_	
231-175	52166-52167	*	_	
231-176	52168-52170	F7	_	
231-177	52170-52171	,	_	
231-178	52172-52175	441	_	
231-179	52175-52176	=	_	
231-180	52176-52180	1.99	_	
231-181	52180-52181	,	_	
231-182	52182-52183	p	_	
231-183	52183-52184	=	_	
231-184	52184-52189	0.055	_	
231-185	52190-52191	(	_	
231-186	52191-52195	0.09	_	
231-187	52195-52196	)	_	
231-188	52197-52199	F7	_	
231-189	52199-52200	,	_	
231-190	52201-52204	539	_	
231-191	52204-52205	=	_	
231-192	52205-52209	3.43	_	
231-193	52209-52210	,	_	
231-194	52211-52212	p	_	
231-195	52212-52213	=	_	
231-196	52213-52218	0.001	_	
231-197	52219-52220	(	_	
231-198	52220-52228	0.000009	_	
231-199	52228-52229	)	_	
231-200	52229-52230	*	_	
231-201	52231-52233	F7	_	
231-202	52233-52234	,	_	
231-203	52235-52238	651	_	
231-204	52238-52239	=	_	
231-205	52239-52243	5.70	_	
231-206	52243-52244	,	_	
231-207	52245-52246	p	_	
231-208	52246-52247	=	_	
231-209	52247-52255	0.000002	_	
231-210	52256-52257	(	_	
231-211	52257-52264	0.00015	_	
231-212	52264-52265	)	_	
231-213	52265-52266	*	_	
231-214	52269-52278	Occipital	_	
231-215	52279-52283	lobe	_	
231-216	52284-52285	g	_	
231-217	52285-52286	×	_	
231-218	52286-52288	BA	_	
231-219	52289-52291	F4	_	
231-220	52291-52292	,	_	
231-221	52293-52296	234	_	
231-222	52296-52297	=	_	
231-223	52297-52301	2.52	_	
231-224	52301-52302	,	_	
231-225	52303-52304	p	_	
231-226	52304-52305	=	_	
231-227	52305-52309	0.04	_	
231-228	52310-52311	(	_	
231-229	52311-52315	0.05	_	
231-230	52315-52316	)	_	
231-231	52319-52321	F2	_	
231-232	52321-52322	,	_	
231-233	52323-52326	186	_	
231-234	52326-52327	=	_	
231-235	52327-52331	3.90	_	
231-236	52331-52332	,	_	
231-237	52333-52334	p	_	
231-238	52334-52335	=	_	
231-239	52335-52339	0.02	_	
231-240	52340-52341	(	_	
231-241	52341-52345	0.09	_	
231-242	52345-52346	)	_	
231-243	52349-52360	Hippocampus	_	
231-244	52361-52363	ME	_	
231-245	52364-52366	F2	_	
231-246	52366-52367	,	_	
231-247	52368-52371	117	_	
231-248	52371-52372	=	_	
231-249	52372-52376	9.71	_	
231-250	52376-52377	,	_	
231-251	52378-52379	p	_	
231-252	52379-52380	=	_	
231-253	52380-52386	0.0001	_	
231-254	52386-52387	*	_	
231-255	52389-52391	F1	_	
231-256	52391-52392	,	_	
231-257	52393-52395	77	_	
231-258	52395-52396	=	_	
231-259	52396-52401	13.76	_	
231-260	52401-52402	,	_	
231-261	52403-52404	p	_	
231-262	52404-52405	=	_	
231-263	52405-52411	0.0004	_	
231-264	52411-52412	*	_	
231-265	52413-52415	F1	_	
231-266	52415-52416	,	_	
231-267	52417-52419	93	_	
231-268	52419-52420	=	_	
231-269	52420-52425	18.22	_	
231-270	52425-52426	,	_	
231-271	52427-52428	p	_	
231-272	52428-52429	=	_	
231-273	52429-52436	0.00005	_	
231-274	52436-52437	*	_	
231-275	52440-52452	Hypothalamus	_	
231-276	52453-52455	ME	_	
231-277	52456-52458	F2	_	
231-278	52458-52459	,	_	
231-279	52460-52463	117	_	
231-280	52463-52464	=	_	
231-281	52464-52468	4.08	_	
231-282	52468-52469	,	_	
231-283	52470-52471	p	_	
231-284	52471-52472	=	_	
231-285	52472-52476	0.02	_	
231-286	52477-52479	F1	_	
231-287	52479-52480	,	_	
231-288	52481-52483	63	_	
231-289	52483-52484	=	_	
231-290	52484-52488	7.05	_	
231-291	52488-52489	,	_	
231-292	52490-52491	p	_	
231-293	52491-52492	=	_	
231-294	52492-52496	0.01	_	
231-295	52498-52500	F1	_	
231-296	52500-52501	,	_	
231-297	52502-52504	93	_	
231-298	52504-52505	=	_	
231-299	52505-52509	6.26	_	
231-300	52509-52510	,	_	
231-301	52511-52512	p	_	
231-302	52512-52513	=	_	
231-303	52513-52518	0.007	_	
231-304	52521-52530	Mammilary	_	
231-305	52531-52537	bodies	_	
231-306	52540-52542	F1	_	
231-307	52542-52543	,	_	
231-308	52544-52546	63	_	
231-309	52546-52547	=	_	
231-310	52547-52551	4.38	_	
231-311	52551-52552	,	_	
231-312	52553-52554	p	_	
231-313	52554-52555	=	_	
231-314	52555-52559	0.04	_	
231-315	52564-52572	Thalamic	_	
231-316	52573-52579	nuclei	_	
231-317	52583-52590	Lateral	_	
231-318	52591-52600	posterior	_	
231-319	52601-52603	ME	_	
231-320	52604-52606	F2	_	
231-321	52606-52607	,	_	
231-322	52608-52611	117	_	
231-323	52611-52612	=	_	
231-324	52612-52616	6.35	_	
231-325	52616-52617	,	_	
231-326	52618-52619	p	_	
231-327	52619-52620	=	_	
231-328	52620-52625	0.002	_	
231-329	52625-52626	*	_	
231-330	52627-52629	F1	_	
231-331	52629-52630	,	_	
231-332	52631-52633	63	_	
231-333	52633-52634	=	_	
231-334	52634-52638	3.84	_	
231-335	52638-52639	,	_	
231-336	52640-52641	p	_	
231-337	52641-52642	=	_	
231-338	52642-52647	0.055	_	
231-339	52649-52651	F1	_	
231-340	52651-52652	,	_	
231-341	52653-52655	93	_	
231-342	52655-52656	=	_	
231-343	52656-52661	10.85	_	
231-344	52661-52662	,	_	
231-345	52663-52664	p	_	
231-346	52664-52665	=	_	
231-347	52665-52670	0.001	_	
231-348	52670-52671	*	_	
231-349	52675-52682	Ventral	_	
231-350	52683-52696	posteromedial	_	
231-351	52697-52699	ME	_	
231-352	52700-52702	F2	_	
231-353	52702-52703	,	_	
231-354	52704-52707	117	_	
231-355	52707-52708	=	_	
231-356	52708-52712	2.59	_	
231-357	52712-52713	,	_	
231-358	52714-52715	p	_	
231-359	52715-52716	=	_	
231-360	52716-52720	0.08	_	
231-361	52723-52725	F1	_	
231-362	52725-52726	,	_	
231-363	52727-52729	93	_	
231-364	52729-52730	=	_	
231-365	52730-52734	5.10	_	
231-366	52734-52735	,	_	
231-367	52736-52737	p	_	
231-368	52737-52738	=	_	
231-369	52738-52743	0.026	_	
231-370	52747-52754	Ventral	_	
231-371	52755-52769	posterolateral	_	
231-372	52770-52772	ME	_	
231-373	52773-52775	F2	_	
231-374	52775-52776	,	_	
231-375	52777-52780	117	_	
231-376	52780-52781	=	_	
231-377	52781-52785	4.34	_	
231-378	52785-52786	,	_	
231-379	52787-52788	p	_	
231-380	52788-52789	=	_	
231-381	52789-52794	0.015	_	
231-382	52797-52799	F1	_	
231-383	52799-52800	,	_	
231-384	52801-52803	93	_	
231-385	52803-52804	=	_	
231-386	52804-52808	7.93	_	
231-387	52808-52809	,	_	
231-388	52810-52811	p	_	
231-389	52811-52812	=	_	
231-390	52812-52817	0.006	_	
231-391	52821-52829	Pulvinar	_	
231-392	52830-52832	ME	_	
231-393	52833-52835	F2	_	
231-394	52835-52836	,	_	
231-395	52837-52840	117	_	
231-396	52840-52841	=	_	
231-397	52841-52845	4.06	_	
231-398	52845-52846	,	_	
231-399	52847-52848	p	_	
231-400	52848-52849	=	_	
231-401	52849-52853	0.02	_	
231-402	52856-52858	F1	_	
231-403	52858-52859	,	_	
231-404	52860-52862	93	_	
231-405	52862-52863	=	_	
231-406	52863-52867	7.62	_	
231-407	52867-52868	,	_	
231-408	52869-52870	p	_	
231-409	52870-52871	=	_	
231-410	52871-52876	0.007	_	
231-411	52880-52891	Mediodorsal	_	
231-412	52892-52894	ME	_	
231-413	52895-52897	F2	_	
231-414	52897-52898	,	_	
231-415	52899-52902	117	_	
231-416	52902-52903	=	_	
231-417	52903-52907	2.50	_	
231-418	52907-52908	,	_	
231-419	52909-52910	p	_	
231-420	52910-52911	=	_	
231-421	52911-52915	0.09	_	
231-422	52918-52920	F1	_	
231-423	52920-52921	,	_	
231-424	52922-52924	93	_	
231-425	52924-52925	=	_	
231-426	52925-52929	4.07	_	
231-427	52929-52930	,	_	
231-428	52931-52932	p	_	
231-429	52932-52933	=	_	
231-430	52933-52938	0.047	_	
231-431	52941-52948	Caudate	_	
231-432	52949-52961	subdivisions	_	
231-433	52962-52963	g	_	
231-434	52963-52964	×	_	
231-435	52964-52965	R	_	
231-436	52966-52968	F4	_	
231-437	52968-52969	,	_	
231-438	52970-52973	234	_	
231-439	52973-52974	=	_	
231-440	52974-52979	10.15	_	
231-441	52979-52980	,	_	
231-442	52981-52982	p	_	
231-443	52982-52983	<	_	
231-444	52983-52992	0.0000001	_	
231-445	52993-52994	(	_	
231-446	52994-53002	0.000035	_	
231-447	53002-53003	)	_	
231-448	53003-53004	*	_	
231-449	53006-53008	F2	_	
231-450	53008-53009	,	_	
231-451	53010-53013	154	_	
231-452	53013-53014	=	_	
231-453	53014-53018	6.41	_	
231-454	53018-53019	,	_	
231-455	53020-53021	p	_	
231-456	53021-53022	=	_	
231-457	53022-53027	0.002	_	
231-458	53028-53029	(	_	
231-459	53029-53033	0.01	_	
231-460	53033-53034	)	_	
231-461	53035-53037	F2	_	
231-462	53037-53038	,	_	
231-463	53039-53042	186	_	
231-464	53042-53043	=	_	
231-465	53043-53048	18.64	_	
231-466	53048-53049	,	_	
231-467	53050-53051	p	_	
231-468	53051-53052	<	_	
231-469	53052-53062	0.00000001	_	
231-470	53063-53064	(	_	
231-471	53064-53072	0.000007	_	
231-472	53072-53073	)	_	
231-473	53073-53074	*	_	
231-474	53078-53082	Head	_	
231-475	53083-53085	of	_	
231-476	53086-53089	the	_	
231-477	53090-53097	caudate	_	
231-478	53098-53100	ME	_	
231-479	53101-53103	F2	_	
231-480	53103-53104	,	_	
231-481	53105-53108	117	_	
231-482	53108-53109	=	_	
231-483	53109-53113	2.64	_	
231-484	53113-53114	,	_	
231-485	53115-53116	p	_	
231-486	53116-53117	=	_	
231-487	53117-53121	0.08	_	
231-488	53124-53126	F1	_	
231-489	53126-53127	,	_	
231-490	53128-53130	93	_	
231-491	53130-53131	=	_	
231-492	53131-53135	4.92	_	
231-493	53135-53136	,	_	
231-494	53137-53138	p	_	
231-495	53138-53139	=	_	
231-496	53139-53143	0.03	_	
231-497	53147-53151	Tail	_	
231-498	53152-53154	of	_	
231-499	53155-53158	the	_	
231-500	53159-53166	caudate	_	
231-501	53167-53169	ME	_	
231-502	53170-53172	F2	_	
231-503	53172-53173	,	_	
231-504	53174-53177	117	_	
231-505	53177-53178	=	_	
231-506	53178-53183	10.87	_	
231-507	53183-53184	,	_	
231-508	53185-53186	p	_	
231-509	53186-53187	=	_	
231-510	53187-53194	0.00005	_	
231-511	53194-53195	*	_	
231-512	53197-53199	F1	_	
231-513	53199-53200	,	_	
231-514	53201-53203	77	_	
231-515	53203-53204	=	_	
231-516	53204-53208	9.69	_	
231-517	53208-53209	,	_	
231-518	53210-53211	p	_	
231-519	53211-53212	=	_	
231-520	53212-53217	0.003	_	
231-521	53217-53218	*	_	
231-522	53219-53221	F1	_	
231-523	53221-53222	,	_	
231-524	53223-53225	93	_	
231-525	53225-53226	=	_	
231-526	53226-53231	25.79	_	
231-527	53231-53232	,	_	
231-528	53233-53234	p	_	
231-529	53234-53235	=	_	
231-530	53235-53243	0.000002	_	
231-531	53243-53244	*	_	
231-532	53247-53254	Putamen	_	
231-533	53255-53257	ME	_	
231-534	53258-53260	F2	_	
231-535	53260-53261	,	_	
231-536	53262-53265	117	_	
231-537	53265-53266	=	_	
231-538	53266-53270	6.18	_	
231-539	53270-53271	,	_	
231-540	53272-53273	p	_	
231-541	53273-53274	=	_	
231-542	53274-53279	0.003	_	
231-543	53279-53280	*	_	
231-544	53282-53284	F1	_	
231-545	53284-53285	,	_	
231-546	53286-53288	77	_	
231-547	53288-53289	=	_	
231-548	53289-53293	5.76	_	
231-549	53293-53294	,	_	
231-550	53295-53296	p	_	
231-551	53296-53297	=	_	
231-552	53297-53301	0.02	_	
231-553	53302-53304	F1	_	
231-554	53304-53305	,	_	
231-555	53306-53308	93	_	
231-556	53308-53309	=	_	
231-557	53309-53314	11.62	_	
231-558	53314-53315	,	_	
231-559	53316-53317	p	_	
231-560	53317-53318	=	_	
231-561	53318-53323	0.001	_	
231-562	53323-53324	*	_	
231-563	53327-53333	Medial	_	
231-564	53334-53340	globus	_	
231-565	53341-53349	pallidus	_	
231-566	53350-53352	ME	_	
231-567	53353-53355	F2	_	
231-568	53355-53356	,	_	
231-569	53357-53360	117	_	
231-570	53360-53361	=	_	
231-571	53361-53365	4.18	_	
231-572	53365-53366	,	_	
231-573	53367-53368	p	_	
231-574	53368-53369	=	_	
231-575	53369-53373	0.02	_	
231-576	53375-53377	F1	_	
231-577	53377-53378	,	_	
231-578	53379-53381	77	_	
231-579	53381-53382	=	_	
231-580	53382-53386	7.80	_	
231-581	53386-53387	,	_	
231-582	53388-53389	p	_	
231-583	53389-53390	=	_	
231-584	53390-53395	0.007	_	
231-585	53399-53406	Lateral	_	
231-586	53407-53413	globus	_	
231-587	53414-53422	pallidus	_	
231-588	53423-53425	ME	_	
231-589	53426-53428	F2	_	
231-590	53428-53429	,	_	
231-591	53430-53433	117	_	
231-592	53433-53434	=	_	
231-593	53434-53438	4.83	_	
231-594	53438-53439	,	_	
231-595	53440-53441	p	_	
231-596	53441-53442	=	_	
231-597	53442-53446	0.01	_	
231-598	53448-53450	F1	_	
231-599	53450-53451	,	_	
231-600	53452-53454	77	_	
231-601	53454-53455	=	_	
231-602	53455-53459	8.52	_	
231-603	53459-53460	,	_	
231-604	53461-53462	p	_	
231-605	53462-53463	=	_	
231-606	53463-53468	0.005	_	
231-607	53469-53471	F1	_	
231-608	53471-53472	,	_	
231-609	53473-53475	93	_	
231-610	53475-53476	=	_	
231-611	53476-53480	4.67	_	
231-612	53480-53481	,	_	
231-613	53482-53483	p	_	
231-614	53483-53484	=	_	
231-615	53484-53488	0.03	_	
231-616	53491-53500	Claustrum	_	
231-617	53501-53503	ME	_	
231-618	53504-53506	F2	_	
231-619	53506-53507	,	_	
231-620	53508-53511	117	_	
231-621	53511-53512	=	_	
231-622	53512-53517	10.36	_	
231-623	53517-53518	,	_	
231-624	53519-53520	p	_	
231-625	53520-53521	=	_	
231-626	53521-53528	0.00007	_	
231-627	53528-53529	*	_	
231-628	53531-53533	F1	_	
231-629	53533-53534	,	_	
231-630	53535-53537	77	_	
231-631	53537-53538	=	_	
231-632	53538-53543	13.14	_	
231-633	53543-53544	,	_	
231-634	53545-53546	p	_	
231-635	53546-53547	=	_	
231-636	53547-53553	0.0005	_	
231-637	53553-53554	*	_	
231-638	53555-53557	F1	_	
231-639	53557-53558	,	_	
231-640	53559-53561	93	_	
231-641	53561-53562	=	_	
231-642	53562-53567	16.86	_	
231-643	53567-53568	,	_	
231-644	53569-53570	p	_	
231-645	53570-53571	=	_	
231-646	53571-53578	0.00009	_	
231-647	53578-53579	*	_	
231-648	53582-53590	Amygdala	_	
231-649	53591-53593	ME	_	
231-650	53594-53596	F2	_	
231-651	53596-53597	,	_	
231-652	53598-53601	117	_	
231-653	53601-53602	=	_	
231-654	53602-53606	4.87	_	
231-655	53606-53607	,	_	
231-656	53608-53609	p	_	
231-657	53609-53610	=	_	
231-658	53610-53615	0.009	_	
231-659	53617-53619	F1	_	
231-660	53619-53620	,	_	
231-661	53621-53623	77	_	
231-662	53623-53624	=	_	
231-663	53624-53628	7.48	_	
231-664	53628-53629	,	_	
231-665	53630-53631	p	_	
231-666	53631-53632	=	_	
231-667	53632-53637	0.008	_	
231-668	53638-53640	F1	_	
231-669	53640-53641	,	_	
231-670	53642-53644	93	_	
231-671	53644-53645	=	_	
231-672	53645-53649	8.09	_	
231-673	53649-53650	,	_	
231-674	53651-53652	p	_	
231-675	53652-53653	=	_	
231-676	53653-53659	0.0055	_	
231-677	53663-53666	For	_	
231-678	53667-53670	all	_	
231-679	53671-53683	higher-order	_	
231-680	53684-53690	ANCOVA	_	
231-681	53691-53703	interactions	_	
231-682	53704-53705	(	_	
231-683	53705-53708	i.e	_	
231-684	53708-53709	.	_	
231-685	53710-53715	other	_	
231-686	53716-53720	than	_	
231-687	53721-53724	the	_	
231-688	53725-53729	main	_	
231-689	53730-53737	effects	_	
231-690	53737-53738	)	_	
231-691	53739-53749	univariate	_	
231-692	53750-53758	p-values	_	
231-693	53759-53762	are	_	
231-694	53763-53771	followed	_	
231-695	53772-53774	by	_	
231-696	53775-53787	multivariate	_	
231-697	53788-53793	Wilks	_	
231-698	53793-53794	’	_	
231-699	53795-53796	λ	_	
231-700	53797-53805	p-values	_	
231-701	53806-53808	in	_	
231-702	53809-53820	parentheses	_	
231-703	53820-53821	;	_	
231-704	53822-53830	p-values	_	
231-705	53831-53833	at	_	
231-706	53834-53839	trend	_	
231-707	53840-53845	level	_	
231-708	53846-53848	of	_	
231-709	53849-53861	significance	_	
231-710	53862-53863	(	_	
231-711	53863-53864	<	_	
231-712	53864-53867	0.1	_	
231-713	53867-53868	)	_	
231-714	53869-53872	are	_	
231-715	53873-53883	italicized	_	
231-716	53883-53884	.	_	

#Text=Abbreviations: ME – main effect of diagnostic group, g×R – group-by-region interaction, g×BA – group-by-Brodmann area interaction.
232-1	53885-53898	Abbreviations	_	
232-2	53898-53899	:	_	
232-3	53900-53902	ME	_	
232-4	53903-53904	–	_	
232-5	53905-53909	main	_	
232-6	53910-53916	effect	_	
232-7	53917-53919	of	_	
232-8	53920-53930	diagnostic	_	
232-9	53931-53936	group	_	
232-10	53936-53937	,	_	
232-11	53938-53939	g	_	
232-12	53939-53940	×	_	
232-13	53940-53941	R	_	
232-14	53942-53943	–	_	
232-15	53944-53959	group-by-region	_	
232-16	53960-53971	interaction	_	
232-17	53971-53972	,	_	
232-18	53973-53974	g	_	
232-19	53974-53975	×	_	
232-20	53975-53977	BA	_	
232-21	53978-53979	–	_	
232-22	53980-53997	group-by-Brodmann	_	
232-23	53998-54002	area	_	
232-24	54003-54014	interaction	_	
232-25	54014-54015	.	_	

#Text=MANOVA interactions that met the Bonferroni correction are indicated by asterisks.
233-1	54016-54022	MANOVA	_	
233-2	54023-54035	interactions	_	
233-3	54036-54040	that	_	
233-4	54041-54044	met	_	
233-5	54045-54048	the	_	
233-6	54049-54059	Bonferroni	_	
233-7	54060-54070	correction	_	
233-8	54071-54074	are	_	
233-9	54075-54084	indicated	_	
233-10	54085-54087	by	_	
233-11	54088-54097	asterisks	_	
233-12	54097-54098	.	_	

#Text=The frontal and parietal lobe group×Brodmann area interactions met the Bonferroni criteria for four brain lobes and two hemispheres (0.05/8=0.00625).
234-1	54099-54102	The	_	
234-2	54103-54110	frontal	_	
234-3	54111-54114	and	_	
234-4	54115-54123	parietal	_	
234-5	54124-54128	lobe	_	
234-6	54129-54134	group	_	
234-7	54134-54135	×	_	
234-8	54135-54143	Brodmann	_	
234-9	54144-54148	area	_	
234-10	54149-54161	interactions	_	
234-11	54162-54165	met	_	
234-12	54166-54169	the	_	
234-13	54170-54180	Bonferroni	_	
234-14	54181-54189	criteria	_	
234-15	54190-54193	for	_	
234-16	54194-54198	four	_	
234-17	54199-54204	brain	_	
234-18	54205-54210	lobes	_	
234-19	54211-54214	and	_	
234-20	54215-54218	two	_	
234-21	54219-54230	hemispheres	_	
234-22	54231-54232	(	_	
234-23	54232-54236	0.05	_	
234-24	54236-54237	/	_	
234-25	54237-54238	8	_	
234-26	54238-54239	=	_	
234-27	54239-54246	0.00625	_	
234-28	54246-54247	)	_	
234-29	54247-54248	.	_	

#Text=We chose all ANOVAs (three diagnostic groups and the 3 paired comparisons by four lobes, 4 x 4=16) as a divisor, but note that this correction could be considered to be spuriously failing to replicate published findings in schizophrenia and autism literature.
235-1	54249-54251	We	_	
235-2	54252-54257	chose	_	
235-3	54258-54261	all	_	
235-4	54262-54268	ANOVAs	_	
235-5	54269-54270	(	_	
235-6	54270-54275	three	_	
235-7	54276-54286	diagnostic	_	
235-8	54287-54293	groups	_	
235-9	54294-54297	and	_	
235-10	54298-54301	the	_	
235-11	54302-54303	3	_	
235-12	54304-54310	paired	_	
235-13	54311-54322	comparisons	_	
235-14	54323-54325	by	_	
235-15	54326-54330	four	_	
235-16	54331-54336	lobes	_	
235-17	54336-54337	,	_	
235-18	54338-54339	4	_	
235-19	54340-54341	x	_	
235-20	54342-54343	4	_	
235-21	54343-54344	=	_	
235-22	54344-54346	16	_	
235-23	54346-54347	)	_	
235-24	54348-54350	as	_	
235-25	54351-54352	a	_	
235-26	54353-54360	divisor	_	
235-27	54360-54361	,	_	
235-28	54362-54365	but	_	
235-29	54366-54370	note	_	
235-30	54371-54375	that	_	
235-31	54376-54380	this	_	
235-32	54381-54391	correction	_	
235-33	54392-54397	could	_	
235-34	54398-54400	be	_	
235-35	54401-54411	considered	_	
235-36	54412-54414	to	_	
235-37	54415-54417	be	_	
235-38	54418-54428	spuriously	_	
235-39	54429-54436	failing	_	
235-40	54437-54439	to	_	
235-41	54440-54449	replicate	_	
235-42	54450-54459	published	_	
235-43	54460-54468	findings	_	
235-44	54469-54471	in	_	
235-45	54472-54485	schizophrenia	_	
235-46	54486-54489	and	_	
235-47	54490-54496	autism	_	
235-48	54497-54507	literature	_	
235-49	54507-54508	.	_	

#Text=For the 16 subcortical regions, at the p<0.05 level the three-group main effect was significant for 15 out of 16 tests, the main effect of group for healthy controls vs. schizophrenia comparisons was significant in 14 out of 16 tests, and the main effect of group for healthy controls vs ASD comparisons was significant in 9 out of 16 tests.
236-1	54509-54512	For	_	
236-2	54513-54516	the	_	
236-3	54517-54519	16	_	
236-4	54520-54531	subcortical	_	
236-5	54532-54539	regions	_	
236-6	54539-54540	,	_	
236-7	54541-54543	at	_	
236-8	54544-54547	the	_	
236-9	54548-54549	p	_	
236-10	54549-54550	<	_	
236-11	54550-54554	0.05	_	
236-12	54555-54560	level	_	
236-13	54561-54564	the	_	
236-14	54565-54576	three-group	_	
236-15	54577-54581	main	_	
236-16	54582-54588	effect	_	
236-17	54589-54592	was	_	
236-18	54593-54604	significant	_	
236-19	54605-54608	for	_	
236-20	54609-54611	15	_	
236-21	54612-54615	out	_	
236-22	54616-54618	of	_	
236-23	54619-54621	16	_	
236-24	54622-54627	tests	_	
236-25	54627-54628	,	_	
236-26	54629-54632	the	_	
236-27	54633-54637	main	_	
236-28	54638-54644	effect	_	
236-29	54645-54647	of	_	
236-30	54648-54653	group	_	
236-31	54654-54657	for	_	
236-32	54658-54665	healthy	_	
236-33	54666-54674	controls	_	
236-34	54675-54677	vs	_	
236-35	54677-54678	.	_	
236-36	54679-54692	schizophrenia	_	
236-37	54693-54704	comparisons	_	
236-38	54705-54708	was	_	
236-39	54709-54720	significant	_	
236-40	54721-54723	in	_	
236-41	54724-54726	14	_	
236-42	54727-54730	out	_	
236-43	54731-54733	of	_	
236-44	54734-54736	16	_	
236-45	54737-54742	tests	_	
236-46	54742-54743	,	_	
236-47	54744-54747	and	_	
236-48	54748-54751	the	_	
236-49	54752-54756	main	_	
236-50	54757-54763	effect	_	
236-51	54764-54766	of	_	
236-52	54767-54772	group	_	
236-53	54773-54776	for	_	
236-54	54777-54784	healthy	_	
236-55	54785-54793	controls	_	
236-56	54794-54796	vs	_	
236-57	54797-54800	ASD	_	
236-58	54801-54812	comparisons	_	
236-59	54813-54816	was	_	
236-60	54817-54828	significant	_	
236-61	54829-54831	in	_	
236-62	54832-54833	9	_	
236-63	54834-54837	out	_	
236-64	54838-54840	of	_	
236-65	54841-54843	16	_	
236-66	54844-54849	tests	_	
236-67	54849-54850	.	_	

#Text=The Bonferroni correction criterion for 16 subcortical regions was 0.00315 (0.05/16).
237-1	54851-54854	The	_	
237-2	54855-54865	Bonferroni	_	
237-3	54866-54876	correction	_	
237-4	54877-54886	criterion	_	
237-5	54887-54890	for	_	
237-6	54891-54893	16	_	
237-7	54894-54905	subcortical	_	
237-8	54906-54913	regions	_	
237-9	54914-54917	was	_	
237-10	54918-54925	0.00315	_	
237-11	54926-54927	(	_	
237-12	54927-54931	0.05	_	
237-13	54931-54932	/	_	
237-14	54932-54934	16	_	
237-15	54934-54935	)	_	
237-16	54935-54936	.	_	

#Text=Changes in metabolic rates in ASD and schizophrenia
#Text=ASD and schizophrenia in relation to normal controls\t \tGreater-than-normal in ASD, lower-than-normal in schizophrenia\tAnterior cingulate (areas 32 and 33), frontal area 9*\t \tHypothalamus\t \tGreater-than-normal in schizophrenia, lower-than-normal in ASD\tPrecentral/postcentral region (areas 2, 3, 4, and 5*)\t \tBoth ASD and schizophrenia are lower-than-normal\tFrontal cortex (areas 8*, 10*, 11*, 45*, 46*, and 47*), parietal cortex (39*, 40*)\t \tAmygdala\t \tVentral posteromedial nucleus of the thalamus\t \tClaustrum\t \tBoth ASD and schizophrenia are higher-than-normal\tOccipital cortex (areas 17 and 18)\t \tHippocampus, tail of the caudate\t \tPulvinar\t \tLateral globus pallidus, medial globus pallidus, putamen\t \tOnly ASD is lower-than-normal (no changes in schizophrenia)\tWhole parietal lobe**, postcentral areas 1* and 7*\t \tOnly schizophrenia is lower-than-normal (no changes in ASD)\tWhole frontal lobe**\t \tHead and body of the caudate\t \tMediodorsal nucleus of the thalamus\t \tOnly schizophrenia is higher-than-normal (no changes in ASD)\tPosterior and ventroposterior lateral nuclei of the thalamus\t \tSchizophrenia vs. normal controls\t \tSchizophrenia is lower-than-normal\tWhole frontal lobe**, all frontal areas except area 4\t \tParietal area 40, anterior cingulate (24, 25, 32, 33), temporal area 22\t \tAmygdala\t \tHead of the caudate\t \tMediodorsal and ventral posteromedial nuclei of the thalamus\t \tSchizophrenia is higher-than-normal\tOccipital areas 17 and 18\t \tHippocampus\t \tPulvinar, ventroposterior lateral and lateral posterior nuclei of the thalamus\t \tTail of the caudate\t \tLateral globus pallidus, putamen, claustrum\t \tASD vs. normal controls\t \tASD is lower-than-normal\tWhole parietal lobe**, all parietal areas except area 43\t \tFrontal areas 6, 8, 11\t \tAmygdala\t \tASD is higher-than-normal\tPosterior cingulate (23, 29, 30), orbitofrontal (12), occipital areas 17 and 18\t \tHippocampus\t \tTail of the caudate\t \tPutamen, medial and lateral globi pallidi, claustrum\t \t
#Text=Statistically significant (p<0.05) or trend-level (p<0.1) interaction in follow-up simple ANCOVA (with age as covariate) with 3 diagnostic groups for individual Brodmann areas (BA, df=2, 117): BA1 F=6.54, p=0.002; BA5 F=3.03, p=0.05; BA7 F=3.44, p=0.035; BA8 F=2.87, p=0.06; BA9 F=2.56, p=0.08; BA10=8.10, p=0.0005; BA11 F=6.35, p=0.002; BA39 F=2.88, p=0.06; BA40 F=6.64, p=0.002; BA44 F=4.31, p=0.02; BA45 F=3.41, p=0.04; BA46 F=3.63, p=0.03; BA47 F=3.44, p=0.035.
238-1	54937-54944	Changes	_	
238-2	54945-54947	in	_	
238-3	54948-54957	metabolic	_	
238-4	54958-54963	rates	_	
238-5	54964-54966	in	_	
238-6	54967-54970	ASD	_	
238-7	54971-54974	and	_	
238-8	54975-54988	schizophrenia	_	
238-9	54989-54992	ASD	_	
238-10	54993-54996	and	_	
238-11	54997-55010	schizophrenia	_	
238-12	55011-55013	in	_	
238-13	55014-55022	relation	_	
238-14	55023-55025	to	_	
238-15	55026-55032	normal	_	
238-16	55033-55041	controls	_	
238-17	55044-55063	Greater-than-normal	_	
238-18	55064-55066	in	_	
238-19	55067-55070	ASD	_	
238-20	55070-55071	,	_	
238-21	55072-55089	lower-than-normal	_	
238-22	55090-55092	in	_	
238-23	55093-55106	schizophrenia	_	
238-24	55107-55115	Anterior	_	
238-25	55116-55125	cingulate	_	
238-26	55126-55127	(	_	
238-27	55127-55132	areas	_	
238-28	55133-55135	32	_	
238-29	55136-55139	and	_	
238-30	55140-55142	33	_	
238-31	55142-55143	)	_	
238-32	55143-55144	,	_	
238-33	55145-55152	frontal	_	
238-34	55153-55157	area	_	
238-35	55158-55159	9	_	
238-36	55159-55160	*	_	
238-37	55163-55175	Hypothalamus	_	
238-38	55178-55197	Greater-than-normal	_	
238-39	55198-55200	in	_	
238-40	55201-55214	schizophrenia	_	
238-41	55214-55215	,	_	
238-42	55216-55233	lower-than-normal	_	
238-43	55234-55236	in	_	
238-44	55237-55240	ASD	_	
238-45	55241-55251	Precentral	_	
238-46	55251-55252	/	_	
238-47	55252-55263	postcentral	_	
238-48	55264-55270	region	_	
238-49	55271-55272	(	_	
238-50	55272-55277	areas	_	
238-51	55278-55279	2	_	
238-52	55279-55280	,	_	
238-53	55281-55282	3	_	
238-54	55282-55283	,	_	
238-55	55284-55285	4	_	
238-56	55285-55286	,	_	
238-57	55287-55290	and	_	
238-58	55291-55292	5	_	
238-59	55292-55293	*	_	
238-60	55293-55294	)	_	
238-61	55297-55301	Both	_	
238-62	55302-55305	ASD	_	
238-63	55306-55309	and	_	
238-64	55310-55323	schizophrenia	_	
238-65	55324-55327	are	_	
238-66	55328-55345	lower-than-normal	_	
238-67	55346-55353	Frontal	_	
238-68	55354-55360	cortex	_	
238-69	55361-55362	(	_	
238-70	55362-55367	areas	_	
238-71	55368-55369	8	_	
238-72	55369-55370	*	_	
238-73	55370-55371	,	_	
238-74	55372-55374	10	_	
238-75	55374-55375	*	_	
238-76	55375-55376	,	_	
238-77	55377-55379	11	_	
238-78	55379-55380	*	_	
238-79	55380-55381	,	_	
238-80	55382-55384	45	_	
238-81	55384-55385	*	_	
238-82	55385-55386	,	_	
238-83	55387-55389	46	_	
238-84	55389-55390	*	_	
238-85	55390-55391	,	_	
238-86	55392-55395	and	_	
238-87	55396-55398	47	_	
238-88	55398-55399	*	_	
238-89	55399-55400	)	_	
238-90	55400-55401	,	_	
238-91	55402-55410	parietal	_	
238-92	55411-55417	cortex	_	
238-93	55418-55419	(	_	
238-94	55419-55421	39	_	
238-95	55421-55422	*	_	
238-96	55422-55423	,	_	
238-97	55424-55426	40	_	
238-98	55426-55427	*	_	
238-99	55427-55428	)	_	
238-100	55431-55439	Amygdala	_	
238-101	55442-55449	Ventral	_	
238-102	55450-55463	posteromedial	_	
238-103	55464-55471	nucleus	_	
238-104	55472-55474	of	_	
238-105	55475-55478	the	_	
238-106	55479-55487	thalamus	_	
238-107	55490-55499	Claustrum	_	
238-108	55502-55506	Both	_	
238-109	55507-55510	ASD	_	
238-110	55511-55514	and	_	
238-111	55515-55528	schizophrenia	_	
238-112	55529-55532	are	_	
238-113	55533-55551	higher-than-normal	_	
238-114	55552-55561	Occipital	_	
238-115	55562-55568	cortex	_	
238-116	55569-55570	(	_	
238-117	55570-55575	areas	_	
238-118	55576-55578	17	_	
238-119	55579-55582	and	_	
238-120	55583-55585	18	_	
238-121	55585-55586	)	_	
238-122	55589-55600	Hippocampus	_	
238-123	55600-55601	,	_	
238-124	55602-55606	tail	_	
238-125	55607-55609	of	_	
238-126	55610-55613	the	_	
238-127	55614-55621	caudate	_	
238-128	55624-55632	Pulvinar	_	
238-129	55635-55642	Lateral	_	
238-130	55643-55649	globus	_	
238-131	55650-55658	pallidus	_	
238-132	55658-55659	,	_	
238-133	55660-55666	medial	_	
238-134	55667-55673	globus	_	
238-135	55674-55682	pallidus	_	
238-136	55682-55683	,	_	
238-137	55684-55691	putamen	_	
238-138	55694-55698	Only	_	
238-139	55699-55702	ASD	_	
238-140	55703-55705	is	_	
238-141	55706-55723	lower-than-normal	_	
238-142	55724-55725	(	_	
238-143	55725-55727	no	_	
238-144	55728-55735	changes	_	
238-145	55736-55738	in	_	
238-146	55739-55752	schizophrenia	_	
238-147	55752-55753	)	_	
238-148	55754-55759	Whole	_	
238-149	55760-55768	parietal	_	
238-150	55769-55773	lobe	_	
238-151	55773-55774	*	_	
238-152	55774-55775	*	_	
238-153	55775-55776	,	_	
238-154	55777-55788	postcentral	_	
238-155	55789-55794	areas	_	
238-156	55795-55796	1	_	
238-157	55796-55797	*	_	
238-158	55798-55801	and	_	
238-159	55802-55803	7	_	
238-160	55803-55804	*	_	
238-161	55807-55811	Only	_	
238-162	55812-55825	schizophrenia	_	
238-163	55826-55828	is	_	
238-164	55829-55846	lower-than-normal	_	
238-165	55847-55848	(	_	
238-166	55848-55850	no	_	
238-167	55851-55858	changes	_	
238-168	55859-55861	in	_	
238-169	55862-55865	ASD	_	
238-170	55865-55866	)	_	
238-171	55867-55872	Whole	_	
238-172	55873-55880	frontal	_	
238-173	55881-55885	lobe	_	
238-174	55885-55886	*	_	
238-175	55886-55887	*	_	
238-176	55890-55894	Head	_	
238-177	55895-55898	and	_	
238-178	55899-55903	body	_	
238-179	55904-55906	of	_	
238-180	55907-55910	the	_	
238-181	55911-55918	caudate	_	
238-182	55921-55932	Mediodorsal	_	
238-183	55933-55940	nucleus	_	
238-184	55941-55943	of	_	
238-185	55944-55947	the	_	
238-186	55948-55956	thalamus	_	
238-187	55959-55963	Only	_	
238-188	55964-55977	schizophrenia	_	
238-189	55978-55980	is	_	
238-190	55981-55999	higher-than-normal	_	
238-191	56000-56001	(	_	
238-192	56001-56003	no	_	
238-193	56004-56011	changes	_	
238-194	56012-56014	in	_	
238-195	56015-56018	ASD	_	
238-196	56018-56019	)	_	
238-197	56020-56029	Posterior	_	
238-198	56030-56033	and	_	
238-199	56034-56049	ventroposterior	_	
238-200	56050-56057	lateral	_	
238-201	56058-56064	nuclei	_	
238-202	56065-56067	of	_	
238-203	56068-56071	the	_	
238-204	56072-56080	thalamus	_	
238-205	56083-56096	Schizophrenia	_	
238-206	56097-56099	vs	_	
238-207	56099-56100	.	_	
238-208	56101-56107	normal	_	
238-209	56108-56116	controls	_	
238-210	56119-56132	Schizophrenia	_	
238-211	56133-56135	is	_	
238-212	56136-56153	lower-than-normal	_	
238-213	56154-56159	Whole	_	
238-214	56160-56167	frontal	_	
238-215	56168-56172	lobe	_	
238-216	56172-56173	*	_	
238-217	56173-56174	*	_	
238-218	56174-56175	,	_	
238-219	56176-56179	all	_	
238-220	56180-56187	frontal	_	
238-221	56188-56193	areas	_	
238-222	56194-56200	except	_	
238-223	56201-56205	area	_	
238-224	56206-56207	4	_	
238-225	56210-56218	Parietal	_	
238-226	56219-56223	area	_	
238-227	56224-56226	40	_	
238-228	56226-56227	,	_	
238-229	56228-56236	anterior	_	
238-230	56237-56246	cingulate	_	
238-231	56247-56248	(	_	
238-232	56248-56250	24	_	
238-233	56250-56251	,	_	
238-234	56252-56254	25	_	
238-235	56254-56255	,	_	
238-236	56256-56258	32	_	
238-237	56258-56259	,	_	
238-238	56260-56262	33	_	
238-239	56262-56263	)	_	
238-240	56263-56264	,	_	
238-241	56265-56273	temporal	_	
238-242	56274-56278	area	_	
238-243	56279-56281	22	_	
238-244	56284-56292	Amygdala	_	
238-245	56295-56299	Head	_	
238-246	56300-56302	of	_	
238-247	56303-56306	the	_	
238-248	56307-56314	caudate	_	
238-249	56317-56328	Mediodorsal	_	
238-250	56329-56332	and	_	
238-251	56333-56340	ventral	_	
238-252	56341-56354	posteromedial	_	
238-253	56355-56361	nuclei	_	
238-254	56362-56364	of	_	
238-255	56365-56368	the	_	
238-256	56369-56377	thalamus	_	
238-257	56380-56393	Schizophrenia	_	
238-258	56394-56396	is	_	
238-259	56397-56415	higher-than-normal	_	
238-260	56416-56425	Occipital	_	
238-261	56426-56431	areas	_	
238-262	56432-56434	17	_	
238-263	56435-56438	and	_	
238-264	56439-56441	18	_	
238-265	56444-56455	Hippocampus	_	
238-266	56458-56466	Pulvinar	_	
238-267	56466-56467	,	_	
238-268	56468-56483	ventroposterior	_	
238-269	56484-56491	lateral	_	
238-270	56492-56495	and	_	
238-271	56496-56503	lateral	_	
238-272	56504-56513	posterior	_	
238-273	56514-56520	nuclei	_	
238-274	56521-56523	of	_	
238-275	56524-56527	the	_	
238-276	56528-56536	thalamus	_	
238-277	56539-56543	Tail	_	
238-278	56544-56546	of	_	
238-279	56547-56550	the	_	
238-280	56551-56558	caudate	_	
238-281	56561-56568	Lateral	_	
238-282	56569-56575	globus	_	
238-283	56576-56584	pallidus	_	
238-284	56584-56585	,	_	
238-285	56586-56593	putamen	_	
238-286	56593-56594	,	_	
238-287	56595-56604	claustrum	_	
238-288	56607-56610	ASD	_	
238-289	56611-56613	vs	_	
238-290	56613-56614	.	_	
238-291	56615-56621	normal	_	
238-292	56622-56630	controls	_	
238-293	56633-56636	ASD	_	
238-294	56637-56639	is	_	
238-295	56640-56657	lower-than-normal	_	
238-296	56658-56663	Whole	_	
238-297	56664-56672	parietal	_	
238-298	56673-56677	lobe	_	
238-299	56677-56678	*	_	
238-300	56678-56679	*	_	
238-301	56679-56680	,	_	
238-302	56681-56684	all	_	
238-303	56685-56693	parietal	_	
238-304	56694-56699	areas	_	
238-305	56700-56706	except	_	
238-306	56707-56711	area	_	
238-307	56712-56714	43	_	
238-308	56717-56724	Frontal	_	
238-309	56725-56730	areas	_	
238-310	56731-56732	6	_	
238-311	56732-56733	,	_	
238-312	56734-56735	8	_	
238-313	56735-56736	,	_	
238-314	56737-56739	11	_	
238-315	56742-56750	Amygdala	_	
238-316	56753-56756	ASD	_	
238-317	56757-56759	is	_	
238-318	56760-56778	higher-than-normal	_	
238-319	56779-56788	Posterior	_	
238-320	56789-56798	cingulate	_	
238-321	56799-56800	(	_	
238-322	56800-56802	23	_	
238-323	56802-56803	,	_	
238-324	56804-56806	29	_	
238-325	56806-56807	,	_	
238-326	56808-56810	30	_	
238-327	56810-56811	)	_	
238-328	56811-56812	,	_	
238-329	56813-56826	orbitofrontal	_	
238-330	56827-56828	(	_	
238-331	56828-56830	12	_	
238-332	56830-56831	)	_	
238-333	56831-56832	,	_	
238-334	56833-56842	occipital	_	
238-335	56843-56848	areas	_	
238-336	56849-56851	17	_	
238-337	56852-56855	and	_	
238-338	56856-56858	18	_	
238-339	56861-56872	Hippocampus	_	
238-340	56875-56879	Tail	_	
238-341	56880-56882	of	_	
238-342	56883-56886	the	_	
238-343	56887-56894	caudate	_	
238-344	56897-56904	Putamen	_	
238-345	56904-56905	,	_	
238-346	56906-56912	medial	_	
238-347	56913-56916	and	_	
238-348	56917-56924	lateral	_	
238-349	56925-56930	globi	_	
238-350	56931-56938	pallidi	_	
238-351	56938-56939	,	_	
238-352	56940-56949	claustrum	_	
238-353	56953-56966	Statistically	_	
238-354	56967-56978	significant	_	
238-355	56979-56980	(	_	
238-356	56980-56981	p	_	
238-357	56981-56982	<	_	
238-358	56982-56986	0.05	_	
238-359	56986-56987	)	_	
238-360	56988-56990	or	_	
238-361	56991-57002	trend-level	_	
238-362	57003-57004	(	_	
238-363	57004-57005	p	_	
238-364	57005-57006	<	_	
238-365	57006-57009	0.1	_	
238-366	57009-57010	)	_	
238-367	57011-57022	interaction	_	
238-368	57023-57025	in	_	
238-369	57026-57035	follow-up	_	
238-370	57036-57042	simple	_	
238-371	57043-57049	ANCOVA	_	
238-372	57050-57051	(	_	
238-373	57051-57055	with	_	
238-374	57056-57059	age	_	
238-375	57060-57062	as	_	
238-376	57063-57072	covariate	_	
238-377	57072-57073	)	_	
238-378	57074-57078	with	_	
238-379	57079-57080	3	_	
238-380	57081-57091	diagnostic	_	
238-381	57092-57098	groups	_	
238-382	57099-57102	for	_	
238-383	57103-57113	individual	_	
238-384	57114-57122	Brodmann	_	
238-385	57123-57128	areas	_	
238-386	57129-57130	(	_	
238-387	57130-57132	BA	_	
238-388	57132-57133	,	_	
238-389	57134-57136	df	_	
238-390	57136-57137	=	_	
238-391	57137-57138	2	_	
238-392	57138-57139	,	_	
238-393	57140-57143	117	_	
238-394	57143-57144	)	_	
238-395	57144-57145	:	_	
238-396	57146-57149	BA1	_	
238-397	57150-57151	F	_	
238-398	57151-57152	=	_	
238-399	57152-57156	6.54	_	
238-400	57156-57157	,	_	
238-401	57158-57159	p	_	
238-402	57159-57160	=	_	
238-403	57160-57165	0.002	_	
238-404	57165-57166	;	_	
238-405	57167-57170	BA5	_	
238-406	57171-57172	F	_	
238-407	57172-57173	=	_	
238-408	57173-57177	3.03	_	
238-409	57177-57178	,	_	
238-410	57179-57180	p	_	
238-411	57180-57181	=	_	
238-412	57181-57185	0.05	_	
238-413	57185-57186	;	_	
238-414	57187-57190	BA7	_	
238-415	57191-57192	F	_	
238-416	57192-57193	=	_	
238-417	57193-57197	3.44	_	
238-418	57197-57198	,	_	
238-419	57199-57200	p	_	
238-420	57200-57201	=	_	
238-421	57201-57206	0.035	_	
238-422	57206-57207	;	_	
238-423	57208-57211	BA8	_	
238-424	57212-57213	F	_	
238-425	57213-57214	=	_	
238-426	57214-57218	2.87	_	
238-427	57218-57219	,	_	
238-428	57220-57221	p	_	
238-429	57221-57222	=	_	
238-430	57222-57226	0.06	_	
238-431	57226-57227	;	_	
238-432	57228-57231	BA9	_	
238-433	57232-57233	F	_	
238-434	57233-57234	=	_	
238-435	57234-57238	2.56	_	
238-436	57238-57239	,	_	
238-437	57240-57241	p	_	
238-438	57241-57242	=	_	
238-439	57242-57246	0.08	_	
238-440	57246-57247	;	_	
238-441	57248-57252	BA10	_	
238-442	57252-57253	=	_	
238-443	57253-57257	8.10	_	
238-444	57257-57258	,	_	
238-445	57259-57260	p	_	
238-446	57260-57261	=	_	
238-447	57261-57267	0.0005	_	
238-448	57267-57268	;	_	
238-449	57269-57273	BA11	_	
238-450	57274-57275	F	_	
238-451	57275-57276	=	_	
238-452	57276-57280	6.35	_	
238-453	57280-57281	,	_	
238-454	57282-57283	p	_	
238-455	57283-57284	=	_	
238-456	57284-57289	0.002	_	
238-457	57289-57290	;	_	
238-458	57291-57295	BA39	_	
238-459	57296-57297	F	_	
238-460	57297-57298	=	_	
238-461	57298-57302	2.88	_	
238-462	57302-57303	,	_	
238-463	57304-57305	p	_	
238-464	57305-57306	=	_	
238-465	57306-57310	0.06	_	
238-466	57310-57311	;	_	
238-467	57312-57316	BA40	_	
238-468	57317-57318	F	_	
238-469	57318-57319	=	_	
238-470	57319-57323	6.64	_	
238-471	57323-57324	,	_	
238-472	57325-57326	p	_	
238-473	57326-57327	=	_	
238-474	57327-57332	0.002	_	
238-475	57332-57333	;	_	
238-476	57334-57338	BA44	_	
238-477	57339-57340	F	_	
238-478	57340-57341	=	_	
238-479	57341-57345	4.31	_	
238-480	57345-57346	,	_	
238-481	57347-57348	p	_	
238-482	57348-57349	=	_	
238-483	57349-57353	0.02	_	
238-484	57353-57354	;	_	
238-485	57355-57359	BA45	_	
238-486	57360-57361	F	_	
238-487	57361-57362	=	_	
238-488	57362-57366	3.41	_	
238-489	57366-57367	,	_	
238-490	57368-57369	p	_	
238-491	57369-57370	=	_	
238-492	57370-57374	0.04	_	
238-493	57374-57375	;	_	
238-494	57376-57380	BA46	_	
238-495	57381-57382	F	_	
238-496	57382-57383	=	_	
238-497	57383-57387	3.63	_	
238-498	57387-57388	,	_	
238-499	57389-57390	p	_	
238-500	57390-57391	=	_	
238-501	57391-57395	0.03	_	
238-502	57395-57396	;	_	
238-503	57397-57401	BA47	_	
238-504	57402-57403	F	_	
238-505	57403-57404	=	_	
238-506	57404-57408	3.44	_	
238-507	57408-57409	,	_	
238-508	57410-57411	p	_	
238-509	57411-57412	=	_	
238-510	57412-57417	0.035	_	
238-511	57417-57418	.	_	

#Text=Significant main effect of diagnosis in lobar analyses.
239-1	57419-57430	Significant	_	
239-2	57431-57435	main	_	
239-3	57436-57442	effect	_	
239-4	57443-57445	of	_	
239-5	57446-57455	diagnosis	_	
239-6	57456-57458	in	_	
239-7	57459-57464	lobar	_	
239-8	57465-57473	analyses	_	
239-9	57473-57474	.	_	
